{"protocolSection":{"identificationModule":{"nctId":"NCT01970865","orgStudyIdInfo":{"id":"B7461001"},"secondaryIdInfos":[{"id":"2013-002620-17","type":"EUDRACT_NUMBER"}],"organization":{"fullName":"Pfizer","class":"INDUSTRY"},"briefTitle":"A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations","officialTitle":"PHASE 1/2 STUDY OF PF-06463922 (AN ALK/ROS1 TYROSINE KINASE INHIBITOR) IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER HARBORING SPECIFIC MOLECULAR ALTERATIONS"},"statusModule":{"statusVerifiedDate":"2024-07","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":true,"nctId":"NCT03127618","statusForNctId":"APPROVED_FOR_MARKETING"},"startDateStruct":{"date":"2014-01-08","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2017-03-15","type":"ACTUAL"},"completionDateStruct":{"date":"2023-05-24","type":"ACTUAL"},"studyFirstSubmitDate":"2013-10-16","studyFirstSubmitQcDate":"2013-10-22","studyFirstPostDateStruct":{"date":"2013-10-28","type":"ESTIMATED"},"resultsFirstSubmitDate":"2018-03-05","resultsFirstSubmitQcDate":"2018-05-08","resultsFirstPostDateStruct":{"date":"2018-05-29","type":"ACTUAL"},"lastUpdateSubmitDate":"2024-07-16","lastUpdatePostDateStruct":{"date":"2024-08-12","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Pfizer","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false},"descriptionModule":{"briefSummary":"Phase 1 and 2 trial to study the safety, pharmacokinetics, pharmacodynamics, patient reported outcomes and efficacy of PF-06463922 in ALK + advanced non-small cell lung cancer patients and ROS1+ advanced non small cell lung cancer patients ."},"conditionsModule":{"conditions":["ALK-positive Non Small Cell Lung Cancer (NSCLC) and ROS1-positive NSCLC"],"keywords":["Phase 1","Phase 2","safety","pharmacokinetic","pharmacodynamic","efficacy"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE1","PHASE2"],"designInfo":{"allocation":"NON_RANDOMIZED","interventionModel":"SINGLE_GROUP","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":364,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"PF-06463922","type":"EXPERIMENTAL","interventionNames":["Drug: PF-06463922"]},{"label":"Crizotinib","type":"OTHER","description":"ALK+ NSCLC patients who are treatment naÃ¯ve may be eligible to receive crizotinib following PF-06463922 as a substudy to the main study.","interventionNames":["Drug: Crizotinib"]}],"interventions":[{"type":"DRUG","name":"PF-06463922","description":"Oral, starting dose 10mg once a day, dose escalation in Phase 1 until recommended Phase 2 dose determined, continuous daily dosing, cycles lasting 21 days","armGroupLabels":["PF-06463922"]},{"type":"DRUG","name":"Crizotinib","description":"Oral, starting dose of 250 mg BID continuous daily dosing every 21 days","armGroupLabels":["Crizotinib"],"otherNames":["Xalkori"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Number of Participants With Cycle 1 Dose-Limiting Toxicities (DLTs) in Phase 1","description":"DLT: any of following adverse events (AEs) attributable to PF-06463922: (1) hematologic: grade 4 neutropenia for \\>7 days; febrile neutropenia; grade\\>=3 neutropenic infection; grade\\>=3 thrombocytopenia with bleeding; grade 4 thrombocytopenia; (2) non-hematologic: grade\\>=3 pancreatitis; grade\\>=3 toxicities (excluding grade \\>=3 laboratory abnormalities not requiring dose modifications) persisting after optimal treatment with standard medical therapy; symptomatic grade \\>=3 QT interval corrected for heart rate (QTc) prolongation, or asymptomatic grade \\>=3 prolongation that had been confirmed by repeat testing, re-evaluation by qualified person, persisted after correction of reversible causes; \\>=20% decrease from baseline in left ventricular ejection fraction (LVEF); (3) other: failure to deliver at least 16 out of 21 prescribed daily total dose due to toxicities attributable to study drug; failure to restart dosing after 21 days (1 cycle) delay due to toxicity attributable to study drug.","timeFrame":"Cycle 1 (21 days)"},{"measure":"Percentage of Participants With Overall and Intracranial Objective Response (Phase 2)","description":"Objective response (OR) refers to confirmed complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumor (RECIST) version 1.1. Intracranial OR refers to confirmed CR or PR considering only lesions within brain. CR was defined as the disappearance of all non-lymph node target lesions (where all target lesions are recorded with a length of 0 milliliter (mm) on Target Lesions electronic case report form (eCRF). Any pathological lymph nodes (recorded as target lesion) must have reduction in short axis to \\<10 mm. PR was defined as a 30 percent (%) or more decrease in sum of lesion dimensions (SLD) of target lesions, taking as reference the baseline SLD. Results presented here were based on independent central review.","timeFrame":"3 years"}],"secondaryOutcomes":[{"measure":"Percentage of Participants With Overall and Intracranial Objective Response (Phase 1)","description":"Objective response (OR) refers to confirmed CR or PR according to RECIST version 1.1. Intracranial OR refers to confirmed CR or PR considering only lesions within brain. CR was defined as the disappearance of all non-lymph node target lesions (where all target lesions are recorded with a length of 0 mm on Target Lesions eCRF). Any pathological lymph nodes (recorded as target lesion) must have reduction in short axis to \\<10 mm. PR was defined as a 30 % or more decrease in SLD of target lesions, taking as reference the baseline SLD. Results presented here were based on independent central review.","timeFrame":"From start of study treatment until CR or PR (maximum of 8 years approximately)"},{"measure":"Time to Tumor Response (TTR) and Intracranial TTR (Phase 1)","description":"Time to tumor response (TTR) was defined as the time from the first dose of study treatment to the first documentation of objective tumor response (CR or PR). For participants whose objective response proceeded from PR to CR, the onset of PR was taken as the onset of response. CR was defined as the disappearance of all non-lymph node target lesions (where all target lesions are recorded with a length of 0 mm on Target Lesions eCRF). Any pathological lymph nodes (recorded as target lesion) must have reduction in short axis to \\<10 mm. PR was defined as a 30 % or more decrease in SLD of target lesions, taking as reference the baseline SLD. TTR was only calculated for the subgroup of participants with a confirmed objective tumor response. Intracranial TTR was only calculated for participants with confirmed intracranial objective response. Results presented here were based on independent central review.","timeFrame":"From start of study treatment to the first documentation of objective tumor response (CR or PR) (maximum of 8 years approximately)"},{"measure":"Number of Participants With Duration of Response (DOR) and Intracranial DOR (Phase 1)","description":"Duration of response(DOR): time from first documentation of objective tumor response (CR/PR) to first documentation of disease progression (PD) or to death due to any cause, whichever occurred first. DOR: calculated for subgroup of participants with confirmed objective tumor response. Intracranial DOR: calculated for participants with confirmed intracranial objective response. CR:disappearance of all non-lymph node target lesions (where all target lesions are recorded with length of 0mm on Target Lesion eCRF). Any pathological lymph node (recorded as target lesion) must have reduction in short axis to \\<10mm. PR:30% or more decrease in SLD of target lesion, taking as reference baseline SLD. PD:20% or more increase in the SLD of target lesions relative to baseline or smallest SLD (nadir) recorded since first dose. In addition, also demonstrate absolute increase of at least 5mm (\\>=5mm) relative to baseline or smallest SLD (nadir) recorded since first dose.","timeFrame":"From start of study treatment to first documentation of PD or to death due to any cause, whichever occurred first (maximum of 8 years approximately)"},{"measure":"Percentage of Participants Achieving Disease Control and Intracranial Disease Control at 12 and 24 Weeks (Phase 1)","description":"Tumor response was evaluated according to RECIST version 1.1, and disease control: confirmed CR, confirmed PR, or stable disease (SD). Intracranial assessment was only performed for participants CNS metastases. CR was defined as disappearance of all non-lymph node target lesions (where all target lesions are recorded with length of 0mm on Target Lesions eCRF). Any pathological lymph nodes (recorded as target lesion) must have reduction in short axis to \\<10 mm. PR was defined as 30% or more decrease in SLD of target lesions, taking as reference baseline SLD. Progressive disease: 20% or more increase in SLD of target lesions relative to baseline or smallest SLD (nadir) recorded since first dose. In addition to relative increase of 20%, SLD must also demonstrate absolute increase of at least 5mm (\\>=5mm) relative to baseline or smallest SLD (nadir) recorded since first dose. Results presented here were based on independent central review.","timeFrame":"12 and 24 weeks"},{"measure":"Probability of First Event Being a Central Nervous System (CNS) Progression, Non CNS Progression, or Death (Phase 1)","description":"The probability of the first event being a CNS progression, a non-CNS progression, or death was evaluated with a competing risk approach by estimating cumulative incidence functions (range: 0-1) relative to the analysis set. The time to first event being a Competing Event (either \"CNS progression\" or \"non CNS progression\" or \"Death\") was defined as time from first dose until the date of that specific event. Participants not known to have any of the Competing Events were censored on the date they were last assessed for disease status for PFS. Participants who presented one type of event were counted as a competing cause of failure for the analysis of other type of events. For each type of event, the cumulative incidence function corresponding to the nearest time point preceding 1 year is presented. The results are based on independent central review.","timeFrame":"3 years"},{"measure":"Progression-Free Survival (PFS) (Phase 1)","description":"PFS was defined as the time from the first dose of study treatment to the first documentation of objective PD or to death on study due to any cause, whichever came first. Progressive disease was defined by a 20% or more increase in the SLD of target lesions relative to baseline or the smallest SLD (nadir) recorded since first dose. In addition to the relative increase of 20%, SLD must also demonstrate an absolute increase of at least 5 mm (\\>= 5 mm) relative to baseline or the smallest SLD (nadir) recorded since the first dose. Results presented here were based on independent central review.","timeFrame":"From start of study treatment to first documentation of PD or to death due to any cause, whichever occurred first (maximum of 8 years approximately)"},{"measure":"Overall Survival (OS) (Phase 1)","description":"OS was defined as the time from first dose to the date of death due to any cause. For participants still alive at the time of analysis, the OS time was censored on the last date the participants were known to be alive. Estimates of OS and its 95% confidence interval were determined using Kaplan-Meier method.","timeFrame":"3 years"},{"measure":"Maximum Observed Plasma Concentration (Cmax) of PF-06463922 Following Single Oral Doses (Phase 1)","description":"Maximum observed plasma concentration (Cmax) of PF-06463922 was observed directly from data.","timeFrame":"Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9 and 24 hours post-dose on Cycle 1 Day 1 for 25 mg QD and 150 mg QD groups; pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9, 24, 48, 72, 96 and 120 hours post-dose on Day -7 for all other groups."},{"measure":"Maximum Observed Plasma Concentration (Cmax) of PF-06463922 Following Multiple Oral Doses (Phase 1)","description":"Maximum Observed Plasma Concentration (Cmax) of PF-06463922 was observed directly from data.","timeFrame":"Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9, 24 hours post-dose on Cycle 1 Day 15 (24-hour samples not collected for BID groups)."},{"measure":"Time for Cmax (Tmax) of PF-06463922 Following Single Oral Doses (Phase 1)","description":"Tmax of PF-06463922 was observed directly from data as time of first occurrence.","timeFrame":"Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9 and 24 hours post-dose on Cycle 1 Day 1 for 25 mg QD and 150 mg QD groups; pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9, 24, 48, 72, 96 and 120 hours post-dose on Day -7 for all other groups."},{"measure":"Time for Cmax (Tmax) of PF-06463922 Following Multiple Oral Doses (Phase 1)","description":"Tmax of PF-06463922 was observed directly from data as time of first occurrence.","timeFrame":"Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9, 24 hours post-dose on Cycle 1 Day 15 (24-hour samples not collected for BID groups)."},{"measure":"Area Under the Plasma Concentration-Time Profile From Time Zero to Time Tau (AUCtau) of PF-06463922 Following Single Oral Doses (Phase 1)","description":"Tau refers to the dosing interval, and it equals to 12 or 24 hours for BID or QD dosing, respectively. AUCtau was determined using linear/log trapezoidal method.","timeFrame":"Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9 and 24 hours post-dose on Cycle 1 Day 1 for 25 mg QD and 150 mg QD groups; pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9, and 24 hours post-dose on Day -7 for all other groups."},{"measure":"Area Under the Plasma Concentration-Time Profile From Time Zero to Time Tau (AUCtau) of PF-06463922 Following Multiple Oral Doses (Phase 1)","description":"Tau refers to the dosing interval, and it equals to 12 or 24 hours for BID or QD dosing, respectively. AUCtau was determined using linear/log trapezoidal method.","timeFrame":"Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9, 24 hours post-dose on Cycle 1 Day 15 (24-hour samples not collected for BID groups)"},{"measure":"Area Under the Plasma Concentration-Time Profile From Time Zero Extrapolated to Infinite Time (AUCinf) of PF-06463922 Following Single Oral Doses (Phase 1)","description":"AUCinf was calculated as AUClast + (Clast\\*/kel), where AUClast was the area under the plasma concentration-time profile from time 0 to the time of the last quantifiable concentration, Clast\\* was the predicted plasma concentration at the last quantifiable time point estimated from the log-linear regression analysis, and kel was the rate constant for terminal phase.","timeFrame":"Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9 and 24 hours post-dose on Cycle 1 Day 1 for 25 mg QD and 150 mg QD groups; pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9, 24, 48, 72, 96 and 120 hours post-dose on Day -7 for all other groups."},{"measure":"Apparent Oral Clearance (CL/F) of PF-06463922 Following Single Oral Doses (Phase 1)","description":"Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. CL/F was calculated as dose/AUCinf, where AUCinf was the area under the plasma concentration-time profile from time 0 extrapolated to infinite time.","timeFrame":"Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9 and 24 hours post-dose on Cycle 1 Day 1 for 25 mg QD and 150 mg QD groups; pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9, 24, 48, 72, 96 and 120 hours post-dose on Day -7 for all other groups."},{"measure":"Apparent Oral Clearance (CL/F) of PF-06463922 Following Multiple Oral Doses (Phase 1)","description":"Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. CL/F was calculated as dose/AUCinf, where AUCinf was the area under the plasma concentration-time profile from time 0 extrapolated to infinite time.","timeFrame":"Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9, 24 hours post-dose on Cycle 1 Day 15 (24-hour samples not collected for BID groups)"},{"measure":"Apparent Volume of Distribution (Vz/F) of PF-06463922 Following Single Oral Doses (Phase 1)","description":"Vz/F was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug, and calculated as dose/(AUCinf\\*kel), where AUCinf was the area under the plasma concentration-time profile from time 0 extrapolated to infinite time, kel was the rate constant for terminal phase.","timeFrame":"Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9 and 24 hours post-dose on Cycle 1 Day 1 for 25 mg QD and 150 mg QD groups; pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9, 24, 48, 72, 96 and 120 hours post-dose on Day -7 for all other groups."},{"measure":"Observed Accumulation Ratio (Rac) of PF-06463922 Following Multiple Oral Doses (Phase 1)","description":"Rac was calculated as Day 15 AUCtau/Day -7 AUCtau or Day 1 AUCtau, where AUCtau was the area under the plasma concentration-time profile from time 0 to time tau (12 and 24 hours for BID and QD dosing regimen, respectively).","timeFrame":"Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9, 24 hours post-dose on Cycle 1 Day 15 (24-hour samples not collected for BID groups)"},{"measure":"Terminal Half-Life of PF-06463922 Following Single Oral Doses (Phase 1)","description":"Terminal plasma half-life was defined as the time measured for the plasma concentration to decrease by one half, and calculated as loge(2)/kel, where kel was the rate constant for terminal phase.","timeFrame":"Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9 and 24 hours post-dose on Cycle 1 Day 1 for 25 mg QD and 150 mg QD groups; pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9, 24, 48, 72, 96 and 120 hours post-dose on Day -7 for all other groups."},{"measure":"Steady State Accumulation Ratio (Rss) of PF-06463922 Following Multiple Oral Doses (Phase 1)","description":"Rss was calculated as Day 15 AUCtau/Day -7 AUCinf, where AUCtau was the area under the plasma concentration-time profile from time 0 to time tau (12 and 24 hours for BID and QD dosing regimen, respectively), and AUCinf was the area under the plasma concentration-time profile from time 0 extrapolated to infinite time.","timeFrame":"Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9, 24 hours post-dose on Cycle 1 Day 15 (24-hour samples not collected for BID groups)"},{"measure":"Renal Clearance (CLr) of PF-06463922 (Phase 1)","description":"Renal clearance was calculated as Aetau/AUCtau, where Aetau was the cumulative amount of drug recovered unchanged in urine up to dosing interval tau (24 hours for QD dosing regimen), and AUCtau was the area under the plasma concentration-time profile from time 0 to time tau (24 hours for QD dosing regimen).","timeFrame":"0-4 hours, 4-12 hours and 12-24 hours post-dose on Cycle 1 Day 15"},{"measure":"Percent of PF-06463922 Recovered Unchanged in Urine up to Dosing Interval (AEtau%) (Phase 1)","description":"Dosing interval was 24 hours for QD dosing regimen. Aetau% was calculated as 100\\*Ae24/dose, where Ae24 was the cumulative amount of drug recovered unchanged in urine up to 24 hours post-dose.","timeFrame":"0-4 hours, 4-12 hours and 12-24 hours post-dose on Cycle 1 Day 15"},{"measure":"Maximum Observed Plasma Concentration (Cmax) of Midazolam (Phase 1)","description":"Cmax of midazolam was observed directly from data. Only participants in 25 mg and 150 mg QD groups were given midazolam. Day -7 data reflected the PK assessment before administration of PF-06463922, and Cycle 1 Day 15 data reflected the PK assessment after multiple doses of PF-06463922 were administered.","timeFrame":"Pre-dose, 0.5, 1, 2, 4, 6, 8, 9 and 24 hours post-dose on Day -7 and pre-dose, 0.5, 1, 2, 4, 6, 8, 9 and 24 hours post-dose on Cycle 1 Day 15"},{"measure":"Time for Cmax (Tmax) of Midazolam (Phase 1)","description":"Tmax of midazolam was observed directly from data as time of first occurrence. Only participants in 25 mg and 150 mg QD groups were given midazolam. Day -7 data reflect the PK assessment before administration of PF-06463922, and Cycle 1 Day 15 data reflect the PK assessment after multiple doses of PF-06463922 were administered.","timeFrame":"Pre-dose, 0.5, 1, 2, 4, 6, 8, 9 and 24 hours post-dose on Day -7 and pre-dose, 0.5, 1, 2, 4, 6, 8, 9 and 24 hours post-dose on Cycle 1 Day 15"},{"measure":"Area Under the Plasma Concentration-Time Profile From Time Zero to the Time of the Last Quantifiable Concentration (AUClast) of Midazolam (Phase 1)","description":"Area under the plasma concentration-time profile from time 0 to the time of the last quantifiable concentration (AUClast) of midazolam was determined using linear/log trapezoidal method. Only participants in 25 mg and 150 mg QD groups were given midazolam. Day -7 data reflect the PK assessment before administration of PF-06463922, and Cycle 1 Day 15 data reflect the PK assessment after multiple doses of PF-06463922 were administered.","timeFrame":"Pre-dose, 0.5, 1, 2, 4, 6, 8, 9 and 24 hours post-dose on Day -7 and pre-dose, 0.5, 1, 2, 4, 6, 8, 9 and 24 hours post-dose on Cycle 1 Day 15"},{"measure":"Area Under the Plasma Concentration-Time Profile From Time Zero Extrapolated to Infinite Time (AUCinf) of Midazolam (Phase 1)","description":"AUCinf was calculated as AUClast + (Clast\\*/kel), where AUClast was the area under the plasma concentration-time profile from time 0 to the time of the last quantifiable concentration, Clast\\* was the predicted plasma concentration at the last quantifiable time point estimated from the log-linear regression analysis, and kel was the rate constant for terminal phase. Only participants in 25 mg and 150 mg QD groups were given midazolam. Day -7 data reflect the PK assessment before administration of PF-06463922, and Cycle 1 Day 15 data reflect the PK assessment after multiple doses of PF-06463922 were administered.","timeFrame":"Pre-dose, 0.5, 1, 2, 4, 6, 8, 9 and 24 hours post-dose on Day -7 and pre-dose, 0.5, 1, 2, 4, 6, 8, 9 and 24 hours post-dose on Cycle 1 Day 15"},{"measure":"Apparent Oral Clearance (CL/F) of Midazolam (Phase 1)","description":"Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. CL/F was calculated as dose/AUCinf, where AUCinf was the area under the plasma concentration-time profile from time 0 extrapolated to infinite time. Only participants in 25 mg and 150 mg QD groups were given midazolam. Day -7 data reflect the PK assessment before administration of PF-06463922, and Cycle 1 Day 15 data reflect the PK assessment after multiple doses of PF-06463922 were administered.","timeFrame":"Pre-dose, 0.5, 1, 2, 4, 6, 8, 9 and 24 hours post-dose on Day -7 and pre-dose, 0.5, 1, 2, 4, 6, 8, 9 and 24 hours post-dose on Cycle 1 Day 15"},{"measure":"Apparent Volume of Distribution (Vz/F) of Midazolam (Phase 1)","description":"Vz/F was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug, and calculated as dose/(AUCinf\\*kel), where AUCinf was the area under the plasma concentration-time profile from time 0 extrapolated to infinite time, kel was the rate constant for terminal phase. Only participants in 25 mg and 150 mg QD groups were given midazolam. Day -7 data reflect the PK assessment before administration of PF-06463922, and Cycle 1 Day 15 data reflect the PK assessment after multiple doses of PF-06463922 were administered.","timeFrame":"Pre-dose, 0.5, 1, 2, 4, 6, 8, 9 and 24 hours post-dose on Day -7 and pre-dose, 0.5, 1, 2, 4, 6, 8, 9 and 24 hours post-dose on Cycle 1 Day 15"},{"measure":"Terminal Half-Life of Midazolam (Phase 1)","description":"Terminal plasma half-life was defined as the time measured for the plasma concentration to decrease by one half, and calculated as loge(2)/kel, where kel was the rate constant for terminal phase. Only participants in 25 mg and 150 mg QD groups were given midazolam. Day -7 data reflect the PK assessment before administration of PF-06463922, and Cycle 1 Day 15 data reflect the PK assessment after multiple doses of PF-06463922 were administered.","timeFrame":"Pre-dose, 0.5, 1, 2, 4, 6, 8, 9 and 24 hours post-dose on Day -7 and pre-dose, 0.5, 1, 2, 4, 6, 8, 9 and 24 hours post-dose on Cycle 1 Day 15"},{"measure":"Number of Participants With ALK Mutation Based on Plasma CNA Analysis (Phase 1)","description":"Plasma circulating nucleic acid (CNA) samples were analyzed for ALK kinase domain mutations by digital polymerase chain reaction (PCR) BEAMing technology. Number of participants with one or more ALK mutations is presented.","timeFrame":"Screening (up to 28 days)"},{"measure":"Number of Participants With ALK Mutation Based on Tumor Tissue Analysis (Phase 1)","description":"Tumor tissues from archived tissue specimens and/or a de novo biopsy were analyzed for ALK kinase domain mutations. Number of participants with one or more ALK mutations is presented.","timeFrame":"Screening (up to 28 days)"},{"measure":"Number of Participants Who Improved, Worsened or Remained Stable in EORTC QLQ-C30 (Phase 1)","description":"European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ)-C30 (version 3.0) consists of 30 questions assessing 5 functional domains (physical, role, emotional, cognitive and social), global quality of life (QoL), disease/treatment related symptoms (fatigue, nausea/vomiting, pain, dyspnea, insomnia, appetite loss, constipation and diarrhea), and the perceived financial impact of disease. Each scale was transformed to a range of 0 to 100 using standard EORTC algorithm. For global QoL and functional scales, higher score indicate better performance, and improvement was defined as an increase of at least 10 points, worsening was defined as a decrease of at least 10 points. For symptom scales, higher score indicates worse symptoms, and improvement was defined as a decrease of at least 10 points, worsening was defined as an increase of at least 10 points. All scales which had not improved nor worsened were considered stable.","timeFrame":"From start of study treatment until end of treatment (maximum of 8 years approximately)"},{"measure":"Number of Participants Who Improved, Worsened or Remained Stable in EORTC QLQ-LC13 (Phase 1)","description":"EORTC QLQ-LC13 is the lung cancer module of EORTC QLQ-C30 and includes questions specific to the disease associated symptoms (dyspnea, cough, hemoptysis, and site specific pain), treatment-related symptoms (sore mouth, dysphagia, neuropathy and alopecia), and analgesic use of lung cancer patients. The scale was transformed to a range of 0 to 100 using standard EORTC algorithm. Higher score indicates worse symptoms, and improvement was defined as a decrease of at least 10 points, worsening was defined as an increase of at least 10 points. All scales which had not improved nor worsened were considered stable.","timeFrame":"From start of study treatment until end of treatment (maximum of 8 years approximately)"},{"measure":"Change From Baseline in Mini Mental State Examination (MMSE) Score (Phase 1)","description":"In Phase 1, the MMSE was collected to assess mental status. The MMSE is a 30 item questionnaire that tests 5 areas of cognitive function: orientation, registration, attention and calculation, recall and language. The maximum score is 30 and minimum score is 0. Highest score indicates no cognitive impairment, lowest score indicates severe cognitive impairment. The MMSE was removed under Amendment 6 of the study protocol, and not required for Phase 2, as the tool was not considered meaningful for assessment of cognitive function.","timeFrame":"Baseline, Day 1 of Cycle 1-52, and end of treatment (up to 3 years)"},{"measure":"Time to Tumor Response (TTR) and Intracranial TTR (Phase 2 and DDI Sub-study)","description":"Time to tumor response (TTR) was defined as the time from the first dose of study treatment to the first documentation of objective tumor response (CR or PR). For participants whose objective response proceeded from PR to CR, the onset of PR was taken as the onset of response. TTR was only calculated for the subgroup of participants with a confirmed objective tumor response. Intracranial TTR was only calculated for participants with confirmed intracranial objective response. CR was defined as the disappearance of all non-lymph node target lesions (where all target lesions are recorded with a length of 0 mm on Target Lesions eCRF). Any pathological lymph nodes (recorded as target lesion) must have reduction in short axis to \\<10 mm. PR was defined as a 30 % or more decrease in SLD of target lesions, taking as reference the baseline SLD. Results presented here were based on independent central review.","timeFrame":"From first dose of study treatment to the first documentation of objective tumor response (CR or PR) (maximum of 7.5 years for Phase 2 and up to a maximum of 6 years approx. for DDI sub study)"},{"measure":"Duration of Response (DOR) and Intracranial DOR (Phase 2 and DDI Substudy)","description":"Duration of response(DOR): time from first documentation of objective tumor response (CR/PR) to first documentation of PD or to death due to any cause, whichever occurred first. DOR: calculated for subgroup of participants with confirmed objective tumor response. Intracranial DOR: calculated for participants with confirmed intracranial objective response. CR:disappearance of all non-lymph node target lesions (where all target lesions are recorded with length of 0mm on Target Lesion eCRF). Any pathological lymph node (recorded as target lesion) must have reduction in short axis to \\<10mm. PR:30% or more decrease in SLD of target lesion, taking as reference baseline SLD. PD:20% or more increase in the SLD of target lesions relative to baseline or smallest SLD (nadir) recorded since first dose. In addition, also demonstrate absolute increase of at least 5mm (\\>=5mm) relative to baseline or smallest SLD (nadir) recorded since first dose.","timeFrame":"From first dose of study treatment to first documentation of PD or to death due to any cause, whichever occurred first (maximum of 7.5 years for Phase 2 and up to a maximum of 6 years approx. for DDI sub study)"},{"measure":"Percentage of Participants Achieving Disease Control and Intracranial Disease Control at Week 12 and 24 (Phase 2 and DDI Substudy)","description":"Tumor response was evaluated according to RECIST version 1.1, and disease control was defined as confirmed CR, confirmed PR, or stable disease (SD). CR was defined as the disappearance of all non-lymph node target lesions (where all target lesions are recorded with a length of 0 mm on Target Lesions eCRF). Any pathological lymph nodes (recorded as target lesion) must have reduction in short axis to \\<10 mm. PR was defined as a 30 % or more decrease in SLD of target lesions, taking as reference the baseline SLD. SD= when neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD is observed, taking as reference the smallest sum diameters while on study. Intracranial assessment was only performed for participants CNS metastases. Results presented here were based on independent central review.","timeFrame":"Weeks 12 and 24"},{"measure":"Time to Progression on the Last Prior Therapy (Phase 2)","description":"TTP on the last prior therapy was defined as time from the first dose date of the last prior treatment regimen to the date of progression. Progressive disease was defined by a 20% or more increase in the SLD of target lesions relative to baseline or the smallest SLD (nadir) recorded since first dose. In addition to the relative increase of 20%, SLD must also demonstrate an absolute increase of at least 5 mm (\\>= 5 mm) relative to baseline or the smallest SLD (nadir) recorded since the first dose.","timeFrame":"From first dose of study treatment to the date of progression (maximum of 7.5 years for Phase 2)"},{"measure":"Time to Tumor Progression (TTP) and Intracranial TTP (Phase 2 and DDI Substudy)","description":"Time to progression (TTP) was defined as the time from the first dose of study treatment to the first documentation of objective PD. Intracranial TTP was defined as the time from the first dose of study treatment to the date of the first documentation of objective progression of intracranial disease, based on either new brain metastases or progression of existing brain metastases. Progressive disease was defined by a 20% or more increase in the SLD of target lesions relative to baseline or the smallest SLD (nadir) recorded since first dose. In addition to the relative increase of 20%, SLD must also demonstrate an absolute increase of at least 5 mm (\\>= 5 mm) relative to baseline or the smallest SLD (nadir) recorded since the first dose. Results presented here were based on independent central review.","timeFrame":"From first dose of study treatment to the first documentation of objective PD (maximum of 7.5 years for Phase 2 and up to a maximum of 6 years approx. for DDI sub study)"},{"measure":"Probability of First Event Being a Central Nervous System (CNS) Progression, Non CNS Progression, or Death (Phase 2)","description":"Probability of first event being CNS progression, non-CNS progression, or death was evaluated with competing risk approach by estimating cumulative incidence functions (range: 0-1) relative to analysis set. Time to first event being Competing Event (either \"CNS progression\" or \"non CNS progression\" or \"Death\") = time from first dose until date of that specific event. Participants not known to have any of Competing Events were censored on date they were last assessed for disease status for PFS. Participants who presented one type of event were counted as competing cause of failure for analysis of other type of events. For each type of event, cumulative incidence function corresponding to nearest time point preceding 1 year is presented. PD:20% or more increase in SLD of target lesion relative to baseline or smallest SLD (nadir) recorded since first dose. SLD must demonstrate absolute increase of atleast 5mm(\\>=5 mm) relative to baseline or smallest SLD (nadir) recorded since first dose.","timeFrame":"From first dose of study treatment until first event of CNS progression (maximum of 7.5 years for Phase 2)"},{"measure":"Progression-Free Survival (PFS) (Phase 2 and DDI Substudy)","description":"PFS was defined as the time from the first dose of study treatment to the first documentation of objective PD or to death on study due to any cause, whichever came first. Progressive disease was defined by a 20% or more increase in the SLD of target lesions relative to baseline or the smallest SLD (nadir) recorded since first dose. In addition to the relative increase of 20%, SLD must also demonstrate an absolute increase of at least 5 mm (\\>= 5 mm) relative to baseline or the smallest SLD (nadir) recorded since the first dose. Results presented here were based on independent central review.","timeFrame":"From first dose of study treatment to first documentation of objective PD or death due to any cause, whichever came first (maximum of 7.5 years for Phase 2 and up to a maximum of 6 years approx. for DDI sub study)"},{"measure":"Overall Survival (Phase 2 and DDI Substudy)","description":"OS was defined as the time from first dose to the date of death due to any cause. For participants still alive at the time of analysis, the OS time was censored on the last date the participants were known to be alive. Estimates of OS and its 95% confidence interval were determined using Kaplan-Meier method.","timeFrame":"From first dose of study treatment until date of death (maximum of 7.5 years for Phase 2 and up to a maximum of 6 years approx. for DDI sub study)"},{"measure":"Maximum Observed Plasma Concentration (Cmax) of PF-06463922 (Phase 2)","description":"Maximum observed plasma concentration (Cmax) of PF-06463922 was observed directly from data.","timeFrame":"Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9, 24, 48, 72, 96 and 120 hours post-dose on Day -7 and pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9 and 24 hours post-dose on Cycle 1 Day 15"},{"measure":"Time for Cmax (Tmax) of PF-06463922 (Phase 2)","description":"Tmax of PF-06463922 was observed directly from data as time of first occurrence.","timeFrame":"Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9, 24, 48, 72, 96 and 120 hours post-dose on Day -7 and pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9 and 24 hours post-dose on Cycle 1 Day 15"},{"measure":"Area Under the Plasma Concentration-Time Profile From Time Zero Extrapolated to Infinite Time (AUCinf) of PF-06463922 (Phase 2)","description":"AUCinf was calculated as AUClast + (Clast\\*/kel), where AUClast was the area under the plasma concentration-time profile from time 0 to the time of the last quantifiable concentration, Clast\\* was the predicted plasma concentration at the last quantifiable time point estimated from the log-linear regression analysis, and kel was the rate constant for terminal phase.","timeFrame":"Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9, 24, 48, 72, 96 and 120 hours post-dose on Day -7"},{"measure":"Area Under the Plasma Concentration-Time Profile From Time Zero to Time Tau (AUCtau) of PF-06463922 (Phase 2)","description":"Tau refers to the dosing interval, and it equals to 24 hours for QD dosing which was adopted in Phase 2. AUCtau was determined using linear/log trapezoidal method.","timeFrame":"Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9 and 24 hours post-dose on Day -7 and pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9 and 24 hours post-dose on Cycle 1 Day 15"},{"measure":"Apparent Oral Clearance (CL/F) of PF-06463922 (Phase 2)","description":"Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. CL/F was calculated as dose/AUCinf, where AUCinf was the area under the plasma concentration-time profile from time 0 extrapolated to infinite time.","timeFrame":"Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9, 24, 48, 72, 96 and 120 hours post-dose on Day -7 and pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9 and 24 hours post-dose on Cycle 1 Day 15"},{"measure":"Apparent Volume of Distribution (Vz/F) of PF-06463922 (Phase 2)","description":"Vz/F was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug, and calculated as dose/(AUCinf\\*kel), where AUCinf was the area under the plasma concentration-time profile from time 0 extrapolated to infinite time, kel was the rate constant for terminal phase.","timeFrame":"Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9, 24, 48, 72, 96 and 120 hours post-dose on Day -7"},{"measure":"Terminal Half-Life of PF-06463922 (Phase 2)","description":"Terminal plasma half-life was defined as the time measured for the plasma concentration to decrease by one half, and calculated as loge(2)/kel, where kel was the rate constant for terminal phase.","timeFrame":"Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9, 24, 48, 72, 96 and 120 hours post-dose on Day -7"},{"measure":"Observed Accumulation Ratio (Rac) of PF-06463922 Following Multiple Oral Doses (Phase 2)","description":"Rac was calculated as Day 15 AUCtau/Day -7 AUCtau, where AUCtau was the area under the plasma concentration-time profile from time 0 to time tau (24 hours for QD dosing regimen which was adopted in Phase 2).","timeFrame":"Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9 and 24 hours post-dose on Cycle 1 Day 15"},{"measure":"Steady State Accumulation Ratio (Rss) of PF-06463922 Following Multiple Oral Doses (Phase 2)","description":"Rss was calculated as Day 15 AUCtau/Day -7 AUCinf, where AUCtau was the area under the plasma concentration-time profile from time 0 to time tau (24 hours for QD dosing regimen which was adopted in Phase 2), and AUCinf was the area under the plasma concentration-time profile from time 0 extrapolated to infinite time.","timeFrame":"Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9 and 24 hours post-dose on Cycle 1 Day 15"},{"measure":"Number of Participants With ALK Mutation Based on Plasma CNA Analysis (Phase 2)","description":"Plasma CNA samples were analyzed for ALK kinase domain mutations by Next Generation Sequencing (NGS). Number of participants with one or more ALK mutations is presented.","timeFrame":"Screening (up to 28 days)"},{"measure":"Number of Participants With ALK Mutation Based on Tumor Tissue Analysis (Phase 2)","description":"Tumor tissues from archived tissue specimens and/or a de novo biopsy were analyzed for ALK kinase domain mutations. Number of participants with one or more ALK mutations is presented.","timeFrame":"Screening (up to 28 days)"},{"measure":"Number of Participants Who Improved, Worsened or Remained Stable in EORTC QLQ-C30 (Phase 2 and DDI Sub-study)","description":"European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ)-C30 (version 3.0) consists of 30 questions assessing 5 functional domains (physical, role, emotional, cognitive and social), global quality of life (QoL), disease/treatment related symptoms (fatigue, nausea/vomiting, pain, dyspnea, insomnia, appetite loss, constipation and diarrhea), and the perceived financial impact of disease. Each scale was transformed to a range of 0 to 100 using standard EORTC algorithm. For global QoL and functional scales, higher score indicate better performance, and improvement was defined as an increase of at least 10 points, worsening was defined as a decrease of at least 10 points. For symptom scales, higher score indicates worse symptoms, and improvement was defined as a decrease of at least 10 points, worsening was defined as an increase of at least 10 points. All scales which had not improved nor worsened were considered stable.","timeFrame":"From first dose of study treatment to end of treatment (maximum of 7.5 years for Phase 2 and up to a maximum of 6 years approx. for DDI sub study)"},{"measure":"Number of Participants Who Improved, Worsened or Remained Stable in EORTC QLQ-LC13 (Phase 2 and DDI Sub-study)","description":"EORTC QLQ-LC13 is the lung cancer module of EORTC QLQ-C30 and includes questions specific to the disease associated symptoms (dyspnea, cough, hemoptysis, and site specific pain), treatment-related symptoms (sore mouth, dysphagia, neuropathy and alopecia), and analgesic use of lung cancer patients. The scale was transformed to a range of 0 to 100 using standard EORTC algorithm. Higher score indicates worse symptoms, and improvement was defined as a decrease of at least 10 points, worsening was defined as an increase of at least 10 points. All scales which had not improved nor worsened were considered stable.","timeFrame":"From first dose of study treatment to end of treatment (maximum of 7.5 years for Phase 2 and up to a maximum of 6 years approx. for DDI sub study)"},{"measure":"Number of Participants With Treatment-Emergent Adverse Events (Phase 1, Phase 2 and DDI Sub-study)","description":"AE: any untoward medical occurrence in clinical investigation participant administered a product or medical device, regardless of causal relationship to study treatment. Treatment-emergent AEs (TEAEs): AEs which occurred for first time during effective duration of treatment or AEs that increased in severity during treatment. Serious AEs (SAEs): any untoward medical occurrence at any dose that resulted in death; was life-threatening (immediate risk of death); required inpatient hospitalization or caused prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity (substantial disruption of ability to conduction normal life function). AEs included SAEs and non-serious AEs. Severity was graded as per National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.Grade1: mild, Grade2: moderate, Grade3: severe, Grade4: Life threatening consequences; urgent intervention indicated, Grade 5: death related to AE.","timeFrame":"From first dose of study treatment to end of treatment (maximum of 8 years for Phase 1, maximum of 7.5 years for Phase 2 and up to a maximum of 6 years approx. for DDI sub study)"},{"measure":"Number of Participants With Laboratory Abnormalities (Phase 1, Phase 2 and DDI Sub-study) - Hematology","description":"Hematology evaluation included hemoglobin, platelets, white blood cell, absolute neutrophils, absolute lymphocytes, absolute monocytes, absolute eosinophils and absolute basophils. Hematology parameters with any abnormalities were reported in this outcome measure.","timeFrame":"From first dose of study treatment to end of treatment (maximum of 8 years for Phase 1, maximum of 7.5 years for Phase 2 and up to a maximum of 6 years approx. for DDI sub study)"},{"measure":"Number of Participants With Laboratory Abnormalities (Phase 1, Phase 2 and DDI Sub-study) - Chemistry","description":"Chemistry evaluation included alanine aminotransferase (ALT), alkaline phosphatase, aspartate aminotransferase (AST), blood bilirubin, creatine phosphokinase (CPK), creatinine, gamma-glutamyl transferase (GGT), calcium, sodium, potassium, magnesium, albumin, glucose (non-fasted), albumin, phosphorus or phosphate, serum amylase and lipase.","timeFrame":"From first dose of study treatment to end of treatment (maximum of 8 years for Phase 1, maximum of 7.5 years for Phase 2 and up to a maximum of 6 years approx. for DDI sub study)"},{"measure":"Number of Participants With Laboratory Abnormalities (Phase 1, Phase 2 and DDI Sub-study) - Coagulation, Lipids and Urinalysis","description":"Coagulation evaluation included activated partial thromboplastin time, international normalized ratio (INR), and prothrombin time. Lipid evaluation included Cholesterol and triglycerides.","timeFrame":"From first dose of study treatment to end of treatment (maximum of 8 years for Phase 1, maximum of 7.5 years for Phase 2 and up to a maximum of 6 years approx. for DDI sub study)"},{"measure":"Number of Participants With Vital Signs Data Meeting Pre-defined Criteria (Phase 1, Phase 2 and DDI Sub-study)","description":"Blood pressure (BP), including systolic BP (SBP) and diastolic BP (DBP), and pulse rate were recorded in sitting position. Body weight was also measured.","timeFrame":"From first dose of study treatment to end of treatment (maximum of 8 years for Phase 1, maximum of 7.5 years for Phase 2 and up to a maximum of 6 years approx. for DDI sub study)"},{"measure":"Number of Participants With Maximum Decrease From Baseline Greater Than or Equal to 20 Percent in Left Ventricular Ejection Fraction (LVEF) (Phase 1, Phase 2 and DDI Sub-study)","description":"Left Ventricular Ejection Fraction (LVEF) was determined by echocardiogram. Baseline was defined as the measurement prior to the first dose of study treatment.","timeFrame":"From first dose of study treatment to end of treatment (maximum of 8 years for Phase 1, maximum of 7.5 years for Phase 2 and up to a maximum of 6 years approx. for DDI sub study)"},{"measure":"Number of Participants With Absolute Values and Change From Baseline in QTcF Meeting Pre-defined Criteria (Phase 1, Phase 2 and DDI Sub-study)","description":"Triplicate 12-lead electrocardiograms (ECGs) were performed approximately 2 minutes apart to determine mean QTc interval (QT interval corrected for heart rate). QT interval was corrected for heart rate using Fridericia's formula to provide QTcF. Absolute values and changes from baseline were summarized according to pre-defined criteria. Baseline was defined as the last evaluation on or prior to the first dose of study treatment.","timeFrame":"From first dose of study treatment to end of treatment (maximum of 8 years for Phase 1, maximum of 7.5 years for Phase 2 and up to a maximum of 6 years approx. for DDI sub study)"},{"measure":"Number of Participants With Suicidal Ideation and Suicidal Behavior (Phase 2)","description":"The Columbia Suicide Severity Rating Scale (C-SSRS) was used to analyze participants' suicidal ideation and behavior, and it is a unique, simple and short method of assessing both behavior and ideation that tracks all suicidal events and provides a summary of suicidality. It assesses the lethality of attempts and other features of ideation (frequency, duration, controllability, reasons for ideation and deterrents), all of which are significantly predictive of completed suicide. Maximum score of 4 or 5 indicates maximum suicidal ideation and minimum score of \"0\" indicates no suicidal ideation.","timeFrame":"From first dose of study treatment to end of treatment (maximum of 7.5 years for Phase 2)"},{"measure":"Change From Baseline in Total Scores for Beck Depression Inventory (BDI)-II (Mood Assessment) (Phase 2)","description":"The Beck Depression Inventory (BDI)-II is a 21-item self-report scale, with each item rated by participants on a 4-point scale (ranging from 0-3, where 0 indicated lowest depression and 3 indicated severe depression). The scale includes items capturing mood, (loss of pleasure, sadness, and irritability), suicidal ideation, and cognitive signs (punitive thoughts, self-criticism, self-dislike, pessimism, and poor concentration) as well as somatic signs (appetite, sleep, fatigue and libido). Scores were obtained by adding up the total points from the series of answers. Higher total scores indicate more severe depressive symptoms. The standardized cutoffs are as follows: 0-13: minimal depression; 14-19: mild depression; 20-28: moderate depression; 29-63: severe depression.","timeFrame":"Baseline, Day 1 of Cycles 2-5, Day 1 of every other cycle from Cycle 6, and end of treatment (up to 3 years)"},{"measure":"Change From Baseline in Total Scores for Detection Test (Cognitive Function Assessment) (Phase 2)","description":"The Detection Test is a measure of psychomotor function and uses a well validated simple reaction time paradigm with playing card stimuli. In this test, the on-screen instructions ask: \"Has the card turned over?\". A playing card is presented face down in the center of the screen. The card flips over so it is face up. As soon as the card flips over the participant must press \"Yes\". The participant is encouraged to work as quickly as they can and be as accurate as possible. The speed and accuracy of each response are recorded and mean of the log10 transformed reaction times for correct responses is calculated. Lower values of least square mean change from baseline indicate performance decline. Upper limit of 95% confidence interval of -0.00 or lower indicate statistically significant decline of performance over baseline at that cycle.","timeFrame":"Baseline, Day 1 of Cycles 2-5, Day 1 of every other cycle from Cycle 6, and end of treatment (up to 3 years)"},{"measure":"Change From Baseline in Total Scores for Identification Test (Cognitive Function Assessment) (Phase 2)","description":"The Identification Test is a measure of visual attention and uses a well validated choice reaction time paradigm with playing card stimuli. In this task, the playing cards are all red or black jokers. The on-screen instructions ask: \"Is the card red?\". A playing card is presented face down in the center of the screen. The card flips over so it is face up. As soon as it flips over the participant must decide whether the card is red or not. If it is red the participant should press \"Yes\", and if it is not red the participant should press \"No\". The participant is encouraged to work as quickly and accurately as possible. The speed and accuracy of each response are recorded and mean of the log10 transformed reaction times for correct responses is calculated. Lower values of least square mean change from baseline indicate performance decline. Upper limit of 95% confidence interval of -0.00 or lower indicate statistically significant decline of performance over baseline at that cycle.","timeFrame":"Baseline, Day 1 of Cycles 2-5, Day 1 of every other cycle from Cycle 6, and end of treatment (up to 3 years)"},{"measure":"Change From Baseline in Total Scores for One Back Test (Cognitive Function Assessment) (Phase 2)","description":"The One Back Test is a measure of working memory and uses a well validated n back paradigm with playing cards. In this task, the on-screen instructions ask: \"Is the previous card the same?\". A playing card is presented in the center of the screen. The participant must decide whether the card is the same as the previous card. If it is the same the participant should press \"Yes\", and if not press \"No\". The participant is encouraged to work as quickly and accurately as possible. The speed and accuracy of each response are recorded, mean of the log10 transformed reaction times for correct responses is used to demonstrate speed of performance, and the arcsine transformation of the square root of the proportion of correct responses is used to demonstrate accuracy. Lower values of least square mean change from baseline indicate performance decline. Upper limit of 95% confidence interval of -0.00 or lower indicate statistically significant decline of performance over baseline at that cycle.","timeFrame":"Baseline, Day 1 of Cycles 2-5, Day 1 of every other cycle from Cycle 6, and end of treatment (up to 3 years)"},{"measure":"Change From Baseline in Total Scores for International Shopping List Test (Cognitive Function Assessment) (Phase 2)","description":"The International Shopping List task is a measure of verbal learning and uses a well validated list learning paradigm administered using a computer. High frequencies, high imagery, concrete nouns (items from a shopping list) were read to the participant at the rate of one word every 2 seconds. Once all 12 words had been read, the participant was asked to recall as many of the words as quickly as possible. The words recalled by the participant were marked on the computer screen. When the participant could recall no more words, the same list was read again. The words recalled by the participant were recorded. This was then repeated a third time. Total number of correct responses on 3 consecutive trials at a single assessment was recorded. Lower values of least square mean change from baseline indicate performance decline. Upper limit of 95% confidence interval of -0.00 or lower indicate statistically significant decline of performance over baseline at that cycle.","timeFrame":"Baseline, Day 1 of Cycles 2-5, Day 1 of every other cycle from Cycle 6, and end of treatment (up to 3 years)"},{"measure":"Change From Baseline in Total Scores for International Shopping List Test-Delayed Recall (Cognitive Function Assessment) (Phase 2)","description":"This test was performed in the same way as the International Shopping List Test, with the exception that, the delayed recall condition required the participant to recall the words from the list 15 30 minutes later without having the list read again. During the recognition condition, the qualified personnel read a shopping list item that may or may not have been on the original list and the participant had to respond either affirmatively (if the item was on the original list) or negatively (if it was not). Total number of correct responses made in remembering the word list after a delay was recorded. Lower values of least square mean change from baseline indicate performance decline. Upper limit of 95% confidence interval of -0.00 or lower indicate statistically significant decline of performance over baseline at that cycle.","timeFrame":"Baseline, Day 1 of Cycles 2-5, Day 1 of every other cycle from Cycle 6, and end of treatment (up to 3 years)"},{"measure":"Number of Participants With Absolute Values and Change From Baseline in PR Interval Meeting Pre-defined Criteria (Phase 2 and DDI Substudy)","description":"PR Interval was determined by ECG measurement. PR interval had following categories: change from baseline\\>=25 percent, 40 to \\<60 milliseconds (msec), 60 to \\<80 msec and \\>=80 msec. Baseline was defined as the average of the triplicate measurements prior to the first dose of study drug.","timeFrame":"From first dose of study treatment to end of treatment maximum of 7.5 years for Phase 2 and up to a maximum of 6 years approx. for DDI sub study)"}],"otherOutcomes":[{"measure":"Percentage of Participants With Overall and Intracranial Objective Response (Phase 2 and DDI Sub-study)","description":"Objective response (OR) refers to confirmed complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumor (RECIST) version 1.1. Intracranial OR refers to confirmed CR or PR considering only lesions within brain. CR was defined as the disappearance of all non-lymph node target lesions (where all target lesions are recorded with a length of 0 milliliter (mm) on Target Lesions eCRF). Any pathological lymph nodes (recorded as target lesion) must have reduction in short axis to \\<10 mm. PR was defined as a 30 percent (%) or more decrease in sum of lesion dimensions (SLD) of target lesions, taking as reference the baseline SLD. Results presented here were based on independent central review.","timeFrame":"From first dose of study treatment to end of treatment maximum of 7.5 years for Phase 2 and up to a maximum of 6 years approx. for DDI sub study)"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria\n\n* Evidence of histologically or cytologically confirmed diagnosis of metastatic NSCLC (Stage IV, AJCC v7.0) that carries an ALK rearrangement, as determined by the Food and Drug Administration (FDA) approved FISH assay (Abbott Molecular Inc) or by Immunohistochemistry (IHC) (Ventana Inc), or a ROS1 rearrangement as determined by FISH or RT PCR or Next Generation Sequencing (NGS) via a local diagnostic test (LDT). All patients (ALK positive and ROS1 positive) must have archival tissue sample available and collected prior to enrollment.\n* Disease Status Requirements:\n\nPhase 1: ALK-positive NSCLC and ROS1-positive patients must either be treatment naÃ¯ve in the advanced setting or have had disease progression after at least 1 previous ALK/ROS1 inhibitor therapy(ies).\n\nPhase 2:\n\nALK-positive NSCLC patients must either be or have had:\n\n* Treatment naÃ¯ve (ie, no prior chemotherapy in the metastatic disease setting and no prior ALK inhibitor therapy allowed).\n* Disease progression after crizotinib only. No prior chemotherapy is allowed in the metastatic disease setting.\n* Disease progression after crizotinib and 1 or 2 prior regimens of chemotherapy in the metastatic disease setting.\n* Disease progression after 1 prior ALK inhibitor therapy other than crizotinib. Patients may have had any number of prior chemotherapy regimens in any disease setting.\n* Disease progression after 2 prior ALK inhibitor therapies. Patients may have had any number of prior chemotherapy regimens in any disease setting.\n* Disease progression after 3 prior ALK inhibitor therapies. Patients may have had any number of prior chemotherapy regimens in any disease setting.\n\nROS1-positive NSCLC patients may be:\n\n* Treatment naÃ¯ve (ie, no prior chemotherapy in the metastatic disease setting and no prior ROS inhibitor therapy).\n* Any number of prior therapies (ie, chemotherapy and/or ROS inhibitor therapies).\n\n  * Tumor Requirements:\n\nAll Patients must have at least one measurable target extracranial lesion according to RECIST v1.1. In addition patients with asymptomatic CNS metastases (including patients asymptomatic by means of stable or decreasing doses of steroids within the last 2 weeks prior to study entry) will be eligible. Patients who have leptomeningeal disease (LM) or carcinomatous meningitis (CM) are eligible.\n\n* Adequate Bone Marrow, Pancreatic Function, Renal Function and Liver Function.\n* Negative Serum pregnancy test for females of childbearing potential Exclusion Criteria\n* Radiation therapy (except palliative to relieve bone pain) within 2 weeks of study entry. Whole brain radiation must have completed at least 4 weeks prior to study entry.\n* Systemic anti cancer therapy completed within a minimum of 5 half lives of study entry.\n* Prior therapy with an antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways, including, but not limited to, anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-cytotoxic T lymphocyte associated antigen 4 (anti-CTLA-4) antibody.\n* Active and clinically significant bacterial, fungal, or viral infection including hepatitis B (HBV), hepatitis C (HCV), known human immunodeficiency virus (HIV), or acquired immunodeficiency syndrome (AIDS) related illness.\n* Clinically significant cardiovascular disease (that is, active or \\<3 months prior to enrollment): cerebral vascular accident/stroke, myocardial infarction, unstable angina, congestive heart failure (New York Heart Association Classification Class â¥ II), second-degree or third-degree AV block (unless paced) or any AV block with PR \\>220 msec. Ongoing cardiac dysrhythmias of NCI CTCAE Grade â¥2, uncontrolled atrial fibrillation of any grade, bradycardia defined as \\<50 bpm (unless patient is otherwise healthy such as long-distance runners, etc.), machine-read ECG with QTc \\>470 msec, or congenital long QT syndrome.\n* History of extensive, disseminated, bilateral or presence of Grade 3 or 4 interstitial fibrosis or interstitial lung disease including a history of pneumonitis, hypersensitivity pneumonitis, interstitial pneumonia, interstitial lung disease, obliterative bronchiolitis and pulmonary fibrosis.\n* Current use or anticipated need for food or drugs that are known strong or moderate CYP3A4 inhibitors, inducers and substrates; drugs that are CYP2C9 substrates; drugs that are sensitive CYP2B6 substrates; drugs that are strong CYP2C19 inhibitors; drugs that are strong CYP2C8 inhibitors; and drugs that are P-gp substrates.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Pfizer CT.gov Call Center","affiliation":"Pfizer","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Highlands Oncology Group/Research","city":"Fayetteville","state":"Arkansas","zip":"72703","country":"United States","geoPoint":{"lat":36.06258,"lon":-94.15743}},{"facility":"Highlands Oncology Group","city":"Rogers","state":"Arkansas","zip":"72758","country":"United States","geoPoint":{"lat":36.33202,"lon":-94.11854}},{"facility":"Chao Family Comprehensive Cancer Center","city":"Orange","state":"California","zip":"92868-3201","country":"United States","geoPoint":{"lat":33.78779,"lon":-117.85311}},{"facility":"UC Irvine Medical Center","city":"Orange","state":"California","zip":"92868-3201","country":"United States","geoPoint":{"lat":33.78779,"lon":-117.85311}},{"facility":"University of Colorado Cancer Center","city":"Aurora","state":"Colorado","zip":"80045","country":"United States","geoPoint":{"lat":39.72943,"lon":-104.83192}},{"facility":"University of Colorado Hospital - Anschutz Inpatient Pavilion (AIP)","city":"Aurora","state":"Colorado","zip":"80045","country":"United States","geoPoint":{"lat":39.72943,"lon":-104.83192}},{"facility":"University of Colorado Hospital - Anschutz Outpatient Pavilion (AOP)","city":"Aurora","state":"Colorado","zip":"80045","country":"United States","geoPoint":{"lat":39.72943,"lon":-104.83192}},{"facility":"University of Colorado Hospital - Anschutz Outpatient Pavillion (AOP)","city":"Aurora","state":"Colorado","zip":"80045","country":"United States","geoPoint":{"lat":39.72943,"lon":-104.83192}},{"facility":"University of Colorado Hospital","city":"Aurora","state":"Colorado","zip":"80045","country":"United States","geoPoint":{"lat":39.72943,"lon":-104.83192}},{"facility":"MDZ: Yale-New Haven Hospital","city":"New Haven","state":"Connecticut","zip":"06504","country":"United States","geoPoint":{"lat":41.30815,"lon":-72.92816}},{"facility":"Smilow Cancer Hospital at Yale-New Haven","city":"New Haven","state":"Connecticut","zip":"06510","country":"United States","geoPoint":{"lat":41.30815,"lon":-72.92816}},{"facility":"Georgetown University Medical Center","city":"Washington D.C.","state":"District of Columbia","zip":"20007","country":"United States","geoPoint":{"lat":38.89511,"lon":-77.03637}},{"facility":"Massachusetts General Hospital","city":"Boston","state":"Massachusetts","zip":"02114","country":"United States","geoPoint":{"lat":42.35843,"lon":-71.05977}},{"facility":"Brigham and Women's Hospital","city":"Boston","state":"Massachusetts","zip":"02115","country":"United States","geoPoint":{"lat":42.35843,"lon":-71.05977}},{"facility":"Dana Farber Cancer Institute","city":"Boston","state":"Massachusetts","zip":"02215","country":"United States","geoPoint":{"lat":42.35843,"lon":-71.05977}},{"facility":"Karmanos Cancer Institute","city":"Detroit","state":"Michigan","zip":"48201","country":"United States","geoPoint":{"lat":42.33143,"lon":-83.04575}},{"facility":"Karmanos Center Institute","city":"Detroit","state":"Michigan","zip":"48201","country":"United States","geoPoint":{"lat":42.33143,"lon":-83.04575}},{"facility":"Karmanos Cancer Institute","city":"Farmington Hills","state":"Michigan","zip":"48334","country":"United States","geoPoint":{"lat":42.48531,"lon":-83.37716}},{"facility":"Siteman Cancer Center-West County","city":"Creve Coeur","state":"Missouri","zip":"63141","country":"United States","geoPoint":{"lat":38.66089,"lon":-90.42262}},{"facility":"Barnes-Jewish Hospital","city":"St Louis","state":"Missouri","zip":"63110","country":"United States","geoPoint":{"lat":38.62727,"lon":-90.19789}},{"facility":"Washington University School of Medicine","city":"St Louis","state":"Missouri","zip":"63110","country":"United States","geoPoint":{"lat":38.62727,"lon":-90.19789}},{"facility":"Siteman Cancer Center-South County","city":"St Louis","state":"Missouri","zip":"63129","country":"United States","geoPoint":{"lat":38.62727,"lon":-90.19789}},{"facility":"Rockefeller Patient Pavilion - Memorial Sloan Kettering","city":"New York","state":"New York","zip":"10022","country":"United States","geoPoint":{"lat":40.71427,"lon":-74.00597}},{"facility":"Memorial Sloan Kettering Cancer Center","city":"New York","state":"New York","zip":"10065","country":"United States","geoPoint":{"lat":40.71427,"lon":-74.00597}},{"facility":"Rochester Regional Health System","city":"Rochester","state":"New York","zip":"14621","country":"United States","geoPoint":{"lat":43.15478,"lon":-77.61556}},{"facility":"SUNY Upstate Medical University","city":"Syracuse","state":"New York","zip":"13210","country":"United States","geoPoint":{"lat":43.04812,"lon":-76.14742}},{"facility":"The Ohio State University","city":"Columbus","state":"Ohio","zip":"43205","country":"United States","geoPoint":{"lat":39.96118,"lon":-82.99879}},{"facility":"The Ohio State University","city":"Columbus","state":"Ohio","zip":"43210","country":"United States","geoPoint":{"lat":39.96118,"lon":-82.99879}},{"facility":"The Ohio State University","city":"Columbus","state":"Ohio","zip":"43221","country":"United States","geoPoint":{"lat":39.96118,"lon":-82.99879}},{"facility":"Fox Chase Cancer Center","city":"Philadelphia","state":"Pennsylvania","zip":"19111","country":"United States","geoPoint":{"lat":39.95238,"lon":-75.16362}},{"facility":"Sarah Cannon Research Institute (Pharmacy)","city":"Nashville","state":"Tennessee","zip":"37203","country":"United States","geoPoint":{"lat":36.16589,"lon":-86.78444}},{"facility":"Tennessee Oncology PLLC","city":"Nashville","state":"Tennessee","zip":"37203","country":"United States","geoPoint":{"lat":36.16589,"lon":-86.78444}},{"facility":"Chris O'Brien Lifehouse","city":"Sydney","state":"New South Wales","zip":"2050","country":"Australia","geoPoint":{"lat":-33.86785,"lon":151.20732}},{"facility":"Royal Prince Alfred Hospital","city":"Sydney","state":"New South Wales","zip":"2050","country":"Australia","geoPoint":{"lat":-33.86785,"lon":151.20732}},{"facility":"Chris O'Brien Lifehouse","city":"Sydney Local Health District [rpa]","state":"New South Wales","zip":"2050","country":"Australia"},{"facility":"Peter MacCallum Cancer Centre","city":"Melbourne","state":"Victoria","zip":"3000","country":"Australia","geoPoint":{"lat":-37.814,"lon":144.96332}},{"facility":"Royal Melbourne Hospital","city":"Parkville","state":"Victoria","zip":"3050","country":"Australia","geoPoint":{"lat":-37.78333,"lon":144.95}},{"facility":"University Hospital Antwerp","city":"Edegem","zip":"2650","country":"Belgium","geoPoint":{"lat":51.15662,"lon":4.44504}},{"facility":"British Columbia Cancer Agency-Vancouver Centre","city":"Vancouver","state":"British Columbia","zip":"V5Z 4E6","country":"Canada","geoPoint":{"lat":49.24966,"lon":-123.11934}},{"facility":"The Ottawa Hospital Cancer Centre","city":"Ottawa","state":"Ontario","zip":"K1H 8L6","country":"Canada","geoPoint":{"lat":45.41117,"lon":-75.69812}},{"facility":"Princess Margaret Cancer Centre","city":"Toronto","state":"Ontario","zip":"M5G 2M9","country":"Canada","geoPoint":{"lat":43.70643,"lon":-79.39864}},{"facility":"CHU Grenoble/ HÃ´pital Albert Michallon","city":"Grenoble","zip":"38043","country":"France","geoPoint":{"lat":45.17869,"lon":5.71479}},{"facility":"CHU de Rennes - HÃ´pital Pontchaillou - CIC Inserm","city":"Rennes","zip":"35033","country":"France","geoPoint":{"lat":48.11109,"lon":-1.67431}},{"facility":"CHU de Rennes - HÃ´pital Pontchaillou","city":"Rennes","zip":"35033","country":"France","geoPoint":{"lat":48.11109,"lon":-1.67431}},{"facility":"Institut Universitaire du Cancer de Toulouse (IUCT-O)","city":"Toulouse","zip":"31059","country":"France","geoPoint":{"lat":43.60426,"lon":1.44367}},{"facility":"Institut Gustave Roussy (comite poumon-pneumologie)","city":"Villejuif","zip":"94805","country":"France","geoPoint":{"lat":48.7939,"lon":2.35992}},{"facility":"Institut Gustave Roussy- Pharmacie-Unite Essais Cliniques","city":"Villejuif","zip":"94805","country":"France","geoPoint":{"lat":48.7939,"lon":2.35992}},{"facility":"Universitaetsklinik Koeln","city":"Cologne","zip":"50937","country":"Germany","geoPoint":{"lat":50.93333,"lon":6.95}},{"facility":"Department of Clinical Oncology, Prince of Wales Hospital","city":"Shatin","country":"Hong Kong","geoPoint":{"lat":22.38333,"lon":114.18333}},{"facility":"Struttura Operativa Complessa Oncologia","city":"Aviano (PN)","zip":"33081","country":"Italy","geoPoint":{"lat":46.07056,"lon":12.59472}},{"facility":"Dipartimento di Oncologia Medica, UO Medicina 1Q A, Unita' Nuovi Farmaci e Terapie Innovative","city":"Milan","zip":"20132","country":"Italy","geoPoint":{"lat":42.78235,"lon":12.59836}},{"facility":"Unita di Farmacologia Clinica e Nuovi Farmaci","city":"Milan","zip":"20141","country":"Italy","geoPoint":{"lat":42.78235,"lon":12.59836}},{"facility":"Oncologia Medica","city":"Perugia","zip":"06132","country":"Italy","geoPoint":{"lat":43.1122,"lon":12.38878}},{"facility":"Aichi Cancer Center Hospital","city":"Nagoya","state":"Aichi-ken","zip":"464-8681","country":"Japan","geoPoint":{"lat":35.18147,"lon":136.90641}},{"facility":"Nagoya University Hospital","city":"Nagoya","state":"Aichi-ken","zip":"466-8560","country":"Japan","geoPoint":{"lat":35.18147,"lon":136.90641}},{"facility":"National Cancer Center Hospital East","city":"Kashiwa","state":"Chiba","zip":"277-8577","country":"Japan","geoPoint":{"lat":35.86224,"lon":139.97732}},{"facility":"National Hospital Organization Shikoku Cancer Center","city":"Matsuyama","state":"Ehime","zip":"791-0280","country":"Japan","geoPoint":{"lat":33.83916,"lon":132.76574}},{"facility":"Hokkaido University Hospital","city":"Sapporo","state":"Hokkaido","zip":"060-8648","country":"Japan","geoPoint":{"lat":43.06667,"lon":141.35}},{"facility":"Hyogo Cancer Center","city":"Akashi","state":"HyÅgo","zip":"673-8558","country":"Japan","geoPoint":{"lat":34.65524,"lon":135.00687}},{"facility":"Kindai University Hospital","city":"Sayama","state":"Osaka","zip":"589-8511","country":"Japan","geoPoint":{"lat":34.51685,"lon":135.56298}},{"facility":"Shizuoka Cancer Center","city":"Sunto-gun","state":"Shizuoka","zip":"411-8777","country":"Japan"},{"facility":"National Cancer Center Hospital","city":"Chuo-ku","state":"Tokyo","zip":"104-0045","country":"Japan"},{"facility":"National Hospital Organization Kyushu Cancer Center","city":"Fukuoka","zip":"811-1395","country":"Japan","geoPoint":{"lat":33.6,"lon":130.41667}},{"facility":"The Cancer Institute Hospital of JFCR","city":"Koto-ku, Tokyo","zip":"135-8550","country":"Japan"},{"facility":"National University Hospital","city":"Singapore","zip":"119074","country":"Singapore","geoPoint":{"lat":1.28967,"lon":103.85007}},{"facility":"National University Hospital Medical Centre","city":"Singapore","zip":"119082","country":"Singapore","geoPoint":{"lat":1.28967,"lon":103.85007}},{"facility":"National Cancer Center","city":"Singapore","zip":"168583","country":"Singapore","geoPoint":{"lat":1.28967,"lon":103.85007}},{"facility":"National Cancer Center","city":"Singapore","zip":"169610","country":"Singapore","geoPoint":{"lat":1.28967,"lon":103.85007}},{"facility":"Seoul National University Hospital / Department of Internal Medicine","city":"Seoul","zip":"03080","country":"South Korea","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Hospital Universitario Quiron Madrid","city":"Pozuelo de AlarcÃ³n","state":"Madrid","zip":"28223","country":"Spain","geoPoint":{"lat":40.43293,"lon":-3.81338}},{"facility":"Clinica Universidad De Navarra","city":"Pamplona","state":"Navarre","zip":"31008","country":"Spain","geoPoint":{"lat":42.81687,"lon":-1.64323}},{"facility":"Hospital Universitario Quiron Dexeus","city":"Barcelona","zip":"08028","country":"Spain","geoPoint":{"lat":41.38879,"lon":2.15899}},{"facility":"Hospital Universitari de la Vall D'Hebron Edificio General. Planta Baja. UITM. Servicio de Oncologia","city":"Barcelona","zip":"08035","country":"Spain","geoPoint":{"lat":41.38879,"lon":2.15899}},{"facility":"Hospital of Lausanne (CHUV)","city":"Lausanne","zip":"1011","country":"Switzerland","geoPoint":{"lat":46.516,"lon":6.63282}},{"facility":"Kantonsspital Winterthur","city":"Winterthur","zip":"8401","country":"Switzerland","geoPoint":{"lat":47.50564,"lon":8.72413}},{"facility":"National Taiwan University Hospital","city":"Taipei","zip":"10002","country":"Taiwan","geoPoint":{"lat":25.05306,"lon":121.52639}},{"facility":"National Taiwan University Hospital","city":"Taipei","zip":"100","country":"Taiwan","geoPoint":{"lat":25.05306,"lon":121.52639}}]},"referencesModule":{"references":[{"pmid":"39581380","type":"DERIVED","citation":"Ou SI, Solomon BJ, Besse B, Bearz A, Lin CC, Chiari R, Camidge DR, Lin JJ, Abbattista A, Toffalorio F, Soo RA. Final Overall Survival and Long-Term Safety of Lorlatinib in Patients With ALK-Positive NSCLC From the Pivotal Phase 2 Study: A Brief Report. J Thorac Oncol. 2025 Apr;20(4):513-520. doi: 10.1016/j.jtho.2024.11.021. Epub 2024 Nov 22."},{"pmid":"38079095","type":"DERIVED","citation":"Chen J, Bearz A, Kim DW, Mamdani H, Bauman J, Chiari R, Ou SI, Solomon BJ, Soo RA, Felip E, Shaw AT, Thurm H, Clancy JS, Lee K, O'Gorman M, Tanski C, Pithavala YK. Evaluation of the Effect of Lorlatinib on CYP2B6, CYP2C9, UGT, and P-Glycoprotein Substrates in Patients with Advanced Non-Small Cell Lung Cancer. Clin Pharmacokinet. 2024 Feb;63(2):171-182. doi: 10.1007/s40262-023-01309-4. Epub 2023 Dec 11."},{"pmid":"36184067","type":"DERIVED","citation":"Dagogo-Jack I, Abbattista A, Murphy JF, Krulewicz S, Do A, Peterson J, Lin JJ, Gainor JF, Messina R, Krueger EA, Thurm H, Yeap BY. Factors Associated With Developing Neurocognitive Adverse Events in Patients Receiving Lorlatinib After Progression on Other Targeted Therapies. J Thorac Oncol. 2023 Jan;18(1):67-78. doi: 10.1016/j.jtho.2022.09.219. Epub 2022 Sep 29."},{"pmid":"35660971","type":"DERIVED","citation":"Soo RA, Huat Tan E, Hayashi H, Seto T, Lin CC, Ou SI, Kim DW, Liu G, Abbattista A, Martini JF, Hooi Wong C, Toffalorio F, Solomon BJ. Efficacy and safety of lorlatinib in Asian and non-Asian patients with ALK-positive advanced non-small cell lung cancer: Subgroup analysis of a global phase 2 trial. Lung Cancer. 2022 Jul;169:67-76. doi: 10.1016/j.lungcan.2022.05.012. Epub 2022 May 23."},{"pmid":"35026476","type":"DERIVED","citation":"Ou SI, Solomon BJ, Shaw AT, Gadgeel SM, Besse B, Soo RA, Abbattista A, Toffalorio F, Wiltshire R, Bearz A. Continuation of Lorlatinib in ALK-Positive NSCLC Beyond Progressive Disease. J Thorac Oncol. 2022 Apr;17(4):568-577. doi: 10.1016/j.jtho.2021.12.011. Epub 2022 Jan 10."},{"pmid":"33973232","type":"DERIVED","citation":"Chen J, Ruiz-Garcia A, James LP, Peltz G, Thurm H, Clancy J, Hibma J. Lorlatinib Exposure-Response Analyses for Safety and Efficacy in a Phase I/II Trial to Support Benefit-Risk Assessment in Non-Small Cell Lung Cancer. Clin Pharmacol Ther. 2021 Nov;110(5):1273-1281. doi: 10.1002/cpt.2228. Epub 2021 Jun 26."},{"pmid":"33937954","type":"DERIVED","citation":"Chen J, O'Gorman MT, James LP, Klamerus KJ, Mugundu G, Pithavala YK. Pharmacokinetics of Lorlatinib After Single and Multiple Dosing in Patients with Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer: Results from a Global Phase I/II Study. Clin Pharmacokinet. 2021 Oct;60(10):1313-1324. doi: 10.1007/s40262-021-01015-z. Epub 2021 May 3."},{"pmid":"32344248","type":"DERIVED","citation":"Peters S, Shaw AT, Besse B, Felip E, Solomon BJ, Soo RA, Bearz A, Gadgeel SM, Lin CC, Kao S, Seto T, Masters ET, Abbattista A, Clancy JS, Thurm H, Reisman A, Peltz G, Ross Camidge D. Impact of lorlatinib on patient-reported outcomes in patients with advanced ALK-positive or ROS1-positive non-small cell lung cancer. Lung Cancer. 2020 Jun;144:10-19. doi: 10.1016/j.lungcan.2020.02.011. Epub 2020 Mar 10."},{"pmid":"32060867","type":"DERIVED","citation":"Bauer TM, Shaw AT, Johnson ML, Navarro A, Gainor JF, Thurm H, Pithavala YK, Abbattista A, Peltz G, Felip E. Brain Penetration of Lorlatinib: Cumulative Incidences of CNS and Non-CNS Progression with Lorlatinib in Patients with Previously Treated ALK-Positive Non-Small-Cell Lung Cancer. Target Oncol. 2020 Feb;15(1):55-65. doi: 10.1007/s11523-020-00702-4."},{"pmid":"31669155","type":"DERIVED","citation":"Shaw AT, Solomon BJ, Chiari R, Riely GJ, Besse B, Soo RA, Kao S, Lin CC, Bauer TM, Clancy JS, Thurm H, Martini JF, Peltz G, Abbattista A, Li S, Ou SI. Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1-2 trial. Lancet Oncol. 2019 Dec;20(12):1691-1701. doi: 10.1016/S1470-2045(19)30655-2. Epub 2019 Oct 25."},{"pmid":"30413378","type":"DERIVED","citation":"Solomon BJ, Besse B, Bauer TM, Felip E, Soo RA, Camidge DR, Chiari R, Bearz A, Lin CC, Gadgeel SM, Riely GJ, Tan EH, Seto T, James LP, Clancy JS, Abbattista A, Martini JF, Chen J, Peltz G, Thurm H, Ou SI, Shaw AT. Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study. Lancet Oncol. 2018 Dec;19(12):1654-1667. doi: 10.1016/S1470-2045(18)30649-1. Epub 2018 Nov 6."},{"pmid":"29074098","type":"DERIVED","citation":"Shaw AT, Felip E, Bauer TM, Besse B, Navarro A, Postel-Vinay S, Gainor JF, Johnson M, Dietrich J, James LP, Clancy JS, Chen J, Martini JF, Abbattista A, Solomon BJ. Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial. Lancet Oncol. 2017 Dec;18(12):1590-1599. doi: 10.1016/S1470-2045(17)30680-0. Epub 2017 Oct 23."},{"pmid":"26698910","type":"DERIVED","citation":"Shaw AT, Friboulet L, Leshchiner I, Gainor JF, Bergqvist S, Brooun A, Burke BJ, Deng YL, Liu W, Dardaei L, Frias RL, Schultz KR, Logan J, James LP, Smeal T, Timofeevski S, Katayama R, Iafrate AJ, Le L, McTigue M, Getz G, Johnson TW, Engelman JA. Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F. N Engl J Med. 2016 Jan 7;374(1):54-61. doi: 10.1056/NEJMoa1508887. Epub 2015 Dec 23."}],"seeAlsoLinks":[{"label":"To obtain contact information for a study center near you, click here.","url":"https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B7461001&StudyName=A%20Study%20Of%20PF-06463922%20An%20ALK/ROS1%20Inhibitor%20In%20Patients%20With%20Advanced%20Non%20Small%20Cell%20Lung%20Cancer%20With%20Specific%20Molecular%20Alterations"}]},"ipdSharingStatementModule":{"ipdSharing":"YES","description":"Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical\\_trials/trial\\_data\\_and\\_results/data\\_requests.","url":"https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests"}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"A total of 364 participants were enrolled in this study.","groups":[{"id":"FG000","title":"10 mg QD (Phase 1)","description":"PF-06463922 10 mg was orally given once daily (QD) on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"FG001","title":"25 mg QD (Phase 1)","description":"PF-06463922 25 mg was orally given QD in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal. Midazolam 2 mg was orally given QD on Day -7 and Cycle 1 Day 15."},{"id":"FG002","title":"50 mg QD (Phase 1)","description":"PF-06463922 50 mg was orally given QD on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"FG003","title":"75 mg QD (Phase 1)","description":"PF-06463922 75 mg was orally given QD on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"FG004","title":"100 mg QD (Phase 1)","description":"PF-06463922 100 mg was orally given QD on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"FG005","title":"150 mg QD (Phase 1)","description":"PF-06463922 150 mg was orally given QD in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal. Midazolam 2 mg was orally given QD on Day -7 and Cycle 1 Day 15."},{"id":"FG006","title":"200 mg QD (Phase 1)","description":"PF-06463922 200 mg was orally given QD on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"FG007","title":"35 mg BID (Phase 1)","description":"PF-06463922 35 mg was orally given twice daily (BID) on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"FG008","title":"75 mg BID (Phase 1)","description":"PF-06463922 75 mg was orally given BID on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"FG009","title":"100 mg BID (Phase 1)","description":"PF-06463922 100 mg was orally given BID on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"FG010","title":"EXP-1 (Phase 2)","description":"Treatment-naÃ¯ve participants with advanced anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC) with or without asymptomatic central nervous system (CNS) metastases were given PF-06463922 100 mg orally QD on Day -7 (only participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"FG011","title":"EXP-2 (Phase 2)","description":"Participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after only crizotinib therapy were given PF-06463922 100 mg orally QD on Day -7 (only for participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"FG012","title":"EXP-3 (Phase 2)","description":"Participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after crizotinib therapy and 1 or 2 prior regimens of chemotherapy given before or after crizotinib therapy, or participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after 1 ALK inhibitor therapy other than crizotinib with or without any number of prior chemotherapy regimens in any disease setting were given PF-06463922 100 mg orally QD on Day -7 (only for participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"FG013","title":"EXP-4 (Phase 2)","description":"Participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after 2 prior lines of ALK inhibitor therapies were given PF-06463922 100 mg orally QD on Day -7 (only for participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"FG014","title":"EXP-5 (Phase 2)","description":"Participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after 3 prior lines of ALK inhibitor therapies were given PF-06463922 100 mg orally QD on Day -7 (only for participant scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"FG015","title":"EXP-6 (Phase 2)","description":"Participants with advanced ROS1-positive NSCLC who were treatment naÃ¯ve or had any number of prior cancer therapies with or without asymptomatic CNS metastases were given PF-06463922 100 mg orally QD on Day -7 (only for participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"FG016","title":"Japan Lead-In Cohort (LIC)","description":"Few Japanese participants were given PF-06463922 100 mg orally once daily (QD) in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal to evaluate safety of PF-06463922 in Japanese participants, in order to support inclusion of Japanese participants in Phase 2."},{"id":"FG017","title":"Drug-drug Interaction (DDI) Sub-study","description":"Participants with advanced ALK positive or ROS1-positive NSCLC who were treatment naÃ¯ve or had any number of prior cancer therapies with or without asymptomatic CNS metastases were administered a single dose of a probe substrate alone on Day -2. Participants were given PF-06463922 100 mg orally QD starting on Cycle1 Day 1 and along with probe substrate on Day 15 Cycle 1."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"3"},{"groupId":"FG003","numSubjects":"12"},{"groupId":"FG004","numSubjects":"17"},{"groupId":"FG005","numSubjects":"3"},{"groupId":"FG006","numSubjects":"3"},{"groupId":"FG007","numSubjects":"3"},{"groupId":"FG008","numSubjects":"3"},{"groupId":"FG009","numSubjects":"4"},{"groupId":"FG010","numSubjects":"30"},{"groupId":"FG011","numSubjects":"27"},{"groupId":"FG012","numSubjects":"60"},{"groupId":"FG013","numSubjects":"65"},{"groupId":"FG014","numSubjects":"46"},{"groupId":"FG015","numSubjects":"47"},{"groupId":"FG016","numSubjects":"3"},{"groupId":"FG017","numSubjects":"32"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"2"},{"groupId":"FG004","numSubjects":"3"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"1"},{"groupId":"FG009","numSubjects":"2"},{"groupId":"FG010","numSubjects":"18"},{"groupId":"FG011","numSubjects":"7"},{"groupId":"FG012","numSubjects":"18"},{"groupId":"FG013","numSubjects":"8"},{"groupId":"FG014","numSubjects":"3"},{"groupId":"FG015","numSubjects":"7"},{"groupId":"FG016","numSubjects":"2"},{"groupId":"FG017","numSubjects":"6"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"3"},{"groupId":"FG003","numSubjects":"10"},{"groupId":"FG004","numSubjects":"14"},{"groupId":"FG005","numSubjects":"3"},{"groupId":"FG006","numSubjects":"3"},{"groupId":"FG007","numSubjects":"3"},{"groupId":"FG008","numSubjects":"2"},{"groupId":"FG009","numSubjects":"2"},{"groupId":"FG010","numSubjects":"12"},{"groupId":"FG011","numSubjects":"20"},{"groupId":"FG012","numSubjects":"42"},{"groupId":"FG013","numSubjects":"57"},{"groupId":"FG014","numSubjects":"43"},{"groupId":"FG015","numSubjects":"40"},{"groupId":"FG016","numSubjects":"1"},{"groupId":"FG017","numSubjects":"26"}]}],"dropWithdraws":[{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"3"},{"groupId":"FG003","numSubjects":"6"},{"groupId":"FG004","numSubjects":"9"},{"groupId":"FG005","numSubjects":"3"},{"groupId":"FG006","numSubjects":"2"},{"groupId":"FG007","numSubjects":"3"},{"groupId":"FG008","numSubjects":"2"},{"groupId":"FG009","numSubjects":"2"},{"groupId":"FG010","numSubjects":"8"},{"groupId":"FG011","numSubjects":"13"},{"groupId":"FG012","numSubjects":"25"},{"groupId":"FG013","numSubjects":"46"},{"groupId":"FG014","numSubjects":"37"},{"groupId":"FG015","numSubjects":"22"},{"groupId":"FG016","numSubjects":"1"},{"groupId":"FG017","numSubjects":"17"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"1"},{"groupId":"FG004","numSubjects":"1"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"1"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"2"},{"groupId":"FG013","numSubjects":"0"},{"groupId":"FG014","numSubjects":"1"},{"groupId":"FG015","numSubjects":"4"},{"groupId":"FG016","numSubjects":"0"},{"groupId":"FG017","numSubjects":"1"}]},{"type":"Other","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"1"},{"groupId":"FG004","numSubjects":"1"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"1"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"2"},{"groupId":"FG011","numSubjects":"3"},{"groupId":"FG012","numSubjects":"8"},{"groupId":"FG013","numSubjects":"3"},{"groupId":"FG014","numSubjects":"2"},{"groupId":"FG015","numSubjects":"3"},{"groupId":"FG016","numSubjects":"0"},{"groupId":"FG017","numSubjects":"2"}]},{"type":"Participant refused further follow-up","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"2"},{"groupId":"FG004","numSubjects":"3"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"1"},{"groupId":"FG011","numSubjects":"4"},{"groupId":"FG012","numSubjects":"7"},{"groupId":"FG013","numSubjects":"8"},{"groupId":"FG014","numSubjects":"3"},{"groupId":"FG015","numSubjects":"11"},{"groupId":"FG016","numSubjects":"0"},{"groupId":"FG017","numSubjects":"6"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"The safety analysis set included all enrolled patients who receive at least one dose of PF-06463922 (including Lead-in dose).","groups":[{"id":"BG000","title":"10 mg QD (Phase 1)","description":"PF-06463922 10 mg was orally given once daily (QD) on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"BG001","title":"25 mg QD (Phase 1)","description":"PF-06463922 25 mg was orally given QD in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal. Midazolam 2 mg was orally given QD on Day -7 and Cycle 1 Day 15."},{"id":"BG002","title":"50 mg QD (Phase 1)","description":"PF-06463922 50 mg was orally given QD on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"BG003","title":"75 mg QD (Phase 1)","description":"PF-06463922 75 mg was orally given QD on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"BG004","title":"100 mg QD (Phase 1)","description":"PF-06463922 100 mg was orally given QD on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"BG005","title":"150 mg QD (Phase 1)","description":"PF-06463922 150 mg was orally given QD in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal. Midazolam 2 mg was orally given QD on Day -7 and Cycle 1 Day 15."},{"id":"BG006","title":"200 mg QD (Phase 1)","description":"PF-06463922 200 mg was orally given QD on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"BG007","title":"35 mg BID (Phase 1)","description":"PF-06463922 35 mg was orally given twice daily (BID) on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"BG008","title":"75 mg BID (Phase 1)","description":"PF-06463922 75 mg was orally given BID on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"BG009","title":"100 mg BID (Phase 1)","description":"PF-06463922 100 mg was orally given BID on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"BG010","title":"EXP-1 (Phase 2)","description":"Treatment-naÃ¯ve participants with advanced anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC) with or without asymptomatic central nervous system (CNS) metastases were given PF-06463922 100 mg orally QD on Day -7 (only participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"BG011","title":"EXP-2 (Phase 2)","description":"Participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after only crizotinib therapy were given PF-06463922 100 mg orally QD on Day -7 (only for participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"BG012","title":"EXP-3 (Phase 2)","description":"Participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after crizotinib therapy and 1 or 2 prior regimens of chemotherapy given before or after crizotinib therapy, or participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after 1 ALK inhibitor therapy other than crizotinib with or without any number of prior chemotherapy regimens in any disease setting were given PF-06463922 100 mg orally QD on Day -7 (only for participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"BG013","title":"EXP-4 (Phase 2)","description":"Participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after 2 prior lines of ALK inhibitor therapies were given PF-06463922 100 mg orally QD on Day -7 (only for participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"BG014","title":"EXP-5 (Phase 2)","description":"Participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after 3 prior lines of ALK inhibitor therapies were given PF-06463922 100 mg orally QD on Day -7 (only for participant scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"BG015","title":"EXP-6 (Phase 2)","description":"Participants with advanced ROS1-positive NSCLC who were treatment naÃ¯ve or had any number of prior cancer therapies with or without asymptomatic CNS metastases were given PF-06463922 100 mg orally QD on Day -7 (only for participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"BG016","title":"Japan Lead-In Cohort (LIC)","description":"Few Japanese participants were given PF-06463922 100 mg orally once daily (QD) in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal to evaluate safety of PF-06463922 in Japanese participants, in order to support inclusion of Japanese participants in Phase 2."},{"id":"BG017","title":"Drug-drug Interaction (DDI) Sub-study","description":"Participants with advanced ALK positive or ROS1-positive NSCLC who were treatment naÃ¯ve or had any number of prior cancer therapies with or without asymptomatic CNS metastases were administered a single dose of a probe substrate alone on Day -2. Participants were given PF-06463922 100 mg orally QD starting on Cycle1 Day 1 and along with probe substrate on Day 15 Cycle 1."},{"id":"BG018","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"12"},{"groupId":"BG004","value":"17"},{"groupId":"BG005","value":"3"},{"groupId":"BG006","value":"3"},{"groupId":"BG007","value":"3"},{"groupId":"BG008","value":"3"},{"groupId":"BG009","value":"4"},{"groupId":"BG010","value":"30"},{"groupId":"BG011","value":"27"},{"groupId":"BG012","value":"60"},{"groupId":"BG013","value":"65"},{"groupId":"BG014","value":"46"},{"groupId":"BG015","value":"47"},{"groupId":"BG016","value":"3"},{"groupId":"BG017","value":"32"},{"groupId":"BG018","value":"364"}]}],"measures":[{"title":"Age, Customized","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"<18 years","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"0"},{"groupId":"BG010","value":"0"},{"groupId":"BG011","value":"0"},{"groupId":"BG012","value":"0"},{"groupId":"BG013","value":"0"},{"groupId":"BG014","value":"0"},{"groupId":"BG015","value":"0"},{"groupId":"BG016","value":"0"},{"groupId":"BG017","value":"0"},{"groupId":"BG018","value":"0"}]},{"title":"18-44 years","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"5"},{"groupId":"BG004","value":"7"},{"groupId":"BG005","value":"1"},{"groupId":"BG006","value":"1"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"2"},{"groupId":"BG010","value":"4"},{"groupId":"BG011","value":"5"},{"groupId":"BG012","value":"14"},{"groupId":"BG013","value":"19"},{"groupId":"BG014","value":"13"},{"groupId":"BG015","value":"12"},{"groupId":"BG016","value":"2"},{"groupId":"BG017","value":"5"},{"groupId":"BG018","value":"91"}]},{"title":"45-64 years","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"6"},{"groupId":"BG004","value":"9"},{"groupId":"BG005","value":"1"},{"groupId":"BG006","value":"2"},{"groupId":"BG007","value":"2"},{"groupId":"BG008","value":"2"},{"groupId":"BG009","value":"1"},{"groupId":"BG010","value":"18"},{"groupId":"BG011","value":"13"},{"groupId":"BG012","value":"34"},{"groupId":"BG013","value":"37"},{"groupId":"BG014","value":"26"},{"groupId":"BG015","value":"27"},{"groupId":"BG016","value":"1"},{"groupId":"BG017","value":"20"},{"groupId":"BG018","value":"204"}]},{"title":">=65 years","measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"1"},{"groupId":"BG005","value":"1"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"1"},{"groupId":"BG008","value":"1"},{"groupId":"BG009","value":"1"},{"groupId":"BG010","value":"8"},{"groupId":"BG011","value":"9"},{"groupId":"BG012","value":"12"},{"groupId":"BG013","value":"9"},{"groupId":"BG014","value":"7"},{"groupId":"BG015","value":"8"},{"groupId":"BG016","value":"0"},{"groupId":"BG017","value":"7"},{"groupId":"BG018","value":"69"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"7"},{"groupId":"BG004","value":"11"},{"groupId":"BG005","value":"2"},{"groupId":"BG006","value":"2"},{"groupId":"BG007","value":"2"},{"groupId":"BG008","value":"3"},{"groupId":"BG009","value":"2"},{"groupId":"BG010","value":"13"},{"groupId":"BG011","value":"17"},{"groupId":"BG012","value":"38"},{"groupId":"BG013","value":"37"},{"groupId":"BG014","value":"25"},{"groupId":"BG015","value":"27"},{"groupId":"BG016","value":"2"},{"groupId":"BG017","value":"15"},{"groupId":"BG018","value":"206"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"5"},{"groupId":"BG004","value":"6"},{"groupId":"BG005","value":"1"},{"groupId":"BG006","value":"1"},{"groupId":"BG007","value":"1"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"2"},{"groupId":"BG010","value":"17"},{"groupId":"BG011","value":"10"},{"groupId":"BG012","value":"22"},{"groupId":"BG013","value":"28"},{"groupId":"BG014","value":"21"},{"groupId":"BG015","value":"20"},{"groupId":"BG016","value":"1"},{"groupId":"BG017","value":"17"},{"groupId":"BG018","value":"158"}]}]}]},{"title":"Race/Ethnicity, Customized","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"WHITE","measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"7"},{"groupId":"BG004","value":"13"},{"groupId":"BG005","value":"2"},{"groupId":"BG006","value":"2"},{"groupId":"BG007","value":"1"},{"groupId":"BG008","value":"2"},{"groupId":"BG009","value":"3"},{"groupId":"BG010","value":"10"},{"groupId":"BG011","value":"13"},{"groupId":"BG012","value":"25"},{"groupId":"BG013","value":"32"},{"groupId":"BG014","value":"27"},{"groupId":"BG015","value":"25"},{"groupId":"BG016","value":"0"},{"groupId":"BG017","value":"21"},{"groupId":"BG018","value":"190"}]},{"title":"BLACK","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"1"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"1"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"0"},{"groupId":"BG010","value":"1"},{"groupId":"BG011","value":"0"},{"groupId":"BG012","value":"1"},{"groupId":"BG013","value":"0"},{"groupId":"BG014","value":"0"},{"groupId":"BG015","value":"1"},{"groupId":"BG016","value":"0"},{"groupId":"BG017","value":"0"},{"groupId":"BG018","value":"6"}]},{"title":"ASIAN","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"3"},{"groupId":"BG004","value":"2"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"1"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"0"},{"groupId":"BG010","value":"17"},{"groupId":"BG011","value":"10"},{"groupId":"BG012","value":"23"},{"groupId":"BG013","value":"23"},{"groupId":"BG014","value":"14"},{"groupId":"BG015","value":"16"},{"groupId":"BG016","value":"3"},{"groupId":"BG017","value":"11"},{"groupId":"BG018","value":"124"}]},{"title":"Others","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"1"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"0"},{"groupId":"BG010","value":"1"},{"groupId":"BG011","value":"2"},{"groupId":"BG012","value":"1"},{"groupId":"BG013","value":"3"},{"groupId":"BG014","value":"2"},{"groupId":"BG015","value":"3"},{"groupId":"BG016","value":"0"},{"groupId":"BG017","value":"0"},{"groupId":"BG018","value":"13"}]},{"title":"Unspecified","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"2"},{"groupId":"BG004","value":"1"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"1"},{"groupId":"BG008","value":"1"},{"groupId":"BG009","value":"1"},{"groupId":"BG010","value":"1"},{"groupId":"BG011","value":"2"},{"groupId":"BG012","value":"10"},{"groupId":"BG013","value":"7"},{"groupId":"BG014","value":"3"},{"groupId":"BG015","value":"2"},{"groupId":"BG016","value":"0"},{"groupId":"BG017","value":"0"},{"groupId":"BG018","value":"31"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Cycle 1 Dose-Limiting Toxicities (DLTs) in Phase 1","description":"DLT: any of following adverse events (AEs) attributable to PF-06463922: (1) hematologic: grade 4 neutropenia for \\>7 days; febrile neutropenia; grade\\>=3 neutropenic infection; grade\\>=3 thrombocytopenia with bleeding; grade 4 thrombocytopenia; (2) non-hematologic: grade\\>=3 pancreatitis; grade\\>=3 toxicities (excluding grade \\>=3 laboratory abnormalities not requiring dose modifications) persisting after optimal treatment with standard medical therapy; symptomatic grade \\>=3 QT interval corrected for heart rate (QTc) prolongation, or asymptomatic grade \\>=3 prolongation that had been confirmed by repeat testing, re-evaluation by qualified person, persisted after correction of reversible causes; \\>=20% decrease from baseline in left ventricular ejection fraction (LVEF); (3) other: failure to deliver at least 16 out of 21 prescribed daily total dose due to toxicities attributable to study drug; failure to restart dosing after 21 days (1 cycle) delay due to toxicity attributable to study drug.","populationDescription":"Maximum Tolerated Dose (MTD) evaluable population included all enrolled participants who received at least 75% of the planned PF-06463922 doses in Cycle 1. Participants who received less than 75% of the planned PF-06463922 doses in Cycle 1 due to DLT were also considered evaluable for MTD. Here, \"Overall Number Analyzed\" signifies participants analyzed for this outcome measure.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Cycle 1 (21 days)","groups":[{"id":"OG000","title":"10 mg QD (Phase 1)","description":"PF-06463922 10 mg was orally given once daily (QD) on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG001","title":"25 mg QD (Phase 1)","description":"PF-06463922 25 mg was orally given QD in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal. Midazolam 2 mg was orally given QD on Day -7 and Cycle 1 Day 15."},{"id":"OG002","title":"50 mg QD (Phase 1)","description":"PF-06463922 50 mg was orally given QD on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG003","title":"75 mg QD (Phase 1)","description":"PF-06463922 75 mg was orally given QD on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG004","title":"100 mg QD (Phase 1)","description":"PF-06463922 100 mg was orally given QD on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG005","title":"150 mg QD (Phase 1)","description":"PF-06463922 150 mg was orally given QD in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal. Midazolam 2 mg was orally given QD on Day -7 and Cycle 1 Day 15."},{"id":"OG006","title":"200 mg QD (Phase 1)","description":"PF-06463922 200 mg was orally given QD on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG007","title":"35 mg BID (Phase 1)","description":"PF-06463922 35 mg was orally given twice daily (BID) on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG008","title":"75 mg BID (Phase 1)","description":"PF-06463922 75 mg was orally given BID on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG009","title":"100 mg BID (Phase 1)","description":"PF-06463922 100 mg was orally given BID on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"11"},{"groupId":"OG004","value":"16"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"3"},{"groupId":"OG007","value":"2"},{"groupId":"OG008","value":"3"},{"groupId":"OG009","value":"3"}]}],"classes":[{"title":"With DLT","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"}]}]},{"title":"No DLT","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"8"},{"groupId":"OG005","value":"2"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"2"},{"groupId":"OG008","value":"3"},{"groupId":"OG009","value":"2"}]}]},{"title":"Data missing","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"8"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"1"}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With Overall and Intracranial Objective Response (Phase 2)","description":"Objective response (OR) refers to confirmed complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumor (RECIST) version 1.1. Intracranial OR refers to confirmed CR or PR considering only lesions within brain. CR was defined as the disappearance of all non-lymph node target lesions (where all target lesions are recorded with a length of 0 milliliter (mm) on Target Lesions electronic case report form (eCRF). Any pathological lymph nodes (recorded as target lesion) must have reduction in short axis to \\<10 mm. PR was defined as a 30 percent (%) or more decrease in sum of lesion dimensions (SLD) of target lesions, taking as reference the baseline SLD. Results presented here were based on independent central review.","populationDescription":"The intent-to-treat (ITT) analysis set was used for overall response assessment, and included all enrolled participants with documented ALK or ROS1 rearrangement who received at least 1 dose of PF-06463922; participants with central nervous system (CNS) metastases in the ITT analysis set were used for intracranial response assessment. Here, \"Number Analyzed\" signifies participants evaluable for specified rows.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"3 years","groups":[{"id":"OG000","title":"EXP-1 (Phase 2)","description":"Treatment-naÃ¯ve participants with advanced anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC) with or without asymptomatic central nervous system (CNS) metastases were given PF-06463922 100 mg orally QD on Day -7 (only participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG001","title":"EXP-2 (Phase 2)","description":"Participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after only crizotinib therapy were given PF-06463922 100 mg orally QD on Day -7 (only for participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG002","title":"EXP-3 (Phase 2)","description":"Participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after crizotinib therapy and 1 or 2 prior regimens of chemotherapy given before or after crizotinib therapy, or participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after 1 ALK inhibitor therapy other than crizotinib with or without any number of prior chemotherapy regimens in any disease setting were given PF-06463922 100 mg orally QD on Day -7 (only for participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG003","title":"EXP-4 (Phase 2)","description":"Participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after 2 prior lines of ALK inhibitor therapies were given PF-06463922 100 mg orally QD on Day -7 (only for participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG004","title":"EXP-5 (Phase 2)","description":"Participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after 3 prior lines of ALK inhibitor therapies were given PF-06463922 100 mg orally QD on Day -7 (only for participant scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG005","title":"EXP-6 (Phase 2)","description":"Participants with advanced ROS1-positive NSCLC who were treatment naÃ¯ve or had any number of prior cancer therapies with or without asymptomatic CNS metastases were given PF-06463922 100 mg orally QD on Day -7 (only for participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"27"},{"groupId":"OG002","value":"60"},{"groupId":"OG003","value":"65"},{"groupId":"OG004","value":"46"},{"groupId":"OG005","value":"47"}]}],"classes":[{"title":"Objective response","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"27"},{"groupId":"OG002","value":"59"},{"groupId":"OG003","value":"65"},{"groupId":"OG004","value":"46"},{"groupId":"OG005","value":"47"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"90.0","lowerLimit":"73.5","upperLimit":"97.9"},{"groupId":"OG001","value":"74.1","lowerLimit":"53.7","upperLimit":"88.9"},{"groupId":"OG002","value":"50.8","lowerLimit":"37.5","upperLimit":"64.1"},{"groupId":"OG003","value":"41.5","lowerLimit":"29.4","upperLimit":"54.4"},{"groupId":"OG004","value":"34.8","lowerLimit":"21.4","upperLimit":"50.2"},{"groupId":"OG005","value":"36.2","lowerLimit":"22.7","upperLimit":"51.5"}]}]},{"title":"Intracranial objective response","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"17"},{"groupId":"OG002","value":"32"},{"groupId":"OG003","value":"45"},{"groupId":"OG004","value":"38"},{"groupId":"OG005","value":"25"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"75.0","lowerLimit":"34.9","upperLimit":"96.8"},{"groupId":"OG001","value":"58.8","lowerLimit":"32.9","upperLimit":"81.6"},{"groupId":"OG002","value":"62.5","lowerLimit":"43.7","upperLimit":"78.9"},{"groupId":"OG003","value":"55.6","lowerLimit":"40.0","upperLimit":"70.4"},{"groupId":"OG004","value":"39.5","lowerLimit":"24.0","upperLimit":"56.6"},{"groupId":"OG005","value":"56.0","lowerLimit":"34.9","upperLimit":"75.6"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Overall and Intracranial Objective Response (Phase 1)","description":"Objective response (OR) refers to confirmed CR or PR according to RECIST version 1.1. Intracranial OR refers to confirmed CR or PR considering only lesions within brain. CR was defined as the disappearance of all non-lymph node target lesions (where all target lesions are recorded with a length of 0 mm on Target Lesions eCRF). Any pathological lymph nodes (recorded as target lesion) must have reduction in short axis to \\<10 mm. PR was defined as a 30 % or more decrease in SLD of target lesions, taking as reference the baseline SLD. Results presented here were based on independent central review.","populationDescription":"The ITT analysis set was used for overall response assessment and included all enrolled participants with documented ALK or ROS1 rearrangement who received at least 1 dose of PF-06463922; participants with CNS metastases in the ITT analysis set was used for intracranial response assessment. Here, \"Number Analyzed\" signifies participants analyzed for this outcome measure.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"From start of study treatment until CR or PR (maximum of 8 years approximately)","groups":[{"id":"OG000","title":"ALK Positive Population (Phase 1)","description":"This reporting arm includes all Phase 1 participants who had documented ALK rearrangement."},{"id":"OG001","title":"ROS1 Positive Population (Phase 1)","description":"This reporting arm includes all Phase 1 participants who had documented ROS1 rearrangement."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"41"},{"groupId":"OG001","value":"12"}]}],"classes":[{"title":"Objective response","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"41"},{"groupId":"OG001","value":"12"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"39.0","lowerLimit":"24.2","upperLimit":"55.5"},{"groupId":"OG001","value":"50.0","lowerLimit":"21.1","upperLimit":"78.9"}]}]},{"title":"Intracranial objective response","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"41.2","lowerLimit":"24.6","upperLimit":"59.3"},{"groupId":"OG001","value":"50.0","lowerLimit":"15.7","upperLimit":"84.3"}]}]}]},{"type":"SECONDARY","title":"Time to Tumor Response (TTR) and Intracranial TTR (Phase 1)","description":"Time to tumor response (TTR) was defined as the time from the first dose of study treatment to the first documentation of objective tumor response (CR or PR). For participants whose objective response proceeded from PR to CR, the onset of PR was taken as the onset of response. CR was defined as the disappearance of all non-lymph node target lesions (where all target lesions are recorded with a length of 0 mm on Target Lesions eCRF). Any pathological lymph nodes (recorded as target lesion) must have reduction in short axis to \\<10 mm. PR was defined as a 30 % or more decrease in SLD of target lesions, taking as reference the baseline SLD. TTR was only calculated for the subgroup of participants with a confirmed objective tumor response. Intracranial TTR was only calculated for participants with confirmed intracranial objective response. Results presented here were based on independent central review.","populationDescription":"TTR analysis set included all ITT participants who had confirmed objective response; intracranial TTR analysis set included all ITT participants who had CNS metastases and achieved confirmed intracranial objective response.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Full Range","unitOfMeasure":"Months","timeFrame":"From start of study treatment to the first documentation of objective tumor response (CR or PR) (maximum of 8 years approximately)","groups":[{"id":"OG000","title":"ALK Positive Population (Phase 1)","description":"This reporting arm includes all Phase 1 participants who had documented ALK rearrangement."},{"id":"OG001","title":"ROS1 Positive Population (Phase 1)","description":"This reporting arm includes all Phase 1 participants who had documented ROS1 rearrangement."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"6"}]}],"classes":[{"title":"TTR","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.4","lowerLimit":"1.2","upperLimit":"15.2"},{"groupId":"OG001","value":"1.4","lowerLimit":"1.2","upperLimit":"2.8"}]}]},{"title":"Intracranial TTR","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.4","lowerLimit":"1.2","upperLimit":"20.1"},{"groupId":"OG001","value":"1.4","lowerLimit":"1.1","upperLimit":"2.8"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Duration of Response (DOR) and Intracranial DOR (Phase 1)","description":"Duration of response(DOR): time from first documentation of objective tumor response (CR/PR) to first documentation of disease progression (PD) or to death due to any cause, whichever occurred first. DOR: calculated for subgroup of participants with confirmed objective tumor response. Intracranial DOR: calculated for participants with confirmed intracranial objective response. CR:disappearance of all non-lymph node target lesions (where all target lesions are recorded with length of 0mm on Target Lesion eCRF). Any pathological lymph node (recorded as target lesion) must have reduction in short axis to \\<10mm. PR:30% or more decrease in SLD of target lesion, taking as reference baseline SLD. PD:20% or more increase in the SLD of target lesions relative to baseline or smallest SLD (nadir) recorded since first dose. In addition, also demonstrate absolute increase of at least 5mm (\\>=5mm) relative to baseline or smallest SLD (nadir) recorded since first dose.","populationDescription":"DOR analysis set included all ITT participants who had confirmed objective response; intracranial DOR analysis set included all ITT participants who had CNS metastases and achieved confirmed intracranial objective response. All participants reported under 'Overall Number of Participants Analyzed' contributed data to the table but may not have evaluable data foe every row. Here, 'Number Analyzed' signifies number of participants evaluable for the specified rows.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"From start of study treatment to first documentation of PD or to death due to any cause, whichever occurred first (maximum of 8 years approximately)","groups":[{"id":"OG000","title":"ALK Positive Population (Phase 1)","description":"This reporting arm includes all Phase 1 participants who had documented ALK rearrangement."},{"id":"OG001","title":"ROS1 Positive Population (Phase 1)","description":"This reporting arm includes all Phase 1 participants who had documented ROS1 rearrangement."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"6"}]}],"classes":[{"title":"Participants with DOR","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"4"}]}],"categories":[{"title":"<3 Months","measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]},{"title":"3 Months to <6 Months","measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"0"}]},{"title":"6 Months to <9 Months","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]},{"title":"9 Months to <12 Months","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]},{"title":"12 Months to <15 Months","measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]},{"title":"15 Months to <18 Months","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]},{"title":"18 Months to <21 Months","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]},{"title":"21 Months to <24 Months","measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]},{"title":">=24 Months","measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"}]}]},{"title":"Participants censored-DOR","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"2"}]}],"categories":[{"title":"<3 Months","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]},{"title":"3 Months to <6 Months","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]},{"title":"6 Months to <9 Months","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]},{"title":"9 Months to <12 Months","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]},{"title":"12 Months to <15 Months","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]},{"title":"15 Months to <18 Months","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]},{"title":"18 Months to <21 Months","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]},{"title":"21 Months to <24 Months","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]},{"title":">=24 Months","measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"1"}]}]},{"title":"Participants with intracranial DOR","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"0"}]}],"categories":[{"title":"<3 Months","measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]},{"title":"3 Months to <6 Months","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]},{"title":"6 Months to <9 Months","measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]},{"title":"9 Months to <12 Months","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]},{"title":"12 Months to <15 Months","measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]},{"title":"15 Months to <18 Months","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]},{"title":"18 Months to <21 Months","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]},{"title":"21 Months to <24 Months","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]},{"title":">=24 Months","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Participants censored- intracranial DOR","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"4"}]}],"categories":[{"title":"<3 Months","measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"}]},{"title":"3 Months to <6 Months","measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"}]},{"title":"6 Months to <9 Months","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]},{"title":"9 Months to <12 Months","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]},{"title":"12 Months to <15 Months","measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]},{"title":"15 Months to <18 Months","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]},{"title":"18 Months to <21 Months","measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"}]},{"title":"21 Months to <24 Months","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]},{"title":">=24 Months","measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"1"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving Disease Control and Intracranial Disease Control at 12 and 24 Weeks (Phase 1)","description":"Tumor response was evaluated according to RECIST version 1.1, and disease control: confirmed CR, confirmed PR, or stable disease (SD). Intracranial assessment was only performed for participants CNS metastases. CR was defined as disappearance of all non-lymph node target lesions (where all target lesions are recorded with length of 0mm on Target Lesions eCRF). Any pathological lymph nodes (recorded as target lesion) must have reduction in short axis to \\<10 mm. PR was defined as 30% or more decrease in SLD of target lesions, taking as reference baseline SLD. Progressive disease: 20% or more increase in SLD of target lesions relative to baseline or smallest SLD (nadir) recorded since first dose. In addition to relative increase of 20%, SLD must also demonstrate absolute increase of at least 5mm (\\>=5mm) relative to baseline or smallest SLD (nadir) recorded since first dose. Results presented here were based on independent central review.","populationDescription":"The intent-to-treat (ITT) analysis set was used for overall response assessment, and included all enrolled participants with documented ALK or ROS1 rearrangement who received at least 1 dose of PF-06463922; participants with CNS metastases in the ITT analysis set was used for intracranial response assessment.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"12 and 24 weeks","groups":[{"id":"OG000","title":"ALK Positive Population (Phase 1)","description":"This reporting arm includes all Phase 1 participants who had documented ALK rearrangement."},{"id":"OG001","title":"ROS1 Positive Population (Phase 1)","description":"This reporting arm includes all Phase 1 participants who had documented ROS1 rearrangement."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"41"},{"groupId":"OG001","value":"12"}]}],"classes":[{"title":"DCR at Week 12","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"41"},{"groupId":"OG001","value":"12"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"53.7","lowerLimit":"37.4","upperLimit":"69.3"},{"groupId":"OG001","value":"58.3","lowerLimit":"27.7","upperLimit":"84.8"}]}]},{"title":"DCR at Week 24","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"41"},{"groupId":"OG001","value":"12"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"39.0","lowerLimit":"24.2","upperLimit":"55.5"},{"groupId":"OG001","value":"50.0","lowerLimit":"21.1","upperLimit":"78.9"}]}]},{"title":"Intracranial DCR at Week 12","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"50.0","lowerLimit":"32.4","upperLimit":"67.6"},{"groupId":"OG001","value":"37.5","lowerLimit":"8.5","upperLimit":"75.5"}]}]},{"title":"Intracranial DCR at Week 24","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"41.2","lowerLimit":"24.6","upperLimit":"59.3"},{"groupId":"OG001","value":"37.5","lowerLimit":"8.5","upperLimit":"75.5"}]}]}]},{"type":"SECONDARY","title":"Probability of First Event Being a Central Nervous System (CNS) Progression, Non CNS Progression, or Death (Phase 1)","description":"The probability of the first event being a CNS progression, a non-CNS progression, or death was evaluated with a competing risk approach by estimating cumulative incidence functions (range: 0-1) relative to the analysis set. The time to first event being a Competing Event (either \"CNS progression\" or \"non CNS progression\" or \"Death\") was defined as time from first dose until the date of that specific event. Participants not known to have any of the Competing Events were censored on the date they were last assessed for disease status for PFS. Participants who presented one type of event were counted as a competing cause of failure for the analysis of other type of events. For each type of event, the cumulative incidence function corresponding to the nearest time point preceding 1 year is presented. The results are based on independent central review.","populationDescription":"The intent-to-treat (ITT) analysis set included all enrolled participants with documented ALK or ROS1 rearrangement who received at least 1 dose of PF-06463922.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Probability of events","timeFrame":"3 years","groups":[{"id":"OG000","title":"Phase 1 ITT Population","description":"This reporting group includes all Phase 1 participants in the ITT analysis set."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"53"}]}],"classes":[{"title":"CNS progression","categories":[{"measurements":[{"groupId":"OG000","value":"0.260"}]}]},{"title":"Non CNS progression","categories":[{"measurements":[{"groupId":"OG000","value":"0.352"}]}]},{"title":"Death","categories":[{"measurements":[{"groupId":"OG000","value":"0.060"}]}]}]},{"type":"SECONDARY","title":"Progression-Free Survival (PFS) (Phase 1)","description":"PFS was defined as the time from the first dose of study treatment to the first documentation of objective PD or to death on study due to any cause, whichever came first. Progressive disease was defined by a 20% or more increase in the SLD of target lesions relative to baseline or the smallest SLD (nadir) recorded since first dose. In addition to the relative increase of 20%, SLD must also demonstrate an absolute increase of at least 5 mm (\\>= 5 mm) relative to baseline or the smallest SLD (nadir) recorded since the first dose. Results presented here were based on independent central review.","populationDescription":"PFS analysis set included all participants with documented ALK or ROS1 rearrangement who received at least 1 dose of PF-06463922.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Months","timeFrame":"From start of study treatment to first documentation of PD or to death due to any cause, whichever occurred first (maximum of 8 years approximately)","groups":[{"id":"OG000","title":"ALK Positive Population (Phase 1)","description":"This reporting arm includes all Phase 1 participants who had documented ALK rearrangement."},{"id":"OG001","title":"ROS1 Positive Population (Phase 1)","description":"This reporting arm includes all Phase 1 participants who had documented ROS1 rearrangement."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"41"},{"groupId":"OG001","value":"12"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.4","lowerLimit":"2.7","upperLimit":"11.8"},{"groupId":"OG001","value":"10.1","lowerLimit":"1.6","upperLimit":"33.0"}]}]}]},{"type":"SECONDARY","title":"Overall Survival (OS) (Phase 1)","description":"OS was defined as the time from first dose to the date of death due to any cause. For participants still alive at the time of analysis, the OS time was censored on the last date the participants were known to be alive. Estimates of OS and its 95% confidence interval were determined using Kaplan-Meier method.","populationDescription":"The intent-to-treat (ITT) analysis set included all enrolled participants with documented ALK or ROS1 rearrangement who received at least 1 dose of PF-06463922. Here, \"Number Analyzed\" signifies participants analyzed for this outcome measure.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Months","timeFrame":"3 years","groups":[{"id":"OG000","title":"ALK Positive Population (Phase 1)","description":"This reporting arm includes all Phase 1 participants who had documented ALK rearrangement."},{"id":"OG001","title":"ROS1 Positive Population (Phase 1)","description":"This reporting arm includes all Phase 1 participants who had documented ROS1 rearrangement."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"41"},{"groupId":"OG001","value":"12"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22.3","lowerLimit":"11.4","upperLimit":"NA","comment":"A large proportion of participants in the analysis set had their OS data censored, and number of participants dead by the cutoff date of this report was small, so it's impossible to derive such summary statistics."},{"groupId":"OG001","value":"NA","lowerLimit":"4.7","upperLimit":"NA","comment":"A large proportion of participants in the analysis set had their OS data censored, and number of participants dead by the cutoff date of this report was small, so it's impossible to derive such summary statistics."}]}]}]},{"type":"SECONDARY","title":"Maximum Observed Plasma Concentration (Cmax) of PF-06463922 Following Single Oral Doses (Phase 1)","description":"Maximum observed plasma concentration (Cmax) of PF-06463922 was observed directly from data.","populationDescription":"PK parameter analysis set for PF-06463922 included all enrolled participants who received at least 1 dose of PF-06463922 and had sufficient information to estimate at least one of the PK parameters of interest for PF-06463922.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"Nanograms per milliliter (ng/mL)","timeFrame":"Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9 and 24 hours post-dose on Cycle 1 Day 1 for 25 mg QD and 150 mg QD groups; pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9, 24, 48, 72, 96 and 120 hours post-dose on Day -7 for all other groups.","groups":[{"id":"OG000","title":"10 mg QD (Phase 1)","description":"PF-06463922 10 mg was orally given once daily (QD) on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG001","title":"25 mg QD (Phase 1)","description":"PF-06463922 25 mg was orally given QD in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal. Midazolam 2 mg was orally given QD on Day -7 and Cycle 1 Day 15."},{"id":"OG002","title":"50 mg QD (Phase 1)","description":"PF-06463922 50 mg was orally given QD on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG003","title":"75 mg QD (Phase 1)","description":"PF-06463922 75 mg was orally given QD on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG004","title":"100 mg QD (Phase 1)","description":"PF-06463922 100 mg was orally given QD on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG005","title":"150 mg QD (Phase 1)","description":"PF-06463922 150 mg was orally given QD in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal. Midazolam 2 mg was orally given QD on Day -7 and Cycle 1 Day 15."},{"id":"OG006","title":"200 mg QD (Phase 1)","description":"PF-06463922 200 mg was orally given QD on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG007","title":"35 mg BID (Phase 1)","description":"PF-06463922 35 mg was orally given twice daily (BID) on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG008","title":"75 mg BID (Phase 1)","description":"PF-06463922 75 mg was orally given BID on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG009","title":"100 mg BID (Phase 1)","description":"PF-06463922 100 mg was orally given BID on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"12"},{"groupId":"OG004","value":"16"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"3"},{"groupId":"OG007","value":"3"},{"groupId":"OG008","value":"3"},{"groupId":"OG009","value":"4"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"50.80","spread":"17"},{"groupId":"OG001","value":"149.2","spread":"71"},{"groupId":"OG002","value":"NA","spread":"NA","comment":"Summary statistics were not calculated when fewer than 3 participants had reportable values. Individual values are 390 and 423 ng/mL, respectively."},{"groupId":"OG003","value":"489.1","spread":"45"},{"groupId":"OG004","value":"595.5","spread":"37"},{"groupId":"OG005","value":"760.0","spread":"58"},{"groupId":"OG006","value":"1201","spread":"19"},{"groupId":"OG007","value":"202.2","spread":"57"},{"groupId":"OG008","value":"594.9","spread":"27"},{"groupId":"OG009","value":"507.2","spread":"51"}]}]}]},{"type":"SECONDARY","title":"Maximum Observed Plasma Concentration (Cmax) of PF-06463922 Following Multiple Oral Doses (Phase 1)","description":"Maximum Observed Plasma Concentration (Cmax) of PF-06463922 was observed directly from data.","populationDescription":"PK parameter analysis set for PF-06463922 included all enrolled participants who received at least 1 dose of PF-06463922 and had sufficient information to estimate at least one of the PK parameters of interest for PF-06463922.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"ng/mL","timeFrame":"Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9, 24 hours post-dose on Cycle 1 Day 15 (24-hour samples not collected for BID groups).","groups":[{"id":"OG000","title":"10 mg QD (Phase 1)","description":"PF-06463922 10 mg was orally given once daily (QD) on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG001","title":"25 mg QD (Phase 1)","description":"PF-06463922 25 mg was orally given QD in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal. Midazolam 2 mg was orally given QD on Day -7 and Cycle 1 Day 15."},{"id":"OG002","title":"50 mg QD (Phase 1)","description":"PF-06463922 50 mg was orally given QD on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG003","title":"75 mg QD (Phase 1)","description":"PF-06463922 75 mg was orally given QD on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG004","title":"100 mg QD (Phase 1)","description":"PF-06463922 100 mg was orally given QD on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG005","title":"150 mg QD (Phase 1)","description":"PF-06463922 150 mg was orally given QD in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal. Midazolam 2 mg was orally given QD on Day -7 and Cycle 1 Day 15."},{"id":"OG006","title":"200 mg QD (Phase 1)","description":"PF-06463922 200 mg was orally given QD on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG007","title":"35 mg BID (Phase 1)","description":"PF-06463922 35 mg was orally given twice daily (BID) on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG008","title":"75 mg BID (Phase 1)","description":"PF-06463922 75 mg was orally given BID on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG009","title":"100 mg BID (Phase 1)","description":"PF-06463922 100 mg was orally given BID on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"12"},{"groupId":"OG004","value":"16"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"3"},{"groupId":"OG007","value":"3"},{"groupId":"OG008","value":"3"},{"groupId":"OG009","value":"3"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"67.29","spread":"18"},{"groupId":"OG001","value":"138.1","spread":"35"},{"groupId":"OG002","value":"359.7","spread":"27"},{"groupId":"OG003","value":"429.6","spread":"48"},{"groupId":"OG004","value":"550.2","spread":"32"},{"groupId":"OG005","value":"541.0","spread":"42"},{"groupId":"OG006","value":"NA","spread":"NA","comment":"Summary statistics were not calculated when fewer than 3 participants had reportable values. Individual values are 760 and 1430 ng/mL, respectively."},{"groupId":"OG007","value":"NA","spread":"NA","comment":"Summary statistics were not calculated when fewer than 3 participants had reportable values. The individual value is 370 ng/mL."},{"groupId":"OG008","value":"550.0","spread":"23"},{"groupId":"OG009","value":"600.5","spread":"27"}]}]}]},{"type":"SECONDARY","title":"Time for Cmax (Tmax) of PF-06463922 Following Single Oral Doses (Phase 1)","description":"Tmax of PF-06463922 was observed directly from data as time of first occurrence.","populationDescription":"PK parameter analysis set for PF-06463922 included all enrolled participants who received at least 1 dose of PF-06463922 and had sufficient information to estimate at least one of the PK parameters of interest for PF-06463922.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Full Range","unitOfMeasure":"Hours","timeFrame":"Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9 and 24 hours post-dose on Cycle 1 Day 1 for 25 mg QD and 150 mg QD groups; pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9, 24, 48, 72, 96 and 120 hours post-dose on Day -7 for all other groups.","groups":[{"id":"OG000","title":"10 mg QD (Phase 1)","description":"PF-06463922 10 mg was orally given once daily (QD) on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG001","title":"25 mg QD (Phase 1)","description":"PF-06463922 25 mg was orally given QD in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal. Midazolam 2 mg was orally given QD on Day -7 and Cycle 1 Day 15."},{"id":"OG002","title":"50 mg QD (Phase 1)","description":"PF-06463922 50 mg was orally given QD on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG003","title":"75 mg QD (Phase 1)","description":"PF-06463922 75 mg was orally given QD on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG004","title":"100 mg QD (Phase 1)","description":"PF-06463922 100 mg was orally given QD on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG005","title":"150 mg QD (Phase 1)","description":"PF-06463922 150 mg was orally given QD in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal. Midazolam 2 mg was orally given QD on Day -7 and Cycle 1 Day 15."},{"id":"OG006","title":"200 mg QD (Phase 1)","description":"PF-06463922 200 mg was orally given QD on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG007","title":"35 mg BID (Phase 1)","description":"PF-06463922 35 mg was orally given twice daily (BID) on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG008","title":"75 mg BID (Phase 1)","description":"PF-06463922 75 mg was orally given BID on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG009","title":"100 mg BID (Phase 1)","description":"PF-06463922 100 mg was orally given BID on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"12"},{"groupId":"OG004","value":"16"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"3"},{"groupId":"OG007","value":"3"},{"groupId":"OG008","value":"3"},{"groupId":"OG009","value":"4"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.98","lowerLimit":"1.00","upperLimit":"2.97"},{"groupId":"OG001","value":"2.00","lowerLimit":"0.50","upperLimit":"2.05"},{"groupId":"OG002","value":"1.25","lowerLimit":"0.50","upperLimit":"2.00"},{"groupId":"OG003","value":"1.09","lowerLimit":"0.50","upperLimit":"4.03"},{"groupId":"OG004","value":"1.96","lowerLimit":"0.517","upperLimit":"4.33"},{"groupId":"OG005","value":"1.05","lowerLimit":"1.00","upperLimit":"3.00"},{"groupId":"OG006","value":"2.00","lowerLimit":"1.18","upperLimit":"3.00"},{"groupId":"OG007","value":"1.20","lowerLimit":"0.50","upperLimit":"1.97"},{"groupId":"OG008","value":"1.23","lowerLimit":"1.00","upperLimit":"2.00"},{"groupId":"OG009","value":"2.00","lowerLimit":"1.10","upperLimit":"3.07"}]}]}]},{"type":"SECONDARY","title":"Time for Cmax (Tmax) of PF-06463922 Following Multiple Oral Doses (Phase 1)","description":"Tmax of PF-06463922 was observed directly from data as time of first occurrence.","populationDescription":"PK parameter analysis set for PF-06463922 included all enrolled participants who received at least 1 dose of PF-06463922 and had sufficient information to estimate at least one of the PK parameters of interest for PF-06463922.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Full Range","unitOfMeasure":"Hours","timeFrame":"Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9, 24 hours post-dose on Cycle 1 Day 15 (24-hour samples not collected for BID groups).","groups":[{"id":"OG000","title":"10 mg QD (Phase 1)","description":"PF-06463922 10 mg was orally given once daily (QD) on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG001","title":"25 mg QD (Phase 1)","description":"PF-06463922 25 mg was orally given QD in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal. Midazolam 2 mg was orally given QD on Day -7 and Cycle 1 Day 15."},{"id":"OG002","title":"50 mg QD (Phase 1)","description":"PF-06463922 50 mg was orally given QD on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG003","title":"75 mg QD (Phase 1)","description":"PF-06463922 75 mg was orally given QD on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG004","title":"100 mg QD (Phase 1)","description":"PF-06463922 100 mg was orally given QD on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG005","title":"150 mg QD (Phase 1)","description":"PF-06463922 150 mg was orally given QD in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal. Midazolam 2 mg was orally given QD on Day -7 and Cycle 1 Day 15."},{"id":"OG006","title":"200 mg QD (Phase 1)","description":"PF-06463922 200 mg was orally given QD on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG007","title":"35 mg BID (Phase 1)","description":"PF-06463922 35 mg was orally given twice daily (BID) on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG008","title":"75 mg BID (Phase 1)","description":"PF-06463922 75 mg was orally given BID on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG009","title":"100 mg BID (Phase 1)","description":"PF-06463922 100 mg was orally given BID on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"12"},{"groupId":"OG004","value":"16"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"3"},{"groupId":"OG007","value":"3"},{"groupId":"OG008","value":"3"},{"groupId":"OG009","value":"3"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.00","lowerLimit":"1.00","upperLimit":"1.08"},{"groupId":"OG001","value":"1.00","lowerLimit":"1.00","upperLimit":"2.00"},{"groupId":"OG002","value":"2.00","lowerLimit":"1.92","upperLimit":"2.75"},{"groupId":"OG003","value":"1.03","lowerLimit":"0.50","upperLimit":"2.00"},{"groupId":"OG004","value":"1.13","lowerLimit":"1.00","upperLimit":"4.00"},{"groupId":"OG005","value":"1.30","lowerLimit":"1.00","upperLimit":"24.0"},{"groupId":"OG006","value":"1.61","lowerLimit":"1.22","upperLimit":"2.00"},{"groupId":"OG007","value":"0.50","lowerLimit":"0.50","upperLimit":"0.50"},{"groupId":"OG008","value":"0.55","lowerLimit":"0.50","upperLimit":"2.05"},{"groupId":"OG009","value":"2.00","lowerLimit":"1.00","upperLimit":"2.00"}]}]}]},{"type":"SECONDARY","title":"Area Under the Plasma Concentration-Time Profile From Time Zero to Time Tau (AUCtau) of PF-06463922 Following Single Oral Doses (Phase 1)","description":"Tau refers to the dosing interval, and it equals to 12 or 24 hours for BID or QD dosing, respectively. AUCtau was determined using linear/log trapezoidal method.","populationDescription":"PK parameter analysis set for PF-06463922 included all enrolled participants who received at least 1 dose of PF-06463922 and had sufficient information to estimate at least one of the PK parameters of interest for PF-06463922.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"Nanogram*hour/milliliter (ng*hr/mL)","timeFrame":"Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9 and 24 hours post-dose on Cycle 1 Day 1 for 25 mg QD and 150 mg QD groups; pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9, and 24 hours post-dose on Day -7 for all other groups.","groups":[{"id":"OG000","title":"10 mg QD (Phase 1)","description":"PF-06463922 10 mg was orally given once daily (QD) on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG001","title":"25 mg QD (Phase 1)","description":"PF-06463922 25 mg was orally given QD in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal. Midazolam 2 mg was orally given QD on Day -7 and Cycle 1 Day 15."},{"id":"OG002","title":"50 mg QD (Phase 1)","description":"PF-06463922 50 mg was orally given QD on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG003","title":"75 mg QD (Phase 1)","description":"PF-06463922 75 mg was orally given QD on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG004","title":"100 mg QD (Phase 1)","description":"PF-06463922 100 mg was orally given QD on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG005","title":"150 mg QD (Phase 1)","description":"PF-06463922 150 mg was orally given QD in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal. Midazolam 2 mg was orally given QD on Day -7 and Cycle 1 Day 15."},{"id":"OG006","title":"200 mg QD (Phase 1)","description":"PF-06463922 200 mg was orally given QD on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG007","title":"35 mg BID (Phase 1)","description":"PF-06463922 35 mg was orally given twice daily (BID) on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG008","title":"75 mg BID (Phase 1)","description":"PF-06463922 75 mg was orally given BID on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG009","title":"100 mg BID (Phase 1)","description":"PF-06463922 100 mg was orally given BID on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"12"},{"groupId":"OG004","value":"16"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"3"},{"groupId":"OG007","value":"3"},{"groupId":"OG008","value":"3"},{"groupId":"OG009","value":"4"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"488.2","spread":"21"},{"groupId":"OG001","value":"1387","spread":"35"},{"groupId":"OG002","value":"NA","spread":"NA","comment":"Summary statistics were not calculated when fewer than 3 participants had reportable values. Individual values are 3310 and 3880 ng\\*hr/mL, respectively."},{"groupId":"OG003","value":"3990","spread":"55"},{"groupId":"OG004","value":"5110","spread":"28"},{"groupId":"OG005","value":"7474","spread":"73"},{"groupId":"OG006","value":"11410","spread":"43"},{"groupId":"OG007","value":"982.4","spread":"9"},{"groupId":"OG008","value":"2996","spread":"20"},{"groupId":"OG009","value":"2925","spread":"47"}]}]}]},{"type":"SECONDARY","title":"Area Under the Plasma Concentration-Time Profile From Time Zero to Time Tau (AUCtau) of PF-06463922 Following Multiple Oral Doses (Phase 1)","description":"Tau refers to the dosing interval, and it equals to 12 or 24 hours for BID or QD dosing, respectively. AUCtau was determined using linear/log trapezoidal method.","populationDescription":"PK parameter analysis set for PF-06463922 included all enrolled participants who received at least 1 dose of PF-06463922 and had sufficient information to estimate at least one of the PK parameters of interest for PF-06463922.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"ng*hr/mL","timeFrame":"Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9, 24 hours post-dose on Cycle 1 Day 15 (24-hour samples not collected for BID groups)","groups":[{"id":"OG000","title":"10 mg QD (Phase 1)","description":"PF-06463922 10 mg was orally given once daily (QD) on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG001","title":"25 mg QD (Phase 1)","description":"PF-06463922 25 mg was orally given QD in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal. Midazolam 2 mg was orally given QD on Day -7 and Cycle 1 Day 15."},{"id":"OG002","title":"50 mg QD (Phase 1)","description":"PF-06463922 50 mg was orally given QD on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG003","title":"75 mg QD (Phase 1)","description":"PF-06463922 75 mg was orally given QD on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG004","title":"100 mg QD (Phase 1)","description":"PF-06463922 100 mg was orally given QD on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG005","title":"150 mg QD (Phase 1)","description":"PF-06463922 150 mg was orally given QD in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal. Midazolam 2 mg was orally given QD on Day -7 and Cycle 1 Day 15."},{"id":"OG006","title":"200 mg QD (Phase 1)","description":"PF-06463922 200 mg was orally given QD on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG007","title":"35 mg BID (Phase 1)","description":"PF-06463922 35 mg was orally given twice daily (BID) on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG008","title":"75 mg BID (Phase 1)","description":"PF-06463922 75 mg was orally given BID on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG009","title":"100 mg BID (Phase 1)","description":"PF-06463922 100 mg was orally given BID on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"12"},{"groupId":"OG004","value":"16"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"1"},{"groupId":"OG008","value":"3"},{"groupId":"OG009","value":"3"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"752.1","spread":"26"},{"groupId":"OG001","value":"1701","spread":"29"},{"groupId":"OG002","value":"3367","spread":"39"},{"groupId":"OG003","value":"4107","spread":"53"},{"groupId":"OG004","value":"5121","spread":"30"},{"groupId":"OG005","value":"6157","spread":"9"},{"groupId":"OG006","value":"NA","spread":"NA","comment":"Summary statistics were not calculated when fewer than 3 participants had reportable values. Individual values are 4480 and 12900 ng\\*hr/mL, respectively."},{"groupId":"OG007","value":"NA","spread":"NA","comment":"Summary statistics were not calculated when fewer than 3 participants had reportable values. The individual value is 2140 ng\\*hr/mL."},{"groupId":"OG008","value":"3574","spread":"35"},{"groupId":"OG009","value":"4058","spread":"33"}]}]}]},{"type":"SECONDARY","title":"Area Under the Plasma Concentration-Time Profile From Time Zero Extrapolated to Infinite Time (AUCinf) of PF-06463922 Following Single Oral Doses (Phase 1)","description":"AUCinf was calculated as AUClast + (Clast\\*/kel), where AUClast was the area under the plasma concentration-time profile from time 0 to the time of the last quantifiable concentration, Clast\\* was the predicted plasma concentration at the last quantifiable time point estimated from the log-linear regression analysis, and kel was the rate constant for terminal phase.","populationDescription":"PK parameter analysis set for PF-06463922 included all enrolled participants who received at least 1 dose of PF-06463922 and had sufficient information to estimate at least one of the PK parameters of interest for PF-06463922. Here, \"Overall Number of Participants Analyzed\" signifies participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"ng*hr/mL","timeFrame":"Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9 and 24 hours post-dose on Cycle 1 Day 1 for 25 mg QD and 150 mg QD groups; pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9, 24, 48, 72, 96 and 120 hours post-dose on Day -7 for all other groups.","groups":[{"id":"OG000","title":"10 mg QD (Phase 1)","description":"PF-06463922 10 mg was orally given once daily (QD) on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG001","title":"50 mg QD (Phase 1)","description":"PF-06463922 50 mg was orally given QD on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG002","title":"75 mg QD (Phase 1)","description":"PF-06463922 75 mg was orally given QD on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG003","title":"100 mg QD (Phase 1)","description":"PF-06463922 100 mg was orally given QD on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG004","title":"200 mg QD (Phase 1)","description":"PF-06463922 200 mg was orally given QD on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG005","title":"35 mg BID (Phase 1)","description":"PF-06463922 35 mg was orally given twice daily (BID) on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG006","title":"75 mg BID (Phase 1)","description":"PF-06463922 75 mg was orally given BID on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG007","title":"100 mg BID (Phase 1)","description":"PF-06463922 100 mg was orally given BID on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"11"},{"groupId":"OG003","value":"15"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"2"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"4"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":"NA","comment":"Summary statistics were not calculated when fewer than 3 participants had reportable values. The individual value is 698 ng\\*hr/mL."},{"groupId":"OG001","value":"NA","spread":"NA","comment":"Summary statistics were not calculated when fewer than 3 participants had reportable values. Individual values are 7210 and 7240 ng\\*hr/mL, respectively."},{"groupId":"OG002","value":"7663","spread":"79"},{"groupId":"OG003","value":"8236","spread":"25"},{"groupId":"OG004","value":"18340","spread":"61"},{"groupId":"OG005","value":"NA","spread":"NA","comment":"Summary statistics were not calculated when fewer than 3 participants had reportable values. Individual values are 2630 and 3690 ng\\*hr/mL."},{"groupId":"OG006","value":"NA","spread":"NA","comment":"Summary statistics were not calculated when fewer than 3 participants had reportable values. The individual value is 6860 ng\\*hr/mL."},{"groupId":"OG007","value":"6318","spread":"56"}]}]}]},{"type":"SECONDARY","title":"Apparent Oral Clearance (CL/F) of PF-06463922 Following Single Oral Doses (Phase 1)","description":"Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. CL/F was calculated as dose/AUCinf, where AUCinf was the area under the plasma concentration-time profile from time 0 extrapolated to infinite time.","populationDescription":"PK parameter analysis set for PF-06463922 included all enrolled participants who received at least 1 dose of PF-06463922 and had sufficient information to estimate at least one of the PK parameters of interest for PF-06463922. Here, \"Overall Number of Participants Analyzed\" signifies participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"Liter/hour (L/hr)","timeFrame":"Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9 and 24 hours post-dose on Cycle 1 Day 1 for 25 mg QD and 150 mg QD groups; pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9, 24, 48, 72, 96 and 120 hours post-dose on Day -7 for all other groups.","groups":[{"id":"OG000","title":"10 mg QD (Phase 1)","description":"PF-06463922 10 mg was orally given once daily (QD) on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG001","title":"50 mg QD (Phase 1)","description":"PF-06463922 50 mg was orally given QD on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG002","title":"75 mg QD (Phase 1)","description":"PF-06463922 75 mg was orally given QD on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG003","title":"100 mg QD (Phase 1)","description":"PF-06463922 100 mg was orally given QD on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG004","title":"200 mg QD (Phase 1)","description":"PF-06463922 200 mg was orally given QD on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG005","title":"35 mg BID (Phase 1)","description":"PF-06463922 35 mg was orally given twice daily (BID) on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG006","title":"75 mg BID (Phase 1)","description":"PF-06463922 75 mg was orally given BID on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG007","title":"100 mg BID (Phase 1)","description":"PF-06463922 100 mg was orally given BID on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"11"},{"groupId":"OG003","value":"15"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"2"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"4"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":"NA","comment":"Summary statistics were not calculated when fewer than 3 participants had reportable values. The individual value is 14.3 L/hr."},{"groupId":"OG001","value":"NA","spread":"NA","comment":"Summary statistics were not calculated when fewer than 3 participants had reportable values. Individual values are 6.91 and 6.94 L/hr, respectively."},{"groupId":"OG002","value":"9.788","spread":"79"},{"groupId":"OG003","value":"12.14","spread":"25"},{"groupId":"OG004","value":"10.90","spread":"61"},{"groupId":"OG005","value":"NA","spread":"NA","comment":"Summary statistics were not calculated when fewer than 3 participants had reportable values. Individual values are 9.48 and 13.3 L/hr, respectively."},{"groupId":"OG006","value":"NA","spread":"NA","comment":"Summary statistics were not calculated when fewer than 3 participants had reportable values. The individual value is 10.9 L/hr."},{"groupId":"OG007","value":"15.83","spread":"56"}]}]}]},{"type":"SECONDARY","title":"Apparent Oral Clearance (CL/F) of PF-06463922 Following Multiple Oral Doses (Phase 1)","description":"Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. CL/F was calculated as dose/AUCinf, where AUCinf was the area under the plasma concentration-time profile from time 0 extrapolated to infinite time.","populationDescription":"PK parameter analysis set for PF-06463922 included all enrolled participants who received at least 1 dose of PF-06463922 and had sufficient information to estimate at least one of the PK parameters of interest for PF-06463922.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"L/hr","timeFrame":"Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9, 24 hours post-dose on Cycle 1 Day 15 (24-hour samples not collected for BID groups)","groups":[{"id":"OG000","title":"10 mg QD (Phase 1)","description":"PF-06463922 10 mg was orally given once daily (QD) on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG001","title":"25 mg QD (Phase 1)","description":"PF-06463922 25 mg was orally given QD in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal. Midazolam 2 mg was orally given QD on Day -7 and Cycle 1 Day 15."},{"id":"OG002","title":"50 mg QD (Phase 1)","description":"PF-06463922 50 mg was orally given QD on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG003","title":"75 mg QD (Phase 1)","description":"PF-06463922 75 mg was orally given QD on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG004","title":"100 mg QD (Phase 1)","description":"PF-06463922 100 mg was orally given QD on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG005","title":"150 mg QD (Phase 1)","description":"PF-06463922 150 mg was orally given QD in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal. Midazolam 2 mg was orally given QD on Day -7 and Cycle 1 Day 15."},{"id":"OG006","title":"200 mg QD (Phase 1)","description":"PF-06463922 200 mg was orally given QD on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG007","title":"35 mg BID (Phase 1)","description":"PF-06463922 35 mg was orally given twice daily (BID) on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG008","title":"75 mg BID (Phase 1)","description":"PF-06463922 75 mg was orally given BID on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG009","title":"100 mg BID (Phase 1)","description":"PF-06463922 100 mg was orally given BID on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"12"},{"groupId":"OG004","value":"16"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"1"},{"groupId":"OG008","value":"3"},{"groupId":"OG009","value":"3"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.27","spread":"26"},{"groupId":"OG001","value":"14.72","spread":"29"},{"groupId":"OG002","value":"14.84","spread":"39"},{"groupId":"OG003","value":"17.66","spread":"48"},{"groupId":"OG004","value":"19.52","spread":"30"},{"groupId":"OG005","value":"24.37","spread":"9"},{"groupId":"OG006","value":"NA","spread":"NA","comment":"Summary statistics were not calculated when fewer than 3 participants had reportable values. Individual values are 15.5 and 44.6 L/hr, respectively."},{"groupId":"OG007","value":"NA","spread":"NA","comment":"Summary statistics were not calculated when fewer than 3 participants had reportable values. The individual value is 16.3 L/hr."},{"groupId":"OG008","value":"20.99","spread":"35"},{"groupId":"OG009","value":"22.37","spread":"47"}]}]}]},{"type":"SECONDARY","title":"Apparent Volume of Distribution (Vz/F) of PF-06463922 Following Single Oral Doses (Phase 1)","description":"Vz/F was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug, and calculated as dose/(AUCinf\\*kel), where AUCinf was the area under the plasma concentration-time profile from time 0 extrapolated to infinite time, kel was the rate constant for terminal phase.","populationDescription":"PK parameter analysis set for PF-06463922 included all enrolled participants who received at least 1 dose of PF-06463922 and had sufficient information to estimate at least one of the PK parameters of interest for PF-06463922. Here, \"Overall Number of Participants Analyzed\" signifies participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"Liters (L)","timeFrame":"Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9 and 24 hours post-dose on Cycle 1 Day 1 for 25 mg QD and 150 mg QD groups; pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9, 24, 48, 72, 96 and 120 hours post-dose on Day -7 for all other groups.","groups":[{"id":"OG000","title":"10 mg QD (Phase 1)","description":"PF-06463922 10 mg was orally given once daily (QD) on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG001","title":"50 mg QD (Phase 1)","description":"PF-06463922 50 mg was orally given QD on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG002","title":"75 mg QD (Phase 1)","description":"PF-06463922 75 mg was orally given QD on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG003","title":"100 mg QD (Phase 1)","description":"PF-06463922 100 mg was orally given QD on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG004","title":"200 mg QD (Phase 1)","description":"PF-06463922 200 mg was orally given QD on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG005","title":"35 mg BID (Phase 1)","description":"PF-06463922 35 mg was orally given twice daily (BID) on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG006","title":"75 mg BID (Phase 1)","description":"PF-06463922 75 mg was orally given BID on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG007","title":"100 mg BID (Phase 1)","description":"PF-06463922 100 mg was orally given BID on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"11"},{"groupId":"OG003","value":"15"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"2"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"4"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":"NA","comment":"Summary statistics were not calculated when fewer than 3 participants had reportable values. The individual value is 373 L."},{"groupId":"OG001","value":"NA","spread":"NA","comment":"Summary statistics were not calculated when fewer than 3 participants had reportable values. Individual values are 166 and 307 L, respectively."},{"groupId":"OG002","value":"367.9","spread":"54"},{"groupId":"OG003","value":"356.3","spread":"39"},{"groupId":"OG004","value":"307.8","spread":"41"},{"groupId":"OG005","value":"NA","spread":"NA","comment":"Summary statistics were not calculated when fewer than 3 participants had reportable values. Individual values are 362 and 472 L, respectively."},{"groupId":"OG006","value":"NA","spread":"NA","comment":"Summary statistics were not calculated when fewer than 3 participants had reportable values. The individual value is 410 L."},{"groupId":"OG007","value":"378.3","spread":"54"}]}]}]},{"type":"SECONDARY","title":"Observed Accumulation Ratio (Rac) of PF-06463922 Following Multiple Oral Doses (Phase 1)","description":"Rac was calculated as Day 15 AUCtau/Day -7 AUCtau or Day 1 AUCtau, where AUCtau was the area under the plasma concentration-time profile from time 0 to time tau (12 and 24 hours for BID and QD dosing regimen, respectively).","populationDescription":"PK parameter analysis set for PF-06463922 included all enrolled participants who received at least 1 dose of PF-06463922 and had sufficient information to estimate at least one of the PK parameters of interest for PF-06463922. Here, \"Overall Number of Participants Analyzed\" signifies participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Ratio","timeFrame":"Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9, 24 hours post-dose on Cycle 1 Day 15 (24-hour samples not collected for BID groups)","groups":[{"id":"OG000","title":"10 mg QD (Phase 1)","description":"PF-06463922 10 mg was orally given once daily (QD) on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG001","title":"25 mg QD (Phase 1)","description":"PF-06463922 25 mg was orally given QD in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal. Midazolam 2 mg was orally given QD on Day -7 and Cycle 1 Day 15."},{"id":"OG002","title":"50 mg QD (Phase 1)","description":"PF-06463922 50 mg was orally given QD on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG003","title":"75 mg QD (Phase 1)","description":"PF-06463922 75 mg was orally given QD on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG004","title":"100 mg QD (Phase 1)","description":"PF-06463922 100 mg was orally given QD on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG005","title":"150 mg QD (Phase 1)","description":"PF-06463922 150 mg was orally given QD in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal. Midazolam 2 mg was orally given QD on Day -7 and Cycle 1 Day 15."},{"id":"OG006","title":"200 mg QD (Phase 1)","description":"PF-06463922 200 mg was orally given QD on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG007","title":"35 mg BID (Phase 1)","description":"PF-06463922 35 mg was orally given twice daily (BID) on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG008","title":"75 mg BID (Phase 1)","description":"PF-06463922 75 mg was orally given BID on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG009","title":"100 mg BID (Phase 1)","description":"PF-06463922 100 mg was orally given BID on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"12"},{"groupId":"OG004","value":"15"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"1"},{"groupId":"OG008","value":"3"},{"groupId":"OG009","value":"3"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.543","spread":"0.075056"},{"groupId":"OG001","value":"1.237","spread":"0.20817"},{"groupId":"OG002","value":"1.105","spread":"NA","comment":"Standard deviation was not calculated when fewer than 3 participants had reportable values."},{"groupId":"OG003","value":"1.121","spread":"0.44575"},{"groupId":"OG004","value":"1.071","spread":"0.31138"},{"groupId":"OG005","value":"1.000","spread":"0.79137"},{"groupId":"OG006","value":"0.6500","spread":"NA","comment":"Standard deviation was not calculated when fewer than 3 participants had reportable values."},{"groupId":"OG007","value":"NA","spread":"NA","comment":"These summary statistics were not calculated when fewer than 3 participants had reportable values. The individual value is 2.09."},{"groupId":"OG008","value":"1.231","spread":"0.35228"},{"groupId":"OG009","value":"1.523","spread":"0.29569"}]}]}]},{"type":"SECONDARY","title":"Terminal Half-Life of PF-06463922 Following Single Oral Doses (Phase 1)","description":"Terminal plasma half-life was defined as the time measured for the plasma concentration to decrease by one half, and calculated as loge(2)/kel, where kel was the rate constant for terminal phase.","populationDescription":"PK parameter analysis set for PF-06463922 included all enrolled participants who received at least 1 dose of PF-06463922 and had sufficient information to estimate at least one of the PK parameters of interest for PF-06463922. Here, \"Overall Number of Participants Analyzed\" signifies participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Hours (hr)","timeFrame":"Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9 and 24 hours post-dose on Cycle 1 Day 1 for 25 mg QD and 150 mg QD groups; pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9, 24, 48, 72, 96 and 120 hours post-dose on Day -7 for all other groups.","groups":[{"id":"OG000","title":"10 mg QD (Phase 1)","description":"PF-06463922 10 mg was orally given once daily (QD) on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG001","title":"50 mg QD (Phase 1)","description":"PF-06463922 50 mg was orally given QD on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG002","title":"75 mg QD (Phase 1)","description":"PF-06463922 75 mg was orally given QD on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG003","title":"100 mg QD (Phase 1)","description":"PF-06463922 100 mg was orally given QD on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG004","title":"200 mg QD (Phase 1)","description":"PF-06463922 200 mg was orally given QD on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG005","title":"35 mg BID (Phase 1)","description":"PF-06463922 35 mg was orally given twice daily (BID) on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG006","title":"75 mg BID (Phase 1)","description":"PF-06463922 75 mg was orally given BID on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG007","title":"100 mg BID (Phase 1)","description":"PF-06463922 100 mg was orally given BID on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"11"},{"groupId":"OG003","value":"15"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"2"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"4"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":"NA","comment":"Summary statistics were not calculated when fewer than 3 participants had reportable values. The individual value is 18.0 hr."},{"groupId":"OG001","value":"23.70","spread":"NA","comment":"Standard deviation was not calculated when fewer than 3 participants had reportable values. Individual values are 16.6 and 30.8 hr, respectively."},{"groupId":"OG002","value":"27.22","spread":"8.2961"},{"groupId":"OG003","value":"20.89","spread":"5.0308"},{"groupId":"OG004","value":"19.80","spread":"3.3045"},{"groupId":"OG005","value":"25.55","spread":"NA","comment":"Standard deviation was not calculated when fewer than 3 participants had reportable values. Individual values are 24.6 and 26.5 hr, respectively."},{"groupId":"OG006","value":"NA","spread":"NA","comment":"Summary statistics were not calculated when fewer than 3 participants had reportable values. The individual value is 26.0 hr."},{"groupId":"OG007","value":"17.18","spread":"5.1874"}]}]}]},{"type":"SECONDARY","title":"Steady State Accumulation Ratio (Rss) of PF-06463922 Following Multiple Oral Doses (Phase 1)","description":"Rss was calculated as Day 15 AUCtau/Day -7 AUCinf, where AUCtau was the area under the plasma concentration-time profile from time 0 to time tau (12 and 24 hours for BID and QD dosing regimen, respectively), and AUCinf was the area under the plasma concentration-time profile from time 0 extrapolated to infinite time.","populationDescription":"PK parameter analysis set for PF-06463922 included all enrolled participants who received at least 1 dose of PF-06463922 and had sufficient information to estimate at least one of the PK parameters of interest for PF-06463922. Here, \"Overall Number of Participants Analyzed\" signifies participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Ratio","timeFrame":"Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9, 24 hours post-dose on Cycle 1 Day 15 (24-hour samples not collected for BID groups)","groups":[{"id":"OG000","title":"10 mg QD (Phase 1)","description":"PF-06463922 10 mg was orally given once daily (QD) on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG001","title":"50 mg QD (Phase 1)","description":"PF-06463922 50 mg was orally given QD on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG002","title":"75 mg QD (Phase 1)","description":"PF-06463922 75 mg was orally given QD on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG003","title":"100 mg QD (Phase 1)","description":"PF-06463922 100 mg was orally given QD on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG004","title":"200 mg QD (Phase 1)","description":"PF-06463922 200 mg was orally given QD on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG005","title":"35 mg BID (Phase 1)","description":"PF-06463922 35 mg was orally given twice daily (BID) on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG006","title":"75 mg BID (Phase 1)","description":"PF-06463922 75 mg was orally given BID on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG007","title":"100 mg BID (Phase 1)","description":"PF-06463922 100 mg was orally given BID on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"11"},{"groupId":"OG003","value":"14"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"3"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":"NA","comment":"These summary statistics were not calculated when fewer than 3 participants had reportable values. The individual value is 0.993."},{"groupId":"OG001","value":"0.5600","spread":"NA","comment":"Standard deviation was not calculated when fewer than 3 participants had reportable values. Individual values are 0.401 and 0.719, respectively."},{"groupId":"OG002","value":"0.6131","spread":"0.29021"},{"groupId":"OG003","value":"0.6603","spread":"0.18604"},{"groupId":"OG004","value":"0.3935","spread":"NA","comment":"Standard deviation was not calculated when fewer than 3 participants had reportable values. Individual values are 0.384 and 0.403, respectively."},{"groupId":"OG005","value":"NA","spread":"NA","comment":"These summary statistics were not calculated when fewer than 3 participants had reportable values. The individual value is 0.815."},{"groupId":"OG006","value":"NA","spread":"NA","comment":"These summary statistics were not calculated when fewer than 3 participants had reportable values. The individual value is 0.542."},{"groupId":"OG007","value":"0.7687","spread":"0.13552"}]}]}]},{"type":"SECONDARY","title":"Renal Clearance (CLr) of PF-06463922 (Phase 1)","description":"Renal clearance was calculated as Aetau/AUCtau, where Aetau was the cumulative amount of drug recovered unchanged in urine up to dosing interval tau (24 hours for QD dosing regimen), and AUCtau was the area under the plasma concentration-time profile from time 0 to time tau (24 hours for QD dosing regimen).","populationDescription":"PK parameter analysis set for PF-06463922 included all enrolled participants who received at least 1 dose of PF-06463922 and had sufficient information to estimate at least one of the PK parameters of interest for PF-06463922. As planned, this parameter was only analyzed for 100 mg QD group. Here, \"Overall Number of Participants Analyzed\" signifies participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"ml/hour","timeFrame":"0-4 hours, 4-12 hours and 12-24 hours post-dose on Cycle 1 Day 15","groups":[{"id":"OG000","title":"100 mg QD (Phase 1)","description":"PF-06463922 100 mg was orally given QD on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"61.31","spread":"58"}]}]}]},{"type":"SECONDARY","title":"Percent of PF-06463922 Recovered Unchanged in Urine up to Dosing Interval (AEtau%) (Phase 1)","description":"Dosing interval was 24 hours for QD dosing regimen. Aetau% was calculated as 100\\*Ae24/dose, where Ae24 was the cumulative amount of drug recovered unchanged in urine up to 24 hours post-dose.","populationDescription":"PK parameter analysis set for PF-06463922 included all enrolled participants who received at least 1 dose of PF-06463922 and had sufficient information to estimate at least one of the PK parameters of interest for PF-06463922. As planned, this parameter was only analyzed for 100 mg QD group. Here, \"Overall Number of Participants Analyzed\" signifies participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Percentage of recovered PF-06463922","timeFrame":"0-4 hours, 4-12 hours and 12-24 hours post-dose on Cycle 1 Day 15","groups":[{"id":"OG000","title":"100 mg QD (Phase 1)","description":"PF-06463922 100 mg was orally given QD on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4017","spread":"0.11074"}]}]}]},{"type":"SECONDARY","title":"Maximum Observed Plasma Concentration (Cmax) of Midazolam (Phase 1)","description":"Cmax of midazolam was observed directly from data. Only participants in 25 mg and 150 mg QD groups were given midazolam. Day -7 data reflected the PK assessment before administration of PF-06463922, and Cycle 1 Day 15 data reflected the PK assessment after multiple doses of PF-06463922 were administered.","populationDescription":"PK parameter analysis set for PF-06463922 included all enrolled participants who received at least 1 dose of PF-06463922 and had sufficient information to estimate at least one of the PK parameters of interest for PF-06463922.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"ng/mL","timeFrame":"Pre-dose, 0.5, 1, 2, 4, 6, 8, 9 and 24 hours post-dose on Day -7 and pre-dose, 0.5, 1, 2, 4, 6, 8, 9 and 24 hours post-dose on Cycle 1 Day 15","groups":[{"id":"OG000","title":"25 mg QD (Phase 1)","description":"PF-06463922 25 mg was orally given QD in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal. Midazolam 2 mg was orally given QD on Day -7 and Cycle 1 Day 15."},{"id":"OG001","title":"150 mg QD (Phase 1)","description":"PF-06463922 150 mg was orally given QD in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal. Midazolam 2 mg was orally given QD on Day -7 and Cycle 1 Day 15."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"}]}],"classes":[{"title":"Day -7","categories":[{"measurements":[{"groupId":"OG000","value":"16.06","spread":"42"},{"groupId":"OG001","value":"11.56","spread":"48"}]}]},{"title":"Cycle 1 Day 15","categories":[{"measurements":[{"groupId":"OG000","value":"9.697","spread":"40"},{"groupId":"OG001","value":"5.734","spread":"43"}]}]}]},{"type":"SECONDARY","title":"Time for Cmax (Tmax) of Midazolam (Phase 1)","description":"Tmax of midazolam was observed directly from data as time of first occurrence. Only participants in 25 mg and 150 mg QD groups were given midazolam. Day -7 data reflect the PK assessment before administration of PF-06463922, and Cycle 1 Day 15 data reflect the PK assessment after multiple doses of PF-06463922 were administered.","populationDescription":"PK parameter analysis set for midazolam included all participants who received at least 1 dose of midazolam and for which at least 1 midazolam PK parameter of interest was available.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Full Range","unitOfMeasure":"Hours","timeFrame":"Pre-dose, 0.5, 1, 2, 4, 6, 8, 9 and 24 hours post-dose on Day -7 and pre-dose, 0.5, 1, 2, 4, 6, 8, 9 and 24 hours post-dose on Cycle 1 Day 15","groups":[{"id":"OG000","title":"25 mg QD (Phase 1)","description":"PF-06463922 25 mg was orally given QD in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal. Midazolam 2 mg was orally given QD on Day -7 and Cycle 1 Day 15."},{"id":"OG001","title":"150 mg QD (Phase 1)","description":"PF-06463922 150 mg was orally given QD in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal. Midazolam 2 mg was orally given QD on Day -7 and Cycle 1 Day 15."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"}]}],"classes":[{"title":"Day -7","categories":[{"measurements":[{"groupId":"OG000","value":"0.50","lowerLimit":"0.50","upperLimit":"1.00"},{"groupId":"OG001","value":"0.50","lowerLimit":"0.50","upperLimit":"0.50"}]}]},{"title":"Cycle 1 Day 15","categories":[{"measurements":[{"groupId":"OG000","value":"0.50","lowerLimit":"0.50","upperLimit":"1.00"},{"groupId":"OG001","value":"0.50","lowerLimit":"0.50","upperLimit":"0.533"}]}]}]},{"type":"SECONDARY","title":"Area Under the Plasma Concentration-Time Profile From Time Zero to the Time of the Last Quantifiable Concentration (AUClast) of Midazolam (Phase 1)","description":"Area under the plasma concentration-time profile from time 0 to the time of the last quantifiable concentration (AUClast) of midazolam was determined using linear/log trapezoidal method. Only participants in 25 mg and 150 mg QD groups were given midazolam. Day -7 data reflect the PK assessment before administration of PF-06463922, and Cycle 1 Day 15 data reflect the PK assessment after multiple doses of PF-06463922 were administered.","populationDescription":"PK parameter analysis set for midazolam included all participants who received at least 1 dose of midazolam and for which at least 1 midazolam PK parameter of interest was available.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"ng*hr/mL","timeFrame":"Pre-dose, 0.5, 1, 2, 4, 6, 8, 9 and 24 hours post-dose on Day -7 and pre-dose, 0.5, 1, 2, 4, 6, 8, 9 and 24 hours post-dose on Cycle 1 Day 15","groups":[{"id":"OG000","title":"25 mg QD (Phase 1)","description":"PF-06463922 25 mg was orally given QD in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal. Midazolam 2 mg was orally given QD on Day -7 and Cycle 1 Day 15."},{"id":"OG001","title":"150 mg QD (Phase 1)","description":"PF-06463922 150 mg was orally given QD in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal. Midazolam 2 mg was orally given QD on Day -7 and Cycle 1 Day 15."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"}]}],"classes":[{"title":"Day -7","categories":[{"measurements":[{"groupId":"OG000","value":"51.30","spread":"47"},{"groupId":"OG001","value":"36.49","spread":"20"}]}]},{"title":"Cycle 1 Day 15","categories":[{"measurements":[{"groupId":"OG000","value":"20.43","spread":"18"},{"groupId":"OG001","value":"14.44","spread":"25"}]}]}]},{"type":"SECONDARY","title":"Area Under the Plasma Concentration-Time Profile From Time Zero Extrapolated to Infinite Time (AUCinf) of Midazolam (Phase 1)","description":"AUCinf was calculated as AUClast + (Clast\\*/kel), where AUClast was the area under the plasma concentration-time profile from time 0 to the time of the last quantifiable concentration, Clast\\* was the predicted plasma concentration at the last quantifiable time point estimated from the log-linear regression analysis, and kel was the rate constant for terminal phase. Only participants in 25 mg and 150 mg QD groups were given midazolam. Day -7 data reflect the PK assessment before administration of PF-06463922, and Cycle 1 Day 15 data reflect the PK assessment after multiple doses of PF-06463922 were administered.","populationDescription":"PK parameter analysis set for midazolam included all participants who received at least 1 dose of midazolam and for which at least 1 midazolam PK parameter of interest was available.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"ng*hr/mL","timeFrame":"Pre-dose, 0.5, 1, 2, 4, 6, 8, 9 and 24 hours post-dose on Day -7 and pre-dose, 0.5, 1, 2, 4, 6, 8, 9 and 24 hours post-dose on Cycle 1 Day 15","groups":[{"id":"OG000","title":"25 mg QD (Phase 1)","description":"PF-06463922 25 mg was orally given QD in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal. Midazolam 2 mg was orally given QD on Day -7 and Cycle 1 Day 15."},{"id":"OG001","title":"150 mg QD (Phase 1)","description":"PF-06463922 150 mg was orally given QD in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal. Midazolam 2 mg was orally given QD on Day -7 and Cycle 1 Day 15."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"}]}],"classes":[{"title":"Day -7","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"54.53","spread":"43"},{"groupId":"OG001","value":"NA","spread":"NA","comment":"Summary statistics were not calculated when fewer than 3 participants had reportable values. Individual values are 42.2 and 46.8 ng\\*hr/mL, respectively."}]}]},{"title":"Cycle 1 Day 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"21.32","spread":"18"},{"groupId":"OG001","value":"16.09","spread":"29"}]}]}]},{"type":"SECONDARY","title":"Apparent Oral Clearance (CL/F) of Midazolam (Phase 1)","description":"Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. CL/F was calculated as dose/AUCinf, where AUCinf was the area under the plasma concentration-time profile from time 0 extrapolated to infinite time. Only participants in 25 mg and 150 mg QD groups were given midazolam. Day -7 data reflect the PK assessment before administration of PF-06463922, and Cycle 1 Day 15 data reflect the PK assessment after multiple doses of PF-06463922 were administered.","populationDescription":"PK parameter analysis set for midazolam included all participants who received at least 1 dose of midazolam and for which at least 1 midazolam PK parameter of interest was available. Here, 'Number Analyzed' signifies participants evaluable for specified rows","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"L/hr","timeFrame":"Pre-dose, 0.5, 1, 2, 4, 6, 8, 9 and 24 hours post-dose on Day -7 and pre-dose, 0.5, 1, 2, 4, 6, 8, 9 and 24 hours post-dose on Cycle 1 Day 15","groups":[{"id":"OG000","title":"25 mg QD (Phase 1)","description":"PF-06463922 25 mg was orally given QD in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal. Midazolam 2 mg was orally given QD on Day -7 and Cycle 1 Day 15."},{"id":"OG001","title":"150 mg QD (Phase 1)","description":"PF-06463922 150 mg was orally given QD in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal. Midazolam 2 mg was orally given QD on Day -7 and Cycle 1 Day 15."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"}]}],"classes":[{"title":"Day -7","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"36.68","spread":"43"},{"groupId":"OG001","value":"NA","spread":"NA","comment":"Summary statistics were not calculated when fewer than 3 participants had reportable values. Individual values are 42.7 and 47.4 L/hr, respectively."}]}]},{"title":"Cycle 1 Day 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"93.86","spread":"18"},{"groupId":"OG001","value":"124.2","spread":"29"}]}]}]},{"type":"SECONDARY","title":"Apparent Volume of Distribution (Vz/F) of Midazolam (Phase 1)","description":"Vz/F was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug, and calculated as dose/(AUCinf\\*kel), where AUCinf was the area under the plasma concentration-time profile from time 0 extrapolated to infinite time, kel was the rate constant for terminal phase. Only participants in 25 mg and 150 mg QD groups were given midazolam. Day -7 data reflect the PK assessment before administration of PF-06463922, and Cycle 1 Day 15 data reflect the PK assessment after multiple doses of PF-06463922 were administered.","populationDescription":"PK parameter analysis set for midazolam included all participants who received at least 1 dose of midazolam and for which at least 1 midazolam PK parameter of interest was available. Here, 'Number Analyzed' signifies participants evaluable for specified rows.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"Liters","timeFrame":"Pre-dose, 0.5, 1, 2, 4, 6, 8, 9 and 24 hours post-dose on Day -7 and pre-dose, 0.5, 1, 2, 4, 6, 8, 9 and 24 hours post-dose on Cycle 1 Day 15","groups":[{"id":"OG000","title":"25 mg QD (Phase 1)","description":"PF-06463922 25 mg was orally given QD in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal. Midazolam 2 mg was orally given QD on Day -7 and Cycle 1 Day 15."},{"id":"OG001","title":"150 mg QD (Phase 1)","description":"PF-06463922 150 mg was orally given QD in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal. Midazolam 2 mg was orally given QD on Day -7 and Cycle 1 Day 15."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"}]}],"classes":[{"title":"Day -7","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"229.0","spread":"7"},{"groupId":"OG001","value":"NA","spread":"NA","comment":"Summary statistics were not calculated when fewer than 3 participants had reportable values. Individual values are 161 and 486 L, respectively."}]}]},{"title":"Cycle 1 Day 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"404.4","spread":"51"},{"groupId":"OG001","value":"702.2","spread":"100"}]}]}]},{"type":"SECONDARY","title":"Terminal Half-Life of Midazolam (Phase 1)","description":"Terminal plasma half-life was defined as the time measured for the plasma concentration to decrease by one half, and calculated as loge(2)/kel, where kel was the rate constant for terminal phase. Only participants in 25 mg and 150 mg QD groups were given midazolam. Day -7 data reflect the PK assessment before administration of PF-06463922, and Cycle 1 Day 15 data reflect the PK assessment after multiple doses of PF-06463922 were administered.","populationDescription":"PK parameter analysis set for midazolam included all participants who received at least 1 dose of midazolam and for which at least 1 midazolam PK parameter of interest was available. Here, 'Number Analyzed' signifies participants evaluable for specified rows.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Hours","timeFrame":"Pre-dose, 0.5, 1, 2, 4, 6, 8, 9 and 24 hours post-dose on Day -7 and pre-dose, 0.5, 1, 2, 4, 6, 8, 9 and 24 hours post-dose on Cycle 1 Day 15","groups":[{"id":"OG000","title":"25 mg QD (Phase 1)","description":"PF-06463922 25 mg was orally given QD in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal. Midazolam 2 mg was orally given QD on Day -7 and Cycle 1 Day 15."},{"id":"OG001","title":"150 mg QD (Phase 1)","description":"PF-06463922 150 mg was orally given QD in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal. Midazolam 2 mg was orally given QD on Day -7 and Cycle 1 Day 15."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"}]}],"classes":[{"title":"Day -7","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4.620","spread":"1.9328"},{"groupId":"OG001","value":"5.120","spread":"NA","comment":"Standard deviation was not calculated when fewer than 3 participants had reportable values. Individual values are 2.35 and 7.89 hr, respectively."}]}]},{"title":"Cycle 1 Day 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.343","spread":"2.0358"},{"groupId":"OG001","value":"5.257","spread":"5.0639"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With ALK Mutation Based on Plasma CNA Analysis (Phase 1)","description":"Plasma circulating nucleic acid (CNA) samples were analyzed for ALK kinase domain mutations by digital polymerase chain reaction (PCR) BEAMing technology. Number of participants with one or more ALK mutations is presented.","populationDescription":"CNA peripheral blood analysis set included all participants of the ITT analysis set who had at least 1 molecular biomarker assayed.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Screening (up to 28 days)","groups":[{"id":"OG000","title":"ALK Positive Population (Phase 1)","description":"This reporting arm includes all Phase 1 participants who had documented ALK rearrangement."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"40"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With ALK Mutation Based on Tumor Tissue Analysis (Phase 1)","description":"Tumor tissues from archived tissue specimens and/or a de novo biopsy were analyzed for ALK kinase domain mutations. Number of participants with one or more ALK mutations is presented.","populationDescription":"Tumor Tissue analysis set included all participants of the ITT analysis set who had at least 1 molecular tumor biomarker assayed from either the screening archival or screening de novo tumor biopsy sample (or both).","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Screening (up to 28 days)","groups":[{"id":"OG000","title":"ALK Positive Population (Phase 1)","description":"This reporting arm includes all Phase 1 participants who had documented ALK rearrangement."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"40"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7"}]}]}]},{"type":"SECONDARY","title":"Number of Participants Who Improved, Worsened or Remained Stable in EORTC QLQ-C30 (Phase 1)","description":"European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ)-C30 (version 3.0) consists of 30 questions assessing 5 functional domains (physical, role, emotional, cognitive and social), global quality of life (QoL), disease/treatment related symptoms (fatigue, nausea/vomiting, pain, dyspnea, insomnia, appetite loss, constipation and diarrhea), and the perceived financial impact of disease. Each scale was transformed to a range of 0 to 100 using standard EORTC algorithm. For global QoL and functional scales, higher score indicate better performance, and improvement was defined as an increase of at least 10 points, worsening was defined as a decrease of at least 10 points. For symptom scales, higher score indicates worse symptoms, and improvement was defined as a decrease of at least 10 points, worsening was defined as an increase of at least 10 points. All scales which had not improved nor worsened were considered stable.","populationDescription":"Patient reported outcome (PRO) evaluable analysis set included all enrolled participants who received at least 1 dose of PF-06463922 and completed a baseline and at least 1 post-baseline PRO assessment.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"From start of study treatment until end of treatment (maximum of 8 years approximately)","groups":[{"id":"OG000","title":"Phase 1 PRO Evaluable Population","description":"This reporting group includes all Phase 1 participants who received at least 1 dose of PF-06463922 and completed a baseline and at least 1 post-baseline PRO assessment."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"43"}]}],"classes":[{"title":"Improved in global QoL","categories":[{"measurements":[{"groupId":"OG000","value":"19"}]}]},{"title":"Stable in global QoL","categories":[{"measurements":[{"groupId":"OG000","value":"13"}]}]},{"title":"Worsened in global QoL","categories":[{"measurements":[{"groupId":"OG000","value":"11"}]}]},{"title":"Improved in physical functioning","categories":[{"measurements":[{"groupId":"OG000","value":"5"}]}]},{"title":"Stable in physical functioning","categories":[{"measurements":[{"groupId":"OG000","value":"29"}]}]},{"title":"Worsened in physical functioning","categories":[{"measurements":[{"groupId":"OG000","value":"9"}]}]},{"title":"Improved in role functioning","categories":[{"measurements":[{"groupId":"OG000","value":"14"}]}]},{"title":"Stable in role functioning","categories":[{"measurements":[{"groupId":"OG000","value":"15"}]}]},{"title":"Worsened in role functioning","categories":[{"measurements":[{"groupId":"OG000","value":"14"}]}]},{"title":"Improved in emotional functioning","categories":[{"measurements":[{"groupId":"OG000","value":"15"}]}]},{"title":"Stable in emotional functioning","categories":[{"measurements":[{"groupId":"OG000","value":"21"}]}]},{"title":"Worsened in emotional functioning","categories":[{"measurements":[{"groupId":"OG000","value":"7"}]}]},{"title":"Improved in cognitive functioning","categories":[{"measurements":[{"groupId":"OG000","value":"8"}]}]},{"title":"Stable in cognitive functioning","categories":[{"measurements":[{"groupId":"OG000","value":"21"}]}]},{"title":"Worsened in cognitive functioning","categories":[{"measurements":[{"groupId":"OG000","value":"14"}]}]},{"title":"Improved in social functioning","categories":[{"measurements":[{"groupId":"OG000","value":"13"}]}]},{"title":"Stable in social functioning","categories":[{"measurements":[{"groupId":"OG000","value":"17"}]}]},{"title":"Worsened in social functioning","categories":[{"measurements":[{"groupId":"OG000","value":"13"}]}]},{"title":"Improved in fatigue","categories":[{"measurements":[{"groupId":"OG000","value":"17"}]}]},{"title":"Stable in fatigue","categories":[{"measurements":[{"groupId":"OG000","value":"19"}]}]},{"title":"Worsened in fatigue","categories":[{"measurements":[{"groupId":"OG000","value":"7"}]}]},{"title":"Improved in nausea and vomiting","categories":[{"measurements":[{"groupId":"OG000","value":"10"}]}]},{"title":"Stable in nausea and vomiting","categories":[{"measurements":[{"groupId":"OG000","value":"32"}]}]},{"title":"worsened in nausea and vomiting","categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]},{"title":"Improved in pain","categories":[{"measurements":[{"groupId":"OG000","value":"17"}]}]},{"title":"Stable in pain","categories":[{"measurements":[{"groupId":"OG000","value":"16"}]}]},{"title":"Worsened in pain","categories":[{"measurements":[{"groupId":"OG000","value":"10"}]}]},{"title":"Improved in dyspnea","categories":[{"measurements":[{"groupId":"OG000","value":"13"}]}]},{"title":"Stable in dyspnea","categories":[{"measurements":[{"groupId":"OG000","value":"19"}]}]},{"title":"Worsened in dyspnea","categories":[{"measurements":[{"groupId":"OG000","value":"11"}]}]},{"title":"Improved in insomnia","categories":[{"measurements":[{"groupId":"OG000","value":"19"}]}]},{"title":"Stable in insomnia","categories":[{"measurements":[{"groupId":"OG000","value":"17"}]}]},{"title":"Worsened in insomnia","categories":[{"measurements":[{"groupId":"OG000","value":"7"}]}]},{"title":"Improved in appetite loss","categories":[{"measurements":[{"groupId":"OG000","value":"14"}]}]},{"title":"Stable in appetite loss","categories":[{"measurements":[{"groupId":"OG000","value":"27"}]}]},{"title":"Worsened in appetite loss","categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}]},{"title":"Improved in constipation","categories":[{"measurements":[{"groupId":"OG000","value":"10"}]}]},{"title":"Stable in constipation","categories":[{"measurements":[{"groupId":"OG000","value":"28"}]}]},{"title":"Worsened in constipation","categories":[{"measurements":[{"groupId":"OG000","value":"5"}]}]},{"title":"Improved in diarrhea","categories":[{"measurements":[{"groupId":"OG000","value":"9"}]}]},{"title":"Stable in diarrhea","categories":[{"measurements":[{"groupId":"OG000","value":"28"}]}]},{"title":"Worsened in diarrhea","categories":[{"measurements":[{"groupId":"OG000","value":"6"}]}]},{"title":"Improved in financial difficulties","categories":[{"measurements":[{"groupId":"OG000","value":"7"}]}]},{"title":"Stable in financial difficulties","categories":[{"measurements":[{"groupId":"OG000","value":"20"}]}]},{"title":"Worsened in financial difficulties","categories":[{"measurements":[{"groupId":"OG000","value":"16"}]}]}]},{"type":"SECONDARY","title":"Number of Participants Who Improved, Worsened or Remained Stable in EORTC QLQ-LC13 (Phase 1)","description":"EORTC QLQ-LC13 is the lung cancer module of EORTC QLQ-C30 and includes questions specific to the disease associated symptoms (dyspnea, cough, hemoptysis, and site specific pain), treatment-related symptoms (sore mouth, dysphagia, neuropathy and alopecia), and analgesic use of lung cancer patients. The scale was transformed to a range of 0 to 100 using standard EORTC algorithm. Higher score indicates worse symptoms, and improvement was defined as a decrease of at least 10 points, worsening was defined as an increase of at least 10 points. All scales which had not improved nor worsened were considered stable.","populationDescription":"PRO evaluable analysis set included all enrolled participants who received at least 1 dose of PF-06463922 and completed a baseline and at least 1 post-baseline PRO assessment.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"From start of study treatment until end of treatment (maximum of 8 years approximately)","groups":[{"id":"OG000","title":"Phase 1 PRO Evaluable Population","description":"This reporting group includes all Phase 1 participants who received at least 1 dose of PF-06463922 and completed a baseline and at least 1 post-baseline PRO assessment."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"43"}]}],"classes":[{"title":"Improved in dyspnea","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"43"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"9"}]}]},{"title":"Stable in dyspnea","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"43"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"23"}]}]},{"title":"Worsened in dyspnea","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"43"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"11"}]}]},{"title":"Improved in coughing","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"43"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"23"}]}]},{"title":"Stable in coughing","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"43"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"12"}]}]},{"title":"Worsened in coughing","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"43"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"8"}]}]},{"title":"Improved in hemoptysis","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"43"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]},{"title":"Stable in hemoptysis","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"43"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"42"}]}]},{"title":"Worsened in hemoptysis","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"43"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Improved in sore mouth","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"43"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Stable in sore mouth","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"43"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"40"}]}]},{"title":"Worsened in sore mouth","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"43"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}]},{"title":"Improved in dysphagia","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"43"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}]},{"title":"Stable in dysphagia","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"43"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"37"}]}]},{"title":"Worsened in dysphagia","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"43"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}]},{"title":"Improved in peripheral neuropathy","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"43"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"6"}]}]},{"title":"Stable in peripheral neuropathy","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"43"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"21"}]}]},{"title":"Worsened in peripheral neuropathy","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"43"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"16"}]}]},{"title":"Improved in alopecia","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"42"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}]},{"title":"Stable in alopecia","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"42"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"29"}]}]},{"title":"Worsened in alopecia","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"42"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"9"}]}]},{"title":"Improved in chest pain","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"43"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"16"}]}]},{"title":"Stable in chest pain","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"43"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"22"}]}]},{"title":"Worsened in chest pain","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"43"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5"}]}]},{"title":"Improved in arm or shoulder pain","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"43"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"10"}]}]},{"title":"Stable in arm or shoulder pain","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"43"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"27"}]}]},{"title":"Worsened in arm or shoulder pain","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"43"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"6"}]}]},{"title":"Improved in pain in other parts","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"43"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"20"}]}]},{"title":"Stable in pain in other parts","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"43"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"12"}]}]},{"title":"Worsened in pain in other parts","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"43"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"11"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Mini Mental State Examination (MMSE) Score (Phase 1)","description":"In Phase 1, the MMSE was collected to assess mental status. The MMSE is a 30 item questionnaire that tests 5 areas of cognitive function: orientation, registration, attention and calculation, recall and language. The maximum score is 30 and minimum score is 0. Highest score indicates no cognitive impairment, lowest score indicates severe cognitive impairment. The MMSE was removed under Amendment 6 of the study protocol, and not required for Phase 2, as the tool was not considered meaningful for assessment of cognitive function.","populationDescription":"MMSE assessment evaluable analysis set included all participants in the safety analysis set (all participants who received at least 1 dose of PF-06463922) who completed a baseline and at least 1 post-baseline assessment. Here, \"Overall Number of Participants Analyzed\" signifies participants evaluable for this outcome measure. Here, \"Number Analyzed\" signifies participants evaluable for specified rows.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Units on a scale","timeFrame":"Baseline, Day 1 of Cycle 1-52, and end of treatment (up to 3 years)","groups":[{"id":"OG000","title":"10 mg QD (Phase 1)","description":"PF-06463922 10 mg was orally given once daily (QD) on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG001","title":"25 mg QD (Phase 1)","description":"PF-06463922 25 mg was orally given QD in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal. Midazolam 2 mg was orally given QD on Day -7 and Cycle 1 Day 15."},{"id":"OG002","title":"50 mg QD (Phase 1)","description":"PF-06463922 50 mg was orally given QD on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG003","title":"75 mg QD (Phase 1)","description":"PF-06463922 75 mg was orally given QD on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG004","title":"100 mg QD (Phase 1)","description":"PF-06463922 100 mg was orally given QD on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG005","title":"150 mg QD (Phase 1)","description":"PF-06463922 150 mg was orally given QD in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal. Midazolam 2 mg was orally given QD on Day -7 and Cycle 1 Day 15."},{"id":"OG006","title":"200 mg QD (Phase 1)","description":"PF-06463922 200 mg was orally given QD on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG007","title":"35 mg BID (Phase 1)","description":"PF-06463922 35 mg was orally given twice daily (BID) on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG008","title":"75 mg BID (Phase 1)","description":"PF-06463922 75 mg was orally given BID on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG009","title":"100 mg BID (Phase 1)","description":"PF-06463922 100 mg was orally given BID on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"9"},{"groupId":"OG004","value":"16"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"2"},{"groupId":"OG008","value":"3"},{"groupId":"OG009","value":"4"}]}],"classes":[{"title":"Cycle 1 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"9"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"1"},{"groupId":"OG009","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","spread":"1.41"},{"groupId":"OG002","value":"-0.5","spread":"0.71"},{"groupId":"OG003","value":"-0.9","spread":"2.27"},{"groupId":"OG004","value":"0.8","spread":"1.39"},{"groupId":"OG008","value":"0.0","spread":"NA","comment":"Standard deviation could not be calculated as only 1 participant was analyzed."},{"groupId":"OG009","value":"0.0","spread":"NA","comment":"Standard deviation could not be calculated as only 1 participant was analyzed."}]}]},{"title":"Cycle 2 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"9"},{"groupId":"OG004","value":"16"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"2"},{"groupId":"OG008","value":"2"},{"groupId":"OG009","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.0","spread":"NA","comment":"Standard deviation could not be calculated as only 1 participant was analyzed."},{"groupId":"OG001","value":"-0.3","spread":"0.58"},{"groupId":"OG002","value":"2.0","spread":"NA","comment":"Standard deviation could not be calculated as only 1 participant was analyzed."},{"groupId":"OG003","value":"0.3","spread":"1.41"},{"groupId":"OG004","value":"0.0","spread":"1.79"},{"groupId":"OG005","value":"4.7","spread":"8.08"},{"groupId":"OG006","value":"4.0","spread":"4.24"},{"groupId":"OG007","value":"0.0","spread":"0.00"},{"groupId":"OG008","value":"0.0","spread":"0.00"},{"groupId":"OG009","value":"-0.3","spread":"1.15"}]}]},{"title":"Cycle 3 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"8"},{"groupId":"OG004","value":"15"},{"groupId":"OG005","value":"2"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"1"},{"groupId":"OG009","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.0","spread":"0.00"},{"groupId":"OG001","value":"0.3","spread":"0.58"},{"groupId":"OG002","value":"-0.5","spread":"0.71"},{"groupId":"OG003","value":"-0.6","spread":"1.85"},{"groupId":"OG004","value":"0.2","spread":"1.52"},{"groupId":"OG005","value":"5.0","spread":"8.49"},{"groupId":"OG006","value":"3.0","spread":"2.83"},{"groupId":"OG008","value":"0.0","spread":"NA","comment":"Standard deviation could not be calculated as only 1 participant was analyzed."},{"groupId":"OG009","value":"-1.0","spread":"1.00"}]}]},{"title":"Cycle 4 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"8"},{"groupId":"OG004","value":"14"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"1"},{"groupId":"OG009","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5.0","spread":"NA","comment":"Standard deviation could not be calculated as only 1 participant was analyzed."},{"groupId":"OG001","value":"0.5","spread":"0.71"},{"groupId":"OG002","value":"1.5","spread":"2.12"},{"groupId":"OG003","value":"-1.1","spread":"1.81"},{"groupId":"OG004","value":"0.0","spread":"1.47"},{"groupId":"OG005","value":"2.0","spread":"6.24"},{"groupId":"OG006","value":"-0.5","spread":"3.54"},{"groupId":"OG008","value":"0.0","spread":"NA","comment":"Standard deviation could not be calculated as only 1 participant was analyzed."},{"groupId":"OG009","value":"-0.7","spread":"1.15"}]}]},{"title":"Cycle 5 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"11"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"1"},{"groupId":"OG009","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","spread":"3.54"},{"groupId":"OG001","value":"0.5","spread":"0.71"},{"groupId":"OG002","value":"1.5","spread":"2.12"},{"groupId":"OG003","value":"0.3","spread":"1.25"},{"groupId":"OG004","value":"-0.2","spread":"1.72"},{"groupId":"OG005","value":"4.7","spread":"8.14"},{"groupId":"OG006","value":"0.5","spread":"6.36"},{"groupId":"OG008","value":"0.0","spread":"NA","comment":"Standard deviation could not be calculated as only 1 participant was analyzed."},{"groupId":"OG009","value":"-0.5","spread":"0.71"}]}]},{"title":"Cycle 6 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"11"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"1"},{"groupId":"OG009","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.5","spread":"2.12"},{"groupId":"OG001","value":"0.5","spread":"0.71"},{"groupId":"OG002","value":"1.0","spread":"1.41"},{"groupId":"OG003","value":"-0.4","spread":"2.70"},{"groupId":"OG004","value":"0.3","spread":"0.90"},{"groupId":"OG005","value":"4.3","spread":"5.86"},{"groupId":"OG006","value":"2.0","spread":"4.24"},{"groupId":"OG008","value":"0.0","spread":"NA","comment":"Standard deviation could not be calculated as only 1 participant was analyzed."},{"groupId":"OG009","value":"-1.3","spread":"2.31"}]}]},{"title":"Cycle 7 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"12"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"1"},{"groupId":"OG009","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.0","spread":"NA","comment":"Standard deviation could not be calculated as only 1 participant was analyzed."},{"groupId":"OG001","value":"0.5","spread":"0.71"},{"groupId":"OG002","value":"1.5","spread":"2.12"},{"groupId":"OG003","value":"-0.1","spread":"1.21"},{"groupId":"OG004","value":"0.4","spread":"0.90"},{"groupId":"OG005","value":"4.7","spread":"8.33"},{"groupId":"OG006","value":"3.0","spread":"4.24"},{"groupId":"OG008","value":"0.0","spread":"NA","comment":"Standard deviation could not be calculated as only 1 participant was analyzed."},{"groupId":"OG009","value":"-0.7","spread":"1.15"}]}]},{"title":"Cycle 8 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"12"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"1"},{"groupId":"OG009","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-4.0","spread":"NA","comment":"Standard deviation could not be calculated as only 1 participant was analyzed."},{"groupId":"OG001","value":"0.5","spread":"0.71"},{"groupId":"OG002","value":"1.5","spread":"2.12"},{"groupId":"OG003","value":"-0.1","spread":"2.34"},{"groupId":"OG004","value":"0.2","spread":"1.34"},{"groupId":"OG005","value":"3.0","spread":"7.81"},{"groupId":"OG006","value":"4.0","spread":"4.24"},{"groupId":"OG008","value":"0.0","spread":"NA","comment":"Standard deviation could not be calculated as only 1 participant was analyzed."},{"groupId":"OG009","value":"0.0","spread":"0.00"}]}]},{"title":"Cycle 9 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"11"},{"groupId":"OG005","value":"2"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"0.0","spread":"0.00"},{"groupId":"OG002","value":"0.0","spread":"NA","comment":"Standard deviation could not be calculated as only 1 participant was analyzed."},{"groupId":"OG003","value":"-1.0","spread":"2.31"},{"groupId":"OG004","value":"0.3","spread":"2.10"},{"groupId":"OG005","value":"6.0","spread":"8.49"},{"groupId":"OG006","value":"6.0","spread":"NA","comment":"Standard deviation could not be calculated as only 1 participant was analyzed."},{"groupId":"OG009","value":"-0.3","spread":"0.58"}]}]},{"title":"Cycle 10 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"10"},{"groupId":"OG005","value":"2"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"1"},{"groupId":"OG009","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-5.0","spread":"NA","comment":"Standard deviation could not be calculated as only 1 participant was analyzed."},{"groupId":"OG001","value":"0.5","spread":"0.71"},{"groupId":"OG002","value":"0.0","spread":"NA","comment":"Standard deviation could not be calculated as only 1 participant was analyzed."},{"groupId":"OG003","value":"0.0","spread":"0.00"},{"groupId":"OG004","value":"-0.1","spread":"0.88"},{"groupId":"OG005","value":"6.5","spread":"9.19"},{"groupId":"OG006","value":"6.0","spread":"NA","comment":"Standard deviation could not be calculated as only 1 participant was analyzed."},{"groupId":"OG008","value":"0.0","spread":"NA","comment":"Standard deviation could not be calculated as only 1 participant was analyzed."},{"groupId":"OG009","value":"-1.7","spread":"1.53"}]}]},{"title":"Cycle 11 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"12"},{"groupId":"OG005","value":"2"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"1"},{"groupId":"OG009","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"-0.5","spread":"0.71"},{"groupId":"OG002","value":"0.0","spread":"NA","comment":"Standard deviation could not be calculated as only 1 participant was analyzed."},{"groupId":"OG003","value":"0.3","spread":"1.70"},{"groupId":"OG004","value":"-0.2","spread":"1.53"},{"groupId":"OG005","value":"7.0","spread":"8.49"},{"groupId":"OG006","value":"3.5","spread":"3.54"},{"groupId":"OG008","value":"0.0","spread":"NA","comment":"Standard deviation could not be calculated as only 1 participant was analyzed."},{"groupId":"OG009","value":"0.0","spread":"0.00"}]}]},{"title":"Cycle 12 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"12"},{"groupId":"OG005","value":"2"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"1"},{"groupId":"OG009","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"0.5","spread":"0.71"},{"groupId":"OG003","value":"-0.6","spread":"2.19"},{"groupId":"OG004","value":"-0.2","spread":"2.33"},{"groupId":"OG005","value":"6.5","spread":"9.19"},{"groupId":"OG006","value":"3.5","spread":"3.54"},{"groupId":"OG008","value":"0.0","spread":"NA","comment":"Standard deviation could not be calculated as only 1 participant was analyzed."},{"groupId":"OG009","value":"-0.7","spread":"0.58"}]}]},{"title":"Cycle 13 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"10"},{"groupId":"OG005","value":"2"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"1"},{"groupId":"OG009","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"0.5","spread":"0.71"},{"groupId":"OG003","value":"0.8","spread":"1.79"},{"groupId":"OG004","value":"0.5","spread":"2.22"},{"groupId":"OG005","value":"5.5","spread":"7.78"},{"groupId":"OG006","value":"3.0","spread":"4.24"},{"groupId":"OG008","value":"0.0","spread":"NA","comment":"Standard deviation could not be calculated as only 1 participant was analyzed."},{"groupId":"OG009","value":"-0.5","spread":"0.71"}]}]},{"title":"Cycle 14 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"11"},{"groupId":"OG005","value":"2"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"1"},{"groupId":"OG009","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"0.5","spread":"0.71"},{"groupId":"OG003","value":"-0.3","spread":"3.20"},{"groupId":"OG004","value":"0.3","spread":"0.79"},{"groupId":"OG005","value":"6.0","spread":"8.49"},{"groupId":"OG006","value":"2.5","spread":"3.54"},{"groupId":"OG008","value":"0.0","spread":"NA","comment":"Standard deviation could not be calculated as only 1 participant was analyzed."},{"groupId":"OG009","value":"0.0","spread":"0.00"}]}]},{"title":"Cycle 15 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"9"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"1"},{"groupId":"OG009","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"0.5","spread":"0.71"},{"groupId":"OG003","value":"-1.7","spread":"5.43"},{"groupId":"OG004","value":"0.1","spread":"1.36"},{"groupId":"OG006","value":"4.0","spread":"4.24"},{"groupId":"OG008","value":"0.0","spread":"NA","comment":"Standard deviation could not be calculated as only 1 participant was analyzed."},{"groupId":"OG009","value":"-0.3","spread":"0.58"}]}]},{"title":"Cycle 16 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"9"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"1"},{"groupId":"OG009","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"0.0","spread":"1.41"},{"groupId":"OG003","value":"-0.2","spread":"2.49"},{"groupId":"OG004","value":"-0.2","spread":"1.99"},{"groupId":"OG005","value":"1.0","spread":"NA","comment":"Standard deviation could not be calculated as only 1 participant was analyzed."},{"groupId":"OG006","value":"1.5","spread":"6.36"},{"groupId":"OG008","value":"0.0","spread":"NA","comment":"Standard deviation could not be calculated as only 1 participant was analyzed."},{"groupId":"OG009","value":"0.0","spread":"0.00"}]}]},{"title":"Cycle 17 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"9"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"1"},{"groupId":"OG009","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"-2.0","spread":"2.83"},{"groupId":"OG003","value":"0.6","spread":"1.95"},{"groupId":"OG004","value":"0.1","spread":"1.17"},{"groupId":"OG005","value":"-3.0","spread":"NA","comment":"Standard deviation could not be calculated as only 1 participant was analyzed."},{"groupId":"OG006","value":"4.0","spread":"4.24"},{"groupId":"OG008","value":"0.0","spread":"NA","comment":"Standard deviation could not be calculated as only 1 participant was analyzed."},{"groupId":"OG009","value":"-1.3","spread":"1.53"}]}]},{"title":"Cycle 18 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"9"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"-0.5","spread":"0.71"},{"groupId":"OG003","value":"0.8","spread":"1.79"},{"groupId":"OG004","value":"0.0","spread":"1.73"},{"groupId":"OG005","value":"-2.0","spread":"NA","comment":"Standard deviation could not be calculated as only 1 participant was analyzed."},{"groupId":"OG006","value":"3.0","spread":"4.24"},{"groupId":"OG009","value":"0.0","spread":"0.00"}]}]},{"title":"Cycle 19 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"9"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"1"},{"groupId":"OG009","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"-0.5","spread":"0.71"},{"groupId":"OG003","value":"0.8","spread":"1.79"},{"groupId":"OG004","value":"-0.6","spread":"2.65"},{"groupId":"OG005","value":"0.0","spread":"NA","comment":"Standard deviation could not be calculated as only 1 participant was analyzed."},{"groupId":"OG006","value":"3.5","spread":"4.95"},{"groupId":"OG008","value":"0.0","spread":"NA","comment":"Standard deviation could not be calculated as only 1 participant was analyzed."},{"groupId":"OG009","value":"-0.5","spread":"0.71"}]}]},{"title":"Cycle 20 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"9"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"1"},{"groupId":"OG009","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"0.0","spread":"0.00"},{"groupId":"OG003","value":"0.0","spread":"1.41"},{"groupId":"OG004","value":"0.7","spread":"2.12"},{"groupId":"OG005","value":"0.0","spread":"NA","comment":"Standard deviation could not be calculated as only 1 participant was analyzed."},{"groupId":"OG006","value":"3.5","spread":"3.54"},{"groupId":"OG008","value":"0.0","spread":"NA","comment":"Standard deviation could not be calculated as only 1 participant was analyzed."},{"groupId":"OG009","value":"-0.5","spread":"0.71"}]}]},{"title":"Cycle 21 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"9"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"1"},{"groupId":"OG009","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"-0.5","spread":"0.71"},{"groupId":"OG003","value":"0.0","spread":"1.41"},{"groupId":"OG004","value":"0.1","spread":"2.09"},{"groupId":"OG006","value":"4.0","spread":"4.24"},{"groupId":"OG008","value":"0.0","spread":"NA","comment":"Standard deviation could not be calculated as only 1 participant was analyzed."},{"groupId":"OG009","value":"-0.5","spread":"0.71"}]}]},{"title":"Cycle 22 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"9"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"1"},{"groupId":"OG009","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"0.0","spread":"0.00"},{"groupId":"OG003","value":"0.4","spread":"1.52"},{"groupId":"OG004","value":"0.1","spread":"1.45"},{"groupId":"OG005","value":"0.0","spread":"NA","comment":"Standard deviation could not be calculated as only 1 participant was analyzed."},{"groupId":"OG006","value":"3.5","spread":"3.54"},{"groupId":"OG008","value":"-1.0","spread":"NA","comment":"Standard deviation could not be calculated as only 1 participant was analyzed."},{"groupId":"OG009","value":"-0.3","spread":"0.58"}]}]},{"title":"Cycle 23 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"8"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"1"},{"groupId":"OG009","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"0.5","spread":"0.71"},{"groupId":"OG003","value":"0.0","spread":"1.41"},{"groupId":"OG004","value":"0.1","spread":"1.81"},{"groupId":"OG005","value":"-1.0","spread":"NA","comment":"Standard deviation could not be calculated as only 1 participant was analyzed."},{"groupId":"OG006","value":"1.5","spread":"3.54"},{"groupId":"OG008","value":"0.0","spread":"NA","comment":"Standard deviation could not be calculated as only 1 participant was analyzed."},{"groupId":"OG009","value":"-2.3","spread":"4.04"}]}]},{"title":"Cycle 24 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"8"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"1"},{"groupId":"OG009","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"0.5","spread":"0.71"},{"groupId":"OG003","value":"-0.4","spread":"0.89"},{"groupId":"OG004","value":"0.6","spread":"0.74"},{"groupId":"OG005","value":"1.0","spread":"NA","comment":"Standard deviation could not be calculated as only 1 participant was analyzed."},{"groupId":"OG006","value":"1.5","spread":"4.95"},{"groupId":"OG008","value":"0.0","spread":"NA","comment":"Standard deviation could not be calculated as only 1 participant was analyzed."},{"groupId":"OG009","value":"0.0","spread":"0.00"}]}]},{"title":"Cycle 25 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"7"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"1"},{"groupId":"OG009","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"0.0","spread":"0.00"},{"groupId":"OG003","value":"0.8","spread":"1.79"},{"groupId":"OG004","value":"-0.9","spread":"2.27"},{"groupId":"OG005","value":"-2.0","spread":"NA","comment":"Standard deviation could not be calculated as only 1 participant was analyzed."},{"groupId":"OG006","value":"2.5","spread":"4.95"},{"groupId":"OG008","value":"0.0","spread":"NA","comment":"Standard deviation could not be calculated as only 1 participant was analyzed."},{"groupId":"OG009","value":"0.0","spread":"0.00"}]}]},{"title":"Cycle 26 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"8"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"1"},{"groupId":"OG009","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"0.5","spread":"0.71"},{"groupId":"OG003","value":"0.8","spread":"1.79"},{"groupId":"OG004","value":"-0.4","spread":"2.77"},{"groupId":"OG005","value":"-1.0","spread":"NA","comment":"Standard deviation could not be calculated as only 1 participant was analyzed."},{"groupId":"OG006","value":"2.0","spread":"4.24"},{"groupId":"OG008","value":"0.0","spread":"NA","comment":"Standard deviation could not be calculated as only 1 participant was analyzed."},{"groupId":"OG009","value":"-0.3","spread":"0.58"}]}]},{"title":"Cycle 27 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"7"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"1"},{"groupId":"OG009","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"0.5","spread":"0.71"},{"groupId":"OG003","value":"0.8","spread":"1.79"},{"groupId":"OG004","value":"-0.1","spread":"2.67"},{"groupId":"OG005","value":"-1.0","spread":"NA","comment":"Standard deviation could not be calculated as only 1 participant was analyzed."},{"groupId":"OG006","value":"3.5","spread":"3.54"},{"groupId":"OG008","value":"0.0","spread":"NA","comment":"Standard deviation could not be calculated as only 1 participant was analyzed."},{"groupId":"OG009","value":"-1.0","spread":"1.41"}]}]},{"title":"Cycle 28 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"7"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"1"},{"groupId":"OG009","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"0.5","spread":"0.71"},{"groupId":"OG003","value":"1.0","spread":"2.00"},{"groupId":"OG004","value":"0.7","spread":"0.76"},{"groupId":"OG005","value":"-2.0","spread":"NA","comment":"Standard deviation could not be calculated as only 1 participant was analyzed."},{"groupId":"OG006","value":"3.0","spread":"2.83"},{"groupId":"OG008","value":"0.0","spread":"NA","comment":"Standard deviation could not be calculated as only 1 participant was analyzed."},{"groupId":"OG009","value":"0.0","spread":"0.00"}]}]},{"title":"Cycle 29 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"8"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"1"},{"groupId":"OG009","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"-1.5","spread":"2.12"},{"groupId":"OG003","value":"0.5","spread":"1.73"},{"groupId":"OG004","value":"0.1","spread":"1.81"},{"groupId":"OG005","value":"0.0","spread":"NA","comment":"Standard deviation could not be calculated as only 1 participant was analyzed."},{"groupId":"OG006","value":"3.5","spread":"3.54"},{"groupId":"OG008","value":"0.0","spread":"NA","comment":"Standard deviation could not be calculated as only 1 participant was analyzed."},{"groupId":"OG009","value":"0.0","spread":"0.00"}]}]},{"title":"Cycle 30 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"5"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"1"},{"groupId":"OG009","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"0.0","spread":"0.00"},{"groupId":"OG003","value":"0.8","spread":"1.50"},{"groupId":"OG004","value":"0.4","spread":"0.55"},{"groupId":"OG005","value":"0.0","spread":"NA","comment":"Standard deviation could not be calculated as only 1 participant was analyzed."},{"groupId":"OG006","value":"3.0","spread":"2.83"},{"groupId":"OG008","value":"0.0","spread":"NA","comment":"Standard deviation could not be calculated as only 1 participant was analyzed."},{"groupId":"OG009","value":"-1.0","spread":"1.00"}]}]},{"title":"Cycle 31 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"6"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"0.5","spread":"0.71"},{"groupId":"OG003","value":"1.0","spread":"2.65"},{"groupId":"OG004","value":"0.7","spread":"0.82"},{"groupId":"OG005","value":"0.0","spread":"NA","comment":"Standard deviation could not be calculated as only 1 participant was analyzed."},{"groupId":"OG006","value":"3.0","spread":"4.24"},{"groupId":"OG009","value":"0.0","spread":"0.00"}]}]},{"title":"Cycle 32 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"5"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"1"},{"groupId":"OG009","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"0.0","spread":"0.00"},{"groupId":"OG003","value":"1.3","spread":"2.31"},{"groupId":"OG004","value":"0.4","spread":"0.55"},{"groupId":"OG006","value":"3.5","spread":"3.54"},{"groupId":"OG008","value":"0.0","spread":"NA","comment":"Standard deviation could not be calculated as only 1 participant was analyzed."},{"groupId":"OG009","value":"0.0","spread":"0.00"}]}]},{"title":"Cycle 33 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"4"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"1"},{"groupId":"OG009","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"0.0","spread":"0.00"},{"groupId":"OG003","value":"1.3","spread":"2.31"},{"groupId":"OG004","value":"0.5","spread":"0.58"},{"groupId":"OG006","value":"3.5","spread":"3.54"},{"groupId":"OG008","value":"0.0","spread":"NA","comment":"Standard deviation could not be calculated as only 1 participant was analyzed."},{"groupId":"OG009","value":"0.0","spread":"0.00"}]}]},{"title":"Cycle 34 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"4"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"1"},{"groupId":"OG009","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"0.0","spread":"0.00"},{"groupId":"OG003","value":"0.0","spread":"0.00"},{"groupId":"OG004","value":"0.3","spread":"0.50"},{"groupId":"OG006","value":"4.0","spread":"4.24"},{"groupId":"OG008","value":"0.0","spread":"NA","comment":"Standard deviation could not be calculated as only 1 participant was analyzed."},{"groupId":"OG009","value":"0.0","spread":"0.00"}]}]},{"title":"Cycle 35 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"4"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"1"},{"groupId":"OG009","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"0.5","spread":"0.71"},{"groupId":"OG003","value":"0.0","spread":"NA","comment":"Standard deviation could not be calculated as only 1 participant was analyzed."},{"groupId":"OG004","value":"0.3","spread":"0.50"},{"groupId":"OG006","value":"4.0","spread":"4.24"},{"groupId":"OG008","value":"0.0","spread":"NA","comment":"Standard deviation could not be calculated as only 1 participant was analyzed."},{"groupId":"OG009","value":"0.0","spread":"NA","comment":"Standard deviation could not be calculated as only 1 participant was analyzed."}]}]},{"title":"Cycle 36 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"1"},{"groupId":"OG009","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"-0.5","spread":"0.71"},{"groupId":"OG003","value":"0.0","spread":"NA","comment":"Standard deviation could not be calculated as only 1 participant was analyzed."},{"groupId":"OG004","value":"0.0","spread":"0.00"},{"groupId":"OG006","value":"4.0","spread":"4.24"},{"groupId":"OG008","value":"0.0","spread":"NA","comment":"Standard deviation could not be calculated as only 1 participant was analyzed."},{"groupId":"OG009","value":"0.0","spread":"NA","comment":"Standard deviation could not be calculated as only 1 participant was analyzed."}]}]},{"title":"Cycle 37 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"0.0","spread":"0.00"},{"groupId":"OG003","value":"-1.0","spread":"NA","comment":"Standard deviation could not be calculated as only 1 participant was analyzed."},{"groupId":"OG004","value":"0.0","spread":"0.00"},{"groupId":"OG006","value":"3.5","spread":"4.95"}]}]},{"title":"Cycle 38 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"1"},{"groupId":"OG009","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"0.0","spread":"0.00"},{"groupId":"OG003","value":"0.0","spread":"NA","comment":"Standard deviation could not be calculated as only 1 participant was analyzed."},{"groupId":"OG004","value":"0.0","spread":"0.00"},{"groupId":"OG006","value":"3.0","spread":"2.83"},{"groupId":"OG008","value":"0.0","spread":"NA","comment":"Standard deviation could not be calculated as only 1 participant was analyzed."}]}]},{"title":"Cycle 39 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"0.0","spread":"NA","comment":"Standard deviation could not be calculated as only 1 participant was analyzed."},{"groupId":"OG003","value":"0.0","spread":"NA","comment":"Standard deviation could not be calculated as only 1 participant was analyzed."},{"groupId":"OG004","value":"-0.5","spread":"0.71"},{"groupId":"OG006","value":"3.5","spread":"4.95"}]}]},{"title":"Cycle 40 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"0.5","spread":"0.71"},{"groupId":"OG003","value":"-1.0","spread":"NA","comment":"Standard deviation could not be calculated as only 1 participant was analyzed."},{"groupId":"OG004","value":"0.0","spread":"NA","comment":"Standard deviation could not be calculated as only 1 participant was analyzed."},{"groupId":"OG006","value":"4.0","spread":"4.24"}]}]},{"title":"Cycle 41 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"0.5","spread":"0.71"},{"groupId":"OG003","value":"0.0","spread":"NA","comment":"Standard deviation could not be calculated as only 1 participant was analyzed."},{"groupId":"OG004","value":"0.0","spread":"NA","comment":"Standard deviation could not be calculated as only 1 participant was analyzed."},{"groupId":"OG006","value":"1.5","spread":"6.36"}]}]},{"title":"Cycle 42 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"-0.5","spread":"0.71"},{"groupId":"OG003","value":"0.0","spread":"NA","comment":"Standard deviation could not be calculated as only 1 participant was analyzed."},{"groupId":"OG004","value":"0.0","spread":"NA","comment":"Standard deviation could not be calculated as only 1 participant was analyzed."},{"groupId":"OG006","value":"4.0","spread":"4.24"}]}]},{"title":"Cycle 43 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"0.0","spread":"0.00"},{"groupId":"OG003","value":"0.0","spread":"NA","comment":"Standard deviation could not be calculated as only 1 participant was analyzed."},{"groupId":"OG006","value":"4.0","spread":"4.24"}]}]},{"title":"Cycle 44 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"1.0","spread":"NA","comment":"Standard deviation could not be calculated as only 1 participant was analyzed."},{"groupId":"OG003","value":"-1.0","spread":"NA","comment":"Standard deviation could not be calculated as only 1 participant was analyzed."},{"groupId":"OG006","value":"3.0","spread":"4.24"}]}]},{"title":"Cycle 45 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"1.0","spread":"NA","comment":"Standard deviation could not be calculated as only 1 participant was analyzed."},{"groupId":"OG003","value":"0.0","spread":"NA","comment":"Standard deviation could not be calculated as only 1 participant was analyzed."},{"groupId":"OG006","value":"1.0","spread":"NA","comment":"Standard deviation could not be calculated as only 1 participant was analyzed."}]}]},{"title":"Cycle 46 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"0.0","spread":"NA","comment":"Standard deviation could not be calculated as only 1 participant was analyzed."},{"groupId":"OG003","value":"-1.0","spread":"NA","comment":"Standard deviation could not be calculated as only 1 participant was analyzed."}]}]},{"title":"Cycle 47 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"0.0","spread":"NA","comment":"Standard deviation could not be calculated as only 1 participant was analyzed."},{"groupId":"OG003","value":"0.0","spread":"NA","comment":"Standard deviation could not be calculated as only 1 participant was analyzed."}]}]},{"title":"Cycle 48 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"-3.0","spread":"NA","comment":"Standard deviation could not be calculated as only 1 participant was analyzed."},{"groupId":"OG003","value":"0.0","spread":"NA","comment":"Standard deviation could not be calculated as only 1 participant was analyzed."}]}]},{"title":"Cycle 49 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"0.5","spread":"0.71"}]}]},{"title":"Cycle 50 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"-3.0","spread":"NA","comment":"Standard deviation could not be calculated as only 1 participant was analyzed."}]}]},{"title":"Cycle 51 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"-0.5","spread":"0.71"}]}]},{"title":"Cycle 52 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"1.0","spread":"NA","comment":"Standard deviation could not be calculated as only 1 participant was analyzed."}]}]},{"title":"End of treatment","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"4"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"1"},{"groupId":"OG009","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-8.0","spread":"NA","comment":"Standard deviation could not be calculated as only 1 participant was analyzed."},{"groupId":"OG002","value":"0.7","spread":"1.15"},{"groupId":"OG003","value":"-2.0","spread":"NA","comment":"Standard deviation could not be calculated as only 1 participant was analyzed."},{"groupId":"OG004","value":"-2.3","spread":"5.19"},{"groupId":"OG008","value":"-15.0","spread":"NA","comment":"Standard deviation could not be calculated as only 1 participant was analyzed."},{"groupId":"OG009","value":"0.0","spread":"NA","comment":"Standard deviation could not be calculated as only 1 participant was analyzed."}]}]}]},{"type":"SECONDARY","title":"Time to Tumor Response (TTR) and Intracranial TTR (Phase 2 and DDI Sub-study)","description":"Time to tumor response (TTR) was defined as the time from the first dose of study treatment to the first documentation of objective tumor response (CR or PR). For participants whose objective response proceeded from PR to CR, the onset of PR was taken as the onset of response. TTR was only calculated for the subgroup of participants with a confirmed objective tumor response. Intracranial TTR was only calculated for participants with confirmed intracranial objective response. CR was defined as the disappearance of all non-lymph node target lesions (where all target lesions are recorded with a length of 0 mm on Target Lesions eCRF). Any pathological lymph nodes (recorded as target lesion) must have reduction in short axis to \\<10 mm. PR was defined as a 30 % or more decrease in SLD of target lesions, taking as reference the baseline SLD. Results presented here were based on independent central review.","populationDescription":"TTR analysis set included all ITT participants who had confirmed objective response; intracranial TTR analysis set included all ITT participants who had CNS metastases and achieved confirmed intracranial objective response. Here, \"Number Analyzed\" signifies participants evaluable for specified rows.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Full Range","unitOfMeasure":"Months","timeFrame":"From first dose of study treatment to the first documentation of objective tumor response (CR or PR) (maximum of 7.5 years for Phase 2 and up to a maximum of 6 years approx. for DDI sub study)","groups":[{"id":"OG000","title":"EXP-1 (Phase 2)","description":"Treatment-naÃ¯ve participants with advanced anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC) with or without asymptomatic central nervous system (CNS) metastases were given PF-06463922 100 mg orally QD on Day -7 (only participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG001","title":"EXP-2 (Phase 2)","description":"Participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after only crizotinib therapy were given PF-06463922 100 mg orally QD on Day -7 (only for participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG002","title":"EXP-3 (Phase 2)","description":"Participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after crizotinib therapy and 1 or 2 prior regimens of chemotherapy given before or after crizotinib therapy, or participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after 1 ALK inhibitor therapy other than crizotinib with or without any number of prior chemotherapy regimens in any disease setting were given PF-06463922 100 mg orally QD on Day -7 (only for participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG003","title":"EXP-4 (Phase 2)","description":"Participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after 2 prior lines of ALK inhibitor therapies were given PF-06463922 100 mg orally QD on Day -7 (only for participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG004","title":"EXP-5 (Phase 2)","description":"Participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after 3 prior lines of ALK inhibitor therapies were given PF-06463922 100 mg orally QD on Day -7 (only for participant scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG005","title":"EXP-6 (Phase 2)","description":"Participants with advanced ROS1-positive NSCLC who were treatment naÃ¯ve or had any number of prior cancer therapies with or without asymptomatic CNS metastases were given PF-06463922 100 mg orally QD on Day -7 (only for participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG006","title":"DDI Sub-study","description":"Participants with advanced ALK positive or ROS1-positive NSCLC who were treatment naÃ¯ve or had any number of prior cancer therapies with or without asymptomatic CNS metastases were administered a single dose of a probe substrate alone on Day -2. Participants were given PF-06463922 100 mg orally QD starting on Cycle1 Day 1 and along with probe substrate on Day 15 Cycle 1."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"21"},{"groupId":"OG002","value":"34"},{"groupId":"OG003","value":"26"},{"groupId":"OG004","value":"17"},{"groupId":"OG005","value":"18"},{"groupId":"OG006","value":"13"}]}],"classes":[{"title":"TTR","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"21"},{"groupId":"OG002","value":"34"},{"groupId":"OG003","value":"26"},{"groupId":"OG004","value":"17"},{"groupId":"OG005","value":"18"},{"groupId":"OG006","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.4","lowerLimit":"1.2","upperLimit":"5.4"},{"groupId":"OG001","value":"1.4","lowerLimit":"1.2","upperLimit":"18.0"},{"groupId":"OG002","value":"1.4","lowerLimit":"1.1","upperLimit":"16.6"},{"groupId":"OG003","value":"2.6","lowerLimit":"1.2","upperLimit":"16.4"},{"groupId":"OG004","value":"1.4","lowerLimit":"1.2","upperLimit":"9.3"},{"groupId":"OG005","value":"1.4","lowerLimit":"1.3","upperLimit":"29.7"},{"groupId":"OG006","value":"1.4","lowerLimit":"1.2","upperLimit":"11.0"}]}]},{"title":"Intracranial TTR","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"22"},{"groupId":"OG003","value":"24"},{"groupId":"OG004","value":"16"},{"groupId":"OG005","value":"14"},{"groupId":"OG006","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.1","lowerLimit":"1.2","upperLimit":"2.8"},{"groupId":"OG001","value":"1.4","lowerLimit":"1.2","upperLimit":"1.5"},{"groupId":"OG002","value":"1.4","lowerLimit":"1.1","upperLimit":"5.7"},{"groupId":"OG003","value":"1.7","lowerLimit":"1.2","upperLimit":"17.5"},{"groupId":"OG004","value":"1.4","lowerLimit":"1.2","upperLimit":"10.6"},{"groupId":"OG005","value":"1.4","lowerLimit":"1.2","upperLimit":"28.9"},{"groupId":"OG006","value":"2.0","lowerLimit":"1.1","upperLimit":"4.2"}]}]}]},{"type":"SECONDARY","title":"Duration of Response (DOR) and Intracranial DOR (Phase 2 and DDI Substudy)","description":"Duration of response(DOR): time from first documentation of objective tumor response (CR/PR) to first documentation of PD or to death due to any cause, whichever occurred first. DOR: calculated for subgroup of participants with confirmed objective tumor response. Intracranial DOR: calculated for participants with confirmed intracranial objective response. CR:disappearance of all non-lymph node target lesions (where all target lesions are recorded with length of 0mm on Target Lesion eCRF). Any pathological lymph node (recorded as target lesion) must have reduction in short axis to \\<10mm. PR:30% or more decrease in SLD of target lesion, taking as reference baseline SLD. PD:20% or more increase in the SLD of target lesions relative to baseline or smallest SLD (nadir) recorded since first dose. In addition, also demonstrate absolute increase of at least 5mm (\\>=5mm) relative to baseline or smallest SLD (nadir) recorded since first dose.","populationDescription":"DOR analysis set included all ITT participants who had confirmed objective response; intracranial DOR analysis set included all ITT participants who had CNS metastases and achieved confirmed intracranial objective response. Here, \"Number Analyzed\" signifies participants analyzed for this outcome measure.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Months","timeFrame":"From first dose of study treatment to first documentation of PD or to death due to any cause, whichever occurred first (maximum of 7.5 years for Phase 2 and up to a maximum of 6 years approx. for DDI sub study)","groups":[{"id":"OG000","title":"EXP-1 (Phase 2)","description":"Treatment-naÃ¯ve participants with advanced anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC) with or without asymptomatic central nervous system (CNS) metastases were given PF-06463922 100 mg orally QD on Day -7 (only participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG001","title":"EXP-2 (Phase 2)","description":"Participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after only crizotinib therapy were given PF-06463922 100 mg orally QD on Day -7 (only for participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG002","title":"EXP-3 (Phase 2)","description":"Participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after crizotinib therapy and 1 or 2 prior regimens of chemotherapy given before or after crizotinib therapy, or participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after 1 ALK inhibitor therapy other than crizotinib with or without any number of prior chemotherapy regimens in any disease setting were given PF-06463922 100 mg orally QD on Day -7 (only for participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG003","title":"EXP-4 (Phase 2)","description":"Participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after 2 prior lines of ALK inhibitor therapies were given PF-06463922 100 mg orally QD on Day -7 (only for participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG004","title":"EXP-5 (Phase 2)","description":"Participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after 3 prior lines of ALK inhibitor therapies were given PF-06463922 100 mg orally QD on Day -7 (only for participant scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG005","title":"EXP-6 (Phase 2)","description":"Participants with advanced ROS1-positive NSCLC who were treatment naÃ¯ve or had any number of prior cancer therapies with or without asymptomatic CNS metastases were given PF-06463922 100 mg orally QD on Day -7 (only for participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG006","title":"DDI Sub-study","description":"Participants with advanced ALK positive or ROS1-positive NSCLC who were treatment naÃ¯ve or had any number of prior cancer therapies with or without asymptomatic CNS metastases were administered a single dose of a probe substrate alone on Day -2. Participants were given PF-06463922 100 mg orally QD starting on Cycle1 Day 1 and along with probe substrate on Day 15 Cycle 1."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"21"},{"groupId":"OG002","value":"34"},{"groupId":"OG003","value":"26"},{"groupId":"OG004","value":"17"},{"groupId":"OG005","value":"18"},{"groupId":"OG006","value":"13"}]}],"classes":[{"title":"DOR","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"21"},{"groupId":"OG002","value":"34"},{"groupId":"OG003","value":"26"},{"groupId":"OG004","value":"17"},{"groupId":"OG005","value":"18"},{"groupId":"OG006","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"17.16","lowerLimit":"12.45","upperLimit":"35.09"},{"groupId":"OG001","value":"16.56","lowerLimit":"4.20","upperLimit":"NA","comment":"Upper limit could not be calculated due to insufficient number of participants with events."},{"groupId":"OG002","value":"11.10","lowerLimit":"5.55","upperLimit":"NA","comment":"Upper limit could not be calculated due to insufficient number of participants with events."},{"groupId":"OG003","value":"15.08","lowerLimit":"5.55","upperLimit":"26.28"},{"groupId":"OG004","value":"7.03","lowerLimit":"4.17","upperLimit":"11.01"},{"groupId":"OG005","value":"19.61","lowerLimit":"11.10","upperLimit":"NA","comment":"Upper limit could not be calculated due to insufficient number of participants with events."},{"groupId":"OG006","value":"5.19","lowerLimit":"4.17","upperLimit":"NA","comment":"Upper limit could not be calculated due to insufficient number of participants with events."}]}]},{"title":"Intra-cranial DOR","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"22"},{"groupId":"OG003","value":"24"},{"groupId":"OG004","value":"16"},{"groupId":"OG005","value":"14"},{"groupId":"OG006","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"NA","lowerLimit":"8.28","upperLimit":"NA","comment":"Median and Upper limit could not be calculated due to insufficient number of participants with events.."},{"groupId":"OG001","value":"NA","lowerLimit":"20.99","upperLimit":"NA","comment":"Median and Upper limit could not be calculated due to insufficient number of participants with events."},{"groupId":"OG002","value":"37.12","lowerLimit":"8.38","upperLimit":"NA","comment":"Upper limit could not be calculated due to insufficient number of participants with events."},{"groupId":"OG003","value":"14.52","lowerLimit":"11.07","upperLimit":"NA","comment":"Upper limit could not be calculated due to insufficient number of participants with events."},{"groupId":"OG004","value":"10.32","lowerLimit":"6.90","upperLimit":"14.98"},{"groupId":"OG005","value":"17.62","lowerLimit":"4.99","upperLimit":"NA","comment":"Upper limit could not be calculated due to insufficient number of participants with events."},{"groupId":"OG006","value":"NA","lowerLimit":"2.76","upperLimit":"NA","comment":"Median and upper limit could not be calculated due to insufficient number of participants with events."}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving Disease Control and Intracranial Disease Control at Week 12 and 24 (Phase 2 and DDI Substudy)","description":"Tumor response was evaluated according to RECIST version 1.1, and disease control was defined as confirmed CR, confirmed PR, or stable disease (SD). CR was defined as the disappearance of all non-lymph node target lesions (where all target lesions are recorded with a length of 0 mm on Target Lesions eCRF). Any pathological lymph nodes (recorded as target lesion) must have reduction in short axis to \\<10 mm. PR was defined as a 30 % or more decrease in SLD of target lesions, taking as reference the baseline SLD. SD= when neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD is observed, taking as reference the smallest sum diameters while on study. Intracranial assessment was only performed for participants CNS metastases. Results presented here were based on independent central review.","populationDescription":"The intent-to-treat (ITT) analysis set was used for overall response assessment, and included all enrolled participants with documented ALK or ROS1 rearrangement who received at least 1 dose of PF-06463922; participants with CNS metastases in the ITT analysis set was used for intracranial response assessment. Here, 'Number Analyzed' signifies participants evaluable for specified rows.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Weeks 12 and 24","groups":[{"id":"OG000","title":"EXP-1 (Phase 2)","description":"Treatment-naÃ¯ve participants with advanced anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC) with or without asymptomatic central nervous system (CNS) metastases were given PF-06463922 100 mg orally QD on Day -7 (only participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG001","title":"EXP-2 (Phase 2)","description":"Participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after only crizotinib therapy were given PF-06463922 100 mg orally QD on Day -7 (only for participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG002","title":"EXP-3 (Phase 2)","description":"Participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after crizotinib therapy and 1 or 2 prior regimens of chemotherapy given before or after crizotinib therapy, or participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after 1 ALK inhibitor therapy other than crizotinib with or without any number of prior chemotherapy regimens in any disease setting were given PF-06463922 100 mg orally QD on Day -7 (only for participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG003","title":"EXP-4 (Phase 2)","description":"Participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after 2 prior lines of ALK inhibitor therapies were given PF-06463922 100 mg orally QD on Day -7 (only for participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG004","title":"EXP-5 (Phase 2)","description":"Participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after 3 prior lines of ALK inhibitor therapies were given PF-06463922 100 mg orally QD on Day -7 (only for participant scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG005","title":"EXP-6 (Phase 2)","description":"Participants with advanced ROS1-positive NSCLC who were treatment naÃ¯ve or had any number of prior cancer therapies with or without asymptomatic CNS metastases were given PF-06463922 100 mg orally QD on Day -7 (only for participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG006","title":"DDI Sub-study","description":"Participants with advanced ALK positive or ROS1-positive NSCLC who were treatment naÃ¯ve or had any number of prior cancer therapies with or without asymptomatic CNS metastases were administered a single dose of a probe substrate alone on Day -2. Participants were given PF-06463922 100 mg orally QD starting on Cycle1 Day 1 and along with probe substrate on Day 15 Cycle 1."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"27"},{"groupId":"OG002","value":"60"},{"groupId":"OG003","value":"65"},{"groupId":"OG004","value":"46"},{"groupId":"OG005","value":"47"},{"groupId":"OG006","value":"32"}]}],"classes":[{"title":"Disease control rate at Week 12","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"27"},{"groupId":"OG002","value":"60"},{"groupId":"OG003","value":"65"},{"groupId":"OG004","value":"46"},{"groupId":"OG005","value":"47"},{"groupId":"OG006","value":"32"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"93.3","lowerLimit":"77.9","upperLimit":"99.2"},{"groupId":"OG001","value":"85.2","lowerLimit":"66.3","upperLimit":"95.8"},{"groupId":"OG002","value":"68.3","lowerLimit":"55.0","upperLimit":"79.7"},{"groupId":"OG003","value":"64.6","lowerLimit":"51.8","upperLimit":"76.1"},{"groupId":"OG004","value":"50.0","lowerLimit":"34.9","upperLimit":"65.1"},{"groupId":"OG005","value":"66.0","lowerLimit":"50.7","upperLimit":"79.1"},{"groupId":"OG006","value":"56.3","lowerLimit":"37.7","upperLimit":"73.6"}]}]},{"title":"Disease control rate at Week 24","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"27"},{"groupId":"OG002","value":"60"},{"groupId":"OG003","value":"65"},{"groupId":"OG004","value":"46"},{"groupId":"OG005","value":"47"},{"groupId":"OG006","value":"32"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"83.3","lowerLimit":"65.3","upperLimit":"94.4"},{"groupId":"OG001","value":"63.0","lowerLimit":"42.4","upperLimit":"80.6"},{"groupId":"OG002","value":"51.7","lowerLimit":"38.4","upperLimit":"64.8"},{"groupId":"OG003","value":"49.2","lowerLimit":"36.6","upperLimit":"61.9"},{"groupId":"OG004","value":"32.6","lowerLimit":"19.5","upperLimit":"48.0"},{"groupId":"OG005","value":"48.9","lowerLimit":"34.1","upperLimit":"63.9"},{"groupId":"OG006","value":"34.4","lowerLimit":"18.6","upperLimit":"53.2"}]}]},{"title":"Intra-cranial disease control rate at Week 12","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"17"},{"groupId":"OG002","value":"33"},{"groupId":"OG003","value":"45"},{"groupId":"OG004","value":"37"},{"groupId":"OG005","value":"25"},{"groupId":"OG006","value":"16"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"87.5","lowerLimit":"47.3","upperLimit":"99.7"},{"groupId":"OG001","value":"94.1","lowerLimit":"71.3","upperLimit":"99.9"},{"groupId":"OG002","value":"75.8","lowerLimit":"57.7","upperLimit":"88.9"},{"groupId":"OG003","value":"75.6","lowerLimit":"60.5","upperLimit":"87.1"},{"groupId":"OG004","value":"67.6","lowerLimit":"50.2","upperLimit":"82.0"},{"groupId":"OG005","value":"72.0","lowerLimit":"50.6","upperLimit":"87.9"},{"groupId":"OG006","value":"56.3","lowerLimit":"29.9","upperLimit":"80.2"}]}]},{"title":"Intra-cranial disease control rate at Week 24","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"17"},{"groupId":"OG002","value":"33"},{"groupId":"OG003","value":"45"},{"groupId":"OG004","value":"37"},{"groupId":"OG005","value":"25"},{"groupId":"OG006","value":"16"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"75.0","lowerLimit":"34.9","upperLimit":"96.8"},{"groupId":"OG001","value":"70.6","lowerLimit":"44.0","upperLimit":"89.7"},{"groupId":"OG002","value":"60.6","lowerLimit":"42.1","upperLimit":"77.1"},{"groupId":"OG003","value":"62.2","lowerLimit":"46.5","upperLimit":"76.2"},{"groupId":"OG004","value":"48.6","lowerLimit":"31.9","upperLimit":"65.6"},{"groupId":"OG005","value":"52.0","lowerLimit":"31.3","upperLimit":"72.2"},{"groupId":"OG006","value":"43.8","lowerLimit":"19.8","upperLimit":"70.1"}]}]}]},{"type":"SECONDARY","title":"Time to Progression on the Last Prior Therapy (Phase 2)","description":"TTP on the last prior therapy was defined as time from the first dose date of the last prior treatment regimen to the date of progression. Progressive disease was defined by a 20% or more increase in the SLD of target lesions relative to baseline or the smallest SLD (nadir) recorded since first dose. In addition to the relative increase of 20%, SLD must also demonstrate an absolute increase of at least 5 mm (\\>= 5 mm) relative to baseline or the smallest SLD (nadir) recorded since the first dose.","populationDescription":"ITT analysis set included all enrolled participants with documented ALK or ROS1 rearrangement who received at least 1 dose of PF-06463922. As planned in SAP, this outcome measure was not analyzed for EXP-1 and EXP-6 groups. Here, 'Number Analyzed' signifies participants evaluable for specified rows.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Months","timeFrame":"From first dose of study treatment to the date of progression (maximum of 7.5 years for Phase 2)","groups":[{"id":"OG000","title":"EXP-2 (Phase 2)","description":"Participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after only crizotinib therapy were given PF-06463922 100 mg orally QD on Day -7 (only for participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG001","title":"EXP-3 (Phase 2)","description":"Participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after crizotinib therapy and 1 or 2 prior regimens of chemotherapy given before or after crizotinib therapy, or participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after 1 ALK inhibitor therapy other than crizotinib with or without any number of prior chemotherapy regimens in any disease setting were given PF-06463922 100 mg orally QD on Day -7 (only for participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG002","title":"EXP-4 (Phase 2)","description":"Participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after 2 prior lines of ALK inhibitor therapies were given PF-06463922 100 mg orally QD on Day -7 (only for participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG003","title":"EXP-5 (Phase 2)","description":"Participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after 3 prior lines of ALK inhibitor therapies were given PF-06463922 100 mg orally QD on Day -7 (only for participant scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"65"},{"groupId":"OG003","value":"46"}]}],"classes":[{"title":"Prior systemic therapy before PF-06463922","categories":[{"measurements":[{"groupId":"OG000","value":"11.5","lowerLimit":"7.2","upperLimit":"19.6"},{"groupId":"OG001","value":"12.8","lowerLimit":"10.9","upperLimit":"16.9"},{"groupId":"OG002","value":"10.2","lowerLimit":"7.6","upperLimit":"15.9"},{"groupId":"OG003","value":"3.7","lowerLimit":"2.1","upperLimit":"6.4"}]}]},{"title":"Prior ALK+/ROS1+ TKI treatment","categories":[{"measurements":[{"groupId":"OG000","value":"11.5","lowerLimit":"7.2","upperLimit":"19.6"},{"groupId":"OG001","value":"13.8","lowerLimit":"11.2","upperLimit":"18.1"},{"groupId":"OG002","value":"12.1","lowerLimit":"7.9","upperLimit":"16.4"},{"groupId":"OG003","value":"3.7","lowerLimit":"2.1","upperLimit":"6.6"}]}]},{"title":"Prior systemic therapy other than ALK+/ROS1+ TKI","categories":[{"measurements":[{"groupId":"OG000","value":"19.6","lowerLimit":"16.1","upperLimit":"NA","comment":"Upper limit could not be calculated due to insufficient number of participants with events."},{"groupId":"OG001","value":"8.5","lowerLimit":"5.0","upperLimit":"12.6"},{"groupId":"OG002","value":"5.0","lowerLimit":"3.1","upperLimit":"10.0"},{"groupId":"OG003","value":"5.6","lowerLimit":"3.5","upperLimit":"11.2"}]}]}]},{"type":"SECONDARY","title":"Time to Tumor Progression (TTP) and Intracranial TTP (Phase 2 and DDI Substudy)","description":"Time to progression (TTP) was defined as the time from the first dose of study treatment to the first documentation of objective PD. Intracranial TTP was defined as the time from the first dose of study treatment to the date of the first documentation of objective progression of intracranial disease, based on either new brain metastases or progression of existing brain metastases. Progressive disease was defined by a 20% or more increase in the SLD of target lesions relative to baseline or the smallest SLD (nadir) recorded since first dose. In addition to the relative increase of 20%, SLD must also demonstrate an absolute increase of at least 5 mm (\\>= 5 mm) relative to baseline or the smallest SLD (nadir) recorded since the first dose. Results presented here were based on independent central review.","populationDescription":"ITT analysis set was used for TTP determination and included all enrolled participants with documented ALK or ROS1 rearrangement who received at least 1 dose of PF-06463922; ITT participants with CNS metastases were analyzed for intracranial TTP.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Months","timeFrame":"From first dose of study treatment to the first documentation of objective PD (maximum of 7.5 years for Phase 2 and up to a maximum of 6 years approx. for DDI sub study)","groups":[{"id":"OG000","title":"EXP-1 (Phase 2)","description":"Treatment-naÃ¯ve participants with advanced anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC) with or without asymptomatic central nervous system (CNS) metastases were given PF-06463922 100 mg orally QD on Day -7 (only participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG001","title":"EXP-2 (Phase 2)","description":"Participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after only crizotinib therapy were given PF-06463922 100 mg orally QD on Day -7 (only for participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG002","title":"EXP-3 (Phase 2)","description":"Participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after crizotinib therapy and 1 or 2 prior regimens of chemotherapy given before or after crizotinib therapy, or participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after 1 ALK inhibitor therapy other than crizotinib with or without any number of prior chemotherapy regimens in any disease setting were given PF-06463922 100 mg orally QD on Day -7 (only for participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG003","title":"EXP-4 (Phase 2)","description":"Participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after 2 prior lines of ALK inhibitor therapies were given PF-06463922 100 mg orally QD on Day -7 (only for participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG004","title":"EXP-5 (Phase 2)","description":"Participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after 3 prior lines of ALK inhibitor therapies were given PF-06463922 100 mg orally QD on Day -7 (only for participant scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG005","title":"EXP-6 (Phase 2)","description":"Participants with advanced ROS1-positive NSCLC who were treatment naÃ¯ve or had any number of prior cancer therapies with or without asymptomatic CNS metastases were given PF-06463922 100 mg orally QD on Day -7 (only for participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG006","title":"DDI Sub-study","description":"Participants with advanced ALK positive or ROS1-positive NSCLC who were treatment naÃ¯ve or had any number of prior cancer therapies with or without asymptomatic CNS metastases were administered a single dose of a probe substrate alone on Day -2. Participants were given PF-06463922 100 mg orally QD starting on Cycle1 Day 1 and along with probe substrate on Day 15 Cycle 1."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"27"},{"groupId":"OG002","value":"60"},{"groupId":"OG003","value":"65"},{"groupId":"OG004","value":"46"},{"groupId":"OG005","value":"47"},{"groupId":"OG006","value":"32"}]}],"classes":[{"title":"TTP","categories":[{"measurements":[{"groupId":"OG000","value":"17.7","lowerLimit":"12.5","upperLimit":"40.5"},{"groupId":"OG001","value":"20.6","lowerLimit":"5.5","upperLimit":"NA","comment":"Upper limit could not be calculated due to insufficient number of participants with events."},{"groupId":"OG002","value":"8.2","lowerLimit":"5.5","upperLimit":"12.5"},{"groupId":"OG003","value":"8.4","lowerLimit":"5.6","upperLimit":"13.7"},{"groupId":"OG004","value":"5.6","lowerLimit":"4.0","upperLimit":"8.3"},{"groupId":"OG005","value":"12.5","lowerLimit":"8.2","upperLimit":"26.2"},{"groupId":"OG006","value":"5.7","lowerLimit":"4.1","upperLimit":"8.3"}]}]},{"title":"Intracranial TTP","categories":[{"measurements":[{"groupId":"OG000","value":"NA","lowerLimit":"NA","upperLimit":"NA","comment":"Median and 95% CI could not be calculated due to insufficient number of participants with events."},{"groupId":"OG001","value":"NA","lowerLimit":"NA","upperLimit":"NA","comment":"Median and 95% CI could not be calculated due to insufficient number of participants with events."},{"groupId":"OG002","value":"NA","lowerLimit":"15.0","upperLimit":"NA","comment":"Median and Upper limit could not be calculated due to insufficient number of participants with events."},{"groupId":"OG003","value":"22.1","lowerLimit":"15.7","upperLimit":"NA","comment":"Upper limit could not be calculated due to insufficient number of participants with events."},{"groupId":"OG004","value":"16.4","lowerLimit":"12.7","upperLimit":"NA","comment":"Upper limit could not be calculated due to insufficient number of participants with events."},{"groupId":"OG005","value":"NA","lowerLimit":"34.5","upperLimit":"NA","comment":"Median and Upper limit could not be calculated due to insufficient number of participants with events."},{"groupId":"OG006","value":"NA","lowerLimit":"6.9","upperLimit":"NA","comment":"Median and Upper limit could not be calculated due to insufficient number of participants with events."}]}]}]},{"type":"SECONDARY","title":"Probability of First Event Being a Central Nervous System (CNS) Progression, Non CNS Progression, or Death (Phase 2)","description":"Probability of first event being CNS progression, non-CNS progression, or death was evaluated with competing risk approach by estimating cumulative incidence functions (range: 0-1) relative to analysis set. Time to first event being Competing Event (either \"CNS progression\" or \"non CNS progression\" or \"Death\") = time from first dose until date of that specific event. Participants not known to have any of Competing Events were censored on date they were last assessed for disease status for PFS. Participants who presented one type of event were counted as competing cause of failure for analysis of other type of events. For each type of event, cumulative incidence function corresponding to nearest time point preceding 1 year is presented. PD:20% or more increase in SLD of target lesion relative to baseline or smallest SLD (nadir) recorded since first dose. SLD must demonstrate absolute increase of atleast 5mm(\\>=5 mm) relative to baseline or smallest SLD (nadir) recorded since first dose.","populationDescription":"The ITT analysis set included all enrolled participants with documented ALK or ROS1 rearrangement who received at least 1 dose of PF-06463922.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Probability of events","timeFrame":"From first dose of study treatment until first event of CNS progression (maximum of 7.5 years for Phase 2)","groups":[{"id":"OG000","title":"Phase 2 ITT Population","description":"This reporting group includes all Phase 2 participants in the ITT analysis set."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"274"}]}],"classes":[{"title":"CNS progression","categories":[{"measurements":[{"groupId":"OG000","value":"0.179"}]}]},{"title":"Non CNS progression","categories":[{"measurements":[{"groupId":"OG000","value":"0.325"}]}]},{"title":"Death","categories":[{"measurements":[{"groupId":"OG000","value":"0.055"}]}]}]},{"type":"SECONDARY","title":"Progression-Free Survival (PFS) (Phase 2 and DDI Substudy)","description":"PFS was defined as the time from the first dose of study treatment to the first documentation of objective PD or to death on study due to any cause, whichever came first. Progressive disease was defined by a 20% or more increase in the SLD of target lesions relative to baseline or the smallest SLD (nadir) recorded since first dose. In addition to the relative increase of 20%, SLD must also demonstrate an absolute increase of at least 5 mm (\\>= 5 mm) relative to baseline or the smallest SLD (nadir) recorded since the first dose. Results presented here were based on independent central review.","populationDescription":"PFS analysis set included all participants with documented ALK or ROS1 rearrangement who received at least 1 dose of PF-06463922.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Months","timeFrame":"From first dose of study treatment to first documentation of objective PD or death due to any cause, whichever came first (maximum of 7.5 years for Phase 2 and up to a maximum of 6 years approx. for DDI sub study)","groups":[{"id":"OG000","title":"EXP-1 (Phase 2)","description":"Treatment-naÃ¯ve participants with advanced anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC) with or without asymptomatic central nervous system (CNS) metastases were given PF-06463922 100 mg orally QD on Day -7 (only participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG001","title":"EXP-2 (Phase 2)","description":"Participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after only crizotinib therapy were given PF-06463922 100 mg orally QD on Day -7 (only for participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG002","title":"EXP-3 (Phase 2)","description":"Participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after crizotinib therapy and 1 or 2 prior regimens of chemotherapy given before or after crizotinib therapy, or participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after 1 ALK inhibitor therapy other than crizotinib with or without any number of prior chemotherapy regimens in any disease setting were given PF-06463922 100 mg orally QD on Day -7 (only for participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG003","title":"EXP-4 (Phase 2)","description":"Participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after 2 prior lines of ALK inhibitor therapies were given PF-06463922 100 mg orally QD on Day -7 (only for participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG004","title":"EXP-5 (Phase 2)","description":"Participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after 3 prior lines of ALK inhibitor therapies were given PF-06463922 100 mg orally QD on Day -7 (only for participant scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG005","title":"EXP-6 (Phase 2)","description":"Participants with advanced ROS1-positive NSCLC who were treatment naÃ¯ve or had any number of prior cancer therapies with or without asymptomatic CNS metastases were given PF-06463922 100 mg orally QD on Day -7 (only for participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG006","title":"DDI Sub-study","description":"Participants with advanced ALK positive or ROS1-positive NSCLC who were treatment naÃ¯ve or had any number of prior cancer therapies with or without asymptomatic CNS metastases were administered a single dose of a probe substrate alone on Day -2. Participants were given PF-06463922 100 mg orally QD starting on Cycle1 Day 1 and along with probe substrate on Day 15 Cycle 1."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"27"},{"groupId":"OG002","value":"60"},{"groupId":"OG003","value":"65"},{"groupId":"OG004","value":"46"},{"groupId":"OG005","value":"47"},{"groupId":"OG006","value":"32"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16.6","lowerLimit":"11.8","upperLimit":"28.3"},{"groupId":"OG001","value":"20.6","lowerLimit":"5.5","upperLimit":"NA","comment":"Upper limit could not be calculated due to insufficient number of participants with events."},{"groupId":"OG002","value":"6.9","lowerLimit":"5.5","upperLimit":"11.0"},{"groupId":"OG003","value":"7.3","lowerLimit":"4.2","upperLimit":"11.1"},{"groupId":"OG004","value":"5.5","lowerLimit":"3.9","upperLimit":"8.2"},{"groupId":"OG005","value":"9.9","lowerLimit":"5.5","upperLimit":"21.0"},{"groupId":"OG006","value":"5.7","lowerLimit":"4.0","upperLimit":"7.1"}]}]}]},{"type":"SECONDARY","title":"Overall Survival (Phase 2 and DDI Substudy)","description":"OS was defined as the time from first dose to the date of death due to any cause. For participants still alive at the time of analysis, the OS time was censored on the last date the participants were known to be alive. Estimates of OS and its 95% confidence interval were determined using Kaplan-Meier method.","populationDescription":"ITT analysis set included all enrolled participants with documented ALK or ROS1 rearrangement who received at least 1 dose of PF-06463922.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Months","timeFrame":"From first dose of study treatment until date of death (maximum of 7.5 years for Phase 2 and up to a maximum of 6 years approx. for DDI sub study)","groups":[{"id":"OG000","title":"EXP-1 (Phase 2)","description":"Treatment-naÃ¯ve participants with advanced anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC) with or without asymptomatic central nervous system (CNS) metastases were given PF-06463922 100 mg orally QD on Day -7 (only participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG001","title":"EXP-2 (Phase 2)","description":"Participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after only crizotinib therapy were given PF-06463922 100 mg orally QD on Day -7 (only for participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG002","title":"EXP-3 (Phase 2)","description":"Participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after crizotinib therapy and 1 or 2 prior regimens of chemotherapy given before or after crizotinib therapy, or participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after 1 ALK inhibitor therapy other than crizotinib with or without any number of prior chemotherapy regimens in any disease setting were given PF-06463922 100 mg orally QD on Day -7 (only for participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG003","title":"EXP-4 (Phase 2)","description":"Participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after 2 prior lines of ALK inhibitor therapies were given PF-06463922 100 mg orally QD on Day -7 (only for participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG004","title":"EXP-5 (Phase 2)","description":"Participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after 3 prior lines of ALK inhibitor therapies were given PF-06463922 100 mg orally QD on Day -7 (only for participant scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG005","title":"EXP-6 (Phase 2)","description":"Participants with advanced ROS1-positive NSCLC who were treatment naÃ¯ve or had any number of prior cancer therapies with or without asymptomatic CNS metastases were given PF-06463922 100 mg orally QD on Day -7 (only for participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG006","title":"DDI Sub-study","description":"Participants with advanced ALK positive or ROS1-positive NSCLC who were treatment naÃ¯ve or had any number of prior cancer therapies with or without asymptomatic CNS metastases were administered a single dose of a probe substrate alone on Day -2. Participants were given PF-06463922 100 mg orally QD starting on Cycle1 Day 1 and along with probe substrate on Day 15 Cycle 1."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"27"},{"groupId":"OG002","value":"60"},{"groupId":"OG003","value":"65"},{"groupId":"OG004","value":"46"},{"groupId":"OG005","value":"47"},{"groupId":"OG006","value":"32"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","lowerLimit":"NA","upperLimit":"NA","comment":"Median and 95% CI could not be calculated due to insufficient number of participants with events."},{"groupId":"OG001","value":"52.5","lowerLimit":"24.4","upperLimit":"NA","comment":"Upper limit could not be calculated due to insufficient number of participants with events."},{"groupId":"OG002","value":"NA","lowerLimit":"38.5","upperLimit":"NA","comment":"Median and upper limit could not be calculated due to insufficient number of participants with events."},{"groupId":"OG003","value":"18.7","lowerLimit":"15.1","upperLimit":"34.1"},{"groupId":"OG004","value":"20.4","lowerLimit":"10.5","upperLimit":"31.6"},{"groupId":"OG005","value":"49.7","lowerLimit":"21.0","upperLimit":"NA","comment":"Upper limit could not be calculated due to insufficient number of participants with events."},{"groupId":"OG006","value":"19.8","lowerLimit":"11.1","upperLimit":"NA","comment":"Upper limit could not be calculated due to insufficient number of participants with events."}]}]}]},{"type":"SECONDARY","title":"Maximum Observed Plasma Concentration (Cmax) of PF-06463922 (Phase 2)","description":"Maximum observed plasma concentration (Cmax) of PF-06463922 was observed directly from data.","populationDescription":"PK parameter analysis set for PF-06463922 included all enrolled participants who received at least 1 dose of PF-06463922 and had sufficient information to estimate at least one of the PK parameters of interest for PF-06463922. Here, \"Overall Number Analyzed\" signifies participants analyzed for this outcome measure. Here, 'Number Analyzed' signifies participants evaluable for specified rows.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"ng/mL","timeFrame":"Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9, 24, 48, 72, 96 and 120 hours post-dose on Day -7 and pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9 and 24 hours post-dose on Cycle 1 Day 15","groups":[{"id":"OG000","title":"Phase 2 and Japan LIC PK Analysis Set","description":"PK parameters of PF-06463922 were determined for a small subset of Phase 2 participants and Japan LIC. These participants received PF-06463922 100 mg orally QD and were combined into 1 reporting group for PK analysis. Japan LIC was not included in single-dose PK analysis, ie, they did not contribute to Day -7 data."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"22"}]}],"classes":[{"title":"Day -7","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"695.2","spread":"40"}]}]},{"title":"Cycle 1 Day 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"22"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"576.5","spread":"42"}]}]}]},{"type":"SECONDARY","title":"Time for Cmax (Tmax) of PF-06463922 (Phase 2)","description":"Tmax of PF-06463922 was observed directly from data as time of first occurrence.","populationDescription":"PK parameter analysis set for PF-06463922 included all enrolled participants who received at least 1 dose of PF-06463922 and had sufficient information to estimate at least one of the PK parameters of interest for PF-06463922. Here, \"Number Analyzed\" signifies participants analyzed for this outcome measure. Here, 'Number Analyzed' signifies participants evaluable for specified rows.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Full Range","unitOfMeasure":"Hours","timeFrame":"Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9, 24, 48, 72, 96 and 120 hours post-dose on Day -7 and pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9 and 24 hours post-dose on Cycle 1 Day 15","groups":[{"id":"OG000","title":"Phase 2 and Japan LIC PK Analysis Set","description":"PK parameters of PF-06463922 were determined for a small subset of Phase 2 participants and Japan LIC. These participants received PF-06463922 100 mg orally QD and were combined into 1 reporting group for PK analysis. Japan LIC was not included in single-dose PK analysis, ie, they did not contribute to Day -7 data."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"22"}]}],"classes":[{"title":"Day -7","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.15","lowerLimit":"0.50","upperLimit":"4.02"}]}]},{"title":"Cycle 1 Day 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"22"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.96","lowerLimit":"0.50","upperLimit":"22.7"}]}]}]},{"type":"SECONDARY","title":"Area Under the Plasma Concentration-Time Profile From Time Zero Extrapolated to Infinite Time (AUCinf) of PF-06463922 (Phase 2)","description":"AUCinf was calculated as AUClast + (Clast\\*/kel), where AUClast was the area under the plasma concentration-time profile from time 0 to the time of the last quantifiable concentration, Clast\\* was the predicted plasma concentration at the last quantifiable time point estimated from the log-linear regression analysis, and kel was the rate constant for terminal phase.","populationDescription":"PK parameter analysis set for PF-06463922 included all enrolled participants who received at least 1 dose of PF-06463922 and had sufficient information to estimate at least one of the PK parameters of interest for PF-06463922. Here, 'Overall Number of Participants Analyzed' signifies participants analyzed for this outcome measure.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"ng*hour/mL","timeFrame":"Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9, 24, 48, 72, 96 and 120 hours post-dose on Day -7","groups":[{"id":"OG000","title":"Phase 2 and Japan LIC PK Analysis Set","description":"PK parameters of PF-06463922 were determined for a small subset of Phase 2 participants and Japan LIC. These participants received PF-06463922 100 mg orally QD and were combined into 1 reporting group for PK analysis. Japan LIC was not included in single-dose PK analysis, ie, they did not contribute to Day -7 data."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9088","spread":"35"}]}]}]},{"type":"SECONDARY","title":"Area Under the Plasma Concentration-Time Profile From Time Zero to Time Tau (AUCtau) of PF-06463922 (Phase 2)","description":"Tau refers to the dosing interval, and it equals to 24 hours for QD dosing which was adopted in Phase 2. AUCtau was determined using linear/log trapezoidal method.","populationDescription":"PK parameter analysis set for PF-06463922 included all enrolled participants who received at least 1 dose of PF-06463922 and had sufficient information to estimate at least one of the PK parameters of interest for PF-06463922. Here, 'Number Analyzed' signifies participants evaluable for specified row.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"ng*hour/mL","timeFrame":"Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9 and 24 hours post-dose on Day -7 and pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9 and 24 hours post-dose on Cycle 1 Day 15","groups":[{"id":"OG000","title":"Phase 2 and Japan LIC PK Analysis Set","description":"PK parameters of PF-06463922 were determined for a small subset of Phase 2 participants and Japan LIC. These participants received PF-06463922 100 mg orally QD and were combined into 1 reporting group for PK analysis. Japan LIC was not included in single-dose PK analysis, ie, they did not contribute to Day -7 data."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"22"}]}],"classes":[{"title":"Day -7","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5308","spread":"36"}]}]},{"title":"Cycle 1 Day 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"22"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5650","spread":"39"}]}]}]},{"type":"SECONDARY","title":"Apparent Oral Clearance (CL/F) of PF-06463922 (Phase 2)","description":"Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. CL/F was calculated as dose/AUCinf, where AUCinf was the area under the plasma concentration-time profile from time 0 extrapolated to infinite time.","populationDescription":"PK parameter analysis set for PF-06463922 included all enrolled participants who received at least 1 dose of PF-06463922 and had sufficient information to estimate at least one of the PK parameters of interest for PF-06463922. Here, 'Number Analyzed' signifies participants evaluable for specified row.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"Liter/hour","timeFrame":"Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9, 24, 48, 72, 96 and 120 hours post-dose on Day -7 and pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9 and 24 hours post-dose on Cycle 1 Day 15","groups":[{"id":"OG000","title":"Phase 2 and Japan LIC PK Analysis Set","description":"PK parameters of PF-06463922 were determined for a small subset of Phase 2 participants and Japan LIC. These participants received PF-06463922 100 mg orally QD and were combined into 1 reporting group for PK analysis. Japan LIC was not included in single-dose PK analysis, ie, they did not contribute to Day -7 data."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"22"}]}],"classes":[{"title":"Day -7","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"11.01","spread":"35"}]}]},{"title":"Cycle 1 Day 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"22"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"17.70","spread":"39"}]}]}]},{"type":"SECONDARY","title":"Apparent Volume of Distribution (Vz/F) of PF-06463922 (Phase 2)","description":"Vz/F was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug, and calculated as dose/(AUCinf\\*kel), where AUCinf was the area under the plasma concentration-time profile from time 0 extrapolated to infinite time, kel was the rate constant for terminal phase.","populationDescription":"PK parameter analysis set for PF-06463922 included all enrolled participants who received at least 1 dose of PF-06463922 and had sufficient information to estimate at least one of the PK parameters of interest for PF-06463922. Here, \"Overall Number of Participants Analyzed\" signifies participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"Liters","timeFrame":"Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9, 24, 48, 72, 96 and 120 hours post-dose on Day -7","groups":[{"id":"OG000","title":"Phase 2 and Japan LIC PK Analysis Set","description":"PK parameters of PF-06463922 were determined for a small subset of Phase 2 participants and Japan LIC. These participants received PF-06463922 100 mg orally QD and were combined into 1 reporting group for PK analysis. Japan LIC was not included in single-dose PK analysis, ie, they did not contribute to Day -7 data."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"351.5","spread":"37"}]}]}]},{"type":"SECONDARY","title":"Terminal Half-Life of PF-06463922 (Phase 2)","description":"Terminal plasma half-life was defined as the time measured for the plasma concentration to decrease by one half, and calculated as loge(2)/kel, where kel was the rate constant for terminal phase.","populationDescription":"PK parameter analysis set for PF-06463922 included all enrolled participants who received at least 1 dose of PF-06463922 and had sufficient information to estimate at least one of the PK parameters of interest for PF-06463922. Here, \"Overall Number of Participants Analyzed\" signifies participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Hours","timeFrame":"Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9, 24, 48, 72, 96 and 120 hours post-dose on Day -7","groups":[{"id":"OG000","title":"Phase 2 and Japan LIC PK Analysis Set","description":"PK parameters of PF-06463922 were determined for a small subset of Phase 2 participants and Japan LIC. These participants received PF-06463922 100 mg orally QD and were combined into 1 reporting group for PK analysis. Japan LIC was not included in single-dose PK analysis, ie, they did not contribute to Day -7 data."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23.58","spread":"9.3743"}]}]}]},{"type":"SECONDARY","title":"Observed Accumulation Ratio (Rac) of PF-06463922 Following Multiple Oral Doses (Phase 2)","description":"Rac was calculated as Day 15 AUCtau/Day -7 AUCtau, where AUCtau was the area under the plasma concentration-time profile from time 0 to time tau (24 hours for QD dosing regimen which was adopted in Phase 2).","populationDescription":"PK parameter analysis set for PF-06463922 included all enrolled participants who received at least 1 dose of PF-06463922 and had sufficient information to estimate at least one of the PK parameters of interest for PF-06463922. Here, \"Overall Number of Participants Analyzed\" signifies participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Ratio","timeFrame":"Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9 and 24 hours post-dose on Cycle 1 Day 15","groups":[{"id":"OG000","title":"Phase 2 and Japan LIC PK Analysis Set","description":"PK parameters of PF-06463922 were determined for a small subset of Phase 2 participants and Japan LIC. These participants received PF-06463922 100 mg orally QD and were combined into 1 reporting group for PK analysis. Japan LIC was not included in single-dose PK analysis, ie, they did not contribute to Day -7 data."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"20"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.082","spread":"0.42701"}]}]}]},{"type":"SECONDARY","title":"Steady State Accumulation Ratio (Rss) of PF-06463922 Following Multiple Oral Doses (Phase 2)","description":"Rss was calculated as Day 15 AUCtau/Day -7 AUCinf, where AUCtau was the area under the plasma concentration-time profile from time 0 to time tau (24 hours for QD dosing regimen which was adopted in Phase 2), and AUCinf was the area under the plasma concentration-time profile from time 0 extrapolated to infinite time.","populationDescription":"PK parameter analysis set for PF-06463922 included all enrolled participants who received at least 1 dose of PF-06463922 and had sufficient information to estimate at least one of the PK parameters of interest for PF-06463922. Here, \"Overall Number of Participants Analyzed\" signifies participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Ratio","timeFrame":"Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9 and 24 hours post-dose on Cycle 1 Day 15","groups":[{"id":"OG000","title":"Phase 2 and Japan LIC PK Analysis Set","description":"PK parameters of PF-06463922 were determined for a small subset of Phase 2 participants and Japan LIC. These participants received PF-06463922 100 mg orally QD and were combined into 1 reporting group for PK analysis. Japan LIC was not included in single-dose PK analysis, ie, they did not contribute to Day -7 data."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.6577","spread":"0.28627"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With ALK Mutation Based on Plasma CNA Analysis (Phase 2)","description":"Plasma CNA samples were analyzed for ALK kinase domain mutations by Next Generation Sequencing (NGS). Number of participants with one or more ALK mutations is presented.","populationDescription":"CNA peripheral blood analysis set included all participants of the ITT analysis set who had at least 1 molecular biomarker assayed. Here, \"Overall Number of Participants Analyzed\" signifies participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Screening (up to 28 days)","groups":[{"id":"OG000","title":"EXP-1 (Phase 2)","description":"Treatment-naÃ¯ve participants with advanced anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC) with or without asymptomatic central nervous system (CNS) metastases were given PF-06463922 100 mg orally QD on Day -7 (only participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG001","title":"EXP-2 (Phase 2)","description":"Participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after only crizotinib therapy were given PF-06463922 100 mg orally QD on Day -7 (only for participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG002","title":"EXP-3 (Phase 2)","description":"Participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after crizotinib therapy and 1 or 2 prior regimens of chemotherapy given before or after crizotinib therapy, or participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after 1 ALK inhibitor therapy other than crizotinib with or without any number of prior chemotherapy regimens in any disease setting were given PF-06463922 100 mg orally QD on Day -7 (only for participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG003","title":"EXP-4 (Phase 2)","description":"Participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after 2 prior lines of ALK inhibitor therapies were given PF-06463922 100 mg orally QD on Day -7 (only for participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG004","title":"EXP-5 (Phase 2)","description":"Participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after 3 prior lines of ALK inhibitor therapies were given PF-06463922 100 mg orally QD on Day -7 (only for participant scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"59"},{"groupId":"OG003","value":"61"},{"groupId":"OG004","value":"46"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"8"},{"groupId":"OG003","value":"17"},{"groupId":"OG004","value":"14"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With ALK Mutation Based on Tumor Tissue Analysis (Phase 2)","description":"Tumor tissues from archived tissue specimens and/or a de novo biopsy were analyzed for ALK kinase domain mutations. Number of participants with one or more ALK mutations is presented.","populationDescription":"Tumor Tissue analysis set included all participants of the ITT analysis set who had at least 1 molecular tumor biomarker assayed from either the screening archival or screening de novo tumor biopsy sample (or both).","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Screening (up to 28 days)","groups":[{"id":"OG000","title":"EXP-1 (Phase 2)","description":"Treatment-naÃ¯ve participants with advanced anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC) with or without asymptomatic central nervous system (CNS) metastases were given PF-06463922 100 mg orally QD on Day -7 (only participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG001","title":"EXP-2 (Phase 2)","description":"Participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after only crizotinib therapy were given PF-06463922 100 mg orally QD on Day -7 (only for participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG002","title":"EXP-3 (Phase 2)","description":"Participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after crizotinib therapy and 1 or 2 prior regimens of chemotherapy given before or after crizotinib therapy, or participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after 1 ALK inhibitor therapy other than crizotinib with or without any number of prior chemotherapy regimens in any disease setting were given PF-06463922 100 mg orally QD on Day -7 (only for participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG003","title":"EXP-4 (Phase 2)","description":"Participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after 2 prior lines of ALK inhibitor therapies were given PF-06463922 100 mg orally QD on Day -7 (only for participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG004","title":"EXP-5 (Phase 2)","description":"Participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after 3 prior lines of ALK inhibitor therapies were given PF-06463922 100 mg orally QD on Day -7 (only for participant scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"29"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"58"},{"groupId":"OG003","value":"63"},{"groupId":"OG004","value":"44"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"8"},{"groupId":"OG003","value":"12"},{"groupId":"OG004","value":"13"}]}]}]},{"type":"SECONDARY","title":"Number of Participants Who Improved, Worsened or Remained Stable in EORTC QLQ-C30 (Phase 2 and DDI Sub-study)","description":"European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ)-C30 (version 3.0) consists of 30 questions assessing 5 functional domains (physical, role, emotional, cognitive and social), global quality of life (QoL), disease/treatment related symptoms (fatigue, nausea/vomiting, pain, dyspnea, insomnia, appetite loss, constipation and diarrhea), and the perceived financial impact of disease. Each scale was transformed to a range of 0 to 100 using standard EORTC algorithm. For global QoL and functional scales, higher score indicate better performance, and improvement was defined as an increase of at least 10 points, worsening was defined as a decrease of at least 10 points. For symptom scales, higher score indicates worse symptoms, and improvement was defined as a decrease of at least 10 points, worsening was defined as an increase of at least 10 points. All scales which had not improved nor worsened were considered stable.","populationDescription":"Patient reported outcome (PRO) evaluable analysis set included all enrolled participants who received at least 1 dose of PF-06463922 and completed a baseline and at least 1 post-baseline PRO assessment.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"From first dose of study treatment to end of treatment (maximum of 7.5 years for Phase 2 and up to a maximum of 6 years approx. for DDI sub study)","groups":[{"id":"OG000","title":"EXP-1 (Phase 2)","description":"Treatment-naÃ¯ve participants with advanced anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC) with or without asymptomatic central nervous system (CNS) metastases were given PF-06463922 100 mg orally QD on Day -7 (only participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG001","title":"EXP-2 (Phase 2)","description":"Participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after only crizotinib therapy were given PF-06463922 100 mg orally QD on Day -7 (only for participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG002","title":"EXP-3 (Phase 2)","description":"Participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after crizotinib therapy and 1 or 2 prior regimens of chemotherapy given before or after crizotinib therapy, or participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after 1 ALK inhibitor therapy other than crizotinib with or without any number of prior chemotherapy regimens in any disease setting were given PF-06463922 100 mg orally QD on Day -7 (only for participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG003","title":"EXP-4 (Phase 2)","description":"Participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after 2 prior lines of ALK inhibitor therapies were given PF-06463922 100 mg orally QD on Day -7 (only for participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG004","title":"EXP-5 (Phase 2)","description":"Participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after 3 prior lines of ALK inhibitor therapies were given PF-06463922 100 mg orally QD on Day -7 (only for participant scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG005","title":"EXP-6 (Phase 2)","description":"Participants with advanced ROS1-positive NSCLC who were treatment naÃ¯ve or had any number of prior cancer therapies with or without asymptomatic CNS metastases were given PF-06463922 100 mg orally QD on Day -7 (only for participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG006","title":"DDI Sub-study","description":"Participants with advanced ALK positive or ROS1-positive NSCLC who were treatment naÃ¯ve or had any number of prior cancer therapies with or without asymptomatic CNS metastases were administered a single dose of a probe substrate alone on Day -2. Participants were given PF-06463922 100 mg orally QD starting on Cycle1 Day 1 and along with probe substrate on Day 15 Cycle 1."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"55"},{"groupId":"OG003","value":"60"},{"groupId":"OG004","value":"43"},{"groupId":"OG005","value":"41"},{"groupId":"OG006","value":"32"}]}],"classes":[{"title":"Improved in global QoL","categories":[{"measurements":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"18"},{"groupId":"OG003","value":"25"},{"groupId":"OG004","value":"17"},{"groupId":"OG005","value":"19"},{"groupId":"OG006","value":"12"}]}]},{"title":"Stable in global QoL","categories":[{"measurements":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"24"},{"groupId":"OG003","value":"22"},{"groupId":"OG004","value":"16"},{"groupId":"OG005","value":"15"},{"groupId":"OG006","value":"18"}]}]},{"title":"Worsened in global QoL","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"13"},{"groupId":"OG003","value":"13"},{"groupId":"OG004","value":"10"},{"groupId":"OG005","value":"6"},{"groupId":"OG006","value":"2"}]}]},{"title":"Missing for global QoL","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"0"}]}]},{"title":"Improved in physical functioning","categories":[{"measurements":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"13"},{"groupId":"OG003","value":"24"},{"groupId":"OG004","value":"8"},{"groupId":"OG005","value":"11"},{"groupId":"OG006","value":"5"}]}]},{"title":"Stable in physical functioning","categories":[{"measurements":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"17"},{"groupId":"OG002","value":"38"},{"groupId":"OG003","value":"24"},{"groupId":"OG004","value":"25"},{"groupId":"OG005","value":"23"},{"groupId":"OG006","value":"23"}]}]},{"title":"Worsened in physical functioning","categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"12"},{"groupId":"OG004","value":"10"},{"groupId":"OG005","value":"6"},{"groupId":"OG006","value":"4"}]}]},{"title":"Missing for physical functioning","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"0"}]}]},{"title":"Improved in role functioning","categories":[{"measurements":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"15"},{"groupId":"OG003","value":"25"},{"groupId":"OG004","value":"18"},{"groupId":"OG005","value":"17"},{"groupId":"OG006","value":"10"}]}]},{"title":"Stable in role functioning","categories":[{"measurements":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"16"},{"groupId":"OG002","value":"33"},{"groupId":"OG003","value":"18"},{"groupId":"OG004","value":"13"},{"groupId":"OG005","value":"17"},{"groupId":"OG006","value":"15"}]}]},{"title":"Worsened in role functioning","categories":[{"measurements":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"17"},{"groupId":"OG004","value":"12"},{"groupId":"OG005","value":"5"},{"groupId":"OG006","value":"7"}]}]},{"title":"Missing for role functioning","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"2"},{"groupId":"OG006","value":"0"}]}]},{"title":"Improved in emotional functioning","categories":[{"measurements":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"13"},{"groupId":"OG003","value":"20"},{"groupId":"OG004","value":"17"},{"groupId":"OG005","value":"16"},{"groupId":"OG006","value":"10"}]}]},{"title":"Stable in emotional functioning","categories":[{"measurements":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"14"},{"groupId":"OG002","value":"32"},{"groupId":"OG003","value":"34"},{"groupId":"OG004","value":"20"},{"groupId":"OG005","value":"22"},{"groupId":"OG006","value":"20"}]}]},{"title":"Worsened in emotional functioning","categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"6"},{"groupId":"OG005","value":"2"},{"groupId":"OG006","value":"2"}]}]},{"title":"Missing for emotional functioning","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"0"}]}]},{"title":"Improved in cognitive functioning","categories":[{"measurements":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"12"},{"groupId":"OG004","value":"12"},{"groupId":"OG005","value":"12"},{"groupId":"OG006","value":"9"}]}]},{"title":"Stable in cognitive functioning","categories":[{"measurements":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"14"},{"groupId":"OG002","value":"36"},{"groupId":"OG003","value":"34"},{"groupId":"OG004","value":"19"},{"groupId":"OG005","value":"20"},{"groupId":"OG006","value":"11"}]}]},{"title":"Worsened in cognitive functioning","categories":[{"measurements":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"14"},{"groupId":"OG003","value":"14"},{"groupId":"OG004","value":"12"},{"groupId":"OG005","value":"8"},{"groupId":"OG006","value":"12"}]}]},{"title":"Missing for cognitive functioning","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"0"}]}]},{"title":"Improved in social functioning","categories":[{"measurements":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"16"},{"groupId":"OG003","value":"20"},{"groupId":"OG004","value":"11"},{"groupId":"OG005","value":"13"},{"groupId":"OG006","value":"13"}]}]},{"title":"Stable in social functioning","categories":[{"measurements":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"16"},{"groupId":"OG002","value":"33"},{"groupId":"OG003","value":"29"},{"groupId":"OG004","value":"21"},{"groupId":"OG005","value":"18"},{"groupId":"OG006","value":"13"}]}]},{"title":"Worsened in social functioning","categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"11"},{"groupId":"OG004","value":"11"},{"groupId":"OG005","value":"9"},{"groupId":"OG006","value":"6"}]}]},{"title":"Missing for social functioning","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"0"}]}]},{"title":"Improved in fatigue","categories":[{"measurements":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"14"},{"groupId":"OG002","value":"22"},{"groupId":"OG003","value":"28"},{"groupId":"OG004","value":"26"},{"groupId":"OG005","value":"16"},{"groupId":"OG006","value":"17"}]}]},{"title":"Stable in fatigue","categories":[{"measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"25"},{"groupId":"OG003","value":"23"},{"groupId":"OG004","value":"9"},{"groupId":"OG005","value":"20"},{"groupId":"OG006","value":"9"}]}]},{"title":"Worsened in fatigue","categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"8"},{"groupId":"OG003","value":"9"},{"groupId":"OG004","value":"8"},{"groupId":"OG005","value":"4"},{"groupId":"OG006","value":"6"}]}]},{"title":"Missing for fatigue","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"0"}]}]},{"title":"Improved in nausea and vomiting","categories":[{"measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"16"},{"groupId":"OG004","value":"13"},{"groupId":"OG005","value":"10"},{"groupId":"OG006","value":"6"}]}]},{"title":"Stable in nausea and vomiting","categories":[{"measurements":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"21"},{"groupId":"OG002","value":"44"},{"groupId":"OG003","value":"39"},{"groupId":"OG004","value":"28"},{"groupId":"OG005","value":"28"},{"groupId":"OG006","value":"24"}]}]},{"title":"Worsened in nausea and vomiting","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"2"},{"groupId":"OG006","value":"2"}]}]},{"title":"Missing for nausea and vomiting","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"0"}]}]},{"title":"Improved in pain","categories":[{"measurements":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"20"},{"groupId":"OG003","value":"23"},{"groupId":"OG004","value":"19"},{"groupId":"OG005","value":"21"},{"groupId":"OG006","value":"14"}]}]},{"title":"Stable in pain","categories":[{"measurements":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"14"},{"groupId":"OG002","value":"25"},{"groupId":"OG003","value":"28"},{"groupId":"OG004","value":"19"},{"groupId":"OG005","value":"12"},{"groupId":"OG006","value":"13"}]}]},{"title":"Worsened in pain","categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"9"},{"groupId":"OG004","value":"5"},{"groupId":"OG005","value":"7"},{"groupId":"OG006","value":"5"}]}]},{"title":"Missing for pain","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"0"}]}]},{"title":"Improved in dyspnea","categories":[{"measurements":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"23"},{"groupId":"OG004","value":"14"},{"groupId":"OG005","value":"14"},{"groupId":"OG006","value":"9"}]}]},{"title":"Stable in dyspnea","categories":[{"measurements":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"14"},{"groupId":"OG002","value":"33"},{"groupId":"OG003","value":"22"},{"groupId":"OG004","value":"18"},{"groupId":"OG005","value":"17"},{"groupId":"OG006","value":"15"}]}]},{"title":"Worsened in dyspnea","categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"12"},{"groupId":"OG003","value":"15"},{"groupId":"OG004","value":"11"},{"groupId":"OG005","value":"9"},{"groupId":"OG006","value":"8"}]}]},{"title":"Missing for dyspnea","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"0"}]}]},{"title":"Improved in insomnia","categories":[{"measurements":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"18"},{"groupId":"OG003","value":"30"},{"groupId":"OG004","value":"21"},{"groupId":"OG005","value":"19"},{"groupId":"OG006","value":"12"}]}]},{"title":"Stable in insomnia","categories":[{"measurements":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"13"},{"groupId":"OG002","value":"28"},{"groupId":"OG003","value":"22"},{"groupId":"OG004","value":"16"},{"groupId":"OG005","value":"18"},{"groupId":"OG006","value":"15"}]}]},{"title":"Worsened in insomnia","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"9"},{"groupId":"OG003","value":"8"},{"groupId":"OG004","value":"6"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"5"}]}]},{"title":"Missing for insomnia","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"0"}]}]},{"title":"Improved in appetite loss","categories":[{"measurements":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"18"},{"groupId":"OG003","value":"29"},{"groupId":"OG004","value":"22"},{"groupId":"OG005","value":"20"},{"groupId":"OG006","value":"10"}]}]},{"title":"Stable in appetite loss","categories":[{"measurements":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"22"},{"groupId":"OG002","value":"36"},{"groupId":"OG003","value":"26"},{"groupId":"OG004","value":"21"},{"groupId":"OG005","value":"20"},{"groupId":"OG006","value":"20"}]}]},{"title":"Worsened in appetite loss","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"2"}]}]},{"title":"Missing for appetite loss","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"0"}]}]},{"title":"Improved in constipation","categories":[{"measurements":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"9"},{"groupId":"OG003","value":"16"},{"groupId":"OG004","value":"11"},{"groupId":"OG005","value":"13"},{"groupId":"OG006","value":"10"}]}]},{"title":"Stable in constipation","categories":[{"measurements":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"19"},{"groupId":"OG002","value":"33"},{"groupId":"OG003","value":"33"},{"groupId":"OG004","value":"29"},{"groupId":"OG005","value":"22"},{"groupId":"OG006","value":"12"}]}]},{"title":"Worsened in constipation","categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"13"},{"groupId":"OG003","value":"11"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"5"},{"groupId":"OG006","value":"10"}]}]},{"title":"Missing for constipation","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"0"}]}]},{"title":"Improved in diarrhea","categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"10"},{"groupId":"OG004","value":"10"},{"groupId":"OG005","value":"8"},{"groupId":"OG006","value":"6"}]}]},{"title":"Stable in diarrhea","categories":[{"measurements":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"21"},{"groupId":"OG002","value":"40"},{"groupId":"OG003","value":"39"},{"groupId":"OG004","value":"27"},{"groupId":"OG005","value":"28"},{"groupId":"OG006","value":"21"}]}]},{"title":"Worsened in diarrhea","categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"11"},{"groupId":"OG004","value":"6"},{"groupId":"OG005","value":"4"},{"groupId":"OG006","value":"5"}]}]},{"title":"Missing for diarrhea","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"0"}]}]},{"title":"Improved in financial difficulties","categories":[{"measurements":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"11"},{"groupId":"OG003","value":"13"},{"groupId":"OG004","value":"10"},{"groupId":"OG005","value":"10"},{"groupId":"OG006","value":"9"}]}]},{"title":"Stable in financial difficulties","categories":[{"measurements":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"19"},{"groupId":"OG002","value":"34"},{"groupId":"OG003","value":"38"},{"groupId":"OG004","value":"22"},{"groupId":"OG005","value":"26"},{"groupId":"OG006","value":"16"}]}]},{"title":"Worsened in financial difficulties","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"9"},{"groupId":"OG004","value":"11"},{"groupId":"OG005","value":"4"},{"groupId":"OG006","value":"7"}]}]},{"title":"Missing for financial difficulties","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"0"}]}]}]},{"type":"SECONDARY","title":"Number of Participants Who Improved, Worsened or Remained Stable in EORTC QLQ-LC13 (Phase 2 and DDI Sub-study)","description":"EORTC QLQ-LC13 is the lung cancer module of EORTC QLQ-C30 and includes questions specific to the disease associated symptoms (dyspnea, cough, hemoptysis, and site specific pain), treatment-related symptoms (sore mouth, dysphagia, neuropathy and alopecia), and analgesic use of lung cancer patients. The scale was transformed to a range of 0 to 100 using standard EORTC algorithm. Higher score indicates worse symptoms, and improvement was defined as a decrease of at least 10 points, worsening was defined as an increase of at least 10 points. All scales which had not improved nor worsened were considered stable.","populationDescription":"Patient reported outcome (PRO) evaluable analysis set included all enrolled participants who received at least 1 dose of PF-06463922 and completed a baseline and at least 1 post-baseline PRO assessment. Here, \"Overall Number of Participants Analyzed\" signifies participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"From first dose of study treatment to end of treatment (maximum of 7.5 years for Phase 2 and up to a maximum of 6 years approx. for DDI sub study)","groups":[{"id":"OG000","title":"EXP-1 (Phase 2)","description":"Treatment-naÃ¯ve participants with advanced anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC) with or without asymptomatic central nervous system (CNS) metastases were given PF-06463922 100 mg orally QD on Day -7 (only participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG001","title":"EXP-2 (Phase 2)","description":"Participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after only crizotinib therapy were given PF-06463922 100 mg orally QD on Day -7 (only for participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG002","title":"EXP-3 (Phase 2)","description":"Participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after crizotinib therapy and 1 or 2 prior regimens of chemotherapy given before or after crizotinib therapy, or participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after 1 ALK inhibitor therapy other than crizotinib with or without any number of prior chemotherapy regimens in any disease setting were given PF-06463922 100 mg orally QD on Day -7 (only for participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG003","title":"EXP-4 (Phase 2)","description":"Participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after 2 prior lines of ALK inhibitor therapies were given PF-06463922 100 mg orally QD on Day -7 (only for participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG004","title":"EXP-5 (Phase 2)","description":"Participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after 3 prior lines of ALK inhibitor therapies were given PF-06463922 100 mg orally QD on Day -7 (only for participant scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG005","title":"EXP-6 (Phase 2)","description":"Participants with advanced ROS1-positive NSCLC who were treatment naÃ¯ve or had any number of prior cancer therapies with or without asymptomatic CNS metastases were given PF-06463922 100 mg orally QD on Day -7 (only for participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG006","title":"DDI Sub-study","description":"Participants with advanced ALK positive or ROS1-positive NSCLC who were treatment naÃ¯ve or had any number of prior cancer therapies with or without asymptomatic CNS metastases were administered a single dose of a probe substrate alone on Day -2. Participants were given PF-06463922 100 mg orally QD starting on Cycle1 Day 1 and along with probe substrate on Day 15 Cycle 1."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"55"},{"groupId":"OG003","value":"60"},{"groupId":"OG004","value":"43"},{"groupId":"OG005","value":"41"},{"groupId":"OG006","value":"32"}]}],"classes":[{"title":"Improved in dyspnea","categories":[{"measurements":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"9"},{"groupId":"OG003","value":"21"},{"groupId":"OG004","value":"12"},{"groupId":"OG005","value":"12"},{"groupId":"OG006","value":"6"}]}]},{"title":"Stable in dyspnea","categories":[{"measurements":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"18"},{"groupId":"OG002","value":"36"},{"groupId":"OG003","value":"25"},{"groupId":"OG004","value":"21"},{"groupId":"OG005","value":"23"},{"groupId":"OG006","value":"18"}]}]},{"title":"Worsened in dyspnea","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"14"},{"groupId":"OG004","value":"9"},{"groupId":"OG005","value":"6"},{"groupId":"OG006","value":"8"}]}]},{"title":"Missing-dyspnea","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"}]}]},{"title":"Improved in coughing","categories":[{"measurements":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"22"},{"groupId":"OG003","value":"26"},{"groupId":"OG004","value":"18"},{"groupId":"OG005","value":"17"},{"groupId":"OG006","value":"16"}]}]},{"title":"Stable in coughing","categories":[{"measurements":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"13"},{"groupId":"OG002","value":"26"},{"groupId":"OG003","value":"28"},{"groupId":"OG004","value":"15"},{"groupId":"OG005","value":"18"},{"groupId":"OG006","value":"15"}]}]},{"title":"Worsened in coughing","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"9"},{"groupId":"OG005","value":"6"},{"groupId":"OG006","value":"1"}]}]},{"title":"Missing-coughing","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"}]}]},{"title":"Improved in hemoptysis","categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"5"},{"groupId":"OG005","value":"4"},{"groupId":"OG006","value":"1"}]}]},{"title":"Stable in hemoptysis","categories":[{"measurements":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"25"},{"groupId":"OG002","value":"47"},{"groupId":"OG003","value":"52"},{"groupId":"OG004","value":"34"},{"groupId":"OG005","value":"36"},{"groupId":"OG006","value":"31"}]}]},{"title":"Worsened in hemoptysis","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"0"}]}]},{"title":"Missing-hemoptysis","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"}]}]},{"title":"Improved in sore mouth","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"9"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"5"},{"groupId":"OG006","value":"4"}]}]},{"title":"Stable in sore mouth","categories":[{"measurements":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"20"},{"groupId":"OG002","value":"44"},{"groupId":"OG003","value":"41"},{"groupId":"OG004","value":"33"},{"groupId":"OG005","value":"28"},{"groupId":"OG006","value":"26"}]}]},{"title":"Worsened in sore mouth","categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"10"},{"groupId":"OG004","value":"7"},{"groupId":"OG005","value":"8"},{"groupId":"OG006","value":"2"}]}]},{"title":"Missing-sore mouth","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"}]}]},{"title":"Improved in dysphagia","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"4"},{"groupId":"OG005","value":"5"},{"groupId":"OG006","value":"3"}]}]},{"title":"Stable in dysphagia","categories":[{"measurements":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"46"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"33"},{"groupId":"OG005","value":"30"},{"groupId":"OG006","value":"27"}]}]},{"title":"Worsened in dysphagia","categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"5"},{"groupId":"OG005","value":"6"},{"groupId":"OG006","value":"2"}]}]},{"title":"Missing-dysphagia","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"}]}]},{"title":"Improved in peripheral neuropathy","categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"9"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"6"},{"groupId":"OG005","value":"9"},{"groupId":"OG006","value":"9"}]}]},{"title":"Stable in peripheral neuropathy","categories":[{"measurements":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"13"},{"groupId":"OG002","value":"27"},{"groupId":"OG003","value":"33"},{"groupId":"OG004","value":"22"},{"groupId":"OG005","value":"18"},{"groupId":"OG006","value":"16"}]}]},{"title":"Worsened in peripheral neuropathy","categories":[{"measurements":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"19"},{"groupId":"OG003","value":"22"},{"groupId":"OG004","value":"14"},{"groupId":"OG005","value":"14"},{"groupId":"OG006","value":"7"}]}]},{"title":"Missing-peripheral neuropathy","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"}]}]},{"title":"Improved in alopecia","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"10"},{"groupId":"OG004","value":"10"},{"groupId":"OG005","value":"9"},{"groupId":"OG006","value":"4"}]}]},{"title":"Stable in alopecia","categories":[{"measurements":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"22"},{"groupId":"OG002","value":"41"},{"groupId":"OG003","value":"40"},{"groupId":"OG004","value":"24"},{"groupId":"OG005","value":"27"},{"groupId":"OG006","value":"21"}]}]},{"title":"Worsened in alopecia","categories":[{"measurements":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"12"},{"groupId":"OG003","value":"10"},{"groupId":"OG004","value":"8"},{"groupId":"OG005","value":"5"},{"groupId":"OG006","value":"7"}]}]},{"title":"Missing-alopecia","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"}]}]},{"title":"Improved in chest pain","categories":[{"measurements":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"13"},{"groupId":"OG003","value":"18"},{"groupId":"OG004","value":"14"},{"groupId":"OG005","value":"14"},{"groupId":"OG006","value":"13"}]}]},{"title":"Stable in chest pain","categories":[{"measurements":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"17"},{"groupId":"OG002","value":"35"},{"groupId":"OG003","value":"33"},{"groupId":"OG004","value":"25"},{"groupId":"OG005","value":"24"},{"groupId":"OG006","value":"17"}]}]},{"title":"Worsened in chest pain","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"9"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"2"}]}]},{"title":"Missing-chest pain","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"}]}]},{"title":"Improved in arm or shoulder pain","categories":[{"measurements":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"14"},{"groupId":"OG003","value":"14"},{"groupId":"OG004","value":"12"},{"groupId":"OG005","value":"12"},{"groupId":"OG006","value":"9"}]}]},{"title":"Stable in arm or shoulder pain","categories":[{"measurements":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"19"},{"groupId":"OG002","value":"30"},{"groupId":"OG003","value":"36"},{"groupId":"OG004","value":"21"},{"groupId":"OG005","value":"22"},{"groupId":"OG006","value":"19"}]}]},{"title":"Worsened in arm or shoulder pain","categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"11"},{"groupId":"OG003","value":"10"},{"groupId":"OG004","value":"9"},{"groupId":"OG005","value":"7"},{"groupId":"OG006","value":"4"}]}]},{"title":"Missing- arm or shoulder pain","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"}]}]},{"title":"Improved in pain in other parts","categories":[{"measurements":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"17"},{"groupId":"OG003","value":"20"},{"groupId":"OG004","value":"15"},{"groupId":"OG005","value":"17"},{"groupId":"OG006","value":"9"}]}]},{"title":"Stable in pain in other parts","categories":[{"measurements":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"15"},{"groupId":"OG002","value":"23"},{"groupId":"OG003","value":"24"},{"groupId":"OG004","value":"9"},{"groupId":"OG005","value":"18"},{"groupId":"OG006","value":"10"}]}]},{"title":"Worsened in pain in other parts","categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"15"},{"groupId":"OG003","value":"16"},{"groupId":"OG004","value":"17"},{"groupId":"OG005","value":"6"},{"groupId":"OG006","value":"12"}]}]},{"title":"Missing-Pain in other parts","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"1"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Treatment-Emergent Adverse Events (Phase 1, Phase 2 and DDI Sub-study)","description":"AE: any untoward medical occurrence in clinical investigation participant administered a product or medical device, regardless of causal relationship to study treatment. Treatment-emergent AEs (TEAEs): AEs which occurred for first time during effective duration of treatment or AEs that increased in severity during treatment. Serious AEs (SAEs): any untoward medical occurrence at any dose that resulted in death; was life-threatening (immediate risk of death); required inpatient hospitalization or caused prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity (substantial disruption of ability to conduction normal life function). AEs included SAEs and non-serious AEs. Severity was graded as per National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.Grade1: mild, Grade2: moderate, Grade3: severe, Grade4: Life threatening consequences; urgent intervention indicated, Grade 5: death related to AE.","populationDescription":"The safety analysis set included all enrolled participants who received at least 1 dose of PF-06463922.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"From first dose of study treatment to end of treatment (maximum of 8 years for Phase 1, maximum of 7.5 years for Phase 2 and up to a maximum of 6 years approx. for DDI sub study)","groups":[{"id":"OG000","title":"10 mg QD (Phase 1)","description":"PF-06463922 10 mg was orally given once daily (QD) on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG001","title":"25 mg QD (Phase 1)","description":"PF-06463922 25 mg was orally given QD in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal. Midazolam 2 mg was orally given QD on Day -7 and Cycle 1 Day 15."},{"id":"OG002","title":"50 mg QD (Phase 1)","description":"PF-06463922 50 mg was orally given QD on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG003","title":"75 mg QD (Phase 1)","description":"PF-06463922 75 mg was orally given QD on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG004","title":"100 mg QD (Phase 1)","description":"PF-06463922 100 mg was orally given QD on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG005","title":"150 mg QD (Phase 1)","description":"PF-06463922 150 mg was orally given QD in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal. Midazolam 2 mg was orally given QD on Day -7 and Cycle 1 Day 15."},{"id":"OG006","title":"200 mg QD (Phase 1)","description":"PF-06463922 200 mg was orally given QD on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG007","title":"35 mg BID (Phase 1)","description":"PF-06463922 35 mg was orally given twice daily (BID) on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG008","title":"75 mg BID (Phase 1)","description":"PF-06463922 75 mg was orally given BID on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG009","title":"100 mg BID (Phase 1)","description":"PF-06463922 100 mg was orally given BID on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG010","title":"EXP-1 (Phase 2)","description":"Treatment-naÃ¯ve participants with advanced anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC) with or without asymptomatic central nervous system (CNS) metastases were given PF-06463922 100 mg orally QD on Day -7 (only participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG011","title":"EXP-2 (Phase 2)","description":"Participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after only crizotinib therapy were given PF-06463922 100 mg orally QD on Day -7 (only for participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG012","title":"EXP-3 (Phase 2)","description":"Participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after crizotinib therapy and 1 or 2 prior regimens of chemotherapy given before or after crizotinib therapy, or participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after 1 ALK inhibitor therapy other than crizotinib with or without any number of prior chemotherapy regimens in any disease setting were given PF-06463922 100 mg orally QD on Day -7 (only for participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG013","title":"EXP-4 (Phase 2)","description":"Participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after 2 prior lines of ALK inhibitor therapies were given PF-06463922 100 mg orally QD on Day -7 (only for participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG014","title":"EXP-5 (Phase 2)","description":"Participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after 3 prior lines of ALK inhibitor therapies were given PF-06463922 100 mg orally QD on Day -7 (only for participant scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG015","title":"EXP-6 (Phase 2)","description":"Participants with advanced ROS1-positive NSCLC who were treatment naÃ¯ve or had any number of prior cancer therapies with or without asymptomatic CNS metastases were given PF-06463922 100 mg orally QD on Day -7 (only for participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG016","title":"DDI Sub-study","description":"Participants with advanced ALK positive or ROS1-positive NSCLC who were treatment naÃ¯ve or had any number of prior cancer therapies with or without asymptomatic CNS metastases were administered a single dose of a probe substrate alone on Day -2. Participants were given PF-06463922 100 mg orally QD starting on Cycle1 Day 1 and along with probe substrate on Day 15 Cycle 1."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"12"},{"groupId":"OG004","value":"17"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"3"},{"groupId":"OG007","value":"3"},{"groupId":"OG008","value":"3"},{"groupId":"OG009","value":"4"},{"groupId":"OG010","value":"30"},{"groupId":"OG011","value":"27"},{"groupId":"OG012","value":"60"},{"groupId":"OG013","value":"65"},{"groupId":"OG014","value":"46"},{"groupId":"OG015","value":"47"},{"groupId":"OG016","value":"32"}]}],"classes":[{"title":"AEs (all causality)","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"12"},{"groupId":"OG004","value":"17"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"3"},{"groupId":"OG007","value":"3"},{"groupId":"OG008","value":"3"},{"groupId":"OG009","value":"4"},{"groupId":"OG010","value":"30"},{"groupId":"OG011","value":"27"},{"groupId":"OG012","value":"59"},{"groupId":"OG013","value":"65"},{"groupId":"OG014","value":"46"},{"groupId":"OG015","value":"47"},{"groupId":"OG016","value":"32"}]}]},{"title":"AEs (treatment-related)","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"11"},{"groupId":"OG004","value":"16"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"3"},{"groupId":"OG007","value":"1"},{"groupId":"OG008","value":"3"},{"groupId":"OG009","value":"4"},{"groupId":"OG010","value":"30"},{"groupId":"OG011","value":"27"},{"groupId":"OG012","value":"56"},{"groupId":"OG013","value":"61"},{"groupId":"OG014","value":"43"},{"groupId":"OG015","value":"45"},{"groupId":"OG016","value":"31"}]}]},{"title":"SAEs (all causality)","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"10"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"2"},{"groupId":"OG008","value":"2"},{"groupId":"OG009","value":"2"},{"groupId":"OG010","value":"15"},{"groupId":"OG011","value":"11"},{"groupId":"OG012","value":"34"},{"groupId":"OG013","value":"31"},{"groupId":"OG014","value":"23"},{"groupId":"OG015","value":"21"},{"groupId":"OG016","value":"13"}]}]},{"title":"SAEs (treatment-related)","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"1"},{"groupId":"OG010","value":"3"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"8"},{"groupId":"OG013","value":"6"},{"groupId":"OG014","value":"6"},{"groupId":"OG015","value":"4"},{"groupId":"OG016","value":"1"}]}]},{"title":"Grade 3 or 4 (all causality)","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"12"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"2"},{"groupId":"OG008","value":"1"},{"groupId":"OG009","value":"4"},{"groupId":"OG010","value":"22"},{"groupId":"OG011","value":"22"},{"groupId":"OG012","value":"43"},{"groupId":"OG013","value":"50"},{"groupId":"OG014","value":"36"},{"groupId":"OG015","value":"36"},{"groupId":"OG016","value":"24"}]}]},{"title":"Grade 3 or 4 (treatment-related)","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"6"},{"groupId":"OG005","value":"2"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"1"},{"groupId":"OG009","value":"3"},{"groupId":"OG010","value":"13"},{"groupId":"OG011","value":"15"},{"groupId":"OG012","value":"31"},{"groupId":"OG013","value":"31"},{"groupId":"OG014","value":"22"},{"groupId":"OG015","value":"25"},{"groupId":"OG016","value":"16"}]}]},{"title":"Grade 5 (all causality)","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"4"},{"groupId":"OG005","value":"2"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"1"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"3"},{"groupId":"OG011","value":"3"},{"groupId":"OG012","value":"10"},{"groupId":"OG013","value":"11"},{"groupId":"OG014","value":"9"},{"groupId":"OG015","value":"7"},{"groupId":"OG016","value":"5"}]}]},{"title":"Grade 5 (treatment-related)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"0"},{"groupId":"OG015","value":"0"},{"groupId":"OG016","value":"0"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Laboratory Abnormalities (Phase 1, Phase 2 and DDI Sub-study) - Hematology","description":"Hematology evaluation included hemoglobin, platelets, white blood cell, absolute neutrophils, absolute lymphocytes, absolute monocytes, absolute eosinophils and absolute basophils. Hematology parameters with any abnormalities were reported in this outcome measure.","populationDescription":"The safety analysis set included all enrolled participants who received at least 1 dose of PF-06463922. Here 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure and 'Number Analyzed' signifies participants evaluable for specified rows.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"From first dose of study treatment to end of treatment (maximum of 8 years for Phase 1, maximum of 7.5 years for Phase 2 and up to a maximum of 6 years approx. for DDI sub study)","groups":[{"id":"OG000","title":"10 mg QD (Phase 1)","description":"PF-06463922 10 mg was orally given once daily (QD) on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG001","title":"25 mg QD (Phase 1)","description":"PF-06463922 25 mg was orally given QD in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal. Midazolam 2 mg was orally given QD on Day -7 and Cycle 1 Day 15."},{"id":"OG002","title":"50 mg QD (Phase 1)","description":"PF-06463922 50 mg was orally given QD on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG003","title":"75 mg QD (Phase 1)","description":"PF-06463922 75 mg was orally given QD on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG004","title":"100 mg QD (Phase 1)","description":"PF-06463922 100 mg was orally given QD on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG005","title":"150 mg QD (Phase 1)","description":"PF-06463922 150 mg was orally given QD in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal. Midazolam 2 mg was orally given QD on Day -7 and Cycle 1 Day 15."},{"id":"OG006","title":"200 mg QD (Phase 1)","description":"PF-06463922 200 mg was orally given QD on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG007","title":"35 mg BID (Phase 1)","description":"PF-06463922 35 mg was orally given twice daily (BID) on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG008","title":"75 mg BID (Phase 1)","description":"PF-06463922 75 mg was orally given BID on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG009","title":"100 mg BID (Phase 1)","description":"PF-06463922 100 mg was orally given BID on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG010","title":"EXP-1 (Phase 2)","description":"Treatment-naÃ¯ve participants with advanced anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC) with or without asymptomatic central nervous system (CNS) metastases were given PF-06463922 100 mg orally QD on Day -7 (only participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG011","title":"EXP-2 (Phase 2)","description":"Participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after only crizotinib therapy were given PF-06463922 100 mg orally QD on Day -7 (only for participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG012","title":"EXP-3 (Phase 2)","description":"Participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after crizotinib therapy and 1 or 2 prior regimens of chemotherapy given before or after crizotinib therapy, or participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after 1 ALK inhibitor therapy other than crizotinib with or without any number of prior chemotherapy regimens in any disease setting were given PF-06463922 100 mg orally QD on Day -7 (only for participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG013","title":"EXP-4 (Phase 2)","description":"Participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after 2 prior lines of ALK inhibitor therapies were given PF-06463922 100 mg orally QD on Day -7 (only for participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG014","title":"EXP-5 (Phase 2)","description":"Participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after 3 prior lines of ALK inhibitor therapies were given PF-06463922 100 mg orally QD on Day -7 (only for participant scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG015","title":"EXP-6 (Phase 2)","description":"Participants with advanced ROS1-positive NSCLC who were treatment naÃ¯ve or had any number of prior cancer therapies with or without asymptomatic CNS metastases were given PF-06463922 100 mg orally QD on Day -7 (only for participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG016","title":"DDI Sub-study","description":"Participants with advanced ALK positive or ROS1-positive NSCLC who were treatment naÃ¯ve or had any number of prior cancer therapies with or without asymptomatic CNS metastases were administered a single dose of a probe substrate alone on Day -2. Participants were given PF-06463922 100 mg orally QD starting on Cycle1 Day 1 and along with probe substrate on Day 15 Cycle 1."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"12"},{"groupId":"OG004","value":"17"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"3"},{"groupId":"OG007","value":"3"},{"groupId":"OG008","value":"3"},{"groupId":"OG009","value":"4"},{"groupId":"OG010","value":"30"},{"groupId":"OG011","value":"27"},{"groupId":"OG012","value":"60"},{"groupId":"OG013","value":"64"},{"groupId":"OG014","value":"45"},{"groupId":"OG015","value":"47"},{"groupId":"OG016","value":"32"}]}],"classes":[{"title":"Anemia","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"12"},{"groupId":"OG004","value":"17"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"3"},{"groupId":"OG007","value":"3"},{"groupId":"OG008","value":"3"},{"groupId":"OG009","value":"4"},{"groupId":"OG010","value":"30"},{"groupId":"OG011","value":"27"},{"groupId":"OG012","value":"60"},{"groupId":"OG013","value":"64"},{"groupId":"OG014","value":"45"},{"groupId":"OG015","value":"47"},{"groupId":"OG016","value":"32"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"10"},{"groupId":"OG004","value":"16"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"3"},{"groupId":"OG007","value":"3"},{"groupId":"OG008","value":"3"},{"groupId":"OG009","value":"4"},{"groupId":"OG010","value":"24"},{"groupId":"OG011","value":"22"},{"groupId":"OG012","value":"51"},{"groupId":"OG013","value":"52"},{"groupId":"OG014","value":"35"},{"groupId":"OG015","value":"34"},{"groupId":"OG016","value":"25"}]}]},{"title":"Hemoglobin increased","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"12"},{"groupId":"OG004","value":"17"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"3"},{"groupId":"OG007","value":"3"},{"groupId":"OG008","value":"3"},{"groupId":"OG009","value":"4"},{"groupId":"OG010","value":"30"},{"groupId":"OG011","value":"27"},{"groupId":"OG012","value":"60"},{"groupId":"OG013","value":"64"},{"groupId":"OG014","value":"45"},{"groupId":"OG015","value":"47"},{"groupId":"OG016","value":"32"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"1"},{"groupId":"OG013","value":"3"},{"groupId":"OG014","value":"2"},{"groupId":"OG015","value":"1"},{"groupId":"OG016","value":"1"}]}]},{"title":"Lymphocyte count decreased","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"12"},{"groupId":"OG004","value":"17"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"3"},{"groupId":"OG007","value":"3"},{"groupId":"OG008","value":"3"},{"groupId":"OG009","value":"4"},{"groupId":"OG010","value":"30"},{"groupId":"OG011","value":"27"},{"groupId":"OG012","value":"60"},{"groupId":"OG013","value":"64"},{"groupId":"OG014","value":"45"},{"groupId":"OG015","value":"46"},{"groupId":"OG016","value":"32"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"4"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"3"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"2"},{"groupId":"OG010","value":"12"},{"groupId":"OG011","value":"14"},{"groupId":"OG012","value":"30"},{"groupId":"OG013","value":"31"},{"groupId":"OG014","value":"21"},{"groupId":"OG015","value":"26"},{"groupId":"OG016","value":"15"}]}]},{"title":"Lymphocyte count increased","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"12"},{"groupId":"OG004","value":"17"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"3"},{"groupId":"OG007","value":"3"},{"groupId":"OG008","value":"3"},{"groupId":"OG009","value":"4"},{"groupId":"OG010","value":"30"},{"groupId":"OG011","value":"27"},{"groupId":"OG012","value":"60"},{"groupId":"OG013","value":"64"},{"groupId":"OG014","value":"45"},{"groupId":"OG015","value":"46"},{"groupId":"OG016","value":"32"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"4"},{"groupId":"OG011","value":"3"},{"groupId":"OG012","value":"6"},{"groupId":"OG013","value":"1"},{"groupId":"OG014","value":"1"},{"groupId":"OG015","value":"0"},{"groupId":"OG016","value":"2"}]}]},{"title":"Neutrophil count decreased","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"12"},{"groupId":"OG004","value":"17"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"3"},{"groupId":"OG007","value":"3"},{"groupId":"OG008","value":"3"},{"groupId":"OG009","value":"4"},{"groupId":"OG010","value":"30"},{"groupId":"OG011","value":"27"},{"groupId":"OG012","value":"60"},{"groupId":"OG013","value":"64"},{"groupId":"OG014","value":"45"},{"groupId":"OG015","value":"46"},{"groupId":"OG016","value":"32"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"1"},{"groupId":"OG010","value":"7"},{"groupId":"OG011","value":"3"},{"groupId":"OG012","value":"8"},{"groupId":"OG013","value":"10"},{"groupId":"OG014","value":"2"},{"groupId":"OG015","value":"7"},{"groupId":"OG016","value":"3"}]}]},{"title":"Platelet count decreased","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"12"},{"groupId":"OG004","value":"17"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"3"},{"groupId":"OG007","value":"3"},{"groupId":"OG008","value":"3"},{"groupId":"OG009","value":"4"},{"groupId":"OG010","value":"30"},{"groupId":"OG011","value":"27"},{"groupId":"OG012","value":"60"},{"groupId":"OG013","value":"64"},{"groupId":"OG014","value":"45"},{"groupId":"OG015","value":"47"},{"groupId":"OG016","value":"32"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"5"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"1"},{"groupId":"OG010","value":"8"},{"groupId":"OG011","value":"10"},{"groupId":"OG012","value":"18"},{"groupId":"OG013","value":"12"},{"groupId":"OG014","value":"13"},{"groupId":"OG015","value":"13"},{"groupId":"OG016","value":"8"}]}]},{"title":"White blood cell decreased","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"12"},{"groupId":"OG004","value":"17"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"3"},{"groupId":"OG007","value":"3"},{"groupId":"OG008","value":"3"},{"groupId":"OG009","value":"4"},{"groupId":"OG010","value":"30"},{"groupId":"OG011","value":"27"},{"groupId":"OG012","value":"60"},{"groupId":"OG013","value":"64"},{"groupId":"OG014","value":"45"},{"groupId":"OG015","value":"47"},{"groupId":"OG016","value":"32"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"2"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"1"},{"groupId":"OG010","value":"9"},{"groupId":"OG011","value":"5"},{"groupId":"OG012","value":"9"},{"groupId":"OG013","value":"13"},{"groupId":"OG014","value":"8"},{"groupId":"OG015","value":"10"},{"groupId":"OG016","value":"4"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Laboratory Abnormalities (Phase 1, Phase 2 and DDI Sub-study) - Chemistry","description":"Chemistry evaluation included alanine aminotransferase (ALT), alkaline phosphatase, aspartate aminotransferase (AST), blood bilirubin, creatine phosphokinase (CPK), creatinine, gamma-glutamyl transferase (GGT), calcium, sodium, potassium, magnesium, albumin, glucose (non-fasted), albumin, phosphorus or phosphate, serum amylase and lipase.","populationDescription":"Safety analysis set: all enrolled participants who received at least 1 dose of PF-06463922. \"Overall Number of Participants Analyzed\": participants evaluable for this outcome measure. 'Number Analyzed': participants evaluable for specified rows.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"From first dose of study treatment to end of treatment (maximum of 8 years for Phase 1, maximum of 7.5 years for Phase 2 and up to a maximum of 6 years approx. for DDI sub study)","groups":[{"id":"OG000","title":"10 mg QD (Phase 1)","description":"PF-06463922 10 mg was orally given once daily (QD) on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG001","title":"25 mg QD (Phase 1)","description":"PF-06463922 25 mg was orally given QD in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal. Midazolam 2 mg was orally given QD on Day -7 and Cycle 1 Day 15."},{"id":"OG002","title":"50 mg QD (Phase 1)","description":"PF-06463922 50 mg was orally given QD on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG003","title":"75 mg QD (Phase 1)","description":"PF-06463922 75 mg was orally given QD on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG004","title":"100 mg QD (Phase 1)","description":"PF-06463922 100 mg was orally given QD on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG005","title":"150 mg QD (Phase 1)","description":"PF-06463922 150 mg was orally given QD in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal. Midazolam 2 mg was orally given QD on Day -7 and Cycle 1 Day 15."},{"id":"OG006","title":"200 mg QD (Phase 1)","description":"PF-06463922 200 mg was orally given QD on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG007","title":"35 mg BID (Phase 1)","description":"PF-06463922 35 mg was orally given twice daily (BID) on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG008","title":"75 mg BID (Phase 1)","description":"PF-06463922 75 mg was orally given BID on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG009","title":"100 mg BID (Phase 1)","description":"PF-06463922 100 mg was orally given BID on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG010","title":"EXP-1 (Phase 2)","description":"Treatment-naÃ¯ve participants with advanced anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC) with or without asymptomatic central nervous system (CNS) metastases were given PF-06463922 100 mg orally QD on Day -7 (only participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG011","title":"EXP-2 (Phase 2)","description":"Participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after only crizotinib therapy were given PF-06463922 100 mg orally QD on Day -7 (only for participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG012","title":"EXP-3 (Phase 2)","description":"Participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after crizotinib therapy and 1 or 2 prior regimens of chemotherapy given before or after crizotinib therapy, or participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after 1 ALK inhibitor therapy other than crizotinib with or without any number of prior chemotherapy regimens in any disease setting were given PF-06463922 100 mg orally QD on Day -7 (only for participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG013","title":"EXP-4 (Phase 2)","description":"Participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after 2 prior lines of ALK inhibitor therapies were given PF-06463922 100 mg orally QD on Day -7 (only for participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG014","title":"EXP-5 (Phase 2)","description":"Participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after 3 prior lines of ALK inhibitor therapies were given PF-06463922 100 mg orally QD on Day -7 (only for participant scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG015","title":"EXP-6 (Phase 2)","description":"Participants with advanced ROS1-positive NSCLC who were treatment naÃ¯ve or had any number of prior cancer therapies with or without asymptomatic CNS metastases were given PF-06463922 100 mg orally QD on Day -7 (only for participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG016","title":"DDI Sub-study","description":"Participants with advanced ALK positive or ROS1-positive NSCLC who were treatment naÃ¯ve or had any number of prior cancer therapies with or without asymptomatic CNS metastases were administered a single dose of a probe substrate alone on Day -2. Participants were given PF-06463922 100 mg orally QD starting on Cycle1 Day 1 and along with probe substrate on Day 15 Cycle 1."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"12"},{"groupId":"OG004","value":"17"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"3"},{"groupId":"OG007","value":"3"},{"groupId":"OG008","value":"3"},{"groupId":"OG009","value":"4"},{"groupId":"OG010","value":"30"},{"groupId":"OG011","value":"27"},{"groupId":"OG012","value":"60"},{"groupId":"OG013","value":"64"},{"groupId":"OG014","value":"45"},{"groupId":"OG015","value":"47"},{"groupId":"OG016","value":"32"}]}],"classes":[{"title":"ALT increased","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"12"},{"groupId":"OG004","value":"17"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"3"},{"groupId":"OG007","value":"3"},{"groupId":"OG008","value":"3"},{"groupId":"OG009","value":"4"},{"groupId":"OG010","value":"30"},{"groupId":"OG011","value":"27"},{"groupId":"OG012","value":"60"},{"groupId":"OG013","value":"63"},{"groupId":"OG014","value":"45"},{"groupId":"OG015","value":"47"},{"groupId":"OG016","value":"32"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"9"},{"groupId":"OG005","value":"2"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"3"},{"groupId":"OG010","value":"13"},{"groupId":"OG011","value":"15"},{"groupId":"OG012","value":"25"},{"groupId":"OG013","value":"25"},{"groupId":"OG014","value":"16"},{"groupId":"OG015","value":"15"},{"groupId":"OG016","value":"10"}]}]},{"title":"Alkaline phosphatase increased","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"12"},{"groupId":"OG004","value":"17"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"3"},{"groupId":"OG007","value":"3"},{"groupId":"OG008","value":"3"},{"groupId":"OG009","value":"4"},{"groupId":"OG010","value":"30"},{"groupId":"OG011","value":"27"},{"groupId":"OG012","value":"60"},{"groupId":"OG013","value":"63"},{"groupId":"OG014","value":"45"},{"groupId":"OG015","value":"47"},{"groupId":"OG016","value":"32"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"10"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"2"},{"groupId":"OG009","value":"3"},{"groupId":"OG010","value":"10"},{"groupId":"OG011","value":"13"},{"groupId":"OG012","value":"29"},{"groupId":"OG013","value":"27"},{"groupId":"OG014","value":"25"},{"groupId":"OG015","value":"14"},{"groupId":"OG016","value":"9"}]}]},{"title":"AST increased","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"12"},{"groupId":"OG004","value":"17"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"3"},{"groupId":"OG007","value":"3"},{"groupId":"OG008","value":"3"},{"groupId":"OG009","value":"4"},{"groupId":"OG010","value":"30"},{"groupId":"OG011","value":"27"},{"groupId":"OG012","value":"60"},{"groupId":"OG013","value":"63"},{"groupId":"OG014","value":"45"},{"groupId":"OG015","value":"47"},{"groupId":"OG016","value":"32"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"8"},{"groupId":"OG005","value":"2"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"1"},{"groupId":"OG009","value":"3"},{"groupId":"OG010","value":"16"},{"groupId":"OG011","value":"15"},{"groupId":"OG012","value":"36"},{"groupId":"OG013","value":"33"},{"groupId":"OG014","value":"21"},{"groupId":"OG015","value":"18"},{"groupId":"OG016","value":"11"}]}]},{"title":"Blood bilirubin increased","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"12"},{"groupId":"OG004","value":"17"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"3"},{"groupId":"OG007","value":"3"},{"groupId":"OG008","value":"3"},{"groupId":"OG009","value":"4"},{"groupId":"OG010","value":"30"},{"groupId":"OG011","value":"27"},{"groupId":"OG012","value":"60"},{"groupId":"OG013","value":"63"},{"groupId":"OG014","value":"45"},{"groupId":"OG015","value":"47"},{"groupId":"OG016","value":"32"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"1"},{"groupId":"OG010","value":"1"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"3"},{"groupId":"OG013","value":"1"},{"groupId":"OG014","value":"2"},{"groupId":"OG015","value":"1"},{"groupId":"OG016","value":"1"}]}]},{"title":"CPK increased","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"1"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"3"},{"groupId":"OG011","value":"3"},{"groupId":"OG012","value":"4"},{"groupId":"OG013","value":"3"},{"groupId":"OG014","value":"0"},{"groupId":"OG015","value":"5"},{"groupId":"OG016","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"1"},{"groupId":"OG008","value":"1"},{"groupId":"OG010","value":"2"},{"groupId":"OG011","value":"1"},{"groupId":"OG012","value":"3"},{"groupId":"OG013","value":"1"},{"groupId":"OG015","value":"2"},{"groupId":"OG016","value":"1"}]}]},{"title":"Creatinine increased","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"12"},{"groupId":"OG004","value":"17"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"3"},{"groupId":"OG007","value":"3"},{"groupId":"OG008","value":"3"},{"groupId":"OG009","value":"4"},{"groupId":"OG010","value":"30"},{"groupId":"OG011","value":"27"},{"groupId":"OG012","value":"60"},{"groupId":"OG013","value":"64"},{"groupId":"OG014","value":"45"},{"groupId":"OG015","value":"47"},{"groupId":"OG016","value":"32"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"10"},{"groupId":"OG004","value":"13"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"3"},{"groupId":"OG007","value":"2"},{"groupId":"OG008","value":"2"},{"groupId":"OG009","value":"3"},{"groupId":"OG010","value":"28"},{"groupId":"OG011","value":"22"},{"groupId":"OG012","value":"40"},{"groupId":"OG013","value":"48"},{"groupId":"OG014","value":"34"},{"groupId":"OG015","value":"37"},{"groupId":"OG016","value":"20"}]}]},{"title":"GGT increased","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"4"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"1"},{"groupId":"OG009","value":"2"},{"groupId":"OG010","value":"2"},{"groupId":"OG011","value":"4"},{"groupId":"OG012","value":"3"},{"groupId":"OG013","value":"1"},{"groupId":"OG014","value":"1"},{"groupId":"OG015","value":"2"},{"groupId":"OG016","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"1"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"2"},{"groupId":"OG010","value":"1"},{"groupId":"OG011","value":"3"},{"groupId":"OG012","value":"2"},{"groupId":"OG013","value":"1"},{"groupId":"OG014","value":"0"},{"groupId":"OG015","value":"1"},{"groupId":"OG016","value":"0"}]}]},{"title":"Hypercalcemia","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"12"},{"groupId":"OG004","value":"17"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"3"},{"groupId":"OG007","value":"3"},{"groupId":"OG008","value":"3"},{"groupId":"OG009","value":"4"},{"groupId":"OG010","value":"30"},{"groupId":"OG011","value":"27"},{"groupId":"OG012","value":"60"},{"groupId":"OG013","value":"64"},{"groupId":"OG014","value":"45"},{"groupId":"OG015","value":"47"},{"groupId":"OG016","value":"32"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"1"},{"groupId":"OG010","value":"8"},{"groupId":"OG011","value":"4"},{"groupId":"OG012","value":"7"},{"groupId":"OG013","value":"8"},{"groupId":"OG014","value":"4"},{"groupId":"OG015","value":"2"},{"groupId":"OG016","value":"5"}]}]},{"title":"Hyperglycemia","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"12"},{"groupId":"OG004","value":"17"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"3"},{"groupId":"OG007","value":"3"},{"groupId":"OG008","value":"3"},{"groupId":"OG009","value":"4"},{"groupId":"OG010","value":"30"},{"groupId":"OG011","value":"27"},{"groupId":"OG012","value":"60"},{"groupId":"OG013","value":"64"},{"groupId":"OG014","value":"45"},{"groupId":"OG015","value":"47"},{"groupId":"OG016","value":"32"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"8"},{"groupId":"OG005","value":"2"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"1"},{"groupId":"OG008","value":"2"},{"groupId":"OG009","value":"1"},{"groupId":"OG010","value":"17"},{"groupId":"OG011","value":"18"},{"groupId":"OG012","value":"37"},{"groupId":"OG013","value":"48"},{"groupId":"OG014","value":"34"},{"groupId":"OG015","value":"31"},{"groupId":"OG016","value":"23"}]}]},{"title":"Hyperkalemia","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"12"},{"groupId":"OG004","value":"17"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"3"},{"groupId":"OG007","value":"3"},{"groupId":"OG008","value":"3"},{"groupId":"OG009","value":"4"},{"groupId":"OG010","value":"30"},{"groupId":"OG011","value":"27"},{"groupId":"OG012","value":"60"},{"groupId":"OG013","value":"64"},{"groupId":"OG014","value":"45"},{"groupId":"OG015","value":"47"},{"groupId":"OG016","value":"32"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"6"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"1"},{"groupId":"OG008","value":"1"},{"groupId":"OG009","value":"2"},{"groupId":"OG010","value":"11"},{"groupId":"OG011","value":"13"},{"groupId":"OG012","value":"21"},{"groupId":"OG013","value":"13"},{"groupId":"OG014","value":"7"},{"groupId":"OG015","value":"6"},{"groupId":"OG016","value":"5"}]}]},{"title":"Hypermagnesemia","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"12"},{"groupId":"OG004","value":"17"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"3"},{"groupId":"OG007","value":"3"},{"groupId":"OG008","value":"3"},{"groupId":"OG009","value":"4"},{"groupId":"OG010","value":"30"},{"groupId":"OG011","value":"27"},{"groupId":"OG012","value":"59"},{"groupId":"OG013","value":"64"},{"groupId":"OG014","value":"45"},{"groupId":"OG015","value":"47"},{"groupId":"OG016","value":"32"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"3"},{"groupId":"OG011","value":"2"},{"groupId":"OG012","value":"2"},{"groupId":"OG013","value":"2"},{"groupId":"OG014","value":"1"},{"groupId":"OG015","value":"4"},{"groupId":"OG016","value":"0"}]}]},{"title":"Hypernatremia","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"12"},{"groupId":"OG004","value":"17"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"3"},{"groupId":"OG007","value":"3"},{"groupId":"OG008","value":"3"},{"groupId":"OG009","value":"4"},{"groupId":"OG010","value":"30"},{"groupId":"OG011","value":"27"},{"groupId":"OG012","value":"60"},{"groupId":"OG013","value":"64"},{"groupId":"OG014","value":"45"},{"groupId":"OG015","value":"47"},{"groupId":"OG016","value":"32"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"4"},{"groupId":"OG005","value":"2"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"1"},{"groupId":"OG010","value":"6"},{"groupId":"OG011","value":"6"},{"groupId":"OG012","value":"9"},{"groupId":"OG013","value":"5"},{"groupId":"OG014","value":"4"},{"groupId":"OG015","value":"5"},{"groupId":"OG016","value":"3"}]}]},{"title":"Hypoalbuminemia","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"12"},{"groupId":"OG004","value":"17"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"3"},{"groupId":"OG007","value":"3"},{"groupId":"OG008","value":"3"},{"groupId":"OG009","value":"4"},{"groupId":"OG010","value":"30"},{"groupId":"OG011","value":"27"},{"groupId":"OG012","value":"60"},{"groupId":"OG013","value":"63"},{"groupId":"OG014","value":"45"},{"groupId":"OG015","value":"46"},{"groupId":"OG016","value":"32"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"7"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"1"},{"groupId":"OG008","value":"3"},{"groupId":"OG009","value":"1"},{"groupId":"OG010","value":"19"},{"groupId":"OG011","value":"20"},{"groupId":"OG012","value":"37"},{"groupId":"OG013","value":"43"},{"groupId":"OG014","value":"32"},{"groupId":"OG015","value":"29"},{"groupId":"OG016","value":"18"}]}]},{"title":"Hypocalcemia","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"12"},{"groupId":"OG004","value":"17"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"3"},{"groupId":"OG007","value":"3"},{"groupId":"OG008","value":"3"},{"groupId":"OG009","value":"4"},{"groupId":"OG010","value":"30"},{"groupId":"OG011","value":"27"},{"groupId":"OG012","value":"60"},{"groupId":"OG013","value":"64"},{"groupId":"OG014","value":"45"},{"groupId":"OG015","value":"47"},{"groupId":"OG016","value":"32"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"5"},{"groupId":"OG005","value":"2"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"1"},{"groupId":"OG010","value":"5"},{"groupId":"OG011","value":"5"},{"groupId":"OG012","value":"16"},{"groupId":"OG013","value":"9"},{"groupId":"OG014","value":"6"},{"groupId":"OG015","value":"12"},{"groupId":"OG016","value":"6"}]}]},{"title":"Hypoglycemia","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"12"},{"groupId":"OG004","value":"17"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"3"},{"groupId":"OG007","value":"3"},{"groupId":"OG008","value":"3"},{"groupId":"OG009","value":"4"},{"groupId":"OG010","value":"30"},{"groupId":"OG011","value":"27"},{"groupId":"OG012","value":"60"},{"groupId":"OG013","value":"64"},{"groupId":"OG014","value":"45"},{"groupId":"OG015","value":"47"},{"groupId":"OG016","value":"32"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"4"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"1"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"1"},{"groupId":"OG011","value":"4"},{"groupId":"OG012","value":"10"},{"groupId":"OG013","value":"9"},{"groupId":"OG014","value":"6"},{"groupId":"OG015","value":"3"},{"groupId":"OG016","value":"6"}]}]},{"title":"Hypokalemia","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"12"},{"groupId":"OG004","value":"17"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"3"},{"groupId":"OG007","value":"3"},{"groupId":"OG008","value":"3"},{"groupId":"OG009","value":"4"},{"groupId":"OG010","value":"30"},{"groupId":"OG011","value":"27"},{"groupId":"OG012","value":"60"},{"groupId":"OG013","value":"64"},{"groupId":"OG014","value":"45"},{"groupId":"OG015","value":"47"},{"groupId":"OG016","value":"32"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"1"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"2"},{"groupId":"OG010","value":"11"},{"groupId":"OG011","value":"2"},{"groupId":"OG012","value":"10"},{"groupId":"OG013","value":"12"},{"groupId":"OG014","value":"8"},{"groupId":"OG015","value":"14"},{"groupId":"OG016","value":"7"}]}]},{"title":"Hypomagnesemia","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"12"},{"groupId":"OG004","value":"17"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"3"},{"groupId":"OG007","value":"3"},{"groupId":"OG008","value":"3"},{"groupId":"OG009","value":"4"},{"groupId":"OG010","value":"30"},{"groupId":"OG011","value":"27"},{"groupId":"OG012","value":"59"},{"groupId":"OG013","value":"64"},{"groupId":"OG014","value":"45"},{"groupId":"OG015","value":"47"},{"groupId":"OG016","value":"32"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"1"},{"groupId":"OG008","value":"1"},{"groupId":"OG009","value":"3"},{"groupId":"OG010","value":"6"},{"groupId":"OG011","value":"9"},{"groupId":"OG012","value":"23"},{"groupId":"OG013","value":"20"},{"groupId":"OG014","value":"16"},{"groupId":"OG015","value":"15"},{"groupId":"OG016","value":"15"}]}]},{"title":"Hyponatremia","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"12"},{"groupId":"OG004","value":"17"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"3"},{"groupId":"OG007","value":"3"},{"groupId":"OG008","value":"3"},{"groupId":"OG009","value":"4"},{"groupId":"OG010","value":"30"},{"groupId":"OG011","value":"27"},{"groupId":"OG012","value":"60"},{"groupId":"OG013","value":"64"},{"groupId":"OG014","value":"45"},{"groupId":"OG015","value":"47"},{"groupId":"OG016","value":"32"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"4"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"2"},{"groupId":"OG009","value":"2"},{"groupId":"OG010","value":"7"},{"groupId":"OG011","value":"9"},{"groupId":"OG012","value":"15"},{"groupId":"OG013","value":"23"},{"groupId":"OG014","value":"12"},{"groupId":"OG015","value":"12"},{"groupId":"OG016","value":"10"}]}]},{"title":"Hypophosphatemia","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"12"},{"groupId":"OG004","value":"17"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"3"},{"groupId":"OG007","value":"3"},{"groupId":"OG008","value":"3"},{"groupId":"OG009","value":"4"},{"groupId":"OG010","value":"30"},{"groupId":"OG011","value":"27"},{"groupId":"OG012","value":"59"},{"groupId":"OG013","value":"64"},{"groupId":"OG014","value":"45"},{"groupId":"OG015","value":"47"},{"groupId":"OG016","value":"32"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"2"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"1"},{"groupId":"OG008","value":"2"},{"groupId":"OG009","value":"1"},{"groupId":"OG010","value":"8"},{"groupId":"OG011","value":"9"},{"groupId":"OG012","value":"23"},{"groupId":"OG013","value":"19"},{"groupId":"OG014","value":"8"},{"groupId":"OG015","value":"15"},{"groupId":"OG016","value":"9"}]}]},{"title":"Lipase increased","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"12"},{"groupId":"OG004","value":"17"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"3"},{"groupId":"OG007","value":"3"},{"groupId":"OG008","value":"3"},{"groupId":"OG009","value":"4"},{"groupId":"OG010","value":"30"},{"groupId":"OG011","value":"27"},{"groupId":"OG012","value":"59"},{"groupId":"OG013","value":"63"},{"groupId":"OG014","value":"45"},{"groupId":"OG015","value":"46"},{"groupId":"OG016","value":"32"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"8"},{"groupId":"OG004","value":"6"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"2"},{"groupId":"OG009","value":"2"},{"groupId":"OG010","value":"10"},{"groupId":"OG011","value":"7"},{"groupId":"OG012","value":"14"},{"groupId":"OG013","value":"16"},{"groupId":"OG014","value":"15"},{"groupId":"OG015","value":"18"},{"groupId":"OG016","value":"7"}]}]},{"title":"Serum amylase increased","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"11"},{"groupId":"OG004","value":"16"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"3"},{"groupId":"OG007","value":"3"},{"groupId":"OG008","value":"2"},{"groupId":"OG009","value":"4"},{"groupId":"OG010","value":"30"},{"groupId":"OG011","value":"25"},{"groupId":"OG012","value":"57"},{"groupId":"OG013","value":"63"},{"groupId":"OG014","value":"45"},{"groupId":"OG015","value":"45"},{"groupId":"OG016","value":"32"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"5"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"2"},{"groupId":"OG010","value":"13"},{"groupId":"OG011","value":"6"},{"groupId":"OG012","value":"18"},{"groupId":"OG013","value":"20"},{"groupId":"OG014","value":"11"},{"groupId":"OG015","value":"15"},{"groupId":"OG016","value":"4"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Laboratory Abnormalities (Phase 1, Phase 2 and DDI Sub-study) - Coagulation, Lipids and Urinalysis","description":"Coagulation evaluation included activated partial thromboplastin time, international normalized ratio (INR), and prothrombin time. Lipid evaluation included Cholesterol and triglycerides.","populationDescription":"Safety analysis set: all enrolled participants who received at least 1 dose of PF-06463922. \"Overall Number of Participants Analyzed\": participants evaluable for this outcome measure. 'Number Analyzed': participants evaluable for specified rows.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"From first dose of study treatment to end of treatment (maximum of 8 years for Phase 1, maximum of 7.5 years for Phase 2 and up to a maximum of 6 years approx. for DDI sub study)","groups":[{"id":"OG000","title":"10 mg QD (Phase 1)","description":"PF-06463922 10 mg was orally given once daily (QD) on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG001","title":"25 mg QD (Phase 1)","description":"PF-06463922 25 mg was orally given QD in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal. Midazolam 2 mg was orally given QD on Day -7 and Cycle 1 Day 15."},{"id":"OG002","title":"50 mg QD (Phase 1)","description":"PF-06463922 50 mg was orally given QD on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG003","title":"75 mg QD (Phase 1)","description":"PF-06463922 75 mg was orally given QD on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG004","title":"100 mg QD (Phase 1)","description":"PF-06463922 100 mg was orally given QD on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG005","title":"150 mg QD (Phase 1)","description":"PF-06463922 150 mg was orally given QD in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal. Midazolam 2 mg was orally given QD on Day -7 and Cycle 1 Day 15."},{"id":"OG006","title":"200 mg QD (Phase 1)","description":"PF-06463922 200 mg was orally given QD on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG007","title":"35 mg BID (Phase 1)","description":"PF-06463922 35 mg was orally given twice daily (BID) on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG008","title":"75 mg BID (Phase 1)","description":"PF-06463922 75 mg was orally given BID on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG009","title":"100 mg BID (Phase 1)","description":"PF-06463922 100 mg was orally given BID on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG010","title":"EXP-1 (Phase 2)","description":"Treatment-naÃ¯ve participants with advanced anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC) with or without asymptomatic central nervous system (CNS) metastases were given PF-06463922 100 mg orally QD on Day -7 (only participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG011","title":"EXP-2 (Phase 2)","description":"Participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after only crizotinib therapy were given PF-06463922 100 mg orally QD on Day -7 (only for participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG012","title":"EXP-3 (Phase 2)","description":"Participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after crizotinib therapy and 1 or 2 prior regimens of chemotherapy given before or after crizotinib therapy, or participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after 1 ALK inhibitor therapy other than crizotinib with or without any number of prior chemotherapy regimens in any disease setting were given PF-06463922 100 mg orally QD on Day -7 (only for participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG013","title":"EXP-4 (Phase 2)","description":"Participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after 2 prior lines of ALK inhibitor therapies were given PF-06463922 100 mg orally QD on Day -7 (only for participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG014","title":"EXP-5 (Phase 2)","description":"Participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after 3 prior lines of ALK inhibitor therapies were given PF-06463922 100 mg orally QD on Day -7 (only for participant scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG015","title":"EXP-6 (Phase 2)","description":"Participants with advanced ROS1-positive NSCLC who were treatment naÃ¯ve or had any number of prior cancer therapies with or without asymptomatic CNS metastases were given PF-06463922 100 mg orally QD on Day -7 (only for participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG016","title":"DDI Sub-study","description":"Participants with advanced ALK positive or ROS1-positive NSCLC who were treatment naÃ¯ve or had any number of prior cancer therapies with or without asymptomatic CNS metastases were administered a single dose of a probe substrate alone on Day -2. Participants were given PF-06463922 100 mg orally QD starting on Cycle1 Day 1 and along with probe substrate on Day 15 Cycle 1."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"12"},{"groupId":"OG004","value":"17"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"3"},{"groupId":"OG007","value":"3"},{"groupId":"OG008","value":"3"},{"groupId":"OG009","value":"4"},{"groupId":"OG010","value":"30"},{"groupId":"OG011","value":"27"},{"groupId":"OG012","value":"60"},{"groupId":"OG013","value":"64"},{"groupId":"OG014","value":"45"},{"groupId":"OG015","value":"46"},{"groupId":"OG016","value":"32"}]}],"classes":[{"title":"Activated partial thromboplastin time prolonged","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"11"},{"groupId":"OG004","value":"14"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"3"},{"groupId":"OG007","value":"3"},{"groupId":"OG008","value":"3"},{"groupId":"OG009","value":"3"},{"groupId":"OG010","value":"5"},{"groupId":"OG011","value":"5"},{"groupId":"OG012","value":"17"},{"groupId":"OG013","value":"21"},{"groupId":"OG014","value":"15"},{"groupId":"OG015","value":"19"},{"groupId":"OG016","value":"21"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"2"},{"groupId":"OG011","value":"1"},{"groupId":"OG012","value":"3"},{"groupId":"OG013","value":"1"},{"groupId":"OG014","value":"3"},{"groupId":"OG015","value":"4"},{"groupId":"OG016","value":"2"}]}]},{"title":"Cholesterol high","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"12"},{"groupId":"OG004","value":"17"},{"groupId":"OG005","value":"2"},{"groupId":"OG006","value":"3"},{"groupId":"OG007","value":"3"},{"groupId":"OG008","value":"3"},{"groupId":"OG009","value":"4"},{"groupId":"OG010","value":"30"},{"groupId":"OG011","value":"27"},{"groupId":"OG012","value":"60"},{"groupId":"OG013","value":"64"},{"groupId":"OG014","value":"45"},{"groupId":"OG015","value":"46"},{"groupId":"OG016","value":"32"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"10"},{"groupId":"OG004","value":"16"},{"groupId":"OG005","value":"2"},{"groupId":"OG006","value":"3"},{"groupId":"OG007","value":"3"},{"groupId":"OG008","value":"2"},{"groupId":"OG009","value":"3"},{"groupId":"OG010","value":"30"},{"groupId":"OG011","value":"26"},{"groupId":"OG012","value":"58"},{"groupId":"OG013","value":"64"},{"groupId":"OG014","value":"45"},{"groupId":"OG015","value":"44"},{"groupId":"OG016","value":"31"}]}]},{"title":"Hypertriglyceridemia","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"12"},{"groupId":"OG004","value":"17"},{"groupId":"OG005","value":"2"},{"groupId":"OG006","value":"3"},{"groupId":"OG007","value":"3"},{"groupId":"OG008","value":"3"},{"groupId":"OG009","value":"4"},{"groupId":"OG010","value":"30"},{"groupId":"OG011","value":"27"},{"groupId":"OG012","value":"60"},{"groupId":"OG013","value":"64"},{"groupId":"OG014","value":"45"},{"groupId":"OG015","value":"46"},{"groupId":"OG016","value":"32"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"11"},{"groupId":"OG004","value":"16"},{"groupId":"OG005","value":"2"},{"groupId":"OG006","value":"3"},{"groupId":"OG007","value":"2"},{"groupId":"OG008","value":"1"},{"groupId":"OG009","value":"3"},{"groupId":"OG010","value":"30"},{"groupId":"OG011","value":"26"},{"groupId":"OG012","value":"56"},{"groupId":"OG013","value":"61"},{"groupId":"OG014","value":"45"},{"groupId":"OG015","value":"43"},{"groupId":"OG016","value":"31"}]}]},{"title":"INR increased","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"11"},{"groupId":"OG004","value":"14"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"3"},{"groupId":"OG007","value":"3"},{"groupId":"OG008","value":"3"},{"groupId":"OG009","value":"3"},{"groupId":"OG010","value":"6"},{"groupId":"OG011","value":"10"},{"groupId":"OG012","value":"20"},{"groupId":"OG013","value":"31"},{"groupId":"OG014","value":"20"},{"groupId":"OG015","value":"26"},{"groupId":"OG016","value":"24"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"1"},{"groupId":"OG011","value":"2"},{"groupId":"OG012","value":"3"},{"groupId":"OG013","value":"6"},{"groupId":"OG014","value":"2"},{"groupId":"OG015","value":"7"},{"groupId":"OG016","value":"3"}]}]},{"title":"Prothrombin time","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"11"},{"groupId":"OG004","value":"14"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"3"},{"groupId":"OG007","value":"3"},{"groupId":"OG008","value":"3"},{"groupId":"OG009","value":"3"},{"groupId":"OG010","value":"6"},{"groupId":"OG011","value":"8"},{"groupId":"OG012","value":"18"},{"groupId":"OG013","value":"29"},{"groupId":"OG014","value":"21"},{"groupId":"OG015","value":"21"},{"groupId":"OG016","value":"21"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"1"},{"groupId":"OG009","value":"1"},{"groupId":"OG010","value":"1"},{"groupId":"OG011","value":"3"},{"groupId":"OG012","value":"6"},{"groupId":"OG013","value":"6"},{"groupId":"OG014","value":"3"},{"groupId":"OG015","value":"6"},{"groupId":"OG016","value":"6"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Vital Signs Data Meeting Pre-defined Criteria (Phase 1, Phase 2 and DDI Sub-study)","description":"Blood pressure (BP), including systolic BP (SBP) and diastolic BP (DBP), and pulse rate were recorded in sitting position. Body weight was also measured.","populationDescription":"Safety analysis set: all enrolled participants who received at least 1 dose of PF-06463922. \"Overall Number of Participants Analyzed\": participants evaluable for this outcome measure. 'Number Analyzed': participants evaluable for specified row.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"From first dose of study treatment to end of treatment (maximum of 8 years for Phase 1, maximum of 7.5 years for Phase 2 and up to a maximum of 6 years approx. for DDI sub study)","groups":[{"id":"OG000","title":"10 mg QD (Phase 1)","description":"PF-06463922 10 mg was orally given once daily (QD) on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG001","title":"25 mg QD (Phase 1)","description":"PF-06463922 25 mg was orally given QD in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal. Midazolam 2 mg was orally given QD on Day -7 and Cycle 1 Day 15."},{"id":"OG002","title":"50 mg QD (Phase 1)","description":"PF-06463922 50 mg was orally given QD on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG003","title":"75 mg QD (Phase 1)","description":"PF-06463922 75 mg was orally given QD on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG004","title":"100 mg QD (Phase 1)","description":"PF-06463922 100 mg was orally given QD on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG005","title":"150 mg QD (Phase 1)","description":"PF-06463922 150 mg was orally given QD in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal. Midazolam 2 mg was orally given QD on Day -7 and Cycle 1 Day 15."},{"id":"OG006","title":"200 mg QD (Phase 1)","description":"PF-06463922 200 mg was orally given QD on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG007","title":"35 mg BID (Phase 1)","description":"PF-06463922 35 mg was orally given twice daily (BID) on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG008","title":"75 mg BID (Phase 1)","description":"PF-06463922 75 mg was orally given BID on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG009","title":"100 mg BID (Phase 1)","description":"PF-06463922 100 mg was orally given BID on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG010","title":"EXP-1 (Phase 2)","description":"Treatment-naÃ¯ve participants with advanced anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC) with or without asymptomatic central nervous system (CNS) metastases were given PF-06463922 100 mg orally QD on Day -7 (only participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG011","title":"EXP-2 (Phase 2)","description":"Participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after only crizotinib therapy were given PF-06463922 100 mg orally QD on Day -7 (only for participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG012","title":"EXP-3 (Phase 2)","description":"Participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after crizotinib therapy and 1 or 2 prior regimens of chemotherapy given before or after crizotinib therapy, or participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after 1 ALK inhibitor therapy other than crizotinib with or without any number of prior chemotherapy regimens in any disease setting were given PF-06463922 100 mg orally QD on Day -7 (only for participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG013","title":"EXP-4 (Phase 2)","description":"Participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after 2 prior lines of ALK inhibitor therapies were given PF-06463922 100 mg orally QD on Day -7 (only for participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG014","title":"EXP-5 (Phase 2)","description":"Participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after 3 prior lines of ALK inhibitor therapies were given PF-06463922 100 mg orally QD on Day -7 (only for participant scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG015","title":"EXP-6 (Phase 2)","description":"Participants with advanced ROS1-positive NSCLC who were treatment naÃ¯ve or had any number of prior cancer therapies with or without asymptomatic CNS metastases were given PF-06463922 100 mg orally QD on Day -7 (only for participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG016","title":"DDI Sub-study","description":"Participants with advanced ALK positive or ROS1-positive NSCLC who were treatment naÃ¯ve or had any number of prior cancer therapies with or without asymptomatic CNS metastases were administered a single dose of a probe substrate alone on Day -2. Participants were given PF-06463922 100 mg orally QD starting on Cycle1 Day 1 and along with probe substrate on Day 15 Cycle 1."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"12"},{"groupId":"OG004","value":"17"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"3"},{"groupId":"OG007","value":"3"},{"groupId":"OG008","value":"3"},{"groupId":"OG009","value":"4"},{"groupId":"OG010","value":"30"},{"groupId":"OG011","value":"27"},{"groupId":"OG012","value":"60"},{"groupId":"OG013","value":"65"},{"groupId":"OG014","value":"45"},{"groupId":"OG015","value":"46"},{"groupId":"OG016","value":"32"}]}],"classes":[{"title":"Increase in sitting SBP >=40 mmHg","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"12"},{"groupId":"OG004","value":"17"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"3"},{"groupId":"OG007","value":"3"},{"groupId":"OG008","value":"3"},{"groupId":"OG009","value":"4"},{"groupId":"OG010","value":"30"},{"groupId":"OG011","value":"26"},{"groupId":"OG012","value":"60"},{"groupId":"OG013","value":"65"},{"groupId":"OG014","value":"45"},{"groupId":"OG015","value":"44"},{"groupId":"OG016","value":"32"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"2"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"1"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"9"},{"groupId":"OG011","value":"7"},{"groupId":"OG012","value":"10"},{"groupId":"OG013","value":"10"},{"groupId":"OG014","value":"5"},{"groupId":"OG015","value":"4"},{"groupId":"OG016","value":"4"}]}]},{"title":"Increase in sitting SBP >=60 mmHg","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"12"},{"groupId":"OG004","value":"17"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"3"},{"groupId":"OG007","value":"3"},{"groupId":"OG008","value":"3"},{"groupId":"OG009","value":"4"},{"groupId":"OG010","value":"30"},{"groupId":"OG011","value":"26"},{"groupId":"OG012","value":"60"},{"groupId":"OG013","value":"65"},{"groupId":"OG014","value":"45"},{"groupId":"OG015","value":"44"},{"groupId":"OG016","value":"32"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"2"},{"groupId":"OG014","value":"0"},{"groupId":"OG015","value":"0"},{"groupId":"OG016","value":"0"}]}]},{"title":"Decrease in sitting SBP >=40 mmHg","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"12"},{"groupId":"OG004","value":"17"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"3"},{"groupId":"OG007","value":"3"},{"groupId":"OG008","value":"3"},{"groupId":"OG009","value":"4"},{"groupId":"OG010","value":"30"},{"groupId":"OG011","value":"26"},{"groupId":"OG012","value":"60"},{"groupId":"OG013","value":"65"},{"groupId":"OG014","value":"45"},{"groupId":"OG015","value":"44"},{"groupId":"OG016","value":"32"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"2"},{"groupId":"OG012","value":"5"},{"groupId":"OG013","value":"2"},{"groupId":"OG014","value":"2"},{"groupId":"OG015","value":"3"},{"groupId":"OG016","value":"1"}]}]},{"title":"Decrease in sitting SBP >=60 mmHg","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"12"},{"groupId":"OG004","value":"17"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"3"},{"groupId":"OG007","value":"3"},{"groupId":"OG008","value":"3"},{"groupId":"OG009","value":"4"},{"groupId":"OG010","value":"30"},{"groupId":"OG011","value":"26"},{"groupId":"OG012","value":"60"},{"groupId":"OG013","value":"65"},{"groupId":"OG014","value":"45"},{"groupId":"OG015","value":"44"},{"groupId":"OG016","value":"32"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"0"},{"groupId":"OG015","value":"0"},{"groupId":"OG016","value":"0"}]}]},{"title":"Increase in sitting DBP >=20 mmHg","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"12"},{"groupId":"OG004","value":"17"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"3"},{"groupId":"OG007","value":"3"},{"groupId":"OG008","value":"3"},{"groupId":"OG009","value":"4"},{"groupId":"OG010","value":"30"},{"groupId":"OG011","value":"26"},{"groupId":"OG012","value":"60"},{"groupId":"OG013","value":"65"},{"groupId":"OG014","value":"45"},{"groupId":"OG015","value":"44"},{"groupId":"OG016","value":"32"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"7"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"1"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"11"},{"groupId":"OG011","value":"12"},{"groupId":"OG012","value":"21"},{"groupId":"OG013","value":"15"},{"groupId":"OG014","value":"15"},{"groupId":"OG015","value":"12"},{"groupId":"OG016","value":"7"}]}]},{"title":"Increase in sitting DBP >=40 mmHg","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"12"},{"groupId":"OG004","value":"17"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"3"},{"groupId":"OG007","value":"3"},{"groupId":"OG008","value":"3"},{"groupId":"OG009","value":"4"},{"groupId":"OG010","value":"30"},{"groupId":"OG011","value":"26"},{"groupId":"OG012","value":"60"},{"groupId":"OG013","value":"65"},{"groupId":"OG014","value":"45"},{"groupId":"OG015","value":"44"},{"groupId":"OG016","value":"32"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"1"},{"groupId":"OG011","value":"3"},{"groupId":"OG012","value":"1"},{"groupId":"OG013","value":"1"},{"groupId":"OG014","value":"0"},{"groupId":"OG015","value":"2"},{"groupId":"OG016","value":"0"}]}]},{"title":"Decrease in sitting DBP >=20 mmHg","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"12"},{"groupId":"OG004","value":"17"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"3"},{"groupId":"OG007","value":"3"},{"groupId":"OG008","value":"3"},{"groupId":"OG009","value":"4"},{"groupId":"OG010","value":"30"},{"groupId":"OG011","value":"26"},{"groupId":"OG012","value":"60"},{"groupId":"OG013","value":"65"},{"groupId":"OG014","value":"45"},{"groupId":"OG015","value":"44"},{"groupId":"OG016","value":"32"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"2"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"1"},{"groupId":"OG009","value":"2"},{"groupId":"OG010","value":"9"},{"groupId":"OG011","value":"5"},{"groupId":"OG012","value":"15"},{"groupId":"OG013","value":"10"},{"groupId":"OG014","value":"10"},{"groupId":"OG015","value":"9"},{"groupId":"OG016","value":"8"}]}]},{"title":"Decrease in sitting DBP >=40 mmHg","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"12"},{"groupId":"OG004","value":"17"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"3"},{"groupId":"OG007","value":"3"},{"groupId":"OG008","value":"3"},{"groupId":"OG009","value":"4"},{"groupId":"OG010","value":"30"},{"groupId":"OG011","value":"26"},{"groupId":"OG012","value":"60"},{"groupId":"OG013","value":"65"},{"groupId":"OG014","value":"45"},{"groupId":"OG015","value":"44"},{"groupId":"OG016","value":"32"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"0"},{"groupId":"OG015","value":"1"},{"groupId":"OG016","value":"0"}]}]},{"title":"Sitting pulse rate <50 bpm","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"12"},{"groupId":"OG004","value":"17"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"3"},{"groupId":"OG007","value":"3"},{"groupId":"OG008","value":"3"},{"groupId":"OG009","value":"4"},{"groupId":"OG010","value":"30"},{"groupId":"OG011","value":"27"},{"groupId":"OG012","value":"60"},{"groupId":"OG013","value":"65"},{"groupId":"OG014","value":"45"},{"groupId":"OG015","value":"46"},{"groupId":"OG016","value":"32"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"1"},{"groupId":"OG011","value":"2"},{"groupId":"OG012","value":"5"},{"groupId":"OG013","value":"1"},{"groupId":"OG014","value":"0"},{"groupId":"OG015","value":"2"},{"groupId":"OG016","value":"2"}]}]},{"title":"Sitting pulse rate >120 bpm","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"12"},{"groupId":"OG004","value":"17"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"3"},{"groupId":"OG007","value":"3"},{"groupId":"OG008","value":"3"},{"groupId":"OG009","value":"4"},{"groupId":"OG010","value":"30"},{"groupId":"OG011","value":"27"},{"groupId":"OG012","value":"60"},{"groupId":"OG013","value":"65"},{"groupId":"OG014","value":"45"},{"groupId":"OG015","value":"46"},{"groupId":"OG016","value":"32"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"2"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"2"},{"groupId":"OG011","value":"1"},{"groupId":"OG012","value":"5"},{"groupId":"OG013","value":"9"},{"groupId":"OG014","value":"4"},{"groupId":"OG015","value":"2"},{"groupId":"OG016","value":"3"}]}]},{"title":"Increase in sitting pulse rate >=30 bpm","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"12"},{"groupId":"OG004","value":"17"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"3"},{"groupId":"OG007","value":"3"},{"groupId":"OG008","value":"3"},{"groupId":"OG009","value":"4"},{"groupId":"OG010","value":"30"},{"groupId":"OG011","value":"26"},{"groupId":"OG012","value":"60"},{"groupId":"OG013","value":"65"},{"groupId":"OG014","value":"44"},{"groupId":"OG015","value":"44"},{"groupId":"OG016","value":"32"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"7"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"1"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"7"},{"groupId":"OG012","value":"14"},{"groupId":"OG013","value":"19"},{"groupId":"OG014","value":"17"},{"groupId":"OG015","value":"17"},{"groupId":"OG016","value":"8"}]}]},{"title":"Decrease in sitting pulse rate >=30 bpm","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"12"},{"groupId":"OG004","value":"17"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"3"},{"groupId":"OG007","value":"3"},{"groupId":"OG008","value":"3"},{"groupId":"OG009","value":"4"},{"groupId":"OG010","value":"30"},{"groupId":"OG011","value":"26"},{"groupId":"OG012","value":"60"},{"groupId":"OG013","value":"65"},{"groupId":"OG014","value":"44"},{"groupId":"OG015","value":"44"},{"groupId":"OG016","value":"32"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"1"},{"groupId":"OG008","value":"1"},{"groupId":"OG009","value":"2"},{"groupId":"OG010","value":"11"},{"groupId":"OG011","value":"2"},{"groupId":"OG012","value":"8"},{"groupId":"OG013","value":"7"},{"groupId":"OG014","value":"3"},{"groupId":"OG015","value":"5"},{"groupId":"OG016","value":"4"}]}]},{"title":"Increase in weight: 10% to <20%","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"12"},{"groupId":"OG004","value":"17"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"3"},{"groupId":"OG007","value":"3"},{"groupId":"OG008","value":"3"},{"groupId":"OG009","value":"4"},{"groupId":"OG010","value":"30"},{"groupId":"OG011","value":"26"},{"groupId":"OG012","value":"58"},{"groupId":"OG013","value":"61"},{"groupId":"OG014","value":"44"},{"groupId":"OG015","value":"43"},{"groupId":"OG016","value":"32"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"8"},{"groupId":"OG004","value":"6"},{"groupId":"OG005","value":"2"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"9"},{"groupId":"OG011","value":"14"},{"groupId":"OG012","value":"17"},{"groupId":"OG013","value":"15"},{"groupId":"OG014","value":"11"},{"groupId":"OG015","value":"14"},{"groupId":"OG016","value":"9"}]}]},{"title":"Increase in weight: >=20%","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"12"},{"groupId":"OG004","value":"17"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"3"},{"groupId":"OG007","value":"3"},{"groupId":"OG008","value":"3"},{"groupId":"OG009","value":"4"},{"groupId":"OG010","value":"30"},{"groupId":"OG011","value":"26"},{"groupId":"OG012","value":"58"},{"groupId":"OG013","value":"61"},{"groupId":"OG014","value":"44"},{"groupId":"OG015","value":"43"},{"groupId":"OG016","value":"32"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"5"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"1"},{"groupId":"OG009","value":"1"},{"groupId":"OG010","value":"12"},{"groupId":"OG011","value":"2"},{"groupId":"OG012","value":"10"},{"groupId":"OG013","value":"16"},{"groupId":"OG014","value":"9"},{"groupId":"OG015","value":"9"},{"groupId":"OG016","value":"3"}]}]},{"title":"Decrease in weight >=10%","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"12"},{"groupId":"OG004","value":"17"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"3"},{"groupId":"OG007","value":"3"},{"groupId":"OG008","value":"3"},{"groupId":"OG009","value":"4"},{"groupId":"OG010","value":"30"},{"groupId":"OG011","value":"26"},{"groupId":"OG012","value":"58"},{"groupId":"OG013","value":"61"},{"groupId":"OG014","value":"44"},{"groupId":"OG015","value":"43"},{"groupId":"OG016","value":"32"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"2"},{"groupId":"OG010","value":"2"},{"groupId":"OG011","value":"1"},{"groupId":"OG012","value":"3"},{"groupId":"OG013","value":"4"},{"groupId":"OG014","value":"2"},{"groupId":"OG015","value":"2"},{"groupId":"OG016","value":"1"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Maximum Decrease From Baseline Greater Than or Equal to 20 Percent in Left Ventricular Ejection Fraction (LVEF) (Phase 1, Phase 2 and DDI Sub-study)","description":"Left Ventricular Ejection Fraction (LVEF) was determined by echocardiogram. Baseline was defined as the measurement prior to the first dose of study treatment.","populationDescription":"The safety analysis set included all enrolled participants who received at least 1 dose of PF-06463922.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"From first dose of study treatment to end of treatment (maximum of 8 years for Phase 1, maximum of 7.5 years for Phase 2 and up to a maximum of 6 years approx. for DDI sub study)","groups":[{"id":"OG000","title":"10 mg QD (Phase 1)","description":"PF-06463922 10 mg was orally given once daily (QD) on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG001","title":"25 mg QD (Phase 1)","description":"PF-06463922 25 mg was orally given QD in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal. Midazolam 2 mg was orally given QD on Day -7 and Cycle 1 Day 15."},{"id":"OG002","title":"50 mg QD (Phase 1)","description":"PF-06463922 50 mg was orally given QD on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG003","title":"75 mg QD (Phase 1)","description":"PF-06463922 75 mg was orally given QD on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG004","title":"100 mg QD (Phase 1)","description":"PF-06463922 100 mg was orally given QD on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG005","title":"150 mg QD (Phase 1)","description":"PF-06463922 150 mg was orally given QD in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal. Midazolam 2 mg was orally given QD on Day -7 and Cycle 1 Day 15."},{"id":"OG006","title":"200 mg QD (Phase 1)","description":"PF-06463922 200 mg was orally given QD on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG007","title":"35 mg BID (Phase 1)","description":"PF-06463922 35 mg was orally given twice daily (BID) on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG008","title":"75 mg BID (Phase 1)","description":"PF-06463922 75 mg was orally given BID on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG009","title":"100 mg BID (Phase 1)","description":"PF-06463922 100 mg was orally given BID on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG010","title":"EXP-1 (Phase 2)","description":"Treatment-naÃ¯ve participants with advanced anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC) with or without asymptomatic central nervous system (CNS) metastases were given PF-06463922 100 mg orally QD on Day -7 (only participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG011","title":"EXP-2 (Phase 2)","description":"Participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after only crizotinib therapy were given PF-06463922 100 mg orally QD on Day -7 (only for participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG012","title":"EXP-3 (Phase 2)","description":"Participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after crizotinib therapy and 1 or 2 prior regimens of chemotherapy given before or after crizotinib therapy, or participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after 1 ALK inhibitor therapy other than crizotinib with or without any number of prior chemotherapy regimens in any disease setting were given PF-06463922 100 mg orally QD on Day -7 (only for participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG013","title":"EXP-4 (Phase 2)","description":"Participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after 2 prior lines of ALK inhibitor therapies were given PF-06463922 100 mg orally QD on Day -7 (only for participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG014","title":"EXP-5 (Phase 2)","description":"Participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after 3 prior lines of ALK inhibitor therapies were given PF-06463922 100 mg orally QD on Day -7 (only for participant scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG015","title":"EXP-6 (Phase 2)","description":"Participants with advanced ROS1-positive NSCLC who were treatment naÃ¯ve or had any number of prior cancer therapies with or without asymptomatic CNS metastases were given PF-06463922 100 mg orally QD on Day -7 (only for participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG016","title":"DDI Sub-study","description":"Participants with advanced ALK positive or ROS1-positive NSCLC who were treatment naÃ¯ve or had any number of prior cancer therapies with or without asymptomatic CNS metastases were administered a single dose of a probe substrate alone on Day -2. Participants were given PF-06463922 100 mg orally QD starting on Cycle1 Day 1 and along with probe substrate on Day 15 Cycle 1."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"12"},{"groupId":"OG004","value":"17"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"3"},{"groupId":"OG007","value":"3"},{"groupId":"OG008","value":"3"},{"groupId":"OG009","value":"4"},{"groupId":"OG010","value":"30"},{"groupId":"OG011","value":"27"},{"groupId":"OG012","value":"60"},{"groupId":"OG013","value":"65"},{"groupId":"OG014","value":"46"},{"groupId":"OG015","value":"47"},{"groupId":"OG016","value":"32"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"5"},{"groupId":"OG005","value":"2"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"2"},{"groupId":"OG010","value":"4"},{"groupId":"OG011","value":"2"},{"groupId":"OG012","value":"13"},{"groupId":"OG013","value":"14"},{"groupId":"OG014","value":"3"},{"groupId":"OG015","value":"5"},{"groupId":"OG016","value":"2"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Absolute Values and Change From Baseline in QTcF Meeting Pre-defined Criteria (Phase 1, Phase 2 and DDI Sub-study)","description":"Triplicate 12-lead electrocardiograms (ECGs) were performed approximately 2 minutes apart to determine mean QTc interval (QT interval corrected for heart rate). QT interval was corrected for heart rate using Fridericia's formula to provide QTcF. Absolute values and changes from baseline were summarized according to pre-defined criteria. Baseline was defined as the last evaluation on or prior to the first dose of study treatment.","populationDescription":"The safety analysis set included all enrolled participants who received at least 1 dose of PF-06463922.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"From first dose of study treatment to end of treatment (maximum of 8 years for Phase 1, maximum of 7.5 years for Phase 2 and up to a maximum of 6 years approx. for DDI sub study)","groups":[{"id":"OG000","title":"10 mg QD (Phase 1)","description":"PF-06463922 10 mg was orally given once daily (QD) on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG001","title":"25 mg QD (Phase 1)","description":"PF-06463922 25 mg was orally given QD in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal. Midazolam 2 mg was orally given QD on Day -7 and Cycle 1 Day 15."},{"id":"OG002","title":"50 mg QD (Phase 1)","description":"PF-06463922 50 mg was orally given QD on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG003","title":"75 mg QD (Phase 1)","description":"PF-06463922 75 mg was orally given QD on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG004","title":"100 mg QD (Phase 1)","description":"PF-06463922 100 mg was orally given QD on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG005","title":"150 mg QD (Phase 1)","description":"PF-06463922 150 mg was orally given QD in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal. Midazolam 2 mg was orally given QD on Day -7 and Cycle 1 Day 15."},{"id":"OG006","title":"200 mg QD (Phase 1)","description":"PF-06463922 200 mg was orally given QD on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG007","title":"35 mg BID (Phase 1)","description":"PF-06463922 35 mg was orally given twice daily (BID) on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG008","title":"75 mg BID (Phase 1)","description":"PF-06463922 75 mg was orally given BID on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG009","title":"100 mg BID (Phase 1)","description":"PF-06463922 100 mg was orally given BID on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG010","title":"EXP-1 (Phase 2)","description":"Treatment-naÃ¯ve participants with advanced anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC) with or without asymptomatic central nervous system (CNS) metastases were given PF-06463922 100 mg orally QD on Day -7 (only participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG011","title":"EXP-2 (Phase 2)","description":"Participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after only crizotinib therapy were given PF-06463922 100 mg orally QD on Day -7 (only for participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG012","title":"EXP-3 (Phase 2)","description":"Participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after crizotinib therapy and 1 or 2 prior regimens of chemotherapy given before or after crizotinib therapy, or participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after 1 ALK inhibitor therapy other than crizotinib with or without any number of prior chemotherapy regimens in any disease setting were given PF-06463922 100 mg orally QD on Day -7 (only for participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG013","title":"EXP-4 (Phase 2)","description":"Participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after 2 prior lines of ALK inhibitor therapies were given PF-06463922 100 mg orally QD on Day -7 (only for participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG014","title":"EXP-5 (Phase 2)","description":"Participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after 3 prior lines of ALK inhibitor therapies were given PF-06463922 100 mg orally QD on Day -7 (only for participant scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG015","title":"EXP-6 (Phase 2)","description":"Participants with advanced ROS1-positive NSCLC who were treatment naÃ¯ve or had any number of prior cancer therapies with or without asymptomatic CNS metastases were given PF-06463922 100 mg orally QD on Day -7 (only for participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG016","title":"DDI Sub-study","description":"Participants with advanced ALK positive or ROS1-positive NSCLC who were treatment naÃ¯ve or had any number of prior cancer therapies with or without asymptomatic CNS metastases were administered a single dose of a probe substrate alone on Day -2. Participants were given PF-06463922 100 mg orally QD starting on Cycle1 Day 1 and along with probe substrate on Day 15 Cycle 1."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"12"},{"groupId":"OG004","value":"17"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"3"},{"groupId":"OG007","value":"3"},{"groupId":"OG008","value":"3"},{"groupId":"OG009","value":"4"},{"groupId":"OG010","value":"30"},{"groupId":"OG011","value":"27"},{"groupId":"OG012","value":"60"},{"groupId":"OG013","value":"65"},{"groupId":"OG014","value":"46"},{"groupId":"OG015","value":"47"},{"groupId":"OG016","value":"32"}]}],"classes":[{"title":"QTcF: 450 to <480 msec","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"2"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"1"},{"groupId":"OG010","value":"5"},{"groupId":"OG011","value":"8"},{"groupId":"OG012","value":"11"},{"groupId":"OG013","value":"9"},{"groupId":"OG014","value":"13"},{"groupId":"OG015","value":"9"},{"groupId":"OG016","value":"7"}]}]},{"title":"QTcF: 480 to <500 msec","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"1"},{"groupId":"OG010","value":"1"},{"groupId":"OG011","value":"1"},{"groupId":"OG012","value":"3"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"1"},{"groupId":"OG015","value":"1"},{"groupId":"OG016","value":"1"}]}]},{"title":"QTcF: >=500 msec","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"1"},{"groupId":"OG013","value":"1"},{"groupId":"OG014","value":"1"},{"groupId":"OG015","value":"0"},{"groupId":"OG016","value":"1"}]}]},{"title":"QTcF Increase: 30 to <60 msec","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"1"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"1"},{"groupId":"OG010","value":"10"},{"groupId":"OG011","value":"8"},{"groupId":"OG012","value":"18"},{"groupId":"OG013","value":"20"},{"groupId":"OG014","value":"7"},{"groupId":"OG015","value":"12"},{"groupId":"OG016","value":"7"}]}]},{"title":"QTcF: >=60 msec","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"1"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"1"},{"groupId":"OG013","value":"1"},{"groupId":"OG014","value":"3"},{"groupId":"OG015","value":"1"},{"groupId":"OG016","value":"1"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Suicidal Ideation and Suicidal Behavior (Phase 2)","description":"The Columbia Suicide Severity Rating Scale (C-SSRS) was used to analyze participants' suicidal ideation and behavior, and it is a unique, simple and short method of assessing both behavior and ideation that tracks all suicidal events and provides a summary of suicidality. It assesses the lethality of attempts and other features of ideation (frequency, duration, controllability, reasons for ideation and deterrents), all of which are significantly predictive of completed suicide. Maximum score of 4 or 5 indicates maximum suicidal ideation and minimum score of \"0\" indicates no suicidal ideation.","populationDescription":"PRO evaluable analysis set included all enrolled participants who received study treatment, had a baseline test assessment and at least 1 on-study test assessment.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"From first dose of study treatment to end of treatment (maximum of 7.5 years for Phase 2)","groups":[{"id":"OG000","title":"EXP-1 (Phase 2)","description":"Treatment-naÃ¯ve participants with advanced anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC) with or without asymptomatic central nervous system (CNS) metastases were given PF-06463922 100 mg orally QD on Day -7 (only participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG001","title":"EXP-2 (Phase 2)","description":"Participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after only crizotinib therapy were given PF-06463922 100 mg orally QD on Day -7 (only for participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG002","title":"EXP-3 (Phase 2)","description":"Participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after crizotinib therapy and 1 or 2 prior regimens of chemotherapy given before or after crizotinib therapy, or participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after 1 ALK inhibitor therapy other than crizotinib with or without any number of prior chemotherapy regimens in any disease setting were given PF-06463922 100 mg orally QD on Day -7 (only for participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG003","title":"EXP-4 (Phase 2)","description":"Participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after 2 prior lines of ALK inhibitor therapies were given PF-06463922 100 mg orally QD on Day -7 (only for participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG004","title":"EXP-5 (Phase 2)","description":"Participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after 3 prior lines of ALK inhibitor therapies were given PF-06463922 100 mg orally QD on Day -7 (only for participant scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG005","title":"EXP-6 (Phase 2)","description":"Participants with advanced ROS1-positive NSCLC who were treatment naÃ¯ve or had any number of prior cancer therapies with or without asymptomatic CNS metastases were given PF-06463922 100 mg orally QD on Day -7 (only for participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"52"},{"groupId":"OG003","value":"43"},{"groupId":"OG004","value":"30"},{"groupId":"OG005","value":"25"}]}],"classes":[{"title":"Suicidal ideation","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"2"}]}]},{"title":"Suicidal behavior","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"1"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Total Scores for Beck Depression Inventory (BDI)-II (Mood Assessment) (Phase 2)","description":"The Beck Depression Inventory (BDI)-II is a 21-item self-report scale, with each item rated by participants on a 4-point scale (ranging from 0-3, where 0 indicated lowest depression and 3 indicated severe depression). The scale includes items capturing mood, (loss of pleasure, sadness, and irritability), suicidal ideation, and cognitive signs (punitive thoughts, self-criticism, self-dislike, pessimism, and poor concentration) as well as somatic signs (appetite, sleep, fatigue and libido). Scores were obtained by adding up the total points from the series of answers. Higher total scores indicate more severe depressive symptoms. The standardized cutoffs are as follows: 0-13: minimal depression; 14-19: mild depression; 20-28: moderate depression; 29-63: severe depression.","populationDescription":"PRO evaluable analysis set included all enrolled participants who received study treatment, had a baseline test assessment and at least 1 on-study test assessment. Here, 'Number Analyzed' signifies participants evaluable for specified row.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Units on a scale","timeFrame":"Baseline, Day 1 of Cycles 2-5, Day 1 of every other cycle from Cycle 6, and end of treatment (up to 3 years)","groups":[{"id":"OG000","title":"EXP-1 (Phase 2)","description":"Treatment-naÃ¯ve participants with advanced anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC) with or without asymptomatic central nervous system (CNS) metastases were given PF-06463922 100 mg orally QD on Day -7 (only participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG001","title":"EXP-2 (Phase 2)","description":"Participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after only crizotinib therapy were given PF-06463922 100 mg orally QD on Day -7 (only for participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG002","title":"EXP-3 (Phase 2)","description":"Participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after crizotinib therapy and 1 or 2 prior regimens of chemotherapy given before or after crizotinib therapy, or participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after 1 ALK inhibitor therapy other than crizotinib with or without any number of prior chemotherapy regimens in any disease setting were given PF-06463922 100 mg orally QD on Day -7 (only for participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG003","title":"EXP-4 (Phase 2)","description":"Participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after 2 prior lines of ALK inhibitor therapies were given PF-06463922 100 mg orally QD on Day -7 (only for participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG004","title":"EXP-5 (Phase 2)","description":"Participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after 3 prior lines of ALK inhibitor therapies were given PF-06463922 100 mg orally QD on Day -7 (only for participant scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG005","title":"EXP-6 (Phase 2)","description":"Participants with advanced ROS1-positive NSCLC who were treatment naÃ¯ve or had any number of prior cancer therapies with or without asymptomatic CNS metastases were given PF-06463922 100 mg orally QD on Day -7 (only for participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"53"},{"groupId":"OG003","value":"41"},{"groupId":"OG004","value":"28"},{"groupId":"OG005","value":"26"}]}],"classes":[{"title":"Cycle 2 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"53"},{"groupId":"OG003","value":"41"},{"groupId":"OG004","value":"28"},{"groupId":"OG005","value":"26"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-2.59","lowerLimit":"-4.82","upperLimit":"-0.37"},{"groupId":"OG001","value":"-3.27","lowerLimit":"-5.52","upperLimit":"-1.01"},{"groupId":"OG002","value":"-2.26","lowerLimit":"-3.77","upperLimit":"-0.76"},{"groupId":"OG003","value":"-2.17","lowerLimit":"-3.89","upperLimit":"-0.46"},{"groupId":"OG004","value":"-1.52","lowerLimit":"-3.60","upperLimit":"0.56"},{"groupId":"OG005","value":"-2.43","lowerLimit":"-4.57","upperLimit":"-0.29"}]}]},{"title":"Cycle 3 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"53"},{"groupId":"OG003","value":"41"},{"groupId":"OG004","value":"28"},{"groupId":"OG005","value":"26"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-3.34","lowerLimit":"-5.57","upperLimit":"-1.12"},{"groupId":"OG001","value":"-3.18","lowerLimit":"-5.43","upperLimit":"-0.93"},{"groupId":"OG002","value":"-3.03","lowerLimit":"-4.55","upperLimit":"-1.51"},{"groupId":"OG003","value":"-3.10","lowerLimit":"-4.85","upperLimit":"-1.35"},{"groupId":"OG004","value":"-0.46","lowerLimit":"-2.61","upperLimit":"1.69"},{"groupId":"OG005","value":"-1.24","lowerLimit":"-3.37","upperLimit":"0.90"}]}]},{"title":"Cycle 4 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"53"},{"groupId":"OG003","value":"41"},{"groupId":"OG004","value":"28"},{"groupId":"OG005","value":"26"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-3.84","lowerLimit":"-6.07","upperLimit":"-1.62"},{"groupId":"OG001","value":"-4.10","lowerLimit":"-6.38","upperLimit":"-1.82"},{"groupId":"OG002","value":"-2.59","lowerLimit":"-4.14","upperLimit":"-1.05"},{"groupId":"OG003","value":"-1.95","lowerLimit":"-3.72","upperLimit":"-0.19"},{"groupId":"OG004","value":"-1.19","lowerLimit":"-3.38","upperLimit":"1.01"},{"groupId":"OG005","value":"-1.94","lowerLimit":"-4.12","upperLimit":"0.24"}]}]},{"title":"Cycle 5 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"53"},{"groupId":"OG003","value":"41"},{"groupId":"OG004","value":"28"},{"groupId":"OG005","value":"26"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-4.47","lowerLimit":"-6.69","upperLimit":"-2.24"},{"groupId":"OG001","value":"-3.96","lowerLimit":"-6.27","upperLimit":"-1.66"},{"groupId":"OG002","value":"-2.75","lowerLimit":"-4.33","upperLimit":"-1.16"},{"groupId":"OG003","value":"-3.03","lowerLimit":"-4.82","upperLimit":"-1.25"},{"groupId":"OG004","value":"-1.51","lowerLimit":"-3.74","upperLimit":"0.72"},{"groupId":"OG005","value":"-1.25","lowerLimit":"-3.46","upperLimit":"0.95"}]}]},{"title":"Cycle 6 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"53"},{"groupId":"OG003","value":"41"},{"groupId":"OG004","value":"28"},{"groupId":"OG005","value":"26"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-3.51","lowerLimit":"-5.73","upperLimit":"-1.28"},{"groupId":"OG001","value":"-4.25","lowerLimit":"-6.56","upperLimit":"-1.94"},{"groupId":"OG002","value":"-3.31","lowerLimit":"-4.90","upperLimit":"-1.72"},{"groupId":"OG003","value":"-3.79","lowerLimit":"-5.61","upperLimit":"-1.98"},{"groupId":"OG004","value":"-0.42","lowerLimit":"-2.64","upperLimit":"1.81"},{"groupId":"OG005","value":"-0.29","lowerLimit":"-2.54","upperLimit":"1.96"}]}]},{"title":"Cycle 8 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"53"},{"groupId":"OG003","value":"41"},{"groupId":"OG004","value":"28"},{"groupId":"OG005","value":"26"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-4.17","lowerLimit":"-6.41","upperLimit":"-1.92"},{"groupId":"OG001","value":"-4.86","lowerLimit":"-7.23","upperLimit":"-2.50"},{"groupId":"OG002","value":"-2.26","lowerLimit":"-3.86","upperLimit":"-0.66"},{"groupId":"OG003","value":"-4.06","lowerLimit":"-5.90","upperLimit":"-2.22"},{"groupId":"OG004","value":"-1.09","lowerLimit":"-3.34","upperLimit":"1.17"},{"groupId":"OG005","value":"0.17","lowerLimit":"-2.10","upperLimit":"2.45"}]}]},{"title":"Cycle 10 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"53"},{"groupId":"OG003","value":"41"},{"groupId":"OG004","value":"28"},{"groupId":"OG005","value":"26"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-3.09","lowerLimit":"-5.38","upperLimit":"-0.80"},{"groupId":"OG001","value":"-4.92","lowerLimit":"-7.28","upperLimit":"-2.55"},{"groupId":"OG002","value":"-1.94","lowerLimit":"-3.54","upperLimit":"-0.34"},{"groupId":"OG003","value":"-4.27","lowerLimit":"-6.14","upperLimit":"-2.39"},{"groupId":"OG004","value":"-2.97","lowerLimit":"-5.29","upperLimit":"-0.66"},{"groupId":"OG005","value":"-0.19","lowerLimit":"-2.60","upperLimit":"2.22"}]}]},{"title":"Cycle 12 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"53"},{"groupId":"OG003","value":"41"},{"groupId":"OG004","value":"28"},{"groupId":"OG005","value":"26"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-3.95","lowerLimit":"-6.30","upperLimit":"-1.61"},{"groupId":"OG001","value":"-5.60","lowerLimit":"-7.97","upperLimit":"-3.24"},{"groupId":"OG002","value":"-0.72","lowerLimit":"-2.40","upperLimit":"0.95"},{"groupId":"OG003","value":"-4.80","lowerLimit":"-6.83","upperLimit":"-2.77"},{"groupId":"OG004","value":"-1.94","lowerLimit":"-4.29","upperLimit":"0.42"},{"groupId":"OG005","value":"-1.40","lowerLimit":"-3.81","upperLimit":"1.01"}]}]},{"title":"Cycle 14 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"53"},{"groupId":"OG003","value":"41"},{"groupId":"OG004","value":"28"},{"groupId":"OG005","value":"26"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-3.81","lowerLimit":"-6.18","upperLimit":"-1.43"},{"groupId":"OG001","value":"-5.80","lowerLimit":"-8.35","upperLimit":"-3.25"},{"groupId":"OG002","value":"-2.58","lowerLimit":"-4.41","upperLimit":"-0.76"},{"groupId":"OG003","value":"-4.29","lowerLimit":"-6.41","upperLimit":"-2.17"},{"groupId":"OG004","value":"-1.73","lowerLimit":"-4.40","upperLimit":"0.94"},{"groupId":"OG005","value":"-0.08","lowerLimit":"-2.59","upperLimit":"2.42"}]}]},{"title":"Cycle 16 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"53"},{"groupId":"OG003","value":"41"},{"groupId":"OG004","value":"28"},{"groupId":"OG005","value":"26"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.75","lowerLimit":"-4.40","upperLimit":"0.89"},{"groupId":"OG001","value":"-4.61","lowerLimit":"-7.51","upperLimit":"-1.71"},{"groupId":"OG002","value":"-2.15","lowerLimit":"-4.35","upperLimit":"0.06"},{"groupId":"OG003","value":"-4.65","lowerLimit":"-6.90","upperLimit":"-2.41"},{"groupId":"OG004","value":"-2.22","lowerLimit":"-5.50","upperLimit":"1.07"},{"groupId":"OG005","value":"0.03","lowerLimit":"-2.65","upperLimit":"2.71"}]}]},{"title":"Cycle 18 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"53"},{"groupId":"OG003","value":"41"},{"groupId":"OG004","value":"28"},{"groupId":"OG005","value":"26"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-4.49","lowerLimit":"-7.49","upperLimit":"-1.49"},{"groupId":"OG001","value":"-7.02","lowerLimit":"-10.59","upperLimit":"-3.46"},{"groupId":"OG002","value":"-1.96","lowerLimit":"-4.22","upperLimit":"0.31"},{"groupId":"OG003","value":"-2.86","lowerLimit":"-5.21","upperLimit":"-0.51"},{"groupId":"OG004","value":"-1.11","lowerLimit":"-8.25","upperLimit":"6.03"},{"groupId":"OG005","value":"1.88","lowerLimit":"-1.66","upperLimit":"5.41"}]}]},{"title":"Cycle 20 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"53"},{"groupId":"OG003","value":"41"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"26"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-5.01","lowerLimit":"-8.55","upperLimit":"-1.46"},{"groupId":"OG001","value":"-5.17","lowerLimit":"-9.06","upperLimit":"-1.29"},{"groupId":"OG002","value":"-1.82","lowerLimit":"-4.70","upperLimit":"1.06"},{"groupId":"OG003","value":"-3.63","lowerLimit":"-6.31","upperLimit":"-0.95"},{"groupId":"OG005","value":"1.88","lowerLimit":"-1.66","upperLimit":"5.41"}]}]},{"title":"Cycle 22 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"53"},{"groupId":"OG003","value":"41"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"26"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-2.93","lowerLimit":"-6.79","upperLimit":"0.94"},{"groupId":"OG001","value":"-4.63","lowerLimit":"-9.00","upperLimit":"-0.26"},{"groupId":"OG002","value":"-2.36","lowerLimit":"-5.68","upperLimit":"0.96"},{"groupId":"OG003","value":"-5.50","lowerLimit":"-8.87","upperLimit":"-2.12"},{"groupId":"OG005","value":"-2.39","lowerLimit":"-6.73","upperLimit":"1.94"}]}]},{"title":"Cycle 24 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"53"},{"groupId":"OG003","value":"41"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"26"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-7.31","lowerLimit":"-11.66","upperLimit":"-2.96"},{"groupId":"OG001","value":"-5.63","lowerLimit":"-10.00","upperLimit":"-1.26"},{"groupId":"OG002","value":"-2.88","lowerLimit":"-7.04","upperLimit":"1.28"},{"groupId":"OG003","value":"-3.89","lowerLimit":"-8.10","upperLimit":"0.32"},{"groupId":"OG005","value":"2.27","lowerLimit":"-2.06","upperLimit":"6.61"}]}]},{"title":"Cycle 26 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"53"},{"groupId":"OG003","value":"41"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-5.50","lowerLimit":"-10.67","upperLimit":"-0.33"},{"groupId":"OG002","value":"-3.03","lowerLimit":"-10.01","upperLimit":"3.95"},{"groupId":"OG003","value":"-4.30","lowerLimit":"-11.31","upperLimit":"2.70"}]}]},{"title":"End of treatment","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"53"},{"groupId":"OG003","value":"41"},{"groupId":"OG004","value":"28"},{"groupId":"OG005","value":"26"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-4.77","lowerLimit":"-9.23","upperLimit":"-0.32"},{"groupId":"OG001","value":"-0.73","lowerLimit":"-5.61","upperLimit":"4.15"},{"groupId":"OG002","value":"-2.55","lowerLimit":"-5.28","upperLimit":"0.18"},{"groupId":"OG003","value":"-3.22","lowerLimit":"-5.49","upperLimit":"-0.95"},{"groupId":"OG004","value":"0.74","lowerLimit":"-2.70","upperLimit":"4.17"},{"groupId":"OG005","value":"-2.08","lowerLimit":"-5.65","upperLimit":"1.50"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Total Scores for Detection Test (Cognitive Function Assessment) (Phase 2)","description":"The Detection Test is a measure of psychomotor function and uses a well validated simple reaction time paradigm with playing card stimuli. In this test, the on-screen instructions ask: \"Has the card turned over?\". A playing card is presented face down in the center of the screen. The card flips over so it is face up. As soon as the card flips over the participant must press \"Yes\". The participant is encouraged to work as quickly as they can and be as accurate as possible. The speed and accuracy of each response are recorded and mean of the log10 transformed reaction times for correct responses is calculated. Lower values of least square mean change from baseline indicate performance decline. Upper limit of 95% confidence interval of -0.00 or lower indicate statistically significant decline of performance over baseline at that cycle.","populationDescription":"PRO evaluable analysis set included all enrolled participants who received study treatment, had a baseline test assessment and at least 1 on-study test assessment. Here, 'Number Analyzed' signifies participants evaluable for specified row.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Units on a scale","timeFrame":"Baseline, Day 1 of Cycles 2-5, Day 1 of every other cycle from Cycle 6, and end of treatment (up to 3 years)","groups":[{"id":"OG000","title":"EXP-1 (Phase 2)","description":"Treatment-naÃ¯ve participants with advanced anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC) with or without asymptomatic central nervous system (CNS) metastases were given PF-06463922 100 mg orally QD on Day -7 (only participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG001","title":"EXP-2 (Phase 2)","description":"Participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after only crizotinib therapy were given PF-06463922 100 mg orally QD on Day -7 (only for participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG002","title":"EXP-3 (Phase 2)","description":"Participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after crizotinib therapy and 1 or 2 prior regimens of chemotherapy given before or after crizotinib therapy, or participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after 1 ALK inhibitor therapy other than crizotinib with or without any number of prior chemotherapy regimens in any disease setting were given PF-06463922 100 mg orally QD on Day -7 (only for participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG003","title":"EXP-4 (Phase 2)","description":"Participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after 2 prior lines of ALK inhibitor therapies were given PF-06463922 100 mg orally QD on Day -7 (only for participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG004","title":"EXP-5 (Phase 2)","description":"Participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after 3 prior lines of ALK inhibitor therapies were given PF-06463922 100 mg orally QD on Day -7 (only for participant scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG005","title":"EXP-6 (Phase 2)","description":"Participants with advanced ROS1-positive NSCLC who were treatment naÃ¯ve or had any number of prior cancer therapies with or without asymptomatic CNS metastases were given PF-06463922 100 mg orally QD on Day -7 (only for participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"50"},{"groupId":"OG003","value":"46"},{"groupId":"OG004","value":"38"},{"groupId":"OG005","value":"29"}]}],"classes":[{"title":"Cycle 2 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"50"},{"groupId":"OG003","value":"46"},{"groupId":"OG004","value":"38"},{"groupId":"OG005","value":"29"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.01","lowerLimit":"-0.04","upperLimit":"0.05"},{"groupId":"OG001","value":"0.04","lowerLimit":"-0.01","upperLimit":"0.08"},{"groupId":"OG002","value":"-0.01","lowerLimit":"-0.04","upperLimit":"0.02"},{"groupId":"OG003","value":"0.02","lowerLimit":"-0.01","upperLimit":"0.05"},{"groupId":"OG004","value":"-0.02","lowerLimit":"-0.05","upperLimit":"0.02"},{"groupId":"OG005","value":"0.01","lowerLimit":"-0.03","upperLimit":"0.05"}]}]},{"title":"Cycle 3 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"50"},{"groupId":"OG003","value":"46"},{"groupId":"OG004","value":"38"},{"groupId":"OG005","value":"29"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.01","lowerLimit":"-0.05","upperLimit":"0.03"},{"groupId":"OG001","value":"0.01","lowerLimit":"-0.03","upperLimit":"0.05"},{"groupId":"OG002","value":"0.01","lowerLimit":"-0.02","upperLimit":"0.04"},{"groupId":"OG003","value":"-0.01","lowerLimit":"-0.04","upperLimit":"0.02"},{"groupId":"OG004","value":"-0.01","lowerLimit":"-0.05","upperLimit":"0.02"},{"groupId":"OG005","value":"-0.01","lowerLimit":"-0.05","upperLimit":"0.03"}]}]},{"title":"Cycle 4 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"50"},{"groupId":"OG003","value":"46"},{"groupId":"OG004","value":"38"},{"groupId":"OG005","value":"29"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.03","lowerLimit":"-0.02","upperLimit":"0.07"},{"groupId":"OG001","value":"0.00","lowerLimit":"-0.04","upperLimit":"0.04"},{"groupId":"OG002","value":"-0.03","lowerLimit":"-0.06","upperLimit":"0.00"},{"groupId":"OG003","value":"-0.02","lowerLimit":"-0.05","upperLimit":"0.01"},{"groupId":"OG004","value":"-0.04","lowerLimit":"-0.07","upperLimit":"-0.00"},{"groupId":"OG005","value":"-0.01","lowerLimit":"-0.06","upperLimit":"0.03"}]}]},{"title":"Cycle 5 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"50"},{"groupId":"OG003","value":"46"},{"groupId":"OG004","value":"38"},{"groupId":"OG005","value":"29"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.01","lowerLimit":"-0.05","upperLimit":"0.03"},{"groupId":"OG001","value":"-0.01","lowerLimit":"-0.06","upperLimit":"0.03"},{"groupId":"OG002","value":"-0.00","lowerLimit":"-0.03","upperLimit":"0.03"},{"groupId":"OG003","value":"0.00","lowerLimit":"-0.03","upperLimit":"0.03"},{"groupId":"OG004","value":"-0.04","lowerLimit":"-0.08","upperLimit":"-0.01"},{"groupId":"OG005","value":"-0.04","lowerLimit":"-0.08","upperLimit":"0.00"}]}]},{"title":"Cycle 6 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"50"},{"groupId":"OG003","value":"46"},{"groupId":"OG004","value":"38"},{"groupId":"OG005","value":"29"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.03","lowerLimit":"-0.07","upperLimit":"0.01"},{"groupId":"OG001","value":"0.01","lowerLimit":"-0.03","upperLimit":"0.06"},{"groupId":"OG002","value":"-0.02","lowerLimit":"-0.05","upperLimit":"0.01"},{"groupId":"OG003","value":"-0.00","lowerLimit":"-0.04","upperLimit":"0.03"},{"groupId":"OG004","value":"-0.01","lowerLimit":"-0.05","upperLimit":"0.02"},{"groupId":"OG005","value":"-0.02","lowerLimit":"-0.07","upperLimit":"0.02"}]}]},{"title":"Cycle 8 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"50"},{"groupId":"OG003","value":"46"},{"groupId":"OG004","value":"38"},{"groupId":"OG005","value":"29"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.02","lowerLimit":"-0.06","upperLimit":"0.02"},{"groupId":"OG001","value":"0.00","lowerLimit":"-0.04","upperLimit":"0.05"},{"groupId":"OG002","value":"-0.02","lowerLimit":"-0.05","upperLimit":"0.01"},{"groupId":"OG003","value":"-0.03","lowerLimit":"-0.06","upperLimit":"0.01"},{"groupId":"OG004","value":"-0.04","lowerLimit":"-0.07","upperLimit":"0.00"},{"groupId":"OG005","value":"0.00","lowerLimit":"-0.04","upperLimit":"0.05"}]}]},{"title":"Cycle 10 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"50"},{"groupId":"OG003","value":"46"},{"groupId":"OG004","value":"38"},{"groupId":"OG005","value":"29"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.02","lowerLimit":"-0.06","upperLimit":"0.02"},{"groupId":"OG001","value":"0.03","lowerLimit":"-0.01","upperLimit":"0.08"},{"groupId":"OG002","value":"-0.02","lowerLimit":"-0.06","upperLimit":"0.01"},{"groupId":"OG003","value":"-0.01","lowerLimit":"-0.05","upperLimit":"0.02"},{"groupId":"OG004","value":"-0.05","lowerLimit":"-0.09","upperLimit":"-0.01"},{"groupId":"OG005","value":"-0.04","lowerLimit":"-0.08","upperLimit":"0.01"}]}]},{"title":"Cycle 12 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"50"},{"groupId":"OG003","value":"46"},{"groupId":"OG004","value":"38"},{"groupId":"OG005","value":"29"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.04","lowerLimit":"-0.08","upperLimit":"0.01"},{"groupId":"OG001","value":"-0.00","lowerLimit":"-0.05","upperLimit":"0.04"},{"groupId":"OG002","value":"-0.02","lowerLimit":"-0.06","upperLimit":"0.02"},{"groupId":"OG003","value":"-0.03","lowerLimit":"-0.06","upperLimit":"0.01"},{"groupId":"OG004","value":"-0.08","lowerLimit":"-0.13","upperLimit":"-0.04"},{"groupId":"OG005","value":"-0.01","lowerLimit":"-0.05","upperLimit":"0.04"}]}]},{"title":"Cycle 14 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"50"},{"groupId":"OG003","value":"46"},{"groupId":"OG004","value":"38"},{"groupId":"OG005","value":"29"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.02","lowerLimit":"-0.04","upperLimit":"0.07"},{"groupId":"OG001","value":"0.02","lowerLimit":"-0.03","upperLimit":"0.08"},{"groupId":"OG002","value":"-0.05","lowerLimit":"-0.09","upperLimit":"-0.01"},{"groupId":"OG003","value":"-0.04","lowerLimit":"-0.08","upperLimit":"-0.00"},{"groupId":"OG004","value":"-0.02","lowerLimit":"-0.07","upperLimit":"0.04"},{"groupId":"OG005","value":"0.01","lowerLimit":"-0.05","upperLimit":"0.06"}]}]},{"title":"Cycle 16 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"50"},{"groupId":"OG003","value":"46"},{"groupId":"OG004","value":"38"},{"groupId":"OG005","value":"29"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.03","lowerLimit":"-0.09","upperLimit":"0.03"},{"groupId":"OG001","value":"0.01","lowerLimit":"-0.05","upperLimit":"0.07"},{"groupId":"OG002","value":"0.02","lowerLimit":"-0.03","upperLimit":"0.07"},{"groupId":"OG003","value":"-0.03","lowerLimit":"-0.08","upperLimit":"0.01"},{"groupId":"OG004","value":"-0.04","lowerLimit":"-0.14","upperLimit":"0.06"},{"groupId":"OG005","value":"-0.01","lowerLimit":"-0.07","upperLimit":"0.06"}]}]},{"title":"Cycle 18 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"50"},{"groupId":"OG003","value":"46"},{"groupId":"OG004","value":"38"},{"groupId":"OG005","value":"29"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.09","lowerLimit":"0.01","upperLimit":"0.18"},{"groupId":"OG001","value":"-0.02","lowerLimit":"-0.09","upperLimit":"0.05"},{"groupId":"OG002","value":"-0.03","lowerLimit":"-0.09","upperLimit":"0.02"},{"groupId":"OG003","value":"-0.06","lowerLimit":"-0.11","upperLimit":"-0.01"},{"groupId":"OG004","value":"-0.09","lowerLimit":"-0.23","upperLimit":"0.04"},{"groupId":"OG005","value":"-0.01","lowerLimit":"-0.08","upperLimit":"0.05"}]}]},{"title":"Cycle 20 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"50"},{"groupId":"OG003","value":"46"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"29"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.07","lowerLimit":"-0.03","upperLimit":"0.17"},{"groupId":"OG001","value":"0.02","lowerLimit":"-0.06","upperLimit":"0.09"},{"groupId":"OG002","value":"0.01","lowerLimit":"-0.06","upperLimit":"0.08"},{"groupId":"OG003","value":"-0.09","lowerLimit":"-0.16","upperLimit":"-0.03"},{"groupId":"OG005","value":"-0.03","lowerLimit":"-0.11","upperLimit":"0.04"}]}]},{"title":"Cycle 22 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"50"},{"groupId":"OG003","value":"46"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"29"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.02","lowerLimit":"-0.12","upperLimit":"0.08"},{"groupId":"OG001","value":"-0.02","lowerLimit":"-0.10","upperLimit":"0.07"},{"groupId":"OG002","value":"0.00","lowerLimit":"-0.08","upperLimit":"0.08"},{"groupId":"OG003","value":"-0.08","lowerLimit":"-0.16","upperLimit":"0.00"},{"groupId":"OG005","value":"-0.05","lowerLimit":"-0.13","upperLimit":"0.03"}]}]},{"title":"Cycle 24 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"46"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.03","lowerLimit":"-0.11","upperLimit":"0.16"},{"groupId":"OG003","value":"-0.06","lowerLimit":"-0.20","upperLimit":"0.07"}]}]},{"title":"End of treatment","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"50"},{"groupId":"OG003","value":"46"},{"groupId":"OG004","value":"38"},{"groupId":"OG005","value":"29"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.04","lowerLimit":"-0.13","upperLimit":"0.04"},{"groupId":"OG001","value":"-0.01","lowerLimit":"-0.10","upperLimit":"0.08"},{"groupId":"OG002","value":"-0.02","lowerLimit":"-0.08","upperLimit":"0.04"},{"groupId":"OG003","value":"-0.05","lowerLimit":"-0.10","upperLimit":"-0.00"},{"groupId":"OG004","value":"-0.07","lowerLimit":"-0.14","upperLimit":"-0.01"},{"groupId":"OG005","value":"-0.05","lowerLimit":"-0.12","upperLimit":"0.03"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Total Scores for Identification Test (Cognitive Function Assessment) (Phase 2)","description":"The Identification Test is a measure of visual attention and uses a well validated choice reaction time paradigm with playing card stimuli. In this task, the playing cards are all red or black jokers. The on-screen instructions ask: \"Is the card red?\". A playing card is presented face down in the center of the screen. The card flips over so it is face up. As soon as it flips over the participant must decide whether the card is red or not. If it is red the participant should press \"Yes\", and if it is not red the participant should press \"No\". The participant is encouraged to work as quickly and accurately as possible. The speed and accuracy of each response are recorded and mean of the log10 transformed reaction times for correct responses is calculated. Lower values of least square mean change from baseline indicate performance decline. Upper limit of 95% confidence interval of -0.00 or lower indicate statistically significant decline of performance over baseline at that cycle.","populationDescription":"PRO evaluable analysis set included all enrolled participants who received study treatment, had a baseline test assessment and at least 1 on-study test assessment. Here, 'Number Analyzed' signifies participants evaluable for specified row.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Units on a scale","timeFrame":"Baseline, Day 1 of Cycles 2-5, Day 1 of every other cycle from Cycle 6, and end of treatment (up to 3 years)","groups":[{"id":"OG000","title":"EXP-1 (Phase 2)","description":"Treatment-naÃ¯ve participants with advanced anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC) with or without asymptomatic central nervous system (CNS) metastases were given PF-06463922 100 mg orally QD on Day -7 (only participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG001","title":"EXP-2 (Phase 2)","description":"Participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after only crizotinib therapy were given PF-06463922 100 mg orally QD on Day -7 (only for participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG002","title":"EXP-3 (Phase 2)","description":"Participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after crizotinib therapy and 1 or 2 prior regimens of chemotherapy given before or after crizotinib therapy, or participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after 1 ALK inhibitor therapy other than crizotinib with or without any number of prior chemotherapy regimens in any disease setting were given PF-06463922 100 mg orally QD on Day -7 (only for participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG003","title":"EXP-4 (Phase 2)","description":"Participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after 2 prior lines of ALK inhibitor therapies were given PF-06463922 100 mg orally QD on Day -7 (only for participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG004","title":"EXP-5 (Phase 2)","description":"Participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after 3 prior lines of ALK inhibitor therapies were given PF-06463922 100 mg orally QD on Day -7 (only for participant scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG005","title":"EXP-6 (Phase 2)","description":"Participants with advanced ROS1-positive NSCLC who were treatment naÃ¯ve or had any number of prior cancer therapies with or without asymptomatic CNS metastases were given PF-06463922 100 mg orally QD on Day -7 (only for participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"50"},{"groupId":"OG003","value":"46"},{"groupId":"OG004","value":"38"},{"groupId":"OG005","value":"29"}]}],"classes":[{"title":"Cycle 2 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"50"},{"groupId":"OG003","value":"46"},{"groupId":"OG004","value":"38"},{"groupId":"OG005","value":"29"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.02","lowerLimit":"-0.05","upperLimit":"0.01"},{"groupId":"OG001","value":"-0.02","lowerLimit":"-0.05","upperLimit":"0.01"},{"groupId":"OG002","value":"-0.01","lowerLimit":"-0.03","upperLimit":"0.00"},{"groupId":"OG003","value":"-0.01","lowerLimit":"-0.03","upperLimit":"0.01"},{"groupId":"OG004","value":"-0.02","lowerLimit":"-0.04","upperLimit":"0.01"},{"groupId":"OG005","value":"-0.01","lowerLimit":"-0.04","upperLimit":"0.02"}]}]},{"title":"Cycle 3 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"50"},{"groupId":"OG003","value":"46"},{"groupId":"OG004","value":"38"},{"groupId":"OG005","value":"29"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.01","lowerLimit":"-0.04","upperLimit":"0.02"},{"groupId":"OG001","value":"-0.01","lowerLimit":"-0.04","upperLimit":"0.02"},{"groupId":"OG002","value":"-0.02","lowerLimit":"-0.04","upperLimit":"0.00"},{"groupId":"OG003","value":"-0.02","lowerLimit":"-0.04","upperLimit":"0.00"},{"groupId":"OG004","value":"-0.02","lowerLimit":"-0.05","upperLimit":"0.00"},{"groupId":"OG005","value":"-0.01","lowerLimit":"-0.04","upperLimit":"0.02"}]}]},{"title":"Cycle 4 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"50"},{"groupId":"OG003","value":"46"},{"groupId":"OG004","value":"38"},{"groupId":"OG005","value":"29"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.02","lowerLimit":"-0.05","upperLimit":"0.01"},{"groupId":"OG001","value":"-0.01","lowerLimit":"-0.04","upperLimit":"0.01"},{"groupId":"OG002","value":"-0.02","lowerLimit":"-0.04","upperLimit":"0.00"},{"groupId":"OG003","value":"-0.03","lowerLimit":"-0.05","upperLimit":"-0.01"},{"groupId":"OG004","value":"-0.05","lowerLimit":"-0.08","upperLimit":"-0.03"},{"groupId":"OG005","value":"-0.02","lowerLimit":"-0.04","upperLimit":"0.01"}]}]},{"title":"Cycle 5 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"50"},{"groupId":"OG003","value":"46"},{"groupId":"OG004","value":"38"},{"groupId":"OG005","value":"29"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.03","lowerLimit":"-0.06","upperLimit":"-0.00"},{"groupId":"OG001","value":"-0.02","lowerLimit":"-0.05","upperLimit":"0.01"},{"groupId":"OG002","value":"-0.03","lowerLimit":"-0.05","upperLimit":"-0.00"},{"groupId":"OG003","value":"-0.02","lowerLimit":"-0.04","upperLimit":"0.01"},{"groupId":"OG004","value":"-0.05","lowerLimit":"-0.07","upperLimit":"-0.02"},{"groupId":"OG005","value":"-0.02","lowerLimit":"-0.05","upperLimit":"0.00"}]}]},{"title":"Cycle 6 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"50"},{"groupId":"OG003","value":"46"},{"groupId":"OG004","value":"38"},{"groupId":"OG005","value":"29"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.04","lowerLimit":"-0.07","upperLimit":"-0.01"},{"groupId":"OG001","value":"-0.02","lowerLimit":"-0.05","upperLimit":"0.01"},{"groupId":"OG002","value":"-0.02","lowerLimit":"-0.04","upperLimit":"0.00"},{"groupId":"OG003","value":"-0.03","lowerLimit":"-0.06","upperLimit":"-0.01"},{"groupId":"OG004","value":"-0.03","lowerLimit":"-0.06","upperLimit":"-0.01"},{"groupId":"OG005","value":"-0.03","lowerLimit":"-0.06","upperLimit":"-0.00"}]}]},{"title":"Cycle 8 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"50"},{"groupId":"OG003","value":"46"},{"groupId":"OG004","value":"38"},{"groupId":"OG005","value":"29"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.03","lowerLimit":"-0.06","upperLimit":"-0.00"},{"groupId":"OG001","value":"-0.02","lowerLimit":"-0.05","upperLimit":"0.01"},{"groupId":"OG002","value":"-0.03","lowerLimit":"-0.05","upperLimit":"-0.01"},{"groupId":"OG003","value":"-0.03","lowerLimit":"-0.05","upperLimit":"-0.01"},{"groupId":"OG004","value":"-0.05","lowerLimit":"-0.07","upperLimit":"-0.02"},{"groupId":"OG005","value":"-0.03","lowerLimit":"-0.06","upperLimit":"0.00"}]}]},{"title":"Cycle 10 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"50"},{"groupId":"OG003","value":"46"},{"groupId":"OG004","value":"38"},{"groupId":"OG005","value":"29"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.03","lowerLimit":"-0.06","upperLimit":"0.00"},{"groupId":"OG001","value":"-0.01","lowerLimit":"-0.04","upperLimit":"0.02"},{"groupId":"OG002","value":"-0.03","lowerLimit":"-0.05","upperLimit":"-0.01"},{"groupId":"OG003","value":"-0.02","lowerLimit":"-0.05","upperLimit":"0.00"},{"groupId":"OG004","value":"-0.05","lowerLimit":"-0.08","upperLimit":"-0.02"},{"groupId":"OG005","value":"-0.03","lowerLimit":"-0.06","upperLimit":"0.00"}]}]},{"title":"Cycle 12 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"50"},{"groupId":"OG003","value":"46"},{"groupId":"OG004","value":"38"},{"groupId":"OG005","value":"29"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.05","lowerLimit":"-0.08","upperLimit":"-0.02"},{"groupId":"OG001","value":"-0.04","lowerLimit":"-0.07","upperLimit":"-0.01"},{"groupId":"OG002","value":"-0.04","lowerLimit":"-0.06","upperLimit":"-0.01"},{"groupId":"OG003","value":"-0.04","lowerLimit":"-0.07","upperLimit":"-0.01"},{"groupId":"OG004","value":"-0.06","lowerLimit":"-0.09","upperLimit":"-0.03"},{"groupId":"OG005","value":"-0.03","lowerLimit":"-0.06","upperLimit":"0.00"}]}]},{"title":"Cycle 14 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"50"},{"groupId":"OG003","value":"46"},{"groupId":"OG004","value":"38"},{"groupId":"OG005","value":"29"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.04","lowerLimit":"-0.08","upperLimit":"0.00"},{"groupId":"OG001","value":"-0.04","lowerLimit":"-0.07","upperLimit":"-0.00"},{"groupId":"OG002","value":"-0.03","lowerLimit":"-0.06","upperLimit":"-0.00"},{"groupId":"OG003","value":"-0.04","lowerLimit":"-0.07","upperLimit":"-0.01"},{"groupId":"OG004","value":"-0.04","lowerLimit":"-0.08","upperLimit":"-0.00"},{"groupId":"OG005","value":"-0.02","lowerLimit":"-0.06","upperLimit":"0.02"}]}]},{"title":"Cycle 16 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"50"},{"groupId":"OG003","value":"46"},{"groupId":"OG004","value":"38"},{"groupId":"OG005","value":"29"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.09","lowerLimit":"-0.13","upperLimit":"-0.05"},{"groupId":"OG001","value":"-0.00","lowerLimit":"-0.04","upperLimit":"0.04"},{"groupId":"OG002","value":"-0.03","lowerLimit":"-0.07","upperLimit":"0.01"},{"groupId":"OG003","value":"-0.03","lowerLimit":"-0.06","upperLimit":"0.01"},{"groupId":"OG004","value":"-0.07","lowerLimit":"-0.13","upperLimit":"0.00"},{"groupId":"OG005","value":"-0.06","lowerLimit":"-0.10","upperLimit":"-0.01"}]}]},{"title":"Cycle 18 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"50"},{"groupId":"OG003","value":"46"},{"groupId":"OG004","value":"38"},{"groupId":"OG005","value":"29"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.01","lowerLimit":"-0.06","upperLimit":"0.05"},{"groupId":"OG001","value":"-0.05","lowerLimit":"-0.09","upperLimit":"0.00"},{"groupId":"OG002","value":"-0.04","lowerLimit":"-0.08","upperLimit":"0.00"},{"groupId":"OG003","value":"-0.07","lowerLimit":"-0.10","upperLimit":"-0.03"},{"groupId":"OG004","value":"-0.19","lowerLimit":"-0.29","upperLimit":"-0.09"},{"groupId":"OG005","value":"-0.01","lowerLimit":"-0.05","upperLimit":"0.04"}]}]},{"title":"Cycle 20 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"50"},{"groupId":"OG003","value":"46"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"29"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.03","lowerLimit":"-0.10","upperLimit":"0.04"},{"groupId":"OG001","value":"-0.01","lowerLimit":"-0.06","upperLimit":"0.04"},{"groupId":"OG002","value":"-0.03","lowerLimit":"-0.08","upperLimit":"0.02"},{"groupId":"OG003","value":"-0.10","lowerLimit":"-0.15","upperLimit":"-0.06"},{"groupId":"OG005","value":"-0.03","lowerLimit":"-0.08","upperLimit":"0.02"}]}]},{"title":"Cycle 22 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"50"},{"groupId":"OG003","value":"46"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"29"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.04","lowerLimit":"-0.03","upperLimit":"0.11"},{"groupId":"OG001","value":"-0.01","lowerLimit":"-0.07","upperLimit":"0.05"},{"groupId":"OG002","value":"-0.06","lowerLimit":"-0.11","upperLimit":"0.00"},{"groupId":"OG003","value":"-0.05","lowerLimit":"-0.11","upperLimit":"0.00"},{"groupId":"OG005","value":"-0.08","lowerLimit":"-0.14","upperLimit":"-0.03"}]}]},{"title":"Cycle 24 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"46"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.08","lowerLimit":"-0.01","upperLimit":"0.18"},{"groupId":"OG003","value":"-0.06","lowerLimit":"-0.15","upperLimit":"0.04"}]}]},{"title":"End of treatment","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"50"},{"groupId":"OG003","value":"46"},{"groupId":"OG004","value":"38"},{"groupId":"OG005","value":"29"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.07","lowerLimit":"-0.13","upperLimit":"-0.02"},{"groupId":"OG001","value":"-0.03","lowerLimit":"-0.10","upperLimit":"0.03"},{"groupId":"OG002","value":"-0.02","lowerLimit":"-0.06","upperLimit":"0.02"},{"groupId":"OG003","value":"-0.03","lowerLimit":"-0.06","upperLimit":"0.01"},{"groupId":"OG004","value":"-0.09","lowerLimit":"-0.14","upperLimit":"-0.05"},{"groupId":"OG005","value":"-0.06","lowerLimit":"-0.11","upperLimit":"-0.01"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Total Scores for One Back Test (Cognitive Function Assessment) (Phase 2)","description":"The One Back Test is a measure of working memory and uses a well validated n back paradigm with playing cards. In this task, the on-screen instructions ask: \"Is the previous card the same?\". A playing card is presented in the center of the screen. The participant must decide whether the card is the same as the previous card. If it is the same the participant should press \"Yes\", and if not press \"No\". The participant is encouraged to work as quickly and accurately as possible. The speed and accuracy of each response are recorded, mean of the log10 transformed reaction times for correct responses is used to demonstrate speed of performance, and the arcsine transformation of the square root of the proportion of correct responses is used to demonstrate accuracy. Lower values of least square mean change from baseline indicate performance decline. Upper limit of 95% confidence interval of -0.00 or lower indicate statistically significant decline of performance over baseline at that cycle.","populationDescription":"PRO evaluable analysis set included all enrolled participants who received study treatment, had a baseline test assessment and at least 1 on-study test assessment. Here, 'Number Analyzed' signifies participants evaluable for specified row.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Units on a scale","timeFrame":"Baseline, Day 1 of Cycles 2-5, Day 1 of every other cycle from Cycle 6, and end of treatment (up to 3 years)","groups":[{"id":"OG000","title":"EXP-1 (Phase 2)","description":"Treatment-naÃ¯ve participants with advanced anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC) with or without asymptomatic central nervous system (CNS) metastases were given PF-06463922 100 mg orally QD on Day -7 (only participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG001","title":"EXP-2 (Phase 2)","description":"Participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after only crizotinib therapy were given PF-06463922 100 mg orally QD on Day -7 (only for participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG002","title":"EXP-3 (Phase 2)","description":"Participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after crizotinib therapy and 1 or 2 prior regimens of chemotherapy given before or after crizotinib therapy, or participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after 1 ALK inhibitor therapy other than crizotinib with or without any number of prior chemotherapy regimens in any disease setting were given PF-06463922 100 mg orally QD on Day -7 (only for participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG003","title":"EXP-4 (Phase 2)","description":"Participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after 2 prior lines of ALK inhibitor therapies were given PF-06463922 100 mg orally QD on Day -7 (only for participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG004","title":"EXP-5 (Phase 2)","description":"Participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after 3 prior lines of ALK inhibitor therapies were given PF-06463922 100 mg orally QD on Day -7 (only for participant scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG005","title":"EXP-6 (Phase 2)","description":"Participants with advanced ROS1-positive NSCLC who were treatment naÃ¯ve or had any number of prior cancer therapies with or without asymptomatic CNS metastases were given PF-06463922 100 mg orally QD on Day -7 (only for participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"50"},{"groupId":"OG003","value":"46"},{"groupId":"OG004","value":"38"},{"groupId":"OG005","value":"29"}]}],"classes":[{"title":"Cycle 2 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"50"},{"groupId":"OG003","value":"46"},{"groupId":"OG004","value":"38"},{"groupId":"OG005","value":"29"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.01","lowerLimit":"-0.02","upperLimit":"0.05"},{"groupId":"OG001","value":"0.02","lowerLimit":"-0.01","upperLimit":"0.05"},{"groupId":"OG002","value":"0.02","lowerLimit":"0.00","upperLimit":"0.05"},{"groupId":"OG003","value":"0.01","lowerLimit":"-0.01","upperLimit":"0.04"},{"groupId":"OG004","value":"0.02","lowerLimit":"-0.01","upperLimit":"0.05"},{"groupId":"OG005","value":"0.01","lowerLimit":"-0.02","upperLimit":"0.04"}]}]},{"title":"Cycle 3 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"50"},{"groupId":"OG003","value":"46"},{"groupId":"OG004","value":"38"},{"groupId":"OG005","value":"29"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.06","lowerLimit":"0.02","upperLimit":"0.09"},{"groupId":"OG001","value":"0.01","lowerLimit":"-0.02","upperLimit":"0.05"},{"groupId":"OG002","value":"0.01","lowerLimit":"-0.01","upperLimit":"0.04"},{"groupId":"OG003","value":"0.01","lowerLimit":"-0.02","upperLimit":"0.03"},{"groupId":"OG004","value":"-0.01","lowerLimit":"-0.04","upperLimit":"0.02"},{"groupId":"OG005","value":"-0.00","lowerLimit":"-0.04","upperLimit":"0.03"}]}]},{"title":"Cycle 4 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"50"},{"groupId":"OG003","value":"46"},{"groupId":"OG004","value":"38"},{"groupId":"OG005","value":"29"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.04","lowerLimit":"0.01","upperLimit":"0.08"},{"groupId":"OG001","value":"0.03","lowerLimit":"-0.00","upperLimit":"0.06"},{"groupId":"OG002","value":"0.02","lowerLimit":"-0.01","upperLimit":"0.04"},{"groupId":"OG003","value":"-0.01","lowerLimit":"-0.04","upperLimit":"0.01"},{"groupId":"OG004","value":"-0.02","lowerLimit":"-0.05","upperLimit":"0.01"},{"groupId":"OG005","value":"-0.01","lowerLimit":"-0.05","upperLimit":"0.02"}]}]},{"title":"Cycle 5 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"50"},{"groupId":"OG003","value":"46"},{"groupId":"OG004","value":"38"},{"groupId":"OG005","value":"29"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.02","lowerLimit":"-0.01","upperLimit":"0.06"},{"groupId":"OG001","value":"0.03","lowerLimit":"-0.00","upperLimit":"0.07"},{"groupId":"OG002","value":"0.03","lowerLimit":"0.00","upperLimit":"0.05"},{"groupId":"OG003","value":"-0.01","lowerLimit":"-0.04","upperLimit":"0.02"},{"groupId":"OG004","value":"-0.02","lowerLimit":"-0.05","upperLimit":"0.01"},{"groupId":"OG005","value":"0.02","lowerLimit":"-0.01","upperLimit":"0.05"}]}]},{"title":"Cycle 6 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"50"},{"groupId":"OG003","value":"46"},{"groupId":"OG004","value":"38"},{"groupId":"OG005","value":"29"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.03","lowerLimit":"-0.01","upperLimit":"0.06"},{"groupId":"OG001","value":"0.03","lowerLimit":"-0.00","upperLimit":"0.07"},{"groupId":"OG002","value":"0.03","lowerLimit":"0.01","upperLimit":"0.06"},{"groupId":"OG003","value":"0.01","lowerLimit":"-0.02","upperLimit":"0.04"},{"groupId":"OG004","value":"-0.00","lowerLimit":"-0.03","upperLimit":"0.03"},{"groupId":"OG005","value":"0.01","lowerLimit":"-0.03","upperLimit":"0.04"}]}]},{"title":"Cycle 8 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"50"},{"groupId":"OG003","value":"46"},{"groupId":"OG004","value":"38"},{"groupId":"OG005","value":"29"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.03","lowerLimit":"-0.01","upperLimit":"0.06"},{"groupId":"OG001","value":"0.02","lowerLimit":"-0.02","upperLimit":"0.06"},{"groupId":"OG002","value":"0.03","lowerLimit":"0.00","upperLimit":"0.05"},{"groupId":"OG003","value":"0.01","lowerLimit":"-0.02","upperLimit":"0.03"},{"groupId":"OG004","value":"-0.01","lowerLimit":"-0.04","upperLimit":"0.02"},{"groupId":"OG005","value":"0.01","lowerLimit":"-0.02","upperLimit":"0.05"}]}]},{"title":"Cycle 10 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"50"},{"groupId":"OG003","value":"46"},{"groupId":"OG004","value":"38"},{"groupId":"OG005","value":"29"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.07","lowerLimit":"0.03","upperLimit":"0.11"},{"groupId":"OG001","value":"0.03","lowerLimit":"-0.00","upperLimit":"0.07"},{"groupId":"OG002","value":"0.03","lowerLimit":"0.00","upperLimit":"0.05"},{"groupId":"OG003","value":"0.02","lowerLimit":"-0.01","upperLimit":"0.05"},{"groupId":"OG004","value":"-0.01","lowerLimit":"-0.05","upperLimit":"0.02"},{"groupId":"OG005","value":"0.01","lowerLimit":"-0.02","upperLimit":"0.05"}]}]},{"title":"Cycle 12 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"50"},{"groupId":"OG003","value":"46"},{"groupId":"OG004","value":"38"},{"groupId":"OG005","value":"29"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.05","lowerLimit":"0.01","upperLimit":"0.08"},{"groupId":"OG001","value":"0.01","lowerLimit":"-0.03","upperLimit":"0.05"},{"groupId":"OG002","value":"0.02","lowerLimit":"-0.01","upperLimit":"0.05"},{"groupId":"OG003","value":"0.01","lowerLimit":"-0.02","upperLimit":"0.04"},{"groupId":"OG004","value":"-0.00","lowerLimit":"-0.04","upperLimit":"0.03"},{"groupId":"OG005","value":"0.03","lowerLimit":"-0.01","upperLimit":"0.07"}]}]},{"title":"Cycle 14 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"50"},{"groupId":"OG003","value":"46"},{"groupId":"OG004","value":"38"},{"groupId":"OG005","value":"29"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","lowerLimit":"-0.05","upperLimit":"0.05"},{"groupId":"OG001","value":"0.03","lowerLimit":"-0.01","upperLimit":"0.07"},{"groupId":"OG002","value":"0.03","lowerLimit":"-0.01","upperLimit":"0.07"},{"groupId":"OG003","value":"-0.00","lowerLimit":"-0.04","upperLimit":"0.03"},{"groupId":"OG004","value":"0.01","lowerLimit":"-0.04","upperLimit":"0.06"},{"groupId":"OG005","value":"0.02","lowerLimit":"-0.03","upperLimit":"0.07"}]}]},{"title":"Cycle 16 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"50"},{"groupId":"OG003","value":"46"},{"groupId":"OG004","value":"38"},{"groupId":"OG005","value":"29"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.03","lowerLimit":"-0.03","upperLimit":"0.08"},{"groupId":"OG001","value":"0.05","lowerLimit":"-0.01","upperLimit":"0.10"},{"groupId":"OG002","value":"0.05","lowerLimit":"0.00","upperLimit":"0.09"},{"groupId":"OG003","value":"-0.02","lowerLimit":"-0.05","upperLimit":"0.02"},{"groupId":"OG004","value":"-0.01","lowerLimit":"-0.10","upperLimit":"0.08"},{"groupId":"OG005","value":"0.03","lowerLimit":"-0.03","upperLimit":"0.08"}]}]},{"title":"Cycle 18 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"50"},{"groupId":"OG003","value":"46"},{"groupId":"OG004","value":"38"},{"groupId":"OG005","value":"29"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.02","lowerLimit":"-0.06","upperLimit":"0.09"},{"groupId":"OG001","value":"0.01","lowerLimit":"-0.04","upperLimit":"0.07"},{"groupId":"OG002","value":"0.06","lowerLimit":"0.02","upperLimit":"0.11"},{"groupId":"OG003","value":"-0.02","lowerLimit":"-0.06","upperLimit":"0.03"},{"groupId":"OG004","value":"-0.18","lowerLimit":"-0.30","upperLimit":"-0.06"},{"groupId":"OG005","value":"0.05","lowerLimit":"-0.01","upperLimit":"0.10"}]}]},{"title":"Cycle 20 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"50"},{"groupId":"OG003","value":"46"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"29"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.06","lowerLimit":"-0.15","upperLimit":"0.03"},{"groupId":"OG001","value":"0.07","lowerLimit":"0.00","upperLimit":"0.13"},{"groupId":"OG002","value":"0.02","lowerLimit":"-0.05","upperLimit":"0.08"},{"groupId":"OG003","value":"-0.01","lowerLimit":"-0.06","upperLimit":"0.05"},{"groupId":"OG005","value":"0.02","lowerLimit":"-0.04","upperLimit":"0.09"}]}]},{"title":"Cycle 22 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"50"},{"groupId":"OG003","value":"46"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"29"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.02","lowerLimit":"-0.07","upperLimit":"0.11"},{"groupId":"OG001","value":"0.05","lowerLimit":"-0.02","upperLimit":"0.12"},{"groupId":"OG002","value":"0.04","lowerLimit":"-0.03","upperLimit":"0.11"},{"groupId":"OG003","value":"-0.07","lowerLimit":"-0.14","upperLimit":"0.00"},{"groupId":"OG005","value":"0.03","lowerLimit":"-0.04","upperLimit":"0.11"}]}]},{"title":"Cycle 24 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"46"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.09","lowerLimit":"-0.03","upperLimit":"0.21"},{"groupId":"OG003","value":"0.01","lowerLimit":"-0.11","upperLimit":"0.13"}]}]},{"title":"End of treatment","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"50"},{"groupId":"OG003","value":"46"},{"groupId":"OG004","value":"38"},{"groupId":"OG005","value":"29"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.03","lowerLimit":"-0.10","upperLimit":"0.05"},{"groupId":"OG001","value":"0.03","lowerLimit":"-0.05","upperLimit":"0.11"},{"groupId":"OG002","value":"0.03","lowerLimit":"-0.02","upperLimit":"0.07"},{"groupId":"OG003","value":"0.01","lowerLimit":"-0.04","upperLimit":"0.05"},{"groupId":"OG004","value":"-0.03","lowerLimit":"-0.08","upperLimit":"0.02"},{"groupId":"OG005","value":"0.02","lowerLimit":"-0.05","upperLimit":"0.08"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Total Scores for International Shopping List Test (Cognitive Function Assessment) (Phase 2)","description":"The International Shopping List task is a measure of verbal learning and uses a well validated list learning paradigm administered using a computer. High frequencies, high imagery, concrete nouns (items from a shopping list) were read to the participant at the rate of one word every 2 seconds. Once all 12 words had been read, the participant was asked to recall as many of the words as quickly as possible. The words recalled by the participant were marked on the computer screen. When the participant could recall no more words, the same list was read again. The words recalled by the participant were recorded. This was then repeated a third time. Total number of correct responses on 3 consecutive trials at a single assessment was recorded. Lower values of least square mean change from baseline indicate performance decline. Upper limit of 95% confidence interval of -0.00 or lower indicate statistically significant decline of performance over baseline at that cycle.","populationDescription":"PRO evaluable analysis set included all enrolled participants who received study treatment, had a baseline test assessment and at least 1 on-study test assessment. Here, 'Number Analyzed' signifies participants evaluable for specified row.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Units on a scale","timeFrame":"Baseline, Day 1 of Cycles 2-5, Day 1 of every other cycle from Cycle 6, and end of treatment (up to 3 years)","groups":[{"id":"OG000","title":"EXP-1 (Phase 2)","description":"Treatment-naÃ¯ve participants with advanced anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC) with or without asymptomatic central nervous system (CNS) metastases were given PF-06463922 100 mg orally QD on Day -7 (only participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG001","title":"EXP-2 (Phase 2)","description":"Participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after only crizotinib therapy were given PF-06463922 100 mg orally QD on Day -7 (only for participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG002","title":"EXP-3 (Phase 2)","description":"Participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after crizotinib therapy and 1 or 2 prior regimens of chemotherapy given before or after crizotinib therapy, or participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after 1 ALK inhibitor therapy other than crizotinib with or without any number of prior chemotherapy regimens in any disease setting were given PF-06463922 100 mg orally QD on Day -7 (only for participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG003","title":"EXP-4 (Phase 2)","description":"Participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after 2 prior lines of ALK inhibitor therapies were given PF-06463922 100 mg orally QD on Day -7 (only for participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG004","title":"EXP-5 (Phase 2)","description":"Participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after 3 prior lines of ALK inhibitor therapies were given PF-06463922 100 mg orally QD on Day -7 (only for participant scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG005","title":"EXP-6 (Phase 2)","description":"Participants with advanced ROS1-positive NSCLC who were treatment naÃ¯ve or had any number of prior cancer therapies with or without asymptomatic CNS metastases were given PF-06463922 100 mg orally QD on Day -7 (only for participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"50"},{"groupId":"OG003","value":"46"},{"groupId":"OG004","value":"38"},{"groupId":"OG005","value":"29"}]}],"classes":[{"title":"Cycle 2 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"50"},{"groupId":"OG003","value":"46"},{"groupId":"OG004","value":"38"},{"groupId":"OG005","value":"29"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.02","lowerLimit":"-1.89","upperLimit":"1.84"},{"groupId":"OG001","value":"-1.13","lowerLimit":"-2.90","upperLimit":"0.64"},{"groupId":"OG002","value":"0.25","lowerLimit":"-1.01","upperLimit":"1.52"},{"groupId":"OG003","value":"-0.45","lowerLimit":"-1.76","upperLimit":"0.86"},{"groupId":"OG004","value":"0.96","lowerLimit":"-0.50","upperLimit":"2.43"},{"groupId":"OG005","value":"0.16","lowerLimit":"-1.51","upperLimit":"1.83"}]}]},{"title":"Cycle 3 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"50"},{"groupId":"OG003","value":"46"},{"groupId":"OG004","value":"38"},{"groupId":"OG005","value":"29"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.19","lowerLimit":"-1.66","upperLimit":"2.03"},{"groupId":"OG001","value":"-0.81","lowerLimit":"-2.58","upperLimit":"0.96"},{"groupId":"OG002","value":"0.14","lowerLimit":"-1.15","upperLimit":"1.43"},{"groupId":"OG003","value":"-1.04","lowerLimit":"-2.36","upperLimit":"0.29"},{"groupId":"OG004","value":"-0.08","lowerLimit":"-1.59","upperLimit":"1.44"},{"groupId":"OG005","value":"-0.56","lowerLimit":"-2.21","upperLimit":"1.09"}]}]},{"title":"Cycle 4 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"50"},{"groupId":"OG003","value":"46"},{"groupId":"OG004","value":"38"},{"groupId":"OG005","value":"29"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.58","lowerLimit":"-1.26","upperLimit":"2.42"},{"groupId":"OG001","value":"0.26","lowerLimit":"-1.54","upperLimit":"2.05"},{"groupId":"OG002","value":"0.28","lowerLimit":"-1.05","upperLimit":"1.61"},{"groupId":"OG003","value":"0.24","lowerLimit":"-1.12","upperLimit":"1.60"},{"groupId":"OG004","value":"1.30","lowerLimit":"-0.26","upperLimit":"2.86"},{"groupId":"OG005","value":"-0.87","lowerLimit":"-2.59","upperLimit":"0.84"}]}]},{"title":"Cycle 5 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"50"},{"groupId":"OG003","value":"46"},{"groupId":"OG004","value":"38"},{"groupId":"OG005","value":"29"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.30","lowerLimit":"-0.51","upperLimit":"3.12"},{"groupId":"OG001","value":"-0.66","lowerLimit":"-2.53","upperLimit":"1.21"},{"groupId":"OG002","value":"0.59","lowerLimit":"-0.77","upperLimit":"1.95"},{"groupId":"OG003","value":"-0.94","lowerLimit":"-2.33","upperLimit":"0.45"},{"groupId":"OG004","value":"1.23","lowerLimit":"-0.36","upperLimit":"2.82"},{"groupId":"OG005","value":"0.74","lowerLimit":"-0.97","upperLimit":"2.45"}]}]},{"title":"Cycle 6 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"50"},{"groupId":"OG003","value":"46"},{"groupId":"OG004","value":"38"},{"groupId":"OG005","value":"29"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.18","lowerLimit":"-1.64","upperLimit":"1.99"},{"groupId":"OG001","value":"0.81","lowerLimit":"-1.06","upperLimit":"2.68"},{"groupId":"OG002","value":"0.50","lowerLimit":"-0.87","upperLimit":"1.87"},{"groupId":"OG003","value":"0.08","lowerLimit":"-1.31","upperLimit":"1.47"},{"groupId":"OG004","value":"0.82","lowerLimit":"-0.83","upperLimit":"2.46"},{"groupId":"OG005","value":"-0.51","lowerLimit":"-2.31","upperLimit":"1.29"}]}]},{"title":"Cycle 8 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"50"},{"groupId":"OG003","value":"46"},{"groupId":"OG004","value":"38"},{"groupId":"OG005","value":"29"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.84","lowerLimit":"-1.00","upperLimit":"2.68"},{"groupId":"OG001","value":"0.60","lowerLimit":"-1.30","upperLimit":"2.50"},{"groupId":"OG002","value":"1.69","lowerLimit":"0.29","upperLimit":"3.08"},{"groupId":"OG003","value":"0.15","lowerLimit":"-1.27","upperLimit":"1.57"},{"groupId":"OG004","value":"0.44","lowerLimit":"-1.23","upperLimit":"2.11"},{"groupId":"OG005","value":"1.70","lowerLimit":"-0.11","upperLimit":"3.50"}]}]},{"title":"Cycle 10 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"50"},{"groupId":"OG003","value":"46"},{"groupId":"OG004","value":"38"},{"groupId":"OG005","value":"29"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.26","lowerLimit":"-1.68","upperLimit":"2.21"},{"groupId":"OG001","value":"2.59","lowerLimit":"0.65","upperLimit":"4.52"},{"groupId":"OG002","value":"0.86","lowerLimit":"-0.56","upperLimit":"2.27"},{"groupId":"OG003","value":"0.13","lowerLimit":"-1.46","upperLimit":"1.72"},{"groupId":"OG004","value":"2.29","lowerLimit":"0.53","upperLimit":"4.05"},{"groupId":"OG005","value":"0.97","lowerLimit":"-0.99","upperLimit":"2.93"}]}]},{"title":"Cycle 12 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"50"},{"groupId":"OG003","value":"46"},{"groupId":"OG004","value":"38"},{"groupId":"OG005","value":"29"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.87","lowerLimit":"0.86","upperLimit":"4.88"},{"groupId":"OG001","value":"0.02","lowerLimit":"-2.06","upperLimit":"2.10"},{"groupId":"OG002","value":"0.11","lowerLimit":"-1.52","upperLimit":"1.73"},{"groupId":"OG003","value":"0.69","lowerLimit":"-0.98","upperLimit":"2.35"},{"groupId":"OG004","value":"1.74","lowerLimit":"-0.25","upperLimit":"3.72"},{"groupId":"OG005","value":"3.10","lowerLimit":"1.06","upperLimit":"5.14"}]}]},{"title":"Cycle 14 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"50"},{"groupId":"OG003","value":"46"},{"groupId":"OG004","value":"38"},{"groupId":"OG005","value":"29"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.91","lowerLimit":"-0.71","upperLimit":"4.53"},{"groupId":"OG001","value":"1.46","lowerLimit":"-0.85","upperLimit":"3.78"},{"groupId":"OG002","value":"2.27","lowerLimit":"0.36","upperLimit":"4.17"},{"groupId":"OG003","value":"0.94","lowerLimit":"-0.86","upperLimit":"2.73"},{"groupId":"OG004","value":"-4.43","lowerLimit":"-7.11","upperLimit":"-1.75"},{"groupId":"OG005","value":"2.67","lowerLimit":"0.09","upperLimit":"5.25"}]}]},{"title":"Cycle 16 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"50"},{"groupId":"OG003","value":"46"},{"groupId":"OG004","value":"38"},{"groupId":"OG005","value":"29"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4.52","lowerLimit":"1.58","upperLimit":"7.46"},{"groupId":"OG001","value":"0.87","lowerLimit":"-2.06","upperLimit":"3.79"},{"groupId":"OG002","value":"1.36","lowerLimit":"-1.11","upperLimit":"3.84"},{"groupId":"OG003","value":"1.04","lowerLimit":"-0.99","upperLimit":"3.07"},{"groupId":"OG004","value":"3.46","lowerLimit":"-1.26","upperLimit":"8.18"},{"groupId":"OG005","value":"1.97","lowerLimit":"-0.93","upperLimit":"4.87"}]}]},{"title":"Cycle 18 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"50"},{"groupId":"OG003","value":"46"},{"groupId":"OG004","value":"38"},{"groupId":"OG005","value":"29"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4.77","lowerLimit":"0.82","upperLimit":"8.73"},{"groupId":"OG001","value":"0.66","lowerLimit":"-2.50","upperLimit":"3.81"},{"groupId":"OG002","value":"-0.27","lowerLimit":"-2.89","upperLimit":"2.36"},{"groupId":"OG003","value":"-0.52","lowerLimit":"-2.77","upperLimit":"1.73"},{"groupId":"OG004","value":"-0.35","lowerLimit":"-6.90","upperLimit":"6.21"},{"groupId":"OG005","value":"3.13","lowerLimit":"0.00","upperLimit":"6.27"}]}]},{"title":"Cycle 20 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"50"},{"groupId":"OG003","value":"46"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"29"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-2.72","lowerLimit":"-7.47","upperLimit":"2.03"},{"groupId":"OG001","value":"-1.44","lowerLimit":"-4.91","upperLimit":"2.03"},{"groupId":"OG002","value":"0.56","lowerLimit":"-2.81","upperLimit":"3.92"},{"groupId":"OG003","value":"1.20","lowerLimit":"-1.84","upperLimit":"4.24"},{"groupId":"OG005","value":"0.56","lowerLimit":"-2.89","upperLimit":"4.01"}]}]},{"title":"Cycle 22 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"50"},{"groupId":"OG003","value":"46"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"29"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-5.72","lowerLimit":"-10.47","upperLimit":"-0.97"},{"groupId":"OG001","value":"-0.28","lowerLimit":"-4.22","upperLimit":"3.66"},{"groupId":"OG002","value":"2.17","lowerLimit":"-1.68","upperLimit":"6.01"},{"groupId":"OG003","value":"-0.36","lowerLimit":"-4.21","upperLimit":"3.48"},{"groupId":"OG005","value":"3.99","lowerLimit":"0.07","upperLimit":"7.91"}]}]},{"title":"Cycle 24 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"46"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-8.49","lowerLimit":"-15.06","upperLimit":"-1.92"},{"groupId":"OG003","value":"-3.35","lowerLimit":"-9.86","upperLimit":"3.16"}]}]},{"title":"End of treatment","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"50"},{"groupId":"OG003","value":"46"},{"groupId":"OG004","value":"38"},{"groupId":"OG005","value":"29"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.02","lowerLimit":"-2.99","upperLimit":"5.04"},{"groupId":"OG001","value":"-1.62","lowerLimit":"-5.95","upperLimit":"2.71"},{"groupId":"OG002","value":"0.80","lowerLimit":"-1.80","upperLimit":"3.40"},{"groupId":"OG003","value":"-0.27","lowerLimit":"-2.47","upperLimit":"1.92"},{"groupId":"OG004","value":"2.37","lowerLimit":"-0.54","upperLimit":"5.27"},{"groupId":"OG005","value":"-0.60","lowerLimit":"-4.09","upperLimit":"2.89"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Total Scores for International Shopping List Test-Delayed Recall (Cognitive Function Assessment) (Phase 2)","description":"This test was performed in the same way as the International Shopping List Test, with the exception that, the delayed recall condition required the participant to recall the words from the list 15 30 minutes later without having the list read again. During the recognition condition, the qualified personnel read a shopping list item that may or may not have been on the original list and the participant had to respond either affirmatively (if the item was on the original list) or negatively (if it was not). Total number of correct responses made in remembering the word list after a delay was recorded. Lower values of least square mean change from baseline indicate performance decline. Upper limit of 95% confidence interval of -0.00 or lower indicate statistically significant decline of performance over baseline at that cycle.","populationDescription":"PRO evaluable analysis set included all enrolled participants who received study treatment, had a baseline test assessment and at least 1 on-study test assessment. Here, 'Number Analyzed' signifies participants evaluable for specified row.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Units on a scale","timeFrame":"Baseline, Day 1 of Cycles 2-5, Day 1 of every other cycle from Cycle 6, and end of treatment (up to 3 years)","groups":[{"id":"OG000","title":"EXP-1 (Phase 2)","description":"Treatment-naÃ¯ve participants with advanced anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC) with or without asymptomatic central nervous system (CNS) metastases were given PF-06463922 100 mg orally QD on Day -7 (only participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG001","title":"EXP-2 (Phase 2)","description":"Participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after only crizotinib therapy were given PF-06463922 100 mg orally QD on Day -7 (only for participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG002","title":"EXP-3 (Phase 2)","description":"Participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after crizotinib therapy and 1 or 2 prior regimens of chemotherapy given before or after crizotinib therapy, or participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after 1 ALK inhibitor therapy other than crizotinib with or without any number of prior chemotherapy regimens in any disease setting were given PF-06463922 100 mg orally QD on Day -7 (only for participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG003","title":"EXP-4 (Phase 2)","description":"Participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after 2 prior lines of ALK inhibitor therapies were given PF-06463922 100 mg orally QD on Day -7 (only for participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG004","title":"EXP-5 (Phase 2)","description":"Participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after 3 prior lines of ALK inhibitor therapies were given PF-06463922 100 mg orally QD on Day -7 (only for participant scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG005","title":"EXP-6 (Phase 2)","description":"Participants with advanced ROS1-positive NSCLC who were treatment naÃ¯ve or had any number of prior cancer therapies with or without asymptomatic CNS metastases were given PF-06463922 100 mg orally QD on Day -7 (only for participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"50"},{"groupId":"OG003","value":"46"},{"groupId":"OG004","value":"38"},{"groupId":"OG005","value":"29"}]}],"classes":[{"title":"Cycle 2 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"50"},{"groupId":"OG003","value":"46"},{"groupId":"OG004","value":"38"},{"groupId":"OG005","value":"29"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.10","lowerLimit":"-0.85","upperLimit":"1.06"},{"groupId":"OG001","value":"-0.84","lowerLimit":"-1.76","upperLimit":"0.08"},{"groupId":"OG002","value":"-0.12","lowerLimit":"-0.77","upperLimit":"0.53"},{"groupId":"OG003","value":"-0.59","lowerLimit":"-1.28","upperLimit":"0.09"},{"groupId":"OG004","value":"-0.22","lowerLimit":"-0.96","upperLimit":"0.53"},{"groupId":"OG005","value":"-0.25","lowerLimit":"-1.11","upperLimit":"0.62"}]}]},{"title":"Cycle 3 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"50"},{"groupId":"OG003","value":"46"},{"groupId":"OG004","value":"38"},{"groupId":"OG005","value":"29"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.33","lowerLimit":"-1.28","upperLimit":"0.62"},{"groupId":"OG001","value":"-1.32","lowerLimit":"-2.24","upperLimit":"-0.40"},{"groupId":"OG002","value":"-0.14","lowerLimit":"-0.81","upperLimit":"0.52"},{"groupId":"OG003","value":"-0.77","lowerLimit":"-1.46","upperLimit":"-0.07"},{"groupId":"OG004","value":"-0.87","lowerLimit":"-1.64","upperLimit":"-0.10"},{"groupId":"OG005","value":"-0.30","lowerLimit":"-1.15","upperLimit":"0.56"}]}]},{"title":"Cycle 4 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"50"},{"groupId":"OG003","value":"46"},{"groupId":"OG004","value":"38"},{"groupId":"OG005","value":"29"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.44","lowerLimit":"-1.38","upperLimit":"0.50"},{"groupId":"OG001","value":"-0.91","lowerLimit":"-1.86","upperLimit":"0.03"},{"groupId":"OG002","value":"0.03","lowerLimit":"-0.66","upperLimit":"0.72"},{"groupId":"OG003","value":"-0.25","lowerLimit":"-0.97","upperLimit":"0.47"},{"groupId":"OG004","value":"-0.02","lowerLimit":"-0.82","upperLimit":"0.78"},{"groupId":"OG005","value":"-1.06","lowerLimit":"-1.95","upperLimit":"-0.18"}]}]},{"title":"Cycle 5 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"50"},{"groupId":"OG003","value":"46"},{"groupId":"OG004","value":"38"},{"groupId":"OG005","value":"29"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.35","lowerLimit":"-1.29","upperLimit":"0.59"},{"groupId":"OG001","value":"-0.57","lowerLimit":"-1.54","upperLimit":"0.40"},{"groupId":"OG002","value":"0.02","lowerLimit":"-0.69","upperLimit":"0.73"},{"groupId":"OG003","value":"-0.46","lowerLimit":"-1.20","upperLimit":"0.27"},{"groupId":"OG004","value":"0.09","lowerLimit":"-0.74","upperLimit":"0.92"},{"groupId":"OG005","value":"0.17","lowerLimit":"-0.72","upperLimit":"1.05"}]}]},{"title":"Cycle 6 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"50"},{"groupId":"OG003","value":"46"},{"groupId":"OG004","value":"38"},{"groupId":"OG005","value":"29"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.48","lowerLimit":"-0.46","upperLimit":"1.42"},{"groupId":"OG001","value":"-0.38","lowerLimit":"-1.35","upperLimit":"0.59"},{"groupId":"OG002","value":"0.12","lowerLimit":"-0.59","upperLimit":"0.84"},{"groupId":"OG003","value":"-0.22","lowerLimit":"-0.95","upperLimit":"0.52"},{"groupId":"OG004","value":"0.30","lowerLimit":"-0.55","upperLimit":"1.15"},{"groupId":"OG005","value":"-0.28","lowerLimit":"-1.21","upperLimit":"0.66"}]}]},{"title":"Cycle 8 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"50"},{"groupId":"OG003","value":"46"},{"groupId":"OG004","value":"38"},{"groupId":"OG005","value":"29"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.56","lowerLimit":"-0.38","upperLimit":"1.50"},{"groupId":"OG001","value":"-0.24","lowerLimit":"-1.23","upperLimit":"0.75"},{"groupId":"OG002","value":"0.02","lowerLimit":"-0.70","upperLimit":"0.74"},{"groupId":"OG003","value":"-0.49","lowerLimit":"-1.24","upperLimit":"0.25"},{"groupId":"OG004","value":"-1.08","lowerLimit":"-1.94","upperLimit":"-0.22"},{"groupId":"OG005","value":"-0.16","lowerLimit":"-1.10","upperLimit":"0.77"}]}]},{"title":"Cycle 10 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"50"},{"groupId":"OG003","value":"46"},{"groupId":"OG004","value":"38"},{"groupId":"OG005","value":"29"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.29","lowerLimit":"-0.74","upperLimit":"1.31"},{"groupId":"OG001","value":"0.80","lowerLimit":"-0.22","upperLimit":"1.82"},{"groupId":"OG002","value":"0.54","lowerLimit":"-0.20","upperLimit":"1.28"},{"groupId":"OG003","value":"0.23","lowerLimit":"-0.61","upperLimit":"1.08"},{"groupId":"OG004","value":"0.25","lowerLimit":"-0.67","upperLimit":"1.16"},{"groupId":"OG005","value":"-0.00","lowerLimit":"-1.02","upperLimit":"1.02"}]}]},{"title":"Cycle 12 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"50"},{"groupId":"OG003","value":"46"},{"groupId":"OG004","value":"38"},{"groupId":"OG005","value":"29"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.90","lowerLimit":"-0.15","upperLimit":"1.95"},{"groupId":"OG001","value":"0.13","lowerLimit":"-0.95","upperLimit":"1.21"},{"groupId":"OG002","value":"0.22","lowerLimit":"-0.63","upperLimit":"1.07"},{"groupId":"OG003","value":"0.19","lowerLimit":"-0.70","upperLimit":"1.07"},{"groupId":"OG004","value":"0.60","lowerLimit":"-0.43","upperLimit":"1.64"},{"groupId":"OG005","value":"0.42","lowerLimit":"-0.64","upperLimit":"1.49"}]}]},{"title":"Cycle 14 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"50"},{"groupId":"OG003","value":"46"},{"groupId":"OG004","value":"38"},{"groupId":"OG005","value":"29"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.38","lowerLimit":"-0.99","upperLimit":"1.75"},{"groupId":"OG001","value":"0.06","lowerLimit":"-1.15","upperLimit":"1.27"},{"groupId":"OG002","value":"1.06","lowerLimit":"0.06","upperLimit":"2.06"},{"groupId":"OG003","value":"0.11","lowerLimit":"-0.85","upperLimit":"1.07"},{"groupId":"OG004","value":"-1.80","lowerLimit":"-3.31","upperLimit":"-0.30"},{"groupId":"OG005","value":"0.35","lowerLimit":"-1.00","upperLimit":"1.71"}]}]},{"title":"Cycle 16 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"50"},{"groupId":"OG003","value":"46"},{"groupId":"OG004","value":"38"},{"groupId":"OG005","value":"29"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.89","lowerLimit":"-0.66","upperLimit":"2.43"},{"groupId":"OG001","value":"0.52","lowerLimit":"-1.02","upperLimit":"2.05"},{"groupId":"OG002","value":"0.68","lowerLimit":"-0.62","upperLimit":"1.98"},{"groupId":"OG003","value":"-0.12","lowerLimit":"-1.22","upperLimit":"0.98"},{"groupId":"OG004","value":"0.40","lowerLimit":"-2.09","upperLimit":"2.88"},{"groupId":"OG005","value":"-0.22","lowerLimit":"-1.75","upperLimit":"1.30"}]}]},{"title":"Cycle 18 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"50"},{"groupId":"OG003","value":"46"},{"groupId":"OG004","value":"38"},{"groupId":"OG005","value":"29"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.06","lowerLimit":"-1.02","upperLimit":"3.14"},{"groupId":"OG001","value":"0.68","lowerLimit":"-0.98","upperLimit":"2.34"},{"groupId":"OG002","value":"0.38","lowerLimit":"-1.00","upperLimit":"1.76"},{"groupId":"OG003","value":"-0.24","lowerLimit":"-1.54","upperLimit":"1.07"},{"groupId":"OG004","value":"-0.39","lowerLimit":"-3.85","upperLimit":"3.07"},{"groupId":"OG005","value":"-0.33","lowerLimit":"-1.97","upperLimit":"1.32"}]}]},{"title":"Cycle 20 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"50"},{"groupId":"OG003","value":"46"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"29"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.22","lowerLimit":"-3.73","upperLimit":"1.28"},{"groupId":"OG001","value":"0.16","lowerLimit":"-1.67","upperLimit":"1.98"},{"groupId":"OG002","value":"-0.24","lowerLimit":"-2.01","upperLimit":"1.53"},{"groupId":"OG003","value":"-0.18","lowerLimit":"-1.78","upperLimit":"1.43"},{"groupId":"OG005","value":"-0.70","lowerLimit":"-2.52","upperLimit":"1.11"}]}]},{"title":"Cycle 22 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"50"},{"groupId":"OG003","value":"46"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"29"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-3.22","lowerLimit":"-5.73","upperLimit":"-0.72"},{"groupId":"OG001","value":"0.68","lowerLimit":"-1.40","upperLimit":"2.76"},{"groupId":"OG002","value":"0.80","lowerLimit":"-1.23","upperLimit":"2.83"},{"groupId":"OG003","value":"-0.64","lowerLimit":"-2.67","upperLimit":"1.39"},{"groupId":"OG005","value":"0.37","lowerLimit":"-1.70","upperLimit":"2.43"}]}]},{"title":"Cycle 24 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"46"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-2.43","lowerLimit":"-5.89","upperLimit":"1.04"},{"groupId":"OG003","value":"-0.80","lowerLimit":"-4.25","upperLimit":"2.64"}]}]},{"title":"End of treatment","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"50"},{"groupId":"OG003","value":"46"},{"groupId":"OG004","value":"38"},{"groupId":"OG005","value":"29"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.87","lowerLimit":"-2.99","upperLimit":"1.24"},{"groupId":"OG001","value":"-2.31","lowerLimit":"-4.58","upperLimit":"-0.04"},{"groupId":"OG002","value":"0.52","lowerLimit":"-0.84","upperLimit":"1.89"},{"groupId":"OG003","value":"-0.85","lowerLimit":"-2.06","upperLimit":"0.35"},{"groupId":"OG004","value":"-0.19","lowerLimit":"-1.71","upperLimit":"1.34"},{"groupId":"OG005","value":"0.11","lowerLimit":"-1.72","upperLimit":"1.95"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Absolute Values and Change From Baseline in PR Interval Meeting Pre-defined Criteria (Phase 2 and DDI Substudy)","description":"PR Interval was determined by ECG measurement. PR interval had following categories: change from baseline\\>=25 percent, 40 to \\<60 milliseconds (msec), 60 to \\<80 msec and \\>=80 msec. Baseline was defined as the average of the triplicate measurements prior to the first dose of study drug.","populationDescription":"Safety analysis set: all enrolled participants who received at least 1 dose of PF-06463922. Here, \"Overall Number of Participants Analyzed\": participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"From first dose of study treatment to end of treatment maximum of 7.5 years for Phase 2 and up to a maximum of 6 years approx. for DDI sub study)","groups":[{"id":"OG000","title":"EXP-1 (Phase 2)","description":"Treatment-naÃ¯ve participants with advanced anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC) with or without asymptomatic central nervous system (CNS) metastases were given PF-06463922 100 mg orally QD on Day -7 (only participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG001","title":"EXP-2 (Phase 2)","description":"Participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after only crizotinib therapy were given PF-06463922 100 mg orally QD on Day -7 (only for participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG002","title":"EXP-3 (Phase 2)","description":"Participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after crizotinib therapy and 1 or 2 prior regimens of chemotherapy given before or after crizotinib therapy, or participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after 1 ALK inhibitor therapy other than crizotinib with or without any number of prior chemotherapy regimens in any disease setting were given PF-06463922 100 mg orally QD on Day -7 (only for participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG003","title":"EXP-4 (Phase 2)","description":"Participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after 2 prior lines of ALK inhibitor therapies were given PF-06463922 100 mg orally QD on Day -7 (only for participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG004","title":"EXP-5 (Phase 2)","description":"Participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after 3 prior lines of ALK inhibitor therapies were given PF-06463922 100 mg orally QD on Day -7 (only for participant scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG005","title":"EXP-6 (Phase 2)","description":"Participants with advanced ROS1-positive NSCLC who were treatment naÃ¯ve or had any number of prior cancer therapies with or without asymptomatic CNS metastases were given PF-06463922 100 mg orally QD on Day -7 (only for participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG006","title":"DDI Substudy","description":"Participants with advanced ALK positive or ROS1-positive NSCLC who were treatment naÃ¯ve or had any number of prior cancer therapies with or without asymptomatic CNS metastases were administered a single dose of a probe substrate alone on Day -2. Participants were given PF-06463922 100 mg orally QD starting on Cycle1 Day 1 and along with probe substrate on Day 15 Cycle 1."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"29"},{"groupId":"OG001","value":"27"},{"groupId":"OG002","value":"59"},{"groupId":"OG003","value":"64"},{"groupId":"OG004","value":"46"},{"groupId":"OG005","value":"47"},{"groupId":"OG006","value":"32"}]}],"classes":[{"title":"Change from baseline: >25%","categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"8"},{"groupId":"OG003","value":"9"},{"groupId":"OG004","value":"6"},{"groupId":"OG005","value":"10"},{"groupId":"OG006","value":"2"}]}]},{"title":"Absolute value: 40-<60 msec","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"7"},{"groupId":"OG006","value":"2"}]}]},{"title":"Absolute value: 60-<80 msec","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"0"}]}]},{"title":"Absolute value: >=80 msec","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"2"},{"groupId":"OG006","value":"0"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percentage of Participants With Overall and Intracranial Objective Response (Phase 2 and DDI Sub-study)","description":"Objective response (OR) refers to confirmed complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumor (RECIST) version 1.1. Intracranial OR refers to confirmed CR or PR considering only lesions within brain. CR was defined as the disappearance of all non-lymph node target lesions (where all target lesions are recorded with a length of 0 milliliter (mm) on Target Lesions eCRF). Any pathological lymph nodes (recorded as target lesion) must have reduction in short axis to \\<10 mm. PR was defined as a 30 percent (%) or more decrease in sum of lesion dimensions (SLD) of target lesions, taking as reference the baseline SLD. Results presented here were based on independent central review.","populationDescription":"ITT analysis set was used for overall response assessment and included all enrolled participants with documented ALK or ROS1 rearrangement who received at least 1 dose of PF-06463922; participants with central nervous system (CNS) metastases in the ITT analysis set were used for intracranial response assessment. Here, \"Number Analyzed\" signifies participants evaluable for specified rows.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"From first dose of study treatment to end of treatment maximum of 7.5 years for Phase 2 and up to a maximum of 6 years approx. for DDI sub study)","groups":[{"id":"OG000","title":"EXP-1 (Phase 2)","description":"Treatment-naÃ¯ve participants with advanced anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC) with or without asymptomatic central nervous system (CNS) metastases were given PF-06463922 100 mg orally QD on Day -7 (only participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG001","title":"EXP-2 (Phase 2)","description":"Participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after only crizotinib therapy were given PF-06463922 100 mg orally QD on Day -7 (only for participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG002","title":"EXP-3 (Phase 2)","description":"Participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after crizotinib therapy and 1 or 2 prior regimens of chemotherapy given before or after crizotinib therapy, or participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after 1 ALK inhibitor therapy other than crizotinib with or without any number of prior chemotherapy regimens in any disease setting were given PF-06463922 100 mg orally QD on Day -7 (only for participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG003","title":"EXP-4 (Phase 2)","description":"Participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after 2 prior lines of ALK inhibitor therapies were given PF-06463922 100 mg orally QD on Day -7 (only for participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG004","title":"EXP-5 (Phase 2)","description":"Participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after 3 prior lines of ALK inhibitor therapies were given PF-06463922 100 mg orally QD on Day -7 (only for participant scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG005","title":"Phase 2","description":"Participants with advanced ROS1-positive NSCLC who were treatment naÃ¯ve or had any number of prior cancer therapies with or without asymptomatic CNS metastases were given PF-06463922 100 mg orally QD on Day -7 (only for participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal."},{"id":"OG006","title":"DDI Sub-study","description":"Participants with advanced ALK positive or ROS1-positive NSCLC who were treatment naÃ¯ve or had any number of prior cancer therapies with or without asymptomatic CNS metastases were administered a single dose of a probe substrate alone on Day -2. Participants were given PF-06463922 100 mg orally QD starting on Cycle1 Day 1 and along with probe substrate on Day 15 Cycle 1."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"27"},{"groupId":"OG002","value":"60"},{"groupId":"OG003","value":"65"},{"groupId":"OG004","value":"46"},{"groupId":"OG005","value":"47"},{"groupId":"OG006","value":"32"}]}],"classes":[{"title":"Objective response","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"27"},{"groupId":"OG002","value":"60"},{"groupId":"OG003","value":"65"},{"groupId":"OG004","value":"46"},{"groupId":"OG005","value":"47"},{"groupId":"OG006","value":"32"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"90.0","lowerLimit":"73.5","upperLimit":"97.9"},{"groupId":"OG001","value":"77.8","lowerLimit":"57.7","upperLimit":"91.4"},{"groupId":"OG002","value":"56.7","lowerLimit":"43.2","upperLimit":"69.4"},{"groupId":"OG003","value":"40.0","lowerLimit":"28.0","upperLimit":"52.9"},{"groupId":"OG004","value":"37.0","lowerLimit":"23.2","upperLimit":"52.5"},{"groupId":"OG005","value":"38.3","lowerLimit":"24.5","upperLimit":"53.6"},{"groupId":"OG006","value":"40.6","lowerLimit":"23.7","upperLimit":"59.4"}]}]},{"title":"Intracranial objective response","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"17"},{"groupId":"OG002","value":"33"},{"groupId":"OG003","value":"45"},{"groupId":"OG004","value":"37"},{"groupId":"OG005","value":"25"},{"groupId":"OG006","value":"16"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"75.0","lowerLimit":"34.9","upperLimit":"96.8"},{"groupId":"OG001","value":"58.8","lowerLimit":"32.9","upperLimit":"81.6"},{"groupId":"OG002","value":"66.7","lowerLimit":"48.2","upperLimit":"82.0"},{"groupId":"OG003","value":"53.3","lowerLimit":"37.9","upperLimit":"68.3"},{"groupId":"OG004","value":"43.2","lowerLimit":"27.1","upperLimit":"60.5"},{"groupId":"OG005","value":"56.0","lowerLimit":"34.9","upperLimit":"75.6"},{"groupId":"OG006","value":"25.0","lowerLimit":"7.3","upperLimit":"52.4"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"From first dose of study treatment to end of treatment (maximum of 96.58 months of treatment exposure for Phase 1, maximum of 89.65 months of treatment exposure for Phase 2 and maximum of 68.69 months of treatment exposure for DDI participants)","description":"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another participant, or one participant may have experienced both a serious and non-serious event during the study.","eventGroups":[{"id":"EG000","title":"10 mg QD (Phase 1)","description":"PF-06463922 10 mg was orally given once daily (QD) on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal.","deathsNumAffected":3,"deathsNumAtRisk":3,"seriousNumAffected":3,"seriousNumAtRisk":3,"otherNumAffected":3,"otherNumAtRisk":3},{"id":"EG001","title":"25 mg QD (Phase 1)","description":"PF-06463922 25 mg was orally given QD in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal. Midazolam 2 mg was orally given QD on Day -7 and Cycle 1 Day 15.","deathsNumAffected":2,"deathsNumAtRisk":3,"seriousNumAffected":2,"seriousNumAtRisk":3,"otherNumAffected":3,"otherNumAtRisk":3},{"id":"EG002","title":"50 mg QD (Phase 1)","description":"PF-06463922 50 mg was orally given QD on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal.","deathsNumAffected":3,"deathsNumAtRisk":3,"seriousNumAffected":1,"seriousNumAtRisk":3,"otherNumAffected":3,"otherNumAtRisk":3},{"id":"EG003","title":"75 mg QD (Phase 1)","description":"PF-06463922 75 mg was orally given QD on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal.","deathsNumAffected":6,"deathsNumAtRisk":12,"seriousNumAffected":6,"seriousNumAtRisk":12,"otherNumAffected":12,"otherNumAtRisk":12},{"id":"EG004","title":"100 mg QD (Phase 1)","description":"PF-06463922 100 mg was orally given QD on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal.","deathsNumAffected":9,"deathsNumAtRisk":17,"seriousNumAffected":10,"seriousNumAtRisk":17,"otherNumAffected":17,"otherNumAtRisk":17},{"id":"EG005","title":"150 mg QD (Phase 1)","description":"PF-06463922 150 mg was orally given QD in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal. Midazolam 2 mg was orally given QD on Day -7 and Cycle 1 Day 15.","deathsNumAffected":3,"deathsNumAtRisk":3,"seriousNumAffected":3,"seriousNumAtRisk":3,"otherNumAffected":3,"otherNumAtRisk":3},{"id":"EG006","title":"200 mg QD (Phase 1)","description":"PF-06463922 200 mg was orally given QD on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal.","deathsNumAffected":2,"deathsNumAtRisk":3,"seriousNumAffected":2,"seriousNumAtRisk":3,"otherNumAffected":3,"otherNumAtRisk":3},{"id":"EG007","title":"35 mg BID (Phase 1)","description":"PF-06463922 35 mg was orally given twice daily (BID) on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal.","deathsNumAffected":3,"deathsNumAtRisk":3,"seriousNumAffected":2,"seriousNumAtRisk":3,"otherNumAffected":3,"otherNumAtRisk":3},{"id":"EG008","title":"75 mg BID (Phase 1)","description":"PF-06463922 75 mg was orally given BID on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal.","deathsNumAffected":2,"deathsNumAtRisk":3,"seriousNumAffected":2,"seriousNumAtRisk":3,"otherNumAffected":3,"otherNumAtRisk":3},{"id":"EG009","title":"100 mg BID (Phase 1)","description":"PF-06463922 100 mg was orally given BID on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal.","deathsNumAffected":2,"deathsNumAtRisk":4,"seriousNumAffected":2,"seriousNumAtRisk":4,"otherNumAffected":4,"otherNumAtRisk":4},{"id":"EG010","title":"Japan Lead-In Cohort (LIC)","description":"Few Japanese participants were given PF-06463922 100 mg orally once daily (QD) in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal to evaluate safety of PF-06463922 in Japanese participants, in order to support inclusion of Japanese participants in Phase 2.","deathsNumAffected":1,"deathsNumAtRisk":3,"seriousNumAffected":1,"seriousNumAtRisk":3,"otherNumAffected":3,"otherNumAtRisk":3},{"id":"EG011","title":"EXP-1 (Phase 2)","description":"Treatment-naÃ¯ve participants with advanced ALK-positive NSCLC with or without asymptomatic central nervous system (CNS) metastases were given PF-06463922 100 mg orally QD on Day -7 (only participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal.","deathsNumAffected":8,"deathsNumAtRisk":30,"seriousNumAffected":15,"seriousNumAtRisk":30,"otherNumAffected":30,"otherNumAtRisk":30},{"id":"EG012","title":"EXP-2 (Phase 2)","description":"Participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after only crizotinib therapy were given PF-06463922 100 mg orally QD on Day -7 (only for participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal.","deathsNumAffected":13,"deathsNumAtRisk":27,"seriousNumAffected":11,"seriousNumAtRisk":27,"otherNumAffected":27,"otherNumAtRisk":27},{"id":"EG013","title":"EXP-3 (Phase 2)","description":"Participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after crizotinib therapy and 1 or 2 prior regimens of chemotherapy given before or after crizotinib therapy, or participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after 1 ALK inhibitor therapy other than crizotinib with or without any number of prior chemotherapy regimens in any disease setting were given PF-06463922 100 mg orally QD on Day -7 (only for participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal.","deathsNumAffected":25,"deathsNumAtRisk":60,"seriousNumAffected":34,"seriousNumAtRisk":60,"otherNumAffected":59,"otherNumAtRisk":60},{"id":"EG014","title":"EXP-4 (Phase 2)","description":"Participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after 2 prior lines of ALK inhibitor therapies were given PF-06463922 100 mg orally once daily (QD) on Day -7 (only for participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal.","deathsNumAffected":46,"deathsNumAtRisk":65,"seriousNumAffected":31,"seriousNumAtRisk":65,"otherNumAffected":65,"otherNumAtRisk":65},{"id":"EG015","title":"EXP-5 (Phase 2)","description":"Participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after 3 prior lines of ALK inhibitor therapies were given PF-06463922 100 mg orally once daily (QD) on Day -7 (only for participant scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal.","deathsNumAffected":37,"deathsNumAtRisk":46,"seriousNumAffected":23,"seriousNumAtRisk":46,"otherNumAffected":45,"otherNumAtRisk":46},{"id":"EG016","title":"EXP-6 (Phase 2)","description":"Participants with advanced ROS1-positive NSCLC who were treatment naÃ¯ve or had any number of prior cancer therapies with or without asymptomatic CNS metastases were given PF-06463922 100 mg orally once daily (QD) on Day -7 (only for participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal.","deathsNumAffected":22,"deathsNumAtRisk":47,"seriousNumAffected":21,"seriousNumAtRisk":47,"otherNumAffected":47,"otherNumAtRisk":47},{"id":"EG017","title":"DDI Substudy","description":"Participants with advanced ALK positive or ROS1-positive NSCLC who were treatment naÃ¯ve or had any number of prior cancer therapies with or without asymptomatic CNS metastases were administered a single dose of a probe substrate alone on Day -2. Participants were given PF-06463922 100 mg orally QD starting on Cycle1 Day 1 and along with probe substrate on Day 15 Cycle 1.","deathsNumAffected":17,"deathsNumAtRisk":32,"seriousNumAffected":13,"seriousNumAtRisk":32,"otherNumAffected":32,"otherNumAtRisk":32}],"seriousEvents":[{"term":"Cardiac arrest","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":1,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":1,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Pericardial effusion","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":1,"numAtRisk":3},{"groupId":"EG007","numAffected":1,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":1,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":1,"numAtRisk":65},{"groupId":"EG015","numAffected":2,"numAtRisk":46},{"groupId":"EG016","numAffected":1,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Cataract","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":1,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Eye pain","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":1,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":1,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":1,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Ileus","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":1,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":6},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Intestinal perforation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":1,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Large intestinal obstruction","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":1,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Terminal ileitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":1,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":1,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Disease progression","organSystem":"General disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":3},{"groupId":"EG001","numAffected":1,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":1,"numAtRisk":12},{"groupId":"EG004","numAffected":4,"numAtRisk":17},{"groupId":"EG005","numAffected":1,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":1,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":2,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":7,"numAtRisk":60},{"groupId":"EG014","numAffected":8,"numAtRisk":65},{"groupId":"EG015","numAffected":6,"numAtRisk":46},{"groupId":"EG016","numAffected":6,"numAtRisk":47},{"groupId":"EG017","numAffected":5,"numAtRisk":32}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":1,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":4,"numAtRisk":30},{"groupId":"EG012","numAffected":2,"numAtRisk":27},{"groupId":"EG013","numAffected":1,"numAtRisk":60},{"groupId":"EG014","numAffected":1,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":1,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Biloma","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Bronchitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":1,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Cellulitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":1,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":2,"numAtRisk":30},{"groupId":"EG012","numAffected":1,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Influenza","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":1,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":1,"numAtRisk":27},{"groupId":"EG013","numAffected":1,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Lower respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":1,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":2,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":2,"numAtRisk":17},{"groupId":"EG005","numAffected":2,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":4,"numAtRisk":30},{"groupId":"EG012","numAffected":4,"numAtRisk":27},{"groupId":"EG013","numAffected":3,"numAtRisk":60},{"groupId":"EG014","numAffected":5,"numAtRisk":65},{"groupId":"EG015","numAffected":2,"numAtRisk":46},{"groupId":"EG016","numAffected":1,"numAtRisk":47},{"groupId":"EG017","numAffected":1,"numAtRisk":32}]},{"term":"Pneumonia aspiration","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":1,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Pyelonephritis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":1,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":1,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":2,"numAtRisk":30},{"groupId":"EG012","numAffected":1,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":1,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":1,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":1,"numAtRisk":30},{"groupId":"EG012","numAffected":1,"numAtRisk":27},{"groupId":"EG013","numAffected":1,"numAtRisk":60},{"groupId":"EG014","numAffected":1,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Fall","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":1,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":2},{"groupId":"EG011","numAffected":1,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":5,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":1,"numAtRisk":32}]},{"term":"Subdural haematoma","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":1,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Aspartate aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":1,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":1,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":1,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Lipase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":1,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":1,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Hypercalcaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":1,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Hyperuricaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":1,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":64},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Cerebrovascular accident","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":1,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":1,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":1,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":64},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Haemorrhage intracranial","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":1,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":1,"numAtRisk":65},{"groupId":"EG015","numAffected":1,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":1,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":1,"numAtRisk":65},{"groupId":"EG015","numAffected":1,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Neurological symptom","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":1,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Presyncope","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":1,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":1,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Seizure","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":1,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":1,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":1,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":1,"numAtRisk":27},{"groupId":"EG013","numAffected":1,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Confusional state","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":1,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":1,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":1,"numAtRisk":60},{"groupId":"EG014","numAffected":1,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":2,"numAtRisk":32}]},{"term":"Delirium","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":2,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Hallucination","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":1,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Mental status changes","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":17},{"groupId":"EG005","numAffected":1,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":2,"numAtRisk":65},{"groupId":"EG015","numAffected":1,"numAtRisk":46},{"groupId":"EG016","numAffected":1,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":1,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":1,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":2,"numAtRisk":30},{"groupId":"EG012","numAffected":1,"numAtRisk":27},{"groupId":"EG013","numAffected":1,"numAtRisk":60},{"groupId":"EG014","numAffected":4,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":1,"numAtRisk":32}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":1,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":1,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":1,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Hypoxia","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":1,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":1,"numAtRisk":60},{"groupId":"EG014","numAffected":1,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":1,"numAtRisk":32}]},{"term":"Pleural effusion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":1,"numAtRisk":27},{"groupId":"EG013","numAffected":1,"numAtRisk":60},{"groupId":"EG014","numAffected":1,"numAtRisk":65},{"groupId":"EG015","numAffected":1,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Pulmonary embolism","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":1,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":1,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":1,"numAtRisk":60},{"groupId":"EG014","numAffected":1,"numAtRisk":65},{"groupId":"EG015","numAffected":1,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Wheezing","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Dermatomyositis","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":1,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Embolism","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":1,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":1,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":1,"numAtRisk":60},{"groupId":"EG014","numAffected":1,"numAtRisk":65},{"groupId":"EG015","numAffected":1,"numAtRisk":46},{"groupId":"EG016","numAffected":2,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Embolism venous","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":1,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Atrial fibrillation","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":2,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Blepharitis","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":1,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":1,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Vertigo","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":1,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Acute myocardial infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":1,"numAtRisk":3},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Atrial flutter","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":1,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Atrioventricular block complete","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":1,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Coronary artery disease","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":1,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Myocardial infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":1,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Sinus node dysfunction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":1,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Supraventricular tachycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":1,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Abdominal pain upper","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":1,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Abdominal wall haematoma","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":1,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":2,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Dysphagia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":1,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Gastric volvulus","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":1,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Gastritis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":1,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Glossitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":1,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Intestinal obstruction","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":1,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":1,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Pancreatitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":1,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Small intestinal obstruction","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":1,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":1,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":1,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":2,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":1,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":1,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Gait disturbance","organSystem":"General disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":1,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"General physical health deterioration","organSystem":"General disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":1,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":1,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Generalised oedema","organSystem":"General disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":1,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Oedema peripheral","organSystem":"General disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":1,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":1,"numAtRisk":65},{"groupId":"EG015","numAffected":1,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Peripheral swelling","organSystem":"General disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":1,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Bile duct stenosis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":1,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Cholangitis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":1,"numAtRisk":32}]},{"term":"Cholecystocholangitis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":1,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Jaundice","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":1,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"COVID-19","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":1,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Diverticulitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":1,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Erysipelas","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":1,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Escherichia bacteraemia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":1,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":1,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Infectious pleural effusion","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":1,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Lung abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":1,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":2,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Septic shock","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":1,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Skin infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":1,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":1,"numAtRisk":60},{"groupId":"EG014","numAffected":1,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":1,"numAtRisk":32}]},{"term":"Urethritis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":1,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Vestibular neuronitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":1,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Viral upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":1,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Gastroenteritis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":1,"numAtRisk":32}]},{"term":"Ankle fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":1,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Femoral neck fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":1,"numAtRisk":60},{"groupId":"EG014","numAffected":1,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Hip fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":1,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Humerus fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":1,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Pelvic fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":1,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Post procedural haemorrhage","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":1,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Radiation necrosis","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":1,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":1,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Rib fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":1,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Road traffic accident","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":1,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Tendon rupture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":1,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Thoracic vertebral fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":1,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Toxicity to various agents","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":1,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Traumatic intracranial haemorrhage","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":1,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Alanine aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":1,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":1,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Blood cholesterol increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":1,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Blood creatine phosphokinase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":1,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Ejection fraction decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":1,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"SARS-CoV-2 test positive","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":1,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Dehydration","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":3},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":64},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":1,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Hypertriglyceridaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":1,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Hyponatraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":1,"numAtRisk":32}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":1,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":1,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Intervertebral disc protrusion","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":1,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Muscular weakness","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":1,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Musculoskeletal chest pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":1,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Spinal pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":1,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Acute leukaemia","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":1,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Acute myeloid leukaemia","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":1,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Breast cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":1,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Colon cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":1,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Neoplasm progression","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":1,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Pulmonary tumour thrombotic microangiopathy","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":1,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Aphasia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":1,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Brain oedema","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":1,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":1,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Brainstem compression","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":1,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Cerebral infarction","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":1,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Cognitive disorder","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":1,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":1,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Dysarthria","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":1,"numAtRisk":32}]},{"term":"Hemiparesis","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":1,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Ischaemic stroke","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":1,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Lacunar stroke","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":1,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Metabolic encephalopathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":1,"numAtRisk":32}]},{"term":"Nervous system disorder","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":1,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Partial seizures","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":1,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Peripheral sensory neuropathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":1,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Syncope","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":1,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Tremor","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":1,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Hydrocephalus","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":1,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":1,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Vagus nerve disorder","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":1,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Assisted suicide","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":1,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Impulse-control disorder","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":1,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Schizophreniform disorder","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":1,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Acute kidney injury","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":1,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Neurogenic bladder","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":1,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Renal cyst haemorrhage","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":1,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":4},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Renal failure","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":1,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Acute pulmonary oedema","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":1,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Acute respiratory failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":1,"numAtRisk":60},{"groupId":"EG014","numAffected":2,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Asphyxia","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":1,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Asthma","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":1,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Chronic obstructive pulmonary disease","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":1,"numAtRisk":27},{"groupId":"EG013","numAffected":1,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Dyspnoea exertional","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":1,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":1,"numAtRisk":32}]},{"term":"Epistaxis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":1,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Interstitial lung disease","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":1,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Lung disorder","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":1,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":2,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Pleuritic pain","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":1,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Pneumonitis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":2,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":1,"numAtRisk":47},{"groupId":"EG017","numAffected":1,"numAtRisk":32}]},{"term":"Pulmonary congestion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":1,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Pulmonary hypertension","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":1,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Respiratory distress","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":1,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Respiratory failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":1,"numAtRisk":27},{"groupId":"EG013","numAffected":1,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Aortic dissection","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":1,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Haemorrhage","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":1,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Deep vein thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":1,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Hypertensive crisis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":1,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Peripheral artery occlusion","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":1,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Superior vena cava syndrome","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":2,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":2,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Pleural effusion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":1,"numAtRisk":27},{"groupId":"EG013","numAffected":1,"numAtRisk":60},{"groupId":"EG014","numAffected":1,"numAtRisk":65},{"groupId":"EG015","numAffected":1,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]}],"otherEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":3,"numAtRisk":12},{"groupId":"EG004","numAffected":7,"numAtRisk":17},{"groupId":"EG005","numAffected":3,"numAtRisk":3},{"groupId":"EG006","numAffected":1,"numAtRisk":3},{"groupId":"EG007","numAffected":1,"numAtRisk":3},{"groupId":"EG008","numAffected":2,"numAtRisk":3},{"groupId":"EG009","numAffected":2,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":6,"numAtRisk":30},{"groupId":"EG012","numAffected":2,"numAtRisk":27},{"groupId":"EG013","numAffected":6,"numAtRisk":60},{"groupId":"EG014","numAffected":18,"numAtRisk":65},{"groupId":"EG015","numAffected":7,"numAtRisk":46},{"groupId":"EG016","numAffected":7,"numAtRisk":47},{"groupId":"EG017","numAffected":8,"numAtRisk":32}]},{"term":"Febrile neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":1,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Haemorrhagic diathesis","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Iron deficiency anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":1,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Leukocytosis","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":2,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":1,"numAtRisk":27},{"groupId":"EG013","numAffected":1,"numAtRisk":60},{"groupId":"EG014","numAffected":1,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":2,"numAtRisk":32}]},{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":3},{"groupId":"EG001","numAffected":1,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":1,"numAtRisk":12},{"groupId":"EG004","numAffected":2,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":1,"numAtRisk":30},{"groupId":"EG012","numAffected":1,"numAtRisk":27},{"groupId":"EG013","numAffected":1,"numAtRisk":60},{"groupId":"EG014","numAffected":2,"numAtRisk":65},{"groupId":"EG015","numAffected":1,"numAtRisk":46},{"groupId":"EG016","numAffected":5,"numAtRisk":47},{"groupId":"EG017","numAffected":1,"numAtRisk":32}]},{"term":"Thrombocytosis","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Angina pectoris","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Atrial fibrillation","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":1,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":1,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Sinus tachycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":1,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Tachycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":1,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":1,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":5,"numAtRisk":65},{"groupId":"EG015","numAffected":2,"numAtRisk":46},{"groupId":"EG016","numAffected":3,"numAtRisk":47},{"groupId":"EG017","numAffected":2,"numAtRisk":32}]},{"term":"Ventricular dysfunction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Deafness","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":1,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Ear discomfort","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":1,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Ear pain","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":1,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Hypoacusis","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":2,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Tinnitus","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":1,"numAtRisk":3},{"groupId":"EG003","numAffected":3,"numAtRisk":12},{"groupId":"EG004","numAffected":3,"numAtRisk":17},{"groupId":"EG005","numAffected":1,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":1,"numAtRisk":4},{"groupId":"EG010","numAffected":1,"numAtRisk":3},{"groupId":"EG011","numAffected":4,"numAtRisk":30},{"groupId":"EG012","numAffected":2,"numAtRisk":27},{"groupId":"EG013","numAffected":6,"numAtRisk":60},{"groupId":"EG014","numAffected":8,"numAtRisk":65},{"groupId":"EG015","numAffected":4,"numAtRisk":46},{"groupId":"EG016","numAffected":1,"numAtRisk":47},{"groupId":"EG017","numAffected":3,"numAtRisk":32}]},{"term":"Tympanic membrane perforation","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":1,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Vertigo","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":1,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":1,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":2,"numAtRisk":30},{"groupId":"EG012","numAffected":1,"numAtRisk":27},{"groupId":"EG013","numAffected":2,"numAtRisk":60},{"groupId":"EG014","numAffected":2,"numAtRisk":65},{"groupId":"EG015","numAffected":1,"numAtRisk":46},{"groupId":"EG016","numAffected":2,"numAtRisk":47},{"groupId":"EG017","numAffected":1,"numAtRisk":32}]},{"term":"Vertigo positional","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":1,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Cushingoid","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Hyperparathyroidism","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":1,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Hypothyroidism","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":1,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":2,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":1,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":1,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Asthenopia","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":1,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Astigmatism","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Conjunctival oedema","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Diplopia","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":1,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":1,"numAtRisk":60},{"groupId":"EG014","numAffected":4,"numAtRisk":65},{"groupId":"EG015","numAffected":1,"numAtRisk":46},{"groupId":"EG016","numAffected":1,"numAtRisk":47},{"groupId":"EG017","numAffected":1,"numAtRisk":32}]},{"term":"Dry eye","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":2,"numAtRisk":27},{"groupId":"EG013","numAffected":3,"numAtRisk":60},{"groupId":"EG014","numAffected":1,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":2,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Photophobia","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":1,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Photopsia","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":1,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":1,"numAtRisk":27},{"groupId":"EG013","numAffected":2,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":2,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Presbyopia","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Retinal detachment","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Retinal vein occlusion","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":1,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Vision blurred","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":1,"numAtRisk":12},{"groupId":"EG004","numAffected":2,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":1,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":4,"numAtRisk":30},{"groupId":"EG012","numAffected":2,"numAtRisk":27},{"groupId":"EG013","numAffected":1,"numAtRisk":60},{"groupId":"EG014","numAffected":3,"numAtRisk":65},{"groupId":"EG015","numAffected":4,"numAtRisk":46},{"groupId":"EG016","numAffected":2,"numAtRisk":47},{"groupId":"EG017","numAffected":1,"numAtRisk":32}]},{"term":"Visual acuity reduced","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":2,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":1,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Visual impairment","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":1,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":1,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":1,"numAtRisk":3},{"groupId":"EG006","numAffected":1,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":2,"numAtRisk":27},{"groupId":"EG013","numAffected":2,"numAtRisk":60},{"groupId":"EG014","numAffected":5,"numAtRisk":65},{"groupId":"EG015","numAffected":4,"numAtRisk":46},{"groupId":"EG016","numAffected":2,"numAtRisk":47},{"groupId":"EG017","numAffected":2,"numAtRisk":32}]},{"term":"Abdominal discomfort","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":1,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":1,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":2,"numAtRisk":60},{"groupId":"EG014","numAffected":1,"numAtRisk":65},{"groupId":"EG015","numAffected":1,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":2,"numAtRisk":32}]},{"term":"Abdominal distension","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":2,"numAtRisk":30},{"groupId":"EG012","numAffected":2,"numAtRisk":27},{"groupId":"EG013","numAffected":1,"numAtRisk":60},{"groupId":"EG014","numAffected":7,"numAtRisk":65},{"groupId":"EG015","numAffected":3,"numAtRisk":46},{"groupId":"EG016","numAffected":5,"numAtRisk":47},{"groupId":"EG017","numAffected":7,"numAtRisk":32}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":2,"numAtRisk":12},{"groupId":"EG004","numAffected":2,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":1,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":2,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":1,"numAtRisk":30},{"groupId":"EG012","numAffected":2,"numAtRisk":27},{"groupId":"EG013","numAffected":7,"numAtRisk":60},{"groupId":"EG014","numAffected":6,"numAtRisk":65},{"groupId":"EG015","numAffected":3,"numAtRisk":46},{"groupId":"EG016","numAffected":3,"numAtRisk":47},{"groupId":"EG017","numAffected":2,"numAtRisk":32}]},{"term":"Abdominal pain upper","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":1,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":1,"numAtRisk":3},{"groupId":"EG008","numAffected":1,"numAtRisk":3},{"groupId":"EG009","numAffected":2,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":3,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":4,"numAtRisk":60},{"groupId":"EG014","numAffected":5,"numAtRisk":65},{"groupId":"EG015","numAffected":2,"numAtRisk":46},{"groupId":"EG016","numAffected":1,"numAtRisk":47},{"groupId":"EG017","numAffected":3,"numAtRisk":32}]},{"term":"Ascites","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":1,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Colitis ulcerative","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":1,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":1,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":3,"numAtRisk":12},{"groupId":"EG004","numAffected":4,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":2,"numAtRisk":3},{"groupId":"EG007","numAffected":1,"numAtRisk":3},{"groupId":"EG008","numAffected":1,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":9,"numAtRisk":30},{"groupId":"EG012","numAffected":8,"numAtRisk":27},{"groupId":"EG013","numAffected":11,"numAtRisk":60},{"groupId":"EG014","numAffected":8,"numAtRisk":65},{"groupId":"EG015","numAffected":9,"numAtRisk":46},{"groupId":"EG016","numAffected":5,"numAtRisk":47},{"groupId":"EG017","numAffected":8,"numAtRisk":32}]},{"term":"Dental caries","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":1,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":1,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":1,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":1,"numAtRisk":32}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":1,"numAtRisk":3},{"groupId":"EG003","numAffected":3,"numAtRisk":12},{"groupId":"EG004","numAffected":4,"numAtRisk":17},{"groupId":"EG005","numAffected":1,"numAtRisk":3},{"groupId":"EG006","numAffected":2,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":3,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":11,"numAtRisk":30},{"groupId":"EG012","numAffected":6,"numAtRisk":27},{"groupId":"EG013","numAffected":12,"numAtRisk":60},{"groupId":"EG014","numAffected":22,"numAtRisk":65},{"groupId":"EG015","numAffected":9,"numAtRisk":46},{"groupId":"EG016","numAffected":9,"numAtRisk":47},{"groupId":"EG017","numAffected":5,"numAtRisk":32}]},{"term":"Diarrhoea haemorrhagic","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":1,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Dry mouth","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":2,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":5,"numAtRisk":60},{"groupId":"EG014","numAffected":2,"numAtRisk":65},{"groupId":"EG015","numAffected":2,"numAtRisk":46},{"groupId":"EG016","numAffected":1,"numAtRisk":47},{"groupId":"EG017","numAffected":5,"numAtRisk":32}]},{"term":"Dyspepsia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":1,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":2,"numAtRisk":30},{"groupId":"EG012","numAffected":2,"numAtRisk":27},{"groupId":"EG013","numAffected":2,"numAtRisk":60},{"groupId":"EG014","numAffected":6,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":1,"numAtRisk":47},{"groupId":"EG017","numAffected":1,"numAtRisk":32}]},{"term":"Dysphagia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":2,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":1,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":2,"numAtRisk":30},{"groupId":"EG012","numAffected":1,"numAtRisk":27},{"groupId":"EG013","numAffected":5,"numAtRisk":60},{"groupId":"EG014","numAffected":5,"numAtRisk":65},{"groupId":"EG015","numAffected":4,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":3,"numAtRisk":32}]},{"term":"Faeces discoloured","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":1,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Food poisoning","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":1,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Gastrointestinal disorder","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":1,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Gastrooesophageal reflux disease","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":1,"numAtRisk":12},{"groupId":"EG004","numAffected":3,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":1,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":3,"numAtRisk":30},{"groupId":"EG012","numAffected":1,"numAtRisk":27},{"groupId":"EG013","numAffected":7,"numAtRisk":60},{"groupId":"EG014","numAffected":2,"numAtRisk":65},{"groupId":"EG015","numAffected":3,"numAtRisk":46},{"groupId":"EG016","numAffected":4,"numAtRisk":47},{"groupId":"EG017","numAffected":2,"numAtRisk":32}]},{"term":"Intestinal obstruction","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":1,"numAtRisk":3},{"groupId":"EG001","numAffected":1,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":3,"numAtRisk":12},{"groupId":"EG004","numAffected":4,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":1,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":1,"numAtRisk":3},{"groupId":"EG009","numAffected":3,"numAtRisk":4},{"groupId":"EG010","numAffected":1,"numAtRisk":3},{"groupId":"EG011","numAffected":6,"numAtRisk":30},{"groupId":"EG012","numAffected":7,"numAtRisk":27},{"groupId":"EG013","numAffected":9,"numAtRisk":60},{"groupId":"EG014","numAffected":18,"numAtRisk":65},{"groupId":"EG015","numAffected":10,"numAtRisk":46},{"groupId":"EG016","numAffected":9,"numAtRisk":47},{"groupId":"EG017","numAffected":3,"numAtRisk":32}]},{"term":"Oesophagitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":1,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":1,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Pancreatic disorder","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Swollen tongue","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Terminal ileitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":1,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Tooth impacted","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":1,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":2,"numAtRisk":3},{"groupId":"EG002","numAffected":1,"numAtRisk":3},{"groupId":"EG003","numAffected":1,"numAtRisk":12},{"groupId":"EG004","numAffected":3,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":2,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":7,"numAtRisk":30},{"groupId":"EG012","numAffected":3,"numAtRisk":27},{"groupId":"EG013","numAffected":10,"numAtRisk":60},{"groupId":"EG014","numAffected":9,"numAtRisk":65},{"groupId":"EG015","numAffected":8,"numAtRisk":46},{"groupId":"EG016","numAffected":6,"numAtRisk":47},{"groupId":"EG017","numAffected":2,"numAtRisk":32}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":2,"numAtRisk":3},{"groupId":"EG003","numAffected":4,"numAtRisk":12},{"groupId":"EG004","numAffected":4,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":1,"numAtRisk":3},{"groupId":"EG007","numAffected":1,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":6,"numAtRisk":30},{"groupId":"EG012","numAffected":4,"numAtRisk":27},{"groupId":"EG013","numAffected":12,"numAtRisk":60},{"groupId":"EG014","numAffected":7,"numAtRisk":65},{"groupId":"EG015","numAffected":8,"numAtRisk":46},{"groupId":"EG016","numAffected":3,"numAtRisk":47},{"groupId":"EG017","numAffected":8,"numAtRisk":32}]},{"term":"Axillary pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":1,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Catheter site extravasation","organSystem":"General disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":1,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Chest discomfort","organSystem":"General disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":1,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":1,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":1,"numAtRisk":65},{"groupId":"EG015","numAffected":1,"numAtRisk":46},{"groupId":"EG016","numAffected":3,"numAtRisk":47},{"groupId":"EG017","numAffected":1,"numAtRisk":32}]},{"term":"Chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":1,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":1,"numAtRisk":30},{"groupId":"EG012","numAffected":5,"numAtRisk":27},{"groupId":"EG013","numAffected":7,"numAtRisk":60},{"groupId":"EG014","numAffected":7,"numAtRisk":65},{"groupId":"EG015","numAffected":6,"numAtRisk":46},{"groupId":"EG016","numAffected":4,"numAtRisk":47},{"groupId":"EG017","numAffected":2,"numAtRisk":32}]},{"term":"Chills","organSystem":"General disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":1,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Disease progression","organSystem":"General disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":1,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Face oedema","organSystem":"General disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":2,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":2,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":2,"numAtRisk":60},{"groupId":"EG014","numAffected":2,"numAtRisk":65},{"groupId":"EG015","numAffected":1,"numAtRisk":46},{"groupId":"EG016","numAffected":1,"numAtRisk":47},{"groupId":"EG017","numAffected":1,"numAtRisk":32}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":3},{"groupId":"EG001","numAffected":1,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":5,"numAtRisk":12},{"groupId":"EG004","numAffected":5,"numAtRisk":17},{"groupId":"EG005","numAffected":2,"numAtRisk":3},{"groupId":"EG006","numAffected":1,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":1,"numAtRisk":3},{"groupId":"EG009","numAffected":3,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":9,"numAtRisk":30},{"groupId":"EG012","numAffected":6,"numAtRisk":27},{"groupId":"EG013","numAffected":4,"numAtRisk":60},{"groupId":"EG014","numAffected":14,"numAtRisk":65},{"groupId":"EG015","numAffected":7,"numAtRisk":46},{"groupId":"EG016","numAffected":10,"numAtRisk":47},{"groupId":"EG017","numAffected":4,"numAtRisk":32}]},{"term":"Gait disturbance","organSystem":"General disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":3},{"groupId":"EG001","numAffected":1,"numAtRisk":3},{"groupId":"EG002","numAffected":1,"numAtRisk":3},{"groupId":"EG003","numAffected":1,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":1,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":1,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":6,"numAtRisk":65},{"groupId":"EG015","numAffected":5,"numAtRisk":46},{"groupId":"EG016","numAffected":2,"numAtRisk":47},{"groupId":"EG017","numAffected":1,"numAtRisk":32}]},{"term":"Generalised oedema","organSystem":"General disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":1,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":1,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Mucosal inflammation","organSystem":"General disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":1,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":3,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":1,"numAtRisk":60},{"groupId":"EG014","numAffected":4,"numAtRisk":65},{"groupId":"EG015","numAffected":1,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Non-cardiac chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":1,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Oedema","organSystem":"General disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":1,"numAtRisk":3},{"groupId":"EG002","numAffected":1,"numAtRisk":3},{"groupId":"EG003","numAffected":2,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":2,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":1,"numAtRisk":3},{"groupId":"EG009","numAffected":1,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":5,"numAtRisk":30},{"groupId":"EG012","numAffected":1,"numAtRisk":27},{"groupId":"EG013","numAffected":5,"numAtRisk":60},{"groupId":"EG014","numAffected":6,"numAtRisk":65},{"groupId":"EG015","numAffected":4,"numAtRisk":46},{"groupId":"EG016","numAffected":4,"numAtRisk":47},{"groupId":"EG017","numAffected":1,"numAtRisk":32}]},{"term":"Oedema peripheral","organSystem":"General disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":3},{"groupId":"EG001","numAffected":1,"numAtRisk":3},{"groupId":"EG002","numAffected":1,"numAtRisk":3},{"groupId":"EG003","numAffected":4,"numAtRisk":12},{"groupId":"EG004","numAffected":10,"numAtRisk":17},{"groupId":"EG005","numAffected":3,"numAtRisk":3},{"groupId":"EG006","numAffected":1,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":2,"numAtRisk":3},{"groupId":"EG009","numAffected":3,"numAtRisk":4},{"groupId":"EG010","numAffected":1,"numAtRisk":3},{"groupId":"EG011","numAffected":13,"numAtRisk":30},{"groupId":"EG012","numAffected":15,"numAtRisk":27},{"groupId":"EG013","numAffected":33,"numAtRisk":60},{"groupId":"EG014","numAffected":25,"numAtRisk":65},{"groupId":"EG015","numAffected":16,"numAtRisk":46},{"groupId":"EG016","numAffected":25,"numAtRisk":47},{"groupId":"EG017","numAffected":14,"numAtRisk":32}]},{"term":"Pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":1,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":1,"numAtRisk":30},{"groupId":"EG012","numAffected":1,"numAtRisk":27},{"groupId":"EG013","numAffected":1,"numAtRisk":60},{"groupId":"EG014","numAffected":6,"numAtRisk":65},{"groupId":"EG015","numAffected":2,"numAtRisk":46},{"groupId":"EG016","numAffected":3,"numAtRisk":47},{"groupId":"EG017","numAffected":2,"numAtRisk":32}]},{"term":"Performance status decreased","organSystem":"General disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Peripheral swelling","organSystem":"General disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":1,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":1,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":1,"numAtRisk":30},{"groupId":"EG012","numAffected":3,"numAtRisk":27},{"groupId":"EG013","numAffected":2,"numAtRisk":60},{"groupId":"EG014","numAffected":7,"numAtRisk":65},{"groupId":"EG015","numAffected":5,"numAtRisk":46},{"groupId":"EG016","numAffected":3,"numAtRisk":47},{"groupId":"EG017","numAffected":4,"numAtRisk":32}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":1,"numAtRisk":3},{"groupId":"EG003","numAffected":1,"numAtRisk":12},{"groupId":"EG004","numAffected":3,"numAtRisk":17},{"groupId":"EG005","numAffected":1,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":1,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":10,"numAtRisk":30},{"groupId":"EG012","numAffected":6,"numAtRisk":27},{"groupId":"EG013","numAffected":12,"numAtRisk":60},{"groupId":"EG014","numAffected":10,"numAtRisk":65},{"groupId":"EG015","numAffected":4,"numAtRisk":46},{"groupId":"EG016","numAffected":7,"numAtRisk":47},{"groupId":"EG017","numAffected":3,"numAtRisk":32}]},{"term":"Swelling","organSystem":"General disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":4,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":1,"numAtRisk":47},{"groupId":"EG017","numAffected":3,"numAtRisk":32}]},{"term":"Swelling face","organSystem":"General disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":1,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Hepatic cytolysis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":1,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Hypertransaminasaemia","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Hypersensitivity","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":17},{"groupId":"EG005","numAffected":1,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Seasonal allergy","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":1,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":1,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Bacterial infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Bronchitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":2,"numAtRisk":12},{"groupId":"EG004","numAffected":2,"numAtRisk":17},{"groupId":"EG005","numAffected":1,"numAtRisk":3},{"groupId":"EG006","numAffected":1,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":1,"numAtRisk":3},{"groupId":"EG009","numAffected":1,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":4,"numAtRisk":30},{"groupId":"EG012","numAffected":3,"numAtRisk":27},{"groupId":"EG013","numAffected":4,"numAtRisk":60},{"groupId":"EG014","numAffected":6,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":3,"numAtRisk":47},{"groupId":"EG017","numAffected":1,"numAtRisk":32}]},{"term":"Candida infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Cellulitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":1,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":1,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Chronic sinusitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":1,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Clostridium difficile colitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Cystitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":1,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Ear infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Enteritis infectious","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":1,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Enterococcal bacteraemia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":1,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Enterocolitis infectious","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Gastroenteritis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":1,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":1,"numAtRisk":3},{"groupId":"EG011","numAffected":2,"numAtRisk":30},{"groupId":"EG012","numAffected":1,"numAtRisk":27},{"groupId":"EG013","numAffected":1,"numAtRisk":60},{"groupId":"EG014","numAffected":1,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":3,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Helicobacter infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Herpes virus infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":1,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":1,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":2,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Influenza","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":1,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":2,"numAtRisk":30},{"groupId":"EG012","numAffected":2,"numAtRisk":27},{"groupId":"EG013","numAffected":3,"numAtRisk":60},{"groupId":"EG014","numAffected":7,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":3,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Laryngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":3,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":2,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":2,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Lower respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":1,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":1,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Nasopharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":1,"numAtRisk":4},{"groupId":"EG010","numAffected":2,"numAtRisk":3},{"groupId":"EG011","numAffected":2,"numAtRisk":30},{"groupId":"EG012","numAffected":5,"numAtRisk":27},{"groupId":"EG013","numAffected":5,"numAtRisk":60},{"groupId":"EG014","numAffected":4,"numAtRisk":65},{"groupId":"EG015","numAffected":2,"numAtRisk":46},{"groupId":"EG016","numAffected":6,"numAtRisk":47},{"groupId":"EG017","numAffected":1,"numAtRisk":32}]},{"term":"Oral candidiasis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":1,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":1,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":2,"numAtRisk":32}]},{"term":"Paronychia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":1,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":2,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":1,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Periodontitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Pharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":1,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":1,"numAtRisk":46},{"groupId":"EG016","numAffected":1,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":1,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":1,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":1,"numAtRisk":4},{"groupId":"EG010","numAffected":1,"numAtRisk":3},{"groupId":"EG011","numAffected":2,"numAtRisk":30},{"groupId":"EG012","numAffected":4,"numAtRisk":27},{"groupId":"EG013","numAffected":6,"numAtRisk":60},{"groupId":"EG014","numAffected":10,"numAtRisk":65},{"groupId":"EG015","numAffected":4,"numAtRisk":46},{"groupId":"EG016","numAffected":1,"numAtRisk":47},{"groupId":"EG017","numAffected":4,"numAtRisk":32}]},{"term":"Pyelonephritis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":1,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":1,"numAtRisk":12},{"groupId":"EG004","numAffected":3,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Rhinitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":1,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":1,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":1,"numAtRisk":30},{"groupId":"EG012","numAffected":2,"numAtRisk":27},{"groupId":"EG013","numAffected":6,"numAtRisk":60},{"groupId":"EG014","numAffected":4,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":3,"numAtRisk":47},{"groupId":"EG017","numAffected":1,"numAtRisk":32}]},{"term":"Sinusitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":1,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":3,"numAtRisk":60},{"groupId":"EG014","numAffected":1,"numAtRisk":65},{"groupId":"EG015","numAffected":2,"numAtRisk":46},{"groupId":"EG016","numAffected":5,"numAtRisk":47},{"groupId":"EG017","numAffected":1,"numAtRisk":32}]},{"term":"Soft tissue infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":1,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Tooth abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":1,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Tooth infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":1,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":1,"numAtRisk":3},{"groupId":"EG002","numAffected":1,"numAtRisk":3},{"groupId":"EG003","numAffected":3,"numAtRisk":12},{"groupId":"EG004","numAffected":4,"numAtRisk":17},{"groupId":"EG005","numAffected":1,"numAtRisk":3},{"groupId":"EG006","numAffected":2,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":11,"numAtRisk":30},{"groupId":"EG012","numAffected":6,"numAtRisk":27},{"groupId":"EG013","numAffected":6,"numAtRisk":60},{"groupId":"EG014","numAffected":9,"numAtRisk":65},{"groupId":"EG015","numAffected":3,"numAtRisk":46},{"groupId":"EG016","numAffected":3,"numAtRisk":47},{"groupId":"EG017","numAffected":2,"numAtRisk":32}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":1,"numAtRisk":12},{"groupId":"EG004","numAffected":4,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":2,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":1,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":3,"numAtRisk":30},{"groupId":"EG012","numAffected":3,"numAtRisk":27},{"groupId":"EG013","numAffected":6,"numAtRisk":60},{"groupId":"EG014","numAffected":4,"numAtRisk":65},{"groupId":"EG015","numAffected":3,"numAtRisk":46},{"groupId":"EG016","numAffected":1,"numAtRisk":47},{"groupId":"EG017","numAffected":4,"numAtRisk":32}]},{"term":"Viral infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":1,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":1,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Viral rhinitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":1,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Viral upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":2,"numAtRisk":27},{"groupId":"EG013","numAffected":2,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":1,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Contusion","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":1,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Fall","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":1,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":1,"numAtRisk":27},{"groupId":"EG013","numAffected":1,"numAtRisk":60},{"groupId":"EG014","numAffected":8,"numAtRisk":65},{"groupId":"EG015","numAffected":4,"numAtRisk":46},{"groupId":"EG016","numAffected":3,"numAtRisk":47},{"groupId":"EG017","numAffected":5,"numAtRisk":32}]},{"term":"Incision site pain","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":1,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Joint dislocation","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":1,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Ligament sprain","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Limb injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":1,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Road traffic accident","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":1,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Skin abrasion","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":1,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Skin laceration","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":1,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Toxicity to various agents","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Alanine aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":3,"numAtRisk":12},{"groupId":"EG004","numAffected":4,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":1,"numAtRisk":4},{"groupId":"EG010","numAffected":2,"numAtRisk":3},{"groupId":"EG011","numAffected":6,"numAtRisk":30},{"groupId":"EG012","numAffected":2,"numAtRisk":27},{"groupId":"EG013","numAffected":12,"numAtRisk":60},{"groupId":"EG014","numAffected":7,"numAtRisk":65},{"groupId":"EG015","numAffected":8,"numAtRisk":46},{"groupId":"EG016","numAffected":7,"numAtRisk":7},{"groupId":"EG017","numAffected":1,"numAtRisk":32}]},{"term":"Amino acid level increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":1,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Amylase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":1,"numAtRisk":12},{"groupId":"EG004","numAffected":5,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":1,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":1,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":5,"numAtRisk":30},{"groupId":"EG012","numAffected":2,"numAtRisk":27},{"groupId":"EG013","numAffected":7,"numAtRisk":60},{"groupId":"EG014","numAffected":8,"numAtRisk":65},{"groupId":"EG015","numAffected":5,"numAtRisk":46},{"groupId":"EG016","numAffected":10,"numAtRisk":47},{"groupId":"EG017","numAffected":3,"numAtRisk":32}]},{"term":"Aspartate aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":1,"numAtRisk":3},{"groupId":"EG002","numAffected":1,"numAtRisk":3},{"groupId":"EG003","numAffected":3,"numAtRisk":12},{"groupId":"EG004","numAffected":4,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":2,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":2,"numAtRisk":4},{"groupId":"EG010","numAffected":1,"numAtRisk":3},{"groupId":"EG011","numAffected":8,"numAtRisk":30},{"groupId":"EG012","numAffected":2,"numAtRisk":27},{"groupId":"EG013","numAffected":13,"numAtRisk":60},{"groupId":"EG014","numAffected":8,"numAtRisk":65},{"groupId":"EG015","numAffected":9,"numAtRisk":46},{"groupId":"EG016","numAffected":4,"numAtRisk":47},{"groupId":"EG017","numAffected":2,"numAtRisk":32}]},{"term":"Blood alkaline phosphatase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":3},{"groupId":"EG001","numAffected":1,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":1,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":1,"numAtRisk":30},{"groupId":"EG012","numAffected":2,"numAtRisk":27},{"groupId":"EG013","numAffected":3,"numAtRisk":60},{"groupId":"EG014","numAffected":2,"numAtRisk":65},{"groupId":"EG015","numAffected":3,"numAtRisk":46},{"groupId":"EG016","numAffected":1,"numAtRisk":47},{"groupId":"EG017","numAffected":1,"numAtRisk":32}]},{"term":"Blood cholesterol increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":6,"numAtRisk":12},{"groupId":"EG004","numAffected":4,"numAtRisk":17},{"groupId":"EG005","numAffected":1,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":1,"numAtRisk":4},{"groupId":"EG010","numAffected":3,"numAtRisk":3},{"groupId":"EG011","numAffected":11,"numAtRisk":30},{"groupId":"EG012","numAffected":13,"numAtRisk":27},{"groupId":"EG013","numAffected":19,"numAtRisk":60},{"groupId":"EG014","numAffected":19,"numAtRisk":65},{"groupId":"EG015","numAffected":16,"numAtRisk":46},{"groupId":"EG016","numAffected":19,"numAtRisk":47},{"groupId":"EG017","numAffected":17,"numAtRisk":32}]},{"term":"Blood creatine phosphokinase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":1,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":2,"numAtRisk":3},{"groupId":"EG011","numAffected":1,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":3,"numAtRisk":60},{"groupId":"EG014","numAffected":2,"numAtRisk":65},{"groupId":"EG015","numAffected":1,"numAtRisk":46},{"groupId":"EG016","numAffected":6,"numAtRisk":47},{"groupId":"EG017","numAffected":2,"numAtRisk":32}]},{"term":"Blood creatinine increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":1,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":17},{"groupId":"EG005","numAffected":2,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":1,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":3,"numAtRisk":60},{"groupId":"EG014","numAffected":2,"numAtRisk":65},{"groupId":"EG015","numAffected":1,"numAtRisk":46},{"groupId":"EG016","numAffected":6,"numAtRisk":47},{"groupId":"EG017","numAffected":1,"numAtRisk":32}]},{"term":"Blood glucose increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":1,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Blood phosphorus decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":1,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Blood triglycerides increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":1,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":2,"numAtRisk":12},{"groupId":"EG004","numAffected":4,"numAtRisk":17},{"groupId":"EG005","numAffected":1,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":1,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":2,"numAtRisk":30},{"groupId":"EG012","numAffected":2,"numAtRisk":27},{"groupId":"EG013","numAffected":3,"numAtRisk":60},{"groupId":"EG014","numAffected":4,"numAtRisk":65},{"groupId":"EG015","numAffected":3,"numAtRisk":46},{"groupId":"EG016","numAffected":3,"numAtRisk":47},{"groupId":"EG017","numAffected":4,"numAtRisk":32}]},{"term":"Candida test positive","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":1,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Ejection fraction decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":2,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":1,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":1,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":3,"numAtRisk":60},{"groupId":"EG014","numAffected":2,"numAtRisk":65},{"groupId":"EG015","numAffected":2,"numAtRisk":46},{"groupId":"EG016","numAffected":3,"numAtRisk":47},{"groupId":"EG017","numAffected":1,"numAtRisk":32}]},{"term":"Electrocardiogram QT prolonged","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":1,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":1,"numAtRisk":4},{"groupId":"EG010","numAffected":1,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":1,"numAtRisk":27},{"groupId":"EG013","numAffected":3,"numAtRisk":60},{"groupId":"EG014","numAffected":4,"numAtRisk":65},{"groupId":"EG015","numAffected":9,"numAtRisk":46},{"groupId":"EG016","numAffected":2,"numAtRisk":47},{"groupId":"EG017","numAffected":2,"numAtRisk":32}]},{"term":"Gamma-glutamyltransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":1,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":1,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":2,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Glucose urine present","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Haemoglobin decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"International normalised ratio increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Lipase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":3,"numAtRisk":12},{"groupId":"EG004","numAffected":5,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":1,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":1,"numAtRisk":4},{"groupId":"EG010","numAffected":1,"numAtRisk":3},{"groupId":"EG011","numAffected":4,"numAtRisk":30},{"groupId":"EG012","numAffected":4,"numAtRisk":27},{"groupId":"EG013","numAffected":5,"numAtRisk":60},{"groupId":"EG014","numAffected":10,"numAtRisk":65},{"groupId":"EG015","numAffected":7,"numAtRisk":46},{"groupId":"EG016","numAffected":9,"numAtRisk":47},{"groupId":"EG017","numAffected":2,"numAtRisk":32}]},{"term":"Liver function test increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Platelet count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":2,"numAtRisk":27},{"groupId":"EG013","numAffected":1,"numAtRisk":60},{"groupId":"EG014","numAffected":2,"numAtRisk":65},{"groupId":"EG015","numAffected":2,"numAtRisk":46},{"groupId":"EG016","numAffected":3,"numAtRisk":47},{"groupId":"EG017","numAffected":2,"numAtRisk":32}]},{"term":"SARS-CoV-2 test positive","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":1,"numAtRisk":30},{"groupId":"EG012","numAffected":2,"numAtRisk":27},{"groupId":"EG013","numAffected":1,"numAtRisk":60},{"groupId":"EG014","numAffected":1,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Transaminases increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":1,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Weight decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":1,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":2,"numAtRisk":30},{"groupId":"EG012","numAffected":1,"numAtRisk":27},{"groupId":"EG013","numAffected":1,"numAtRisk":60},{"groupId":"EG014","numAffected":1,"numAtRisk":65},{"groupId":"EG015","numAffected":2,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":1,"numAtRisk":32}]},{"term":"Weight increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":1,"numAtRisk":3},{"groupId":"EG002","numAffected":1,"numAtRisk":3},{"groupId":"EG003","numAffected":4,"numAtRisk":12},{"groupId":"EG004","numAffected":4,"numAtRisk":17},{"groupId":"EG005","numAffected":1,"numAtRisk":3},{"groupId":"EG006","numAffected":1,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":1,"numAtRisk":3},{"groupId":"EG009","numAffected":2,"numAtRisk":4},{"groupId":"EG010","numAffected":1,"numAtRisk":3},{"groupId":"EG011","numAffected":6,"numAtRisk":30},{"groupId":"EG012","numAffected":6,"numAtRisk":27},{"groupId":"EG013","numAffected":16,"numAtRisk":60},{"groupId":"EG014","numAffected":25,"numAtRisk":65},{"groupId":"EG015","numAffected":12,"numAtRisk":46},{"groupId":"EG016","numAffected":11,"numAtRisk":47},{"groupId":"EG017","numAffected":9,"numAtRisk":32}]},{"term":"Cell death","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":1,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":2,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":4,"numAtRisk":30},{"groupId":"EG012","numAffected":2,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":6,"numAtRisk":65},{"groupId":"EG015","numAffected":4,"numAtRisk":46},{"groupId":"EG016","numAffected":2,"numAtRisk":47},{"groupId":"EG017","numAffected":2,"numAtRisk":32}]},{"term":"Dehydration","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":1,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":1,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":1,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":1,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":1,"numAtRisk":47},{"groupId":"EG017","numAffected":1,"numAtRisk":32}]},{"term":"Fluid retention","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":2,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":1,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":2,"numAtRisk":60},{"groupId":"EG014","numAffected":4,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":1,"numAtRisk":47},{"groupId":"EG017","numAffected":2,"numAtRisk":32}]},{"term":"Hypercalcaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":1,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Hypercholesterolaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":3},{"groupId":"EG001","numAffected":2,"numAtRisk":3},{"groupId":"EG002","numAffected":1,"numAtRisk":3},{"groupId":"EG003","numAffected":7,"numAtRisk":12},{"groupId":"EG004","numAffected":12,"numAtRisk":17},{"groupId":"EG005","numAffected":2,"numAtRisk":3},{"groupId":"EG006","numAffected":3,"numAtRisk":3},{"groupId":"EG007","numAffected":1,"numAtRisk":3},{"groupId":"EG008","numAffected":1,"numAtRisk":3},{"groupId":"EG009","numAffected":1,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":16,"numAtRisk":30},{"groupId":"EG012","numAffected":14,"numAtRisk":27},{"groupId":"EG013","numAffected":33,"numAtRisk":60},{"groupId":"EG014","numAffected":38,"numAtRisk":65},{"groupId":"EG015","numAffected":27,"numAtRisk":46},{"groupId":"EG016","numAffected":25,"numAtRisk":47},{"groupId":"EG017","numAffected":15,"numAtRisk":32}]},{"term":"Hyperglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":1,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":4,"numAtRisk":30},{"groupId":"EG012","numAffected":4,"numAtRisk":27},{"groupId":"EG013","numAffected":5,"numAtRisk":60},{"groupId":"EG014","numAffected":2,"numAtRisk":65},{"groupId":"EG015","numAffected":6,"numAtRisk":46},{"groupId":"EG016","numAffected":5,"numAtRisk":47},{"groupId":"EG017","numAffected":3,"numAtRisk":32}]},{"term":"Hyperkalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":2,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":2,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":3,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Hyperlipidaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":2,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":1,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":3,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Hypertriglyceridaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":1,"numAtRisk":3},{"groupId":"EG002","numAffected":1,"numAtRisk":3},{"groupId":"EG003","numAffected":5,"numAtRisk":12},{"groupId":"EG004","numAffected":7,"numAtRisk":17},{"groupId":"EG005","numAffected":1,"numAtRisk":3},{"groupId":"EG006","numAffected":2,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":1,"numAtRisk":3},{"groupId":"EG009","numAffected":1,"numAtRisk":4},{"groupId":"EG010","numAffected":3,"numAtRisk":3},{"groupId":"EG011","numAffected":23,"numAtRisk":30},{"groupId":"EG012","numAffected":16,"numAtRisk":27},{"groupId":"EG013","numAffected":37,"numAtRisk":60},{"groupId":"EG014","numAffected":45,"numAtRisk":65},{"groupId":"EG015","numAffected":32,"numAtRisk":46},{"groupId":"EG016","numAffected":25,"numAtRisk":47},{"groupId":"EG017","numAffected":23,"numAtRisk":32}]},{"term":"Hyperuricaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":1,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":1,"numAtRisk":3},{"groupId":"EG009","numAffected":1,"numAtRisk":4},{"groupId":"EG010","numAffected":1,"numAtRisk":3},{"groupId":"EG011","numAffected":3,"numAtRisk":30},{"groupId":"EG012","numAffected":1,"numAtRisk":27},{"groupId":"EG013","numAffected":4,"numAtRisk":60},{"groupId":"EG014","numAffected":3,"numAtRisk":65},{"groupId":"EG015","numAffected":4,"numAtRisk":46},{"groupId":"EG016","numAffected":4,"numAtRisk":47},{"groupId":"EG017","numAffected":1,"numAtRisk":32}]},{"term":"Hypocalcaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":1,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Hypokalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":1,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":17},{"groupId":"EG005","numAffected":2,"numAtRisk":3},{"groupId":"EG006","numAffected":1,"numAtRisk":3},{"groupId":"EG007","numAffected":1,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":4,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":4,"numAtRisk":60},{"groupId":"EG014","numAffected":4,"numAtRisk":65},{"groupId":"EG015","numAffected":2,"numAtRisk":46},{"groupId":"EG016","numAffected":4,"numAtRisk":47},{"groupId":"EG017","numAffected":3,"numAtRisk":32}]},{"term":"Hypomagnesaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":1,"numAtRisk":3},{"groupId":"EG002","numAffected":1,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":3,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":1,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":2,"numAtRisk":30},{"groupId":"EG012","numAffected":1,"numAtRisk":27},{"groupId":"EG013","numAffected":3,"numAtRisk":60},{"groupId":"EG014","numAffected":2,"numAtRisk":65},{"groupId":"EG015","numAffected":5,"numAtRisk":46},{"groupId":"EG016","numAffected":4,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Hypophosphataemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":3},{"groupId":"EG001","numAffected":2,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":1,"numAtRisk":3},{"groupId":"EG006","numAffected":1,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":2,"numAtRisk":30},{"groupId":"EG012","numAffected":3,"numAtRisk":27},{"groupId":"EG013","numAffected":4,"numAtRisk":60},{"groupId":"EG014","numAffected":1,"numAtRisk":65},{"groupId":"EG015","numAffected":3,"numAtRisk":46},{"groupId":"EG016","numAffected":6,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":3},{"groupId":"EG001","numAffected":1,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":3,"numAtRisk":12},{"groupId":"EG004","numAffected":6,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":1,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":1,"numAtRisk":3},{"groupId":"EG009","numAffected":1,"numAtRisk":4},{"groupId":"EG010","numAffected":1,"numAtRisk":3},{"groupId":"EG011","numAffected":10,"numAtRisk":30},{"groupId":"EG012","numAffected":7,"numAtRisk":27},{"groupId":"EG013","numAffected":16,"numAtRisk":60},{"groupId":"EG014","numAffected":18,"numAtRisk":65},{"groupId":"EG015","numAffected":15,"numAtRisk":46},{"groupId":"EG016","numAffected":18,"numAtRisk":47},{"groupId":"EG017","numAffected":6,"numAtRisk":32}]},{"term":"Arthritis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":1,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":1,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":1,"numAtRisk":30},{"groupId":"EG012","numAffected":2,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":2,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":2,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":1,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":2,"numAtRisk":12},{"groupId":"EG004","numAffected":6,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":2,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":1,"numAtRisk":3},{"groupId":"EG009","numAffected":2,"numAtRisk":4},{"groupId":"EG010","numAffected":1,"numAtRisk":3},{"groupId":"EG011","numAffected":7,"numAtRisk":30},{"groupId":"EG012","numAffected":6,"numAtRisk":27},{"groupId":"EG013","numAffected":8,"numAtRisk":60},{"groupId":"EG014","numAffected":15,"numAtRisk":65},{"groupId":"EG015","numAffected":5,"numAtRisk":46},{"groupId":"EG016","numAffected":4,"numAtRisk":47},{"groupId":"EG017","numAffected":6,"numAtRisk":32}]},{"term":"Bone lesion","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Bone pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":1,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":1,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":3,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":3,"numAtRisk":46},{"groupId":"EG016","numAffected":1,"numAtRisk":47},{"groupId":"EG017","numAffected":4,"numAtRisk":32}]},{"term":"Flank pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":3,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":1,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":3,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":3,"numAtRisk":46},{"groupId":"EG016","numAffected":1,"numAtRisk":47},{"groupId":"EG017","numAffected":4,"numAtRisk":32}]},{"term":"Joint lock","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":1,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Joint swelling","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":1,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":2,"numAtRisk":65},{"groupId":"EG015","numAffected":1,"numAtRisk":46},{"groupId":"EG016","numAffected":3,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Limb discomfort","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":1,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Muscle spasms","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":1,"numAtRisk":3},{"groupId":"EG009","numAffected":1,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":1,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":4,"numAtRisk":60},{"groupId":"EG014","numAffected":3,"numAtRisk":65},{"groupId":"EG015","numAffected":6,"numAtRisk":46},{"groupId":"EG016","numAffected":5,"numAtRisk":47},{"groupId":"EG017","numAffected":1,"numAtRisk":32}]},{"term":"Muscular weakness","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":3},{"groupId":"EG001","numAffected":1,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":1,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":2,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":6,"numAtRisk":60},{"groupId":"EG014","numAffected":4,"numAtRisk":65},{"groupId":"EG015","numAffected":3,"numAtRisk":46},{"groupId":"EG016","numAffected":3,"numAtRisk":47},{"groupId":"EG017","numAffected":2,"numAtRisk":32}]},{"term":"Musculoskeletal chest pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":2,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":2,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":4,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":1,"numAtRisk":46},{"groupId":"EG016","numAffected":4,"numAtRisk":47},{"groupId":"EG017","numAffected":2,"numAtRisk":32}]},{"term":"Musculoskeletal discomfort","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Musculoskeletal pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":1,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":4,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":2,"numAtRisk":30},{"groupId":"EG012","numAffected":2,"numAtRisk":27},{"groupId":"EG013","numAffected":2,"numAtRisk":60},{"groupId":"EG014","numAffected":1,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":2,"numAtRisk":32}]},{"term":"Musculoskeletal stiffness","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":1,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":1,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":4,"numAtRisk":65},{"groupId":"EG015","numAffected":1,"numAtRisk":46},{"groupId":"EG016","numAffected":4,"numAtRisk":47},{"groupId":"EG017","numAffected":1,"numAtRisk":32}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":2,"numAtRisk":12},{"groupId":"EG004","numAffected":2,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":1,"numAtRisk":3},{"groupId":"EG009","numAffected":1,"numAtRisk":4},{"groupId":"EG010","numAffected":2,"numAtRisk":3},{"groupId":"EG011","numAffected":5,"numAtRisk":30},{"groupId":"EG012","numAffected":4,"numAtRisk":27},{"groupId":"EG013","numAffected":7,"numAtRisk":60},{"groupId":"EG014","numAffected":9,"numAtRisk":65},{"groupId":"EG015","numAffected":6,"numAtRisk":46},{"groupId":"EG016","numAffected":7,"numAtRisk":47},{"groupId":"EG017","numAffected":5,"numAtRisk":32}]},{"term":"Neck pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":1,"numAtRisk":12},{"groupId":"EG004","numAffected":3,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":3,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":1,"numAtRisk":60},{"groupId":"EG014","numAffected":3,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":1,"numAtRisk":47},{"groupId":"EG017","numAffected":3,"numAtRisk":32}]},{"term":"Osteoarthritis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":1,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":2,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":2,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Osteonecrosis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Osteoporosis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":1,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Pain in extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":2,"numAtRisk":12},{"groupId":"EG004","numAffected":2,"numAtRisk":17},{"groupId":"EG005","numAffected":1,"numAtRisk":3},{"groupId":"EG006","numAffected":1,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":1,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":6,"numAtRisk":30},{"groupId":"EG012","numAffected":10,"numAtRisk":27},{"groupId":"EG013","numAffected":11,"numAtRisk":60},{"groupId":"EG014","numAffected":7,"numAtRisk":65},{"groupId":"EG015","numAffected":8,"numAtRisk":46},{"groupId":"EG016","numAffected":8,"numAtRisk":47},{"groupId":"EG017","numAffected":5,"numAtRisk":32}]},{"term":"Pain in jaw","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":2,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Plantar fasciitis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":2,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Sacral pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":1,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Synovial cyst","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Torticollis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":1,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Trismus","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Melanocytic naevus","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Tumour pain","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":1,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":1,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":1,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Amnesia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":1,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":1,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":2,"numAtRisk":30},{"groupId":"EG012","numAffected":2,"numAtRisk":27},{"groupId":"EG013","numAffected":7,"numAtRisk":60},{"groupId":"EG014","numAffected":8,"numAtRisk":65},{"groupId":"EG015","numAffected":2,"numAtRisk":46},{"groupId":"EG016","numAffected":3,"numAtRisk":47},{"groupId":"EG017","numAffected":1,"numAtRisk":32}]},{"term":"Aphasia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":1,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":1,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":2,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":3,"numAtRisk":65},{"groupId":"EG015","numAffected":2,"numAtRisk":46},{"groupId":"EG016","numAffected":2,"numAtRisk":47},{"groupId":"EG017","numAffected":2,"numAtRisk":32}]},{"term":"Ataxia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":1,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Balance disorder","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":1,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":1,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":3,"numAtRisk":60},{"groupId":"EG014","numAffected":2,"numAtRisk":65},{"groupId":"EG015","numAffected":2,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":2,"numAtRisk":32}]},{"term":"Brachial plexopathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":1,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Bradykinesia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":1,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Carpal tunnel syndrome","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":1,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":1,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":1,"numAtRisk":30},{"groupId":"EG012","numAffected":1,"numAtRisk":27},{"groupId":"EG013","numAffected":4,"numAtRisk":60},{"groupId":"EG014","numAffected":1,"numAtRisk":65},{"groupId":"EG015","numAffected":1,"numAtRisk":46},{"groupId":"EG016","numAffected":2,"numAtRisk":47},{"groupId":"EG017","numAffected":1,"numAtRisk":32}]},{"term":"Cognitive disorder","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":3},{"groupId":"EG001","numAffected":1,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":2,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":17},{"groupId":"EG005","numAffected":2,"numAtRisk":3},{"groupId":"EG006","numAffected":1,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":1,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":1,"numAtRisk":30},{"groupId":"EG012","numAffected":3,"numAtRisk":27},{"groupId":"EG013","numAffected":6,"numAtRisk":60},{"groupId":"EG014","numAffected":6,"numAtRisk":65},{"groupId":"EG015","numAffected":3,"numAtRisk":46},{"groupId":"EG016","numAffected":4,"numAtRisk":47},{"groupId":"EG017","numAffected":1,"numAtRisk":32}]},{"term":"Disturbance in attention","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":1,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":1,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":1,"numAtRisk":27},{"groupId":"EG013","numAffected":1,"numAtRisk":60},{"groupId":"EG014","numAffected":4,"numAtRisk":65},{"groupId":"EG015","numAffected":3,"numAtRisk":46},{"groupId":"EG016","numAffected":4,"numAtRisk":47},{"groupId":"EG017","numAffected":3,"numAtRisk":32}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":3},{"groupId":"EG001","numAffected":1,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":1,"numAtRisk":12},{"groupId":"EG004","numAffected":2,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":1,"numAtRisk":3},{"groupId":"EG009","numAffected":2,"numAtRisk":4},{"groupId":"EG010","numAffected":1,"numAtRisk":3},{"groupId":"EG011","numAffected":8,"numAtRisk":30},{"groupId":"EG012","numAffected":4,"numAtRisk":27},{"groupId":"EG013","numAffected":6,"numAtRisk":60},{"groupId":"EG014","numAffected":12,"numAtRisk":65},{"groupId":"EG015","numAffected":8,"numAtRisk":46},{"groupId":"EG016","numAffected":13,"numAtRisk":47},{"groupId":"EG017","numAffected":6,"numAtRisk":32}]},{"term":"Dysaesthesia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Dysarthria","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":1,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":1,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":1,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":1,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":1,"numAtRisk":3},{"groupId":"EG011","numAffected":1,"numAtRisk":30},{"groupId":"EG012","numAffected":1,"numAtRisk":27},{"groupId":"EG013","numAffected":3,"numAtRisk":60},{"groupId":"EG014","numAffected":4,"numAtRisk":65},{"groupId":"EG015","numAffected":2,"numAtRisk":46},{"groupId":"EG016","numAffected":2,"numAtRisk":47},{"groupId":"EG017","numAffected":1,"numAtRisk":32}]},{"term":"Dysgeusia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":2,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":1,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":3,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":5,"numAtRisk":65},{"groupId":"EG015","numAffected":2,"numAtRisk":46},{"groupId":"EG016","numAffected":1,"numAtRisk":47},{"groupId":"EG017","numAffected":3,"numAtRisk":32}]},{"term":"Facial paralysis","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":1,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Formication","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":1,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":4,"numAtRisk":12},{"groupId":"EG004","numAffected":2,"numAtRisk":17},{"groupId":"EG005","numAffected":1,"numAtRisk":3},{"groupId":"EG006","numAffected":1,"numAtRisk":3},{"groupId":"EG007","numAffected":1,"numAtRisk":3},{"groupId":"EG008","numAffected":1,"numAtRisk":3},{"groupId":"EG009","numAffected":2,"numAtRisk":4},{"groupId":"EG010","numAffected":1,"numAtRisk":3},{"groupId":"EG011","numAffected":6,"numAtRisk":30},{"groupId":"EG012","numAffected":8,"numAtRisk":27},{"groupId":"EG013","numAffected":14,"numAtRisk":60},{"groupId":"EG014","numAffected":12,"numAtRisk":65},{"groupId":"EG015","numAffected":13,"numAtRisk":46},{"groupId":"EG016","numAffected":4,"numAtRisk":47},{"groupId":"EG017","numAffected":4,"numAtRisk":32}]},{"term":"Hemiparesis","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":1,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":1,"numAtRisk":46},{"groupId":"EG016","numAffected":1,"numAtRisk":47},{"groupId":"EG017","numAffected":2,"numAtRisk":32}]},{"term":"Hyperaesthesia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":1,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Hypoaesthesia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":1,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":3,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":1,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":2,"numAtRisk":30},{"groupId":"EG012","numAffected":1,"numAtRisk":27},{"groupId":"EG013","numAffected":2,"numAtRisk":60},{"groupId":"EG014","numAffected":1,"numAtRisk":65},{"groupId":"EG015","numAffected":2,"numAtRisk":46},{"groupId":"EG016","numAffected":2,"numAtRisk":47},{"groupId":"EG017","numAffected":1,"numAtRisk":32}]},{"term":"Memory impairment","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":1,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":2,"numAtRisk":12},{"groupId":"EG004","numAffected":3,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":1,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":2,"numAtRisk":30},{"groupId":"EG012","numAffected":4,"numAtRisk":27},{"groupId":"EG013","numAffected":6,"numAtRisk":60},{"groupId":"EG014","numAffected":12,"numAtRisk":65},{"groupId":"EG015","numAffected":3,"numAtRisk":46},{"groupId":"EG016","numAffected":9,"numAtRisk":47},{"groupId":"EG017","numAffected":3,"numAtRisk":32}]},{"term":"Mental impairment","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":1,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Migraine","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":1,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Motor dysfunction","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Nervous system disorder","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Neuralgia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":1,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":1,"numAtRisk":60},{"groupId":"EG014","numAffected":1,"numAtRisk":65},{"groupId":"EG015","numAffected":2,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":2,"numAtRisk":32}]},{"term":"Neuropathy peripheral","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":1,"numAtRisk":3},{"groupId":"EG003","numAffected":4,"numAtRisk":12},{"groupId":"EG004","numAffected":3,"numAtRisk":17},{"groupId":"EG005","numAffected":1,"numAtRisk":3},{"groupId":"EG006","numAffected":2,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":2,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":7,"numAtRisk":30},{"groupId":"EG012","numAffected":5,"numAtRisk":27},{"groupId":"EG013","numAffected":8,"numAtRisk":60},{"groupId":"EG014","numAffected":11,"numAtRisk":65},{"groupId":"EG015","numAffected":6,"numAtRisk":46},{"groupId":"EG016","numAffected":5,"numAtRisk":47},{"groupId":"EG017","numAffected":3,"numAtRisk":32}]},{"term":"Neurotoxicity","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Paraesthesia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":2,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":1,"numAtRisk":12},{"groupId":"EG004","numAffected":4,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":1,"numAtRisk":3},{"groupId":"EG007","numAffected":2,"numAtRisk":3},{"groupId":"EG008","numAffected":1,"numAtRisk":3},{"groupId":"EG009","numAffected":2,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":5,"numAtRisk":30},{"groupId":"EG012","numAffected":4,"numAtRisk":27},{"groupId":"EG013","numAffected":13,"numAtRisk":60},{"groupId":"EG014","numAffected":8,"numAtRisk":65},{"groupId":"EG015","numAffected":7,"numAtRisk":46},{"groupId":"EG016","numAffected":7,"numAtRisk":47},{"groupId":"EG017","numAffected":8,"numAtRisk":32}]},{"term":"Partial seizures","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":1,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Peripheral sensory neuropathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":1,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":2,"numAtRisk":3},{"groupId":"EG011","numAffected":3,"numAtRisk":30},{"groupId":"EG012","numAffected":3,"numAtRisk":27},{"groupId":"EG013","numAffected":7,"numAtRisk":60},{"groupId":"EG014","numAffected":4,"numAtRisk":65},{"groupId":"EG015","numAffected":5,"numAtRisk":46},{"groupId":"EG016","numAffected":3,"numAtRisk":47},{"groupId":"EG017","numAffected":1,"numAtRisk":32}]},{"term":"Peroneal nerve palsy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Presyncope","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":1,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":1,"numAtRisk":27},{"groupId":"EG013","numAffected":1,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":4,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Psychomotor hyperactivity","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Sciatica","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":1,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":2,"numAtRisk":30},{"groupId":"EG012","numAffected":1,"numAtRisk":27},{"groupId":"EG013","numAffected":1,"numAtRisk":60},{"groupId":"EG014","numAffected":1,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":1,"numAtRisk":32}]},{"term":"Seizure","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":1,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":1,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Sensory disturbance","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":1,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Sleep deficit","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":1,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Slow speech","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":1,"numAtRisk":3},{"groupId":"EG003","numAffected":1,"numAtRisk":12},{"groupId":"EG004","numAffected":3,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":1,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":5,"numAtRisk":60},{"groupId":"EG014","numAffected":2,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Speech disorder","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":1,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":2,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":1,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":1,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Syncope","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":1,"numAtRisk":3},{"groupId":"EG009","numAffected":1,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Tremor","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":1,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":1,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":1,"numAtRisk":47},{"groupId":"EG017","numAffected":2,"numAtRisk":32}]},{"term":"Abnormal dreams","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":1,"numAtRisk":3},{"groupId":"EG006","numAffected":1,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Affect lability","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":3,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":2,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":2,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":2,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":2,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Agitation","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":1,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":1,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":2,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":1,"numAtRisk":47},{"groupId":"EG017","numAffected":2,"numAtRisk":32}]},{"term":"Anxiety","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":2,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":1,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":1,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":1,"numAtRisk":30},{"groupId":"EG012","numAffected":2,"numAtRisk":27},{"groupId":"EG013","numAffected":3,"numAtRisk":60},{"groupId":"EG014","numAffected":7,"numAtRisk":65},{"groupId":"EG015","numAffected":2,"numAtRisk":46},{"groupId":"EG016","numAffected":6,"numAtRisk":47},{"groupId":"EG017","numAffected":1,"numAtRisk":32}]},{"term":"Attention deficit hyperactivity disorder","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Bradyphrenia","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":1,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Confusional state","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":2,"numAtRisk":17},{"groupId":"EG005","numAffected":1,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":1,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":2,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":1,"numAtRisk":60},{"groupId":"EG014","numAffected":4,"numAtRisk":65},{"groupId":"EG015","numAffected":2,"numAtRisk":46},{"groupId":"EG016","numAffected":2,"numAtRisk":47},{"groupId":"EG017","numAffected":2,"numAtRisk":32}]},{"term":"Depressed mood","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":1,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":1,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":1,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Hallucination","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":1,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Insomnia","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":1,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":1,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":4,"numAtRisk":30},{"groupId":"EG012","numAffected":3,"numAtRisk":27},{"groupId":"EG013","numAffected":10,"numAtRisk":60},{"groupId":"EG014","numAffected":5,"numAtRisk":65},{"groupId":"EG015","numAffected":4,"numAtRisk":46},{"groupId":"EG016","numAffected":4,"numAtRisk":47},{"groupId":"EG017","numAffected":3,"numAtRisk":32}]},{"term":"Irritability","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":2,"numAtRisk":12},{"groupId":"EG004","numAffected":2,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":1,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":3,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":4,"numAtRisk":60},{"groupId":"EG014","numAffected":2,"numAtRisk":65},{"groupId":"EG015","numAffected":6,"numAtRisk":46},{"groupId":"EG016","numAffected":1,"numAtRisk":47},{"groupId":"EG017","numAffected":2,"numAtRisk":32}]},{"term":"Mental disorder","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":1,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Mental status changes","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Nightmare","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":1,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Reading disorder","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Sleep disorder","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":1,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Chronic kidney disease","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":1,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":46},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Dysuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Haematuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":1,"numAtRisk":12},{"groupId":"EG004","numAffected":2,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":3,"numAtRisk":30},{"groupId":"EG012","numAffected":1,"numAtRisk":27},{"groupId":"EG013","numAffected":4,"numAtRisk":60},{"groupId":"EG014","numAffected":3,"numAtRisk":65},{"groupId":"EG015","numAffected":2,"numAtRisk":46},{"groupId":"EG016","numAffected":2,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Hydronephrosis","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Micturition urgency","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Pollakiuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Proteinuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":17},{"groupId":"EG005","numAffected":1,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":1,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":1,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":2,"numAtRisk":65},{"groupId":"EG015","numAffected":1,"numAtRisk":46},{"groupId":"EG016","numAffected":1,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Renal colic","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Urinary incontinence","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":17},{"groupId":"EG005","numAffected":1,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":1,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":3,"numAtRisk":60},{"groupId":"EG014","numAffected":4,"numAtRisk":65},{"groupId":"EG015","numAffected":1,"numAtRisk":46},{"groupId":"EG016","numAffected":1,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Breast pain","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Dysmenorrhoea","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Erectile dysfunction","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":1,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Menstruation irregular","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Vaginal haemorrhage","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":1,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Acute respiratory failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":1,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Bronchitis chronic","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":3},{"groupId":"EG001","numAffected":2,"numAtRisk":3},{"groupId":"EG002","numAffected":1,"numAtRisk":3},{"groupId":"EG003","numAffected":2,"numAtRisk":12},{"groupId":"EG004","numAffected":2,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":1,"numAtRisk":3},{"groupId":"EG007","numAffected":1,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":2,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":12,"numAtRisk":30},{"groupId":"EG012","numAffected":9,"numAtRisk":27},{"groupId":"EG013","numAffected":14,"numAtRisk":60},{"groupId":"EG014","numAffected":13,"numAtRisk":65},{"groupId":"EG015","numAffected":10,"numAtRisk":46},{"groupId":"EG016","numAffected":10,"numAtRisk":47},{"groupId":"EG017","numAffected":7,"numAtRisk":32}]},{"term":"Dysphonia","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":2,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":1,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":2,"numAtRisk":30},{"groupId":"EG012","numAffected":2,"numAtRisk":27},{"groupId":"EG013","numAffected":4,"numAtRisk":60},{"groupId":"EG014","numAffected":3,"numAtRisk":65},{"groupId":"EG015","numAffected":2,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":2,"numAtRisk":32}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":3},{"groupId":"EG001","numAffected":1,"numAtRisk":3},{"groupId":"EG002","numAffected":1,"numAtRisk":3},{"groupId":"EG003","numAffected":3,"numAtRisk":12},{"groupId":"EG004","numAffected":4,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":3,"numAtRisk":3},{"groupId":"EG008","numAffected":1,"numAtRisk":3},{"groupId":"EG009","numAffected":2,"numAtRisk":4},{"groupId":"EG010","numAffected":1,"numAtRisk":3},{"groupId":"EG011","numAffected":8,"numAtRisk":30},{"groupId":"EG012","numAffected":6,"numAtRisk":27},{"groupId":"EG013","numAffected":22,"numAtRisk":60},{"groupId":"EG014","numAffected":18,"numAtRisk":65},{"groupId":"EG015","numAffected":11,"numAtRisk":46},{"groupId":"EG016","numAffected":17,"numAtRisk":47},{"groupId":"EG017","numAffected":10,"numAtRisk":32}]},{"term":"Dyspnoea exertional","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":1,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":2,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":1,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":1,"numAtRisk":30},{"groupId":"EG012","numAffected":1,"numAtRisk":27},{"groupId":"EG013","numAffected":3,"numAtRisk":60},{"groupId":"EG014","numAffected":6,"numAtRisk":65},{"groupId":"EG015","numAffected":3,"numAtRisk":46},{"groupId":"EG016","numAffected":1,"numAtRisk":47},{"groupId":"EG017","numAffected":2,"numAtRisk":32}]},{"term":"Epistaxis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":17},{"groupId":"EG005","numAffected":1,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":1,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":2,"numAtRisk":27},{"groupId":"EG013","numAffected":4,"numAtRisk":60},{"groupId":"EG014","numAffected":4,"numAtRisk":65},{"groupId":"EG015","numAffected":1,"numAtRisk":46},{"groupId":"EG016","numAffected":1,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":2,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":2,"numAtRisk":30},{"groupId":"EG012","numAffected":1,"numAtRisk":27},{"groupId":"EG013","numAffected":2,"numAtRisk":60},{"groupId":"EG014","numAffected":5,"numAtRisk":65},{"groupId":"EG015","numAffected":2,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Hypoxia","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":1,"numAtRisk":65},{"groupId":"EG015","numAffected":5,"numAtRisk":46},{"groupId":"EG016","numAffected":1,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Laryngeal inflammation","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":1,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Lung disorder","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":1,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Nasal congestion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":1,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Oropharyngeal pain","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":2,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":1,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":3,"numAtRisk":27},{"groupId":"EG013","numAffected":5,"numAtRisk":60},{"groupId":"EG014","numAffected":2,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":3,"numAtRisk":47},{"groupId":"EG017","numAffected":1,"numAtRisk":32}]},{"term":"Pleural effusion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":1,"numAtRisk":3},{"groupId":"EG008","numAffected":1,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":1,"numAtRisk":30},{"groupId":"EG012","numAffected":1,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":6,"numAtRisk":65},{"groupId":"EG015","numAffected":1,"numAtRisk":46},{"groupId":"EG016","numAffected":6,"numAtRisk":47},{"groupId":"EG017","numAffected":1,"numAtRisk":32}]},{"term":"Pleuritic pain","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":1,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Productive cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":1,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":2,"numAtRisk":30},{"groupId":"EG012","numAffected":3,"numAtRisk":27},{"groupId":"EG013","numAffected":5,"numAtRisk":60},{"groupId":"EG014","numAffected":4,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":1,"numAtRisk":47},{"groupId":"EG017","numAffected":1,"numAtRisk":32}]},{"term":"Pulmonary embolism","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Pulmonary hypertension","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":1,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Pulmonary oedema","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":1,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Rales","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":1,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Respiratory tract congestion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":1,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Rhinitis allergic","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":1,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Rhinorrhoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":1,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Sinus congestion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":1,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Sleep apnoea syndrome","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":1,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Snoring","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Wheezing","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":1,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":1,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":2,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":2,"numAtRisk":60},{"groupId":"EG014","numAffected":3,"numAtRisk":65},{"groupId":"EG015","numAffected":3,"numAtRisk":46},{"groupId":"EG016","numAffected":3,"numAtRisk":47},{"groupId":"EG017","numAffected":1,"numAtRisk":32}]},{"term":"Alopecia","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":1,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":1,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":1,"numAtRisk":4},{"groupId":"EG010","numAffected":1,"numAtRisk":3},{"groupId":"EG011","numAffected":2,"numAtRisk":30},{"groupId":"EG012","numAffected":3,"numAtRisk":27},{"groupId":"EG013","numAffected":3,"numAtRisk":60},{"groupId":"EG014","numAffected":3,"numAtRisk":65},{"groupId":"EG015","numAffected":4,"numAtRisk":46},{"groupId":"EG016","numAffected":3,"numAtRisk":47},{"groupId":"EG017","numAffected":3,"numAtRisk":32}]},{"term":"Dermatitis","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":1,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Dermatitis acneiform","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":1,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Dermatitis contact","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Dermatomyositis","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":1,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Dry skin","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":2,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":1,"numAtRisk":3},{"groupId":"EG008","numAffected":1,"numAtRisk":3},{"groupId":"EG009","numAffected":1,"numAtRisk":4},{"groupId":"EG010","numAffected":1,"numAtRisk":3},{"groupId":"EG011","numAffected":3,"numAtRisk":30},{"groupId":"EG012","numAffected":1,"numAtRisk":27},{"groupId":"EG013","numAffected":2,"numAtRisk":60},{"groupId":"EG014","numAffected":2,"numAtRisk":65},{"groupId":"EG015","numAffected":1,"numAtRisk":46},{"groupId":"EG016","numAffected":2,"numAtRisk":47},{"groupId":"EG017","numAffected":1,"numAtRisk":32}]},{"term":"Eczema","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":1,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Erythema","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":1,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":3,"numAtRisk":30},{"groupId":"EG012","numAffected":2,"numAtRisk":27},{"groupId":"EG013","numAffected":1,"numAtRisk":60},{"groupId":"EG014","numAffected":1,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":1,"numAtRisk":32}]},{"term":"Hand dermatitis","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Hyperhidrosis","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":2,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":1,"numAtRisk":30},{"groupId":"EG012","numAffected":3,"numAtRisk":27},{"groupId":"EG013","numAffected":3,"numAtRisk":60},{"groupId":"EG014","numAffected":5,"numAtRisk":65},{"groupId":"EG015","numAffected":3,"numAtRisk":46},{"groupId":"EG016","numAffected":4,"numAtRisk":47},{"groupId":"EG017","numAffected":1,"numAtRisk":32}]},{"term":"Lipohypertrophy","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":1,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Night sweats","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":1,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Palmar-plantar erythrodysaesthesia syndrome","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Photosensitivity reaction","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":1,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":1,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Pruritus","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":1,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":2,"numAtRisk":60},{"groupId":"EG014","numAffected":1,"numAtRisk":65},{"groupId":"EG015","numAffected":4,"numAtRisk":46},{"groupId":"EG016","numAffected":3,"numAtRisk":47},{"groupId":"EG017","numAffected":3,"numAtRisk":32}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":3},{"groupId":"EG001","numAffected":1,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":3,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":8,"numAtRisk":30},{"groupId":"EG012","numAffected":5,"numAtRisk":27},{"groupId":"EG013","numAffected":3,"numAtRisk":60},{"groupId":"EG014","numAffected":9,"numAtRisk":65},{"groupId":"EG015","numAffected":3,"numAtRisk":46},{"groupId":"EG016","numAffected":5,"numAtRisk":47},{"groupId":"EG017","numAffected":3,"numAtRisk":32}]},{"term":"Rash erythematous","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":1,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Rash maculo-papular","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":1,"numAtRisk":3},{"groupId":"EG011","numAffected":1,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":4,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":2,"numAtRisk":46},{"groupId":"EG016","numAffected":1,"numAtRisk":47},{"groupId":"EG017","numAffected":1,"numAtRisk":32}]},{"term":"Rash papular","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":1,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Rash pruritic","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Rosacea","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":1,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Seborrhoeic dermatitis","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":1,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Skin lesion","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":1,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Menopause","organSystem":"Social circumstances","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Deep vein thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":1,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Flushing","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":1,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":50},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Haematoma","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":1,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Haemorrhage","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":1,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Hot flush","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":1,"numAtRisk":3},{"groupId":"EG009","numAffected":1,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":2,"numAtRisk":27},{"groupId":"EG013","numAffected":2,"numAtRisk":60},{"groupId":"EG014","numAffected":3,"numAtRisk":65},{"groupId":"EG015","numAffected":3,"numAtRisk":46},{"groupId":"EG016","numAffected":1,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Hypertension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":2,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":17},{"groupId":"EG005","numAffected":1,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":1,"numAtRisk":3},{"groupId":"EG008","numAffected":1,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":1,"numAtRisk":3},{"groupId":"EG011","numAffected":7,"numAtRisk":30},{"groupId":"EG012","numAffected":4,"numAtRisk":27},{"groupId":"EG013","numAffected":4,"numAtRisk":60},{"groupId":"EG014","numAffected":11,"numAtRisk":65},{"groupId":"EG015","numAffected":4,"numAtRisk":46},{"groupId":"EG016","numAffected":5,"numAtRisk":47},{"groupId":"EG017","numAffected":2,"numAtRisk":32}]},{"term":"Hypotension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":1,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Raynaud's phenomenon","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":1,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Shock","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":1,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Electrocardiogram PR prolongation","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":1,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":1,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Flatulence","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":3,"numAtRisk":30},{"groupId":"EG012","numAffected":1,"numAtRisk":27},{"groupId":"EG013","numAffected":1,"numAtRisk":60},{"groupId":"EG014","numAffected":4,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":4,"numAtRisk":32}]},{"term":"Stomatitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":1,"numAtRisk":30},{"groupId":"EG012","numAffected":2,"numAtRisk":27},{"groupId":"EG013","numAffected":3,"numAtRisk":60},{"groupId":"EG014","numAffected":4,"numAtRisk":65},{"groupId":"EG015","numAffected":1,"numAtRisk":46},{"groupId":"EG016","numAffected":3,"numAtRisk":47},{"groupId":"EG017","numAffected":1,"numAtRisk":32}]},{"term":"Conjunctivitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":1,"numAtRisk":3},{"groupId":"EG011","numAffected":1,"numAtRisk":30},{"groupId":"EG012","numAffected":1,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":3,"numAtRisk":65},{"groupId":"EG015","numAffected":1,"numAtRisk":46},{"groupId":"EG016","numAffected":1,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":1,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":1,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":1,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Spinal fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":2,"numAtRisk":32}]},{"term":"Gout","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":1,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":2,"numAtRisk":32}]},{"term":"Hypoalbuminaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":3,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":3,"numAtRisk":60},{"groupId":"EG014","numAffected":4,"numAtRisk":65},{"groupId":"EG015","numAffected":4,"numAtRisk":46},{"groupId":"EG016","numAffected":2,"numAtRisk":47},{"groupId":"EG017","numAffected":2,"numAtRisk":32}]},{"term":"Hyponatraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":1,"numAtRisk":30},{"groupId":"EG012","numAffected":1,"numAtRisk":27},{"groupId":"EG013","numAffected":1,"numAtRisk":60},{"groupId":"EG014","numAffected":3,"numAtRisk":65},{"groupId":"EG015","numAffected":1,"numAtRisk":46},{"groupId":"EG016","numAffected":3,"numAtRisk":47},{"groupId":"EG017","numAffected":2,"numAtRisk":32}]},{"term":"Increased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":1,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":3,"numAtRisk":60},{"groupId":"EG014","numAffected":2,"numAtRisk":65},{"groupId":"EG015","numAffected":3,"numAtRisk":46},{"groupId":"EG016","numAffected":1,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Spinal pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":1,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":1,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":1,"numAtRisk":47},{"groupId":"EG017","numAffected":2,"numAtRisk":32}]},{"term":"Fine motor skill dysfunction","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":2,"numAtRisk":32}]},{"term":"Hallucination, auditory","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":1,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":1,"numAtRisk":27},{"groupId":"EG013","numAffected":3,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":1,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":3,"numAtRisk":32}]},{"term":"Depression","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":2,"numAtRisk":30},{"groupId":"EG012","numAffected":2,"numAtRisk":27},{"groupId":"EG013","numAffected":8,"numAtRisk":60},{"groupId":"EG014","numAffected":1,"numAtRisk":65},{"groupId":"EG015","numAffected":1,"numAtRisk":46},{"groupId":"EG016","numAffected":2,"numAtRisk":47},{"groupId":"EG017","numAffected":2,"numAtRisk":32}]},{"term":"Mania","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":1,"numAtRisk":47},{"groupId":"EG017","numAffected":2,"numAtRisk":32}]},{"term":"Pericardial effusion","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":2,"numAtRisk":30},{"groupId":"EG012","numAffected":2,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":1,"numAtRisk":65},{"groupId":"EG015","numAffected":2,"numAtRisk":46},{"groupId":"EG016","numAffected":1,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Gastroenteritis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":2,"numAtRisk":30},{"groupId":"EG012","numAffected":1,"numAtRisk":27},{"groupId":"EG013","numAffected":1,"numAtRisk":60},{"groupId":"EG014","numAffected":1,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":3,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Cataract","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":3,"numAtRisk":30},{"groupId":"EG012","numAffected":2,"numAtRisk":27},{"groupId":"EG013","numAffected":3,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":1,"numAtRisk":46},{"groupId":"EG016","numAffected":1,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Eye irritation","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":2,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":1,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Mouth ulceration","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":4,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":1,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Odynophagia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":2,"numAtRisk":30},{"groupId":"EG012","numAffected":2,"numAtRisk":27},{"groupId":"EG013","numAffected":1,"numAtRisk":60},{"groupId":"EG014","numAffected":1,"numAtRisk":65},{"groupId":"EG015","numAffected":1,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Toothache","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":5,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":3,"numAtRisk":60},{"groupId":"EG014","numAffected":1,"numAtRisk":65},{"groupId":"EG015","numAffected":1,"numAtRisk":46},{"groupId":"EG016","numAffected":1,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Influenza like illness","organSystem":"General disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":2,"numAtRisk":30},{"groupId":"EG012","numAffected":2,"numAtRisk":27},{"groupId":"EG013","numAffected":4,"numAtRisk":60},{"groupId":"EG014","numAffected":1,"numAtRisk":65},{"groupId":"EG015","numAffected":1,"numAtRisk":46},{"groupId":"EG016","numAffected":2,"numAtRisk":47},{"groupId":"EG017","numAffected":1,"numAtRisk":32}]},{"term":"Localised oedema","organSystem":"General disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":0,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":2,"numAtRisk":60},{"groupId":"EG014","numAffected":1,"numAtRisk":65},{"groupId":"EG015","numAffected":2,"numAtRisk":46},{"groupId":"EG016","numAffected":3,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Malaise","organSystem":"General disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":2,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":4,"numAtRisk":60},{"groupId":"EG014","numAffected":2,"numAtRisk":65},{"groupId":"EG015","numAffected":2,"numAtRisk":46},{"groupId":"EG016","numAffected":1,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Ulcer","organSystem":"General disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":2,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Herpes zoster","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":1,"numAtRisk":3},{"groupId":"EG011","numAffected":1,"numAtRisk":30},{"groupId":"EG012","numAffected":1,"numAtRisk":27},{"groupId":"EG013","numAffected":2,"numAtRisk":60},{"groupId":"EG014","numAffected":1,"numAtRisk":65},{"groupId":"EG015","numAffected":1,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":1,"numAtRisk":32}]},{"term":"Skin infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":3,"numAtRisk":30},{"groupId":"EG012","numAffected":3,"numAtRisk":27},{"groupId":"EG013","numAffected":1,"numAtRisk":60},{"groupId":"EG014","numAffected":1,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":2,"numAtRisk":47},{"groupId":"EG017","numAffected":1,"numAtRisk":32}]},{"term":"Suspected COVID-19","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":4,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":1,"numAtRisk":32}]},{"term":"Procedural pain","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":1,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":1,"numAtRisk":60},{"groupId":"EG014","numAffected":2,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":3,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Low density lipoprotein increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":2,"numAtRisk":30},{"groupId":"EG012","numAffected":0,"numAtRisk":27},{"groupId":"EG013","numAffected":2,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":2,"numAtRisk":46},{"groupId":"EG016","numAffected":1,"numAtRisk":47},{"groupId":"EG017","numAffected":1,"numAtRisk":32}]},{"term":"Diabetes mellitus","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":2,"numAtRisk":30},{"groupId":"EG012","numAffected":3,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":1,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]},{"term":"Somnolence","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":1,"numAtRisk":30},{"groupId":"EG012","numAffected":2,"numAtRisk":27},{"groupId":"EG013","numAffected":1,"numAtRisk":60},{"groupId":"EG014","numAffected":1,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":1,"numAtRisk":47},{"groupId":"EG017","numAffected":1,"numAtRisk":32}]},{"term":"Mood swings","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":17},{"groupId":"EG005","numAffected":0,"numAtRisk":3},{"groupId":"EG006","numAffected":0,"numAtRisk":3},{"groupId":"EG007","numAffected":0,"numAtRisk":3},{"groupId":"EG008","numAffected":0,"numAtRisk":3},{"groupId":"EG009","numAffected":0,"numAtRisk":4},{"groupId":"EG010","numAffected":0,"numAtRisk":3},{"groupId":"EG011","numAffected":2,"numAtRisk":30},{"groupId":"EG012","numAffected":1,"numAtRisk":27},{"groupId":"EG013","numAffected":0,"numAtRisk":60},{"groupId":"EG014","numAffected":0,"numAtRisk":65},{"groupId":"EG015","numAffected":0,"numAtRisk":46},{"groupId":"EG016","numAffected":0,"numAtRisk":47},{"groupId":"EG017","numAffected":0,"numAtRisk":32}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results."},"pointOfContact":{"title":"Pfizer ClinicalTrials.gov Call Center","organization":"Pfizer, Inc.","email":"ClinicalTrials.gov_Inquiries@pfizer.com","phone":"1-800-718-1021"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot","hasProtocol":true,"hasSap":false,"hasIcf":false,"label":"Study Protocol","date":"2019-01-23","uploadDate":"2024-05-24T11:29","filename":"Prot_002.pdf","size":2165605},{"typeAbbrev":"SAP","hasProtocol":false,"hasSap":true,"hasIcf":false,"label":"Statistical Analysis Plan","date":"2019-03-15","uploadDate":"2024-05-24T11:30","filename":"SAP_003.pdf","size":950033}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-12-17"},"conditionBrowseModule":{"meshes":[{"id":"D002289","term":"Carcinoma, Non-Small-Cell Lung"}],"ancestors":[{"id":"D002283","term":"Carcinoma, Bronchogenic"},{"id":"D001984","term":"Bronchial Neoplasms"},{"id":"D008175","term":"Lung Neoplasms"},{"id":"D012142","term":"Respiratory Tract Neoplasms"},{"id":"D013899","term":"Thoracic Neoplasms"},{"id":"D009371","term":"Neoplasms by Site"},{"id":"D009369","term":"Neoplasms"},{"id":"D008171","term":"Lung Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"C000590786","term":"lorlatinib"},{"id":"D000077547","term":"Crizotinib"}],"ancestors":[{"id":"D010880","term":"Piperidines"},{"id":"D006573","term":"Heterocyclic Compounds, 1-Ring"},{"id":"D006571","term":"Heterocyclic Compounds"},{"id":"D000631","term":"Aminopyridines"},{"id":"D011725","term":"Pyridines"}]}},"hasResults":true}